---
document_datetime: 2023-11-20 16:34:35
document_pages: 209
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/ebglyss-epar-public-assessment-report_en.pdf
document_name: ebglyss-epar-public-assessment-report_en.pdf
version: success
processing_time: 192.8156156
conversion_datetime: 2025-12-25 04:17:07.820026
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

14 September 2023 EMA/453942/2023 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Ebglyss

International  non-proprietary  name: Lebrikizumab

Procedure No. EMEA/H/C/005894/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................7                        |                                                                                                |
|------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier.............................................................................      | 7                                                                                              |
| 1.2. Legal basis and dossier content......................................................................       | 7                                                                                              |
| 1.3. Information on paediatric requirements............................................................          | 7                                                                                              |
| 1.4. Information relating to orphan market exclusivity...............................................            | 7                                                                                              |
| 1.4.1. Similarity............................................................................................... | 7                                                                                              |
| 1.5. Applicant's request(s) for consideration............................................................        | 7                                                                                              |
| 1.5.1. New active substance status.......................................................................        | 7                                                                                              |
| 1.6. Scientific advice.........................................................................................  | 8                                                                                              |
| 1.7. Steps taken for the assessment of the product...................................................            | 8                                                                                              |
| 2. Scientific discussion................................................................................9        |                                                                                                |
| 2.1. Problem statement.....................................................................................      | 9                                                                                              |
| 2.1.1. Disease or condition.................................................................................     | 9                                                                                              |
| 2.1.2. Epidemiology..........................................................................................    | 9                                                                                              |
| 2.1.3. Aetiology and pathogenesis.......................................................................10       |                                                                                                |
| 2.1.4. Clinical presentation................................................................................10   |                                                                                                |
| 2.1.5. Management .........................................................................................10    |                                                                                                |
| 2.2. About the product                                                                                           | .....................................................................................11        |
| 2.3. Type of application and aspects on development                                                              | ...............................................11                                              |
| 2.4. Quality aspects.........................................................................................12  |                                                                                                |
| 2.4.1. Introduction..........................................................................................12  |                                                                                                |
| 2.4.2. Active Substance....................................................................................12    |                                                                                                |
| 2.4.3. Finished Medicinal Product                                                                                | ........................................................................15                     |
| 2.4.4. Discussion on chemical, pharmaceutical and biological aspects...........................19                |                                                                                                |
| 2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects.....................19                 |                                                                                                |
| 2.4.6. Recommendation(s) for future quality development.........................................19               |                                                                                                |
| 2.5. Non-clinical aspects...................................................................................20   |                                                                                                |
| 2.5.1. Introduction..........................................................................................20  |                                                                                                |
| 2.5.2. Pharmacology........................................................................................20    |                                                                                                |
| 2.5.3. Pharmacokinetics....................................................................................21    |                                                                                                |
| 2.5.4. Toxicology                                                                                                | ............................................................................................23 |
| 2.5.5. Ecotoxicity/environmental risk assessment....................................................26           |                                                                                                |
| 2.5.6. Discussion on non-clinical aspects...............................................................26       |                                                                                                |
| 2.5.7. Conclusion on the non-clinical aspects..........................................................31        |                                                                                                |
| 2.6. Clinical aspects.........................................................................................31 |                                                                                                |
| 2.6.1. Introduction..........................................................................................31  |                                                                                                |
| 2.6.2. Clinical pharmacology..............................................................................37     |                                                                                                |
| 2.6.3. Discussion on clinical pharmacology.............................................................53        |                                                                                                |
| 2.6.4. Conclusions on clinical pharmacology...........................................................57         |                                                                                                |
| 2.6.5. Clinical efficacy                                                                                         | ......................................................................................58       |
| 2.6.6. Discussion on clinical efficacy...................................................................148     |                                                                                                |
| 2.6.7. Conclusions on the clinical efficacy                                                                      | ............................................................157                                |
| 2.6.8. Clinical safety                                                                                           | ......................................................................................158      |

<div style=\"page-break-after: always\"></div>

| 2.6.9. Discussion on clinical safety.....................................................................190    |                                                                                                |
|-----------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|
| 2.6.10. Conclusions on the clinical safety                                                                      | ............................................................196                                |
| 2.7. Risk Management Plan..............................................................................196      |                                                                                                |
| 2.7.1. Safety concerns....................................................................................196   |                                                                                                |
| 2.7.2. Pharmacovigilance plan..........................................................................197      |                                                                                                |
| 2.7.3. Risk minimisation measures                                                                               | ....................................................................198                        |
| 2.7.4. Conclusion..........................................................................................199  |                                                                                                |
| 2.8. Pharmacovigilance...................................................................................199    |                                                                                                |
| 2.8.1. Pharmacovigilance system                                                                                 | ......................................................................199                      |
| 2.8.2. Periodic Safety Update Reports submission requirements................................199                |                                                                                                |
| 2.9. Product information.................................................................................200    |                                                                                                |
| 2.9.1. User consultation..................................................................................200   |                                                                                                |
| 2.9.2. Additional monitoring.............................................................................200    |                                                                                                |
| 3. Benefit-Risk Balance...........................................................................200           |                                                                                                |
| 3.1. Therapeutic Context.................................................................................200    |                                                                                                |
| 3.1.1. Disease or condition..............................................................................200    |                                                                                                |
| 3.1.2. Available therapies and unmet medical need................................................200            |                                                                                                |
| 3.1.3. Main clinical studies...............................................................................201  |                                                                                                |
| 3.2. Favourable effects...................................................................................201   |                                                                                                |
| 3.3. Uncertainties and limitations about favourable effects.......................................202           |                                                                                                |
| 3.4. Unfavourable effects                                                                                       | ................................................................................202            |
| 3.5. Uncertainties and limitations about unfavourable effects....................................205            |                                                                                                |
| 3.6. Effects Table..........................................................................................206 |                                                                                                |
| 3.7. Benefit-risk assessment and discussion.........................................................207         |                                                                                                |
| 3.7.1. Importance of favourable and unfavourable effects........................................207             |                                                                                                |
| 3.7.2. Balance of benefits and risks                                                                            | ...................................................................208                         |
| 3.7.3. Additional considerations on the benefit-risk balance......................................208           |                                                                                                |
| 3.8. Conclusions                                                                                                | ...........................................................................................208 |
| 4. Recommendations...............................................................................208            |                                                                                                |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

(L)LOQ

(lower) imit of quantification

AD

atopic dermatitis

ADA

antidrug antibody

ADCC

antibody-dependent cellular cytotoxicity

ADR

adverse drug reaction

AE

adverse event

AI

autoinjector

AI-PFP

autoinjector - pre-filled pen

ANCOVA

analysis of covariance

anti-ID

anti-idiotypic

AUC

area under the curve

BALF

bronchoalveolar lavage fluid

BMI

body mass index

BP

blood pressure

BSA

body surface area

Cavg,ss

average concentration at steady state

CDC

complement-dependent cytotoxicity

CDR

complementarity-determining region

CE-SDS

capillary electrophoresis sodium dodecyl sulfate

CHMP

Committee for Medicinal Products for Human Use

CHO

Chinese hamster ovary cells

CI

confidence interval

CL

vlearance

Cmax

maximum observed serum concentration

Cmax,ss

maximum concentration at steady state

CMH

Cochran-Mantel-Haenszel

COPD

chronic obstructive pulmonary disease

COVID-19

coronavirus disease 2019

CPP

critical process parameter

CQA

critical quality attribute

CSE

clinical summary of efficacy

CSR

clinical study report

CT

cycle threshold

Ctrough,ss

concentration before the next dose at steady state

DBL

database lock

DDI

drug-drug interactions

DILI

drug-induced liver injury

DLQI

dermatology life quality index

EASI

eczema area and severity index

EASI 50

50% decrease from Baseline in EASI

EASI 75

75% decrease from Baseline in EASI

EASI 90

90% decrease from Baseline in EASI

EC50

drug concentration that produces 50% of maximum effect (Emax)

ECLA

electrochemiluminescence assay

ELISA

enzyme-linked immunosorbent assay

EMA

European Medicines Agency

Emax

maximum effect

EOP

end of production

E-R

exposure-response

FDA

food and drug administration

GCP

good clinical practice

GD

gestation day

HCP

healthcare provider

HCP

host cell protein

HF

human factors

HFE

human factors engineering

HMWS

high molecular weight species

HR

hazard ratio

ICE

intercurrent event

IFU

instructions for use

IGA

investigator's global assessment

IGA 0,1

IGA score of 0 or 1 with a 2-point or greater reduction from baseline

IgG

immunoglobulin G

IgG4

immunoglobulin G4

IL

interleukin

IL-13

interleukin-13

IL-13R α 1

IL-13 receptor alpha-1

IL-4R α

IL4 receptor alpha

improvement

4-point or greater improvement in pruritus NRS, among participants with a

baseline score of at least 4

IND

investigative new drug

IPF

idiopathic pulmonary fibrosis

IR

incidence rate

ISR

injection site reaction

ITT

intention-to-treat

IV

intravenous

JAK

Janus kinase

KD

equilibrium dissociation constant

KLH

keyhole limpet haemocyanin

LD

lactation day

LEB

lebrikizumab

Lilly

Eli Lilly and Company

LIVCA

limit for in vitro cell age

LLOQ

lower limit of quantification

LMWS

low molecular weight species

LTE

long-term extension

MAA

marketing authorisation application

mAb

monoclonal antibody

MACE

major adverse cardiovascular event

MCB

master cell bank

MCMC-MI

Markov chain Monte Carlo multiple imputation

MCV

meningococcal (Groups A, C, Y, and W-135) oligosaccharide diphtheria CRM197

conjugate vaccine

MedDRA

Medical Dictionary for Regulatory Activities

mITT

modified intent-to-treat

NHP

non-human primate

NLT

not less than

NMSC

non-melanoma skin cancer

NMT

not more than

NRS

numeric rating scale

NS0

murine myeloma cell line

PBO

placebo

PFS-NSD

prefilled syringe with needle safety device

PK

Pharmacokinetic(s)

PL

package leaflet

PND

Postnatal day

POEM

patient-oriented eczema measure

PPND

pre- and postnatal development

PRO

patient-reported outcome

PROMIS

patient-reported outcomes measurement information system

PRS

primary reference standard

Pruritus NRS 4-point

PSB

primary seed bank

PT

preferred term

PY

patient-years

Q2W

every 2 weeks

Q4W

every 4 weeks

QoL

quality of life

QRI

quick reference for injection

QXW

every x weeks

ROW

rest of world

RP-HPLC

reversed phase high performance liquid chromatography

RS

reference standard

SA

scientific advice

SAE

serious adverse event

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

| SBL     | Samsung BiologicsSC                                   | subcutaneous      |
|---------|-------------------------------------------------------|-------------------|
| SCE     | summary of clinical efficacy                          |                   |
| SCS     | summary of clinical safety                            |                   |
| SD      | standard deviation                                    |                   |
| SD      | standard deviation                                    |                   |
| SFS     | semi-finished syringe                                 |                   |
| SmPC    | summary of product characteristics                    |                   |
| SOC     | system organ class                                    |                   |
| SPR     | surface plasmon resonance                             |                   |
| STAT6   | Signal transducer and activator of transcription      | 6                 |
| TCI     | topical calcineurin inhibitor                         |                   |
| TCS     | topical corticosteroids                               |                   |
| Tdap    | diphtheria and tetanus toxoids and acellular adsorbed | pertussis vaccine |
| TE ADA  | treatment-emergent antidrug antibody                  |                   |
| TEAE    | treatment-emergent adverse event                      |                   |
| TGF β1  | transforming growth factor- β1                        |                   |
| TK      | toxicokinetic                                         |                   |
| TNX-650 | lebrikizumab                                          |                   |
| ULN     | upper limit of normal                                 |                   |
| ULOQ    | upper limit of quantification                         |                   |
| VAS     | visual analogue scale                                 |                   |
| Vd      | volume of distribution                                |                   |
| WCB     | working cell bank                                     |                   |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant Almirall, S.A. submitted on 5 October 2022 an application for marketing authorisation to the European Medicines Agency (EMA) for Ebglyss, through the centralised procedure falling within the Article 3(1) and point 1 of Annex of Regulation (EC) No 726/2004.

The applicant applied for the following indication: Ebglyss is indicated for the treatment of moderateto-severe atopic dermatitis in adults and adolescents 12 years of age and older who are candidates for systemic therapy.

## 1.2. Legal basis and dossier content

## The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC - complete and independent application.

The application submitted is composed of administrative information, complete quality data, nonclinical and clinical data based on applicants' own tests and studies and/or bibliographic literature substituting/supporting  certain test(s) or study(ies).

## 1.3. Information on paediatric requirements

Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) P/0286/2021 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/0286/2021 was not yet completed as some measures were deferred.

## 1.4. Information relating to orphan market exclusivity

## 1.4.1. Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## 1.5. Applicant's request(s) for consideration

## 1.5.1. New active substance status

The applicant requested the active substance lebrikizumab contained in the above medicinal product to be considered as a new active substance, as the applicant claims that it is not a constituent of a medicinal product previously authorised within the European Union.

<div style=\"page-break-after: always\"></div>

## 1.6. Scientific advice

The applicant received the following scientific advice on the development relevant for the indication subject to the present application:

| Date            | Reference                      | SAWP co-ordinators           |
|-----------------|--------------------------------|------------------------------|
| 23 January 2014 | EMEA/H/SA/2699/1/2013/III      | Peter Kiely, Jens Reinhardt  |
| 26 January 2017 | EMEA/H/SA/2699/1/FU/1/2016/III | Carin Bergquist, Peter Kiely |

The scientific advice pertained to the following non-clinical and clinical aspects:

- Appropriateness of the non-clinical program
- Acceptability of the proposed doses, patient population, inclusion/exclusion criteria, trial size, use of the EASI score, treatment scheme, definitions of flare and rebound, assessment of skin infections, proposed safety assessment, inclusion of adolescents in adult trials, the proposed staggered approach for enrolment of different age groups
- The study design for WS39518 and WS39519, in particular the proposal for tapering of topical corticosteroids, the statistical plan, the re-randomisation proposal, handling of background TCS, allowance for transition to open-label lebrikizumab, and the study design for WS39520, in particular the statistical plan
- The proposed bridging strategy, and proposed plan to support patient self-administration and the acceptability of the proposed filing plan and labelling strategy, proposal to generate safety data.

## 1.7. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Outi Mäki-Ikola Co-Rapporteur:  Selma Arapovic Dzakula

| The application was received by the EMA on                                                                                             | 5 October 2022   |
|----------------------------------------------------------------------------------------------------------------------------------------|------------------|
| The procedure started on                                                                                                               | 27 October 2022  |
| The CHMP Rapporteur's first Assessment Report was circulated to all CHMP and PRAC members on                                           | 16 January 2023  |
| The CHMP Co-Rapporteur's first Assessment Report was circulated to all CHMP and PRAC members on                                        | 30 January 2023  |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC and CHMP members on                                           | 30 January 2023  |
| The CHMP agreed on the consolidated List of Questions to be sent to the applicant during the meeting on                                | 23 February 2023 |
| The applicant submitted the responses to the CHMP consolidated List of Questions on                                                    | 16 May 2023      |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Questions to all | 23 June 2023     |

<div style=\"page-break-after: always\"></div>

| CHMP and PRAC members on                                                                                                                                                                |                   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                                | 06 July 2023      |
| The CHMP agreed on a list of outstanding issues in writing to be sent to the applicant on                                                                                               | 20 July 2023      |
| The applicant submitted the responses to the CHMP List of Outstanding Issues on                                                                                                         | 14 August 2023    |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP and PRAC members on                | 29 August 2023    |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP and PRAC members on                | 07 September 2023 |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Ebglyss on | 14 September 2023 |
| Furthermore, the CHMP adopted a report on New Active Substance (NAS) status of the active substance contained in the medicinal product (see Appendix on NAS)                            | 14 September 2023 |

## 2. Scientific discussion

## 2.1. Problem statement

## 2.1.1. Disease or condition

Atopic dermatitis (AD) is a chronic and relapsing inflammatory disorder characterised by erythematous, pruritic, dry, scaly and often lichenified skin. Pruritus is a hallmark of AD and is responsible for much of the disease burden for patients and their families. Moderate to severe AD is associated with significant burden, impacting sleep, quality of life, and treatment needs.

## 2.1.2. Epidemiology

AD is  the most  common chronic  inflammatory skin disease that  is  often diagnosed in  early years in children, but it may also affect patients in their adult life. Global AD prevalence is increasing in all ages: in children up to 20% 1  , while in adults and elderly up to 10%  1,2,3 . In adolescents (≥12 to &lt;18 years),

1 Silverberg,  J. I.,  et.al. (2021). Atopic  dermatitis  in the pediatric  population:  A cross-sectional,  international  epidemiologic  study. Annals  of allergy,  asthma &amp; immunology  : official publication  of the American  College  of Allergy,  Asthma, &amp; Immunology , 126 (4), 417-428.e2. https://doi.org/10.1016/j.anai.2020.12.020

2 Barbarot  S, Auziere  S, Gadkari  A et al. Epidemiology  of atopic  dermatitis  in adults:  results from an international  survey.  Allergy  2018; 73: 1284- 1293

3 Patruno  C, Napolitano  M, Argenziano  G et al. Dupilumab  therapy  of atopic  dermatitis  of the elderly:  a multicentre,  real-life study.  J Eur Acad Dermatol  Venereol  2021; 35: 958-964

<div style=\"page-break-after: always\"></div>

this prevalence is  up to 16% worldwide 4 .  Among patients with AD in the EU, the proportion with moderate to severe disease varies  from 46% to 66% depending on the patient-reported measurement scale used 2 .

## 2.1.3. Aetiology and pathogenesis

AD is a complex disease with an interplay between abnormal immune response, genetic impairment of skin barrier and environmental factors 5 . The immune response in AD is skewed towards T helper 2 (Th2) cell-mediated pathways 6 . IL-13 is believed to be the central mediator that drives multiple aspects of the pathophysiology underlying the range of signs and symptoms of AD by promoting type 2 inflammation and  mediating  its  effects on  tissue,  resulting  in  skin  barrier dysfunction,  itch,  skin  thickening,  and propensity to infections 7 .

## 2.1.4. Clinical presentation

AD is characterised by xerosis, erythematous crusted eruption (dermatosis), lichenification, and intense pruritus 8 , which  along with  the distribution,  chronicity, and history of skin lesions, form the basis for making the diagnosis. The clinical phenotype can vary depending on the age. In adolescents and adults (12-60  years),  eczematous  lesions  prevalently  affect  head,  neck  and  flexural  areas,  with  xerosis, lichenification, and depigmentation 9 .

## 2.1.5. Management

The goals of AD therapy are to reduce pruritus and establish persistent disease control that is sufficient to  enable  patients  to  be  fully  functional  at  home,  work and  school.  These  goals typically  require a multistep approach with interventions that are aimed at avoiding relevant triggers, improving the skin barrier, normalizing the skin dysbiosis and reducing inflammation 10 .

Topical  therapies, e.g.  moisturisers  are  the  mainstay  of  therapy  for  patients  with  mild-to-moderate disease. Topical corticosteroids (TCS) are used as the first-line anti-inflammatory treatment and reduce disease recurrence when used intermittently. Use of low-potency TCS bears low risk, but inappropriate use  of  high-potency  TCS  can  cause  local  side  effect  such  as  skin  thinning,  purpura,  striae  and dyspigmentation 10 .

Topical calcineurin inhibitors (TCIs) tacrolimus and pimecrolimus are alternative topical immunomodulators for the  treatment  of  AD.  Currently  per  EMA  recommendations,  these  medicines should be only used in patients over the age of 2 years with  mild or moderate disease (in the case of pimecrolimus) and moderate to severe disease (in the case of tacrolimus), when treatment with topical corticosteroids should not or cannot be used 11 .

Other treatment  options  include short-term phototherapy if  disease cannot  be controlled with  topical therapies and oral glucocorticoids. Systemic non-biologic immunomodulatory therapies, e.g. ciclosporin, azathioprine, methotrexate and  mycophenolate mofetil  are also used 10 . Other treatments  options  for

4 Abuabara K, Yu AM, Okhovat  JP et al. The prevalence  of atopic  dermatitis  beyond  childhood:  a systematic  review and  meta-analysis of longitudinal  studies.  Allergy  2018; 73: 696-704

5 Patrick  GJ, Archer  NK, Miller  LS. Which  way do  we go?  Complex  interactions  in  atopic  dermatitis  pathogenesis.  J Invest  Dermatol  2021; 141:274-284.

6 Weidinger  S, Novak  N. Atopic  dermatitis.  Lancet.  2016; 387:1109-1122.

7 Rat narajah K, Le M, Muntyanu  A, et al. Inhibition  of IL-13:  a new pathway  for atopic  dermatitis.  J Cutan Med  Surg. 2021; 25:315-328 8

Bieber  T. Atopic  dermatitis.  N Engl J Med.  2008; 358:1483-1494.

9 Raimondo  A and Lembo  S. Atopic  Dermatitis:  Epidemiology and Clinical  Phenotypes.  Dermatol  Pract Concept  2021; 11:e2021146 10 Weidinger  S, Beck  L, Bieber  T, et al. Atopic  dermatitis.  Nat Rev Dis  Primers. 2018; 4:1.

11 Elidel  | European  Medicines  Agency  (europa.eu)

<div style=\"page-break-after: always\"></div>

moderate-to-severe AD include oral JAK inhibitors abrocitinib, baricitinib, upadacitinib. However, the use of JAK inhibitors has been associated with some serious side effects and should be used with caution 12 .

Two biological therapies have  been approved by EMA for moderate-to-severe disease: dupilumab in 2017 and tralokinumab in 2021. Dupilumab is a mAb against IL-4R α that inhibits IL-4 signalling via the Type I  receptor (IL-4R α/γ c),  and  both  IL-4  and  IL-13  signalling  through  the  Type II receptor (IL-4R α/ IL13R α) 13 . Tralokinumab is a mAb against IL-13 that neutralises the biological activity of IL-13 by blocking its interaction with the IL-13R α1/ IL-4R α receptor complex 14 .

## 2.2. About the product

Lebrikizumab is an immunoglobin G4 (IgG4) monoclonal antibody (mAb) that binds with high affinity to soluble interleukin IL-13 and inhibits IL-13 signalling through the IL-4 receptor alpha (IL-4R α)/ IL-13 receptor alpha 1 (IL-13R α1) pathway, thereby preventing the downstream effects of IL13 with high selectivity. It blocks the binding of IL-13 to IL-4R α, but does not block the binding of IL13 to IL-13R α1 or IL-13 receptor alpha 2 (IL-13R α2).

ATC-code has not yet been assigned.

The proposed indication for lebrikizumab is as follows: 'Lebrikizumab is indicated for the treatment  of moderate-to-severe atopic  dermatitis  in  adults  and  adolescents 12  years of  age and  older  who  are candidates  for  systemic  therapy'.  The  summary  of  product  characteristic  (SmPC)  also  states  that lebrikizumab can be used with  or without  topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI).

The proposed dose of lebrikizumab is an initial dose of 500 mg (two 250 mg injections) at week 0 and week 2, followed by 250 mg every other week administered as subcutaneous injection up to week 16. The recommended maintenance dose is 250 mg every fourth week.

## 2.3. Type of application and aspects on development

The application was submitted under the legal basis 8(3) of Directive 2001/83/EC which corresponds to a complete and independent application.

The applicant received EMA scientific advice on the preclinical and clinical development programme of lebrikizumab in the treatment of AD (see section 1.6. 'Scientific advice').

12 Janus kinase  inhibitors  (JAKi)  | European  Medicines  Agency (europa.eu)

13 Dupixent  | European  Medicines  Agency  (europa.eu)

14 Adtralza  | European  Medicines  Agency (europa.eu)

<div style=\"page-break-after: always\"></div>

## 2.4. Quality aspects

## 2.4.1. Introduction

Lebrikizumab, the active substance contained in Ebglyss, is a monoclonal antibody (MAb) based on a human immunoglobulin G4 (IgG4) framework, produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology.

Ebglyss is presented as a 250 mg/2 mL sterile solution for injection for subcutaneous administration at a concentration of 125 mg/mL. As described in section 6.5 of the SmPC there are two presentations:

- 2 mL solution in a 2.25 mL Type-1 clear glass pre-filled syringe with small round flange, with a 27 gauge special thin wall x 12.7 mm stacked stainless steel needle, closed with a laminated bromobutyl elastomeric plunger and a rigid needle shield and assembled in a passive safety device (further named 'PFS-NSD')
- 2 mL solution in a 2.25 mL Type-1 clear glass syringe in a pre-filled pen with extra-small round flange, with a 27 gauge special thin wall x 8 mm stacked stainless steel needle, and closed with a laminated bromobutyl elastomeric plunger and a rigid needle shield (further named 'autoinjector-pre-filled pen' or 'AI-PFP').

Other ingredients are histidine, glacial acetic acid, sucrose, polysorbate 20, water for injections.

## 2.4.2. Active Substance

## 2.4.2.1. General  information

Lebrikizumab is a monoclonal antibody (MAb) based on a human immunoglobulin G4 (IgG4) framework containing light chain VL κ IV and heavy chain VHII subgroup sequences. The recombinant antibody is produced in  Chinese  Hamster  Ovary (CHO)  cells and  consists  of two  heavy chains (445  amino  acid residues each) and two light  chains (218  amino acid residues each) with  a relative molecular mass of approximately 145 kDa.

Mechanism of action  is binding  with  high  affinity to  interleukin (IL)-13  and inhibiting  IL-13  signalling through the IL-4 receptor alpha (IL-4R α)/ IL-13 receptor alpha 1 (IL-13R α1) pathway, thereby blocking the downstream effects of IL-13 with high selectivity. Blockade of IL-13 signalling is expected to be of benefit in diseases in which IL-13 is a key contributor to the disease pathogenesis. Lebrikizumab does not prevent the binding of IL-13 to the IL-13 receptor  alpha 2 (IL-13R α2 or decoy receptor), which allows the internalisation of IL-13 into the cell.

An N-linked glycosylation site is present on Asn295 in each heavy chain. The predominant form of the fucosylated N-linked oligosaccharide of lebrikizumab is G0 (i.e. . 0 terminal galactose residues).

## 2.4.2.2. Manufacture,  characterisation  and process controls

The active  substance is  manufactured at  Samsung Biologics Co.,  Ltd.  (SBL), 300  Songdo-bio-daero, Yeonsu-gu, Incheon 21987, Republic of Korea.  It was confirmed that the site involved in manufacture and quality control of the active substance operate in accordance with EU GMP.

<div style=\"page-break-after: always\"></div>

## Description of manufacturing process and process controls

The manufacturing process is based on a commonly used monoclonal production technology. Upstream process consists of several cell expansion steps and  a harvest step.  In the  downstream  process the harvested cell culture is purified using a series of purification and formulation steps.

## Control of materials

Sufficient information on raw materials used in the  active substance manufacturing process has been submitted. Compendial raw materials are tested in accordance with the corresponding monograph, while specifications (including  test methods) for non-compendial raw materials are presented. No human or animal  derived  materials  are  used  in  the  active  substance  manufacturing  process  and  acceptable documents have been provided for raw materials of biological origin used in the  establishment of cell substrate.

The source and history of the CHO cell line used for  active substance expression  is stated. The expression construct  is  described in  adequate detail.  The  applicant  provided information  on the  process on  the single-cell selection process of monoclonality. A two-tier cell bank system of master cell bank (MCB) and working cell bank (WCB) is used. Based to the provided results, the genetic stability for MCB and WCB is demonstrated for cells at and beyond the limit of cell age. Sufficient information is provided regarding testing of MCB and WCB and release of future WCBs.

An overview of the raw materials used in the manufacture of the active substance has been provided, with listing per unit operation. Specifications of raw materials have been also provided.

## Control of critical steps and intermediates

A  comprehensive  overview  of  critical  in-process  controls  and  critical  in-process  tests  performed throughout  the lebrikizumab active substance manufacturing process is given. Acceptable information has  been  provided  on  the  control  system  in  place  to  monitor  and  control  the  active  substance manufacturing process. Actions taken if limits are exceeded are specified.

The  lebrikizumab active  substance  manufacturing process  does not produce  isolated process intermediates for long-term storage. Each of the process intermediates are subject to short-term storage and have been evaluated for both physicochemical stability and microbiological control.

The microbiological  testing strategy, consisting of bioburden  and endotoxins testing, sufficiently supports the manufacturing process and hold times.

## Process validation

The lebrikizumab active substance manufacturing process has been validated adequately. Consistency in  production has  been shown on  three full  scale commercial batches. All acceptance criteria for the critical  operational  parameters and  likewise acceptance  criteria  for  the  in-process  tests  are fulfilled demonstrating that  the manufacturing process consistently produces lebrikizumab active substance of reproducible  quality  that  complies  with  the  predetermined  specification  and  in-process  acceptance criteria. Shipping qualification studies were completed to verify that the lebrikizumab active substance can be transported from the active substance manufacturing site to the finished product manufacturing site, with no adverse impact on the product.

An  extractable  and  leachable  risk  assessment  regarding  all  contact  materials  used  during  the manufacturing process of active substance was provided.

## Manufacturing process development

In course of development, changes were introduced to the active substance manufacturing process. The Applicant provided comparability studies  which showed similarity between the  material manufactured

<div style=\"page-break-after: always\"></div>

across the used processes. CQA-based risk assessment was performed in order to establish the control strategy.  Multiple  studies  were  performed  to  understand  the  relationship  between  CQAs  and  the manufacturing process. Results of process characterisation and risk assessment studies were provided for each manufacturing step.

## Characterisation

Characterisation  results  include  determination  of  structure  (primary,  secondary,  and  higher-order structure), oligosaccharide  structure (glycosylation  site, oligosaccharide  profiling and  structural identification, sialic acid content), sulfhydryl groups and disulfide structure, isoform pattern and charge variants, isoelectric point, extinction coefficient, electrophoretic patterns, size variants, thermal stability, biological mechanism and immunological characterisation.

The primary structure of lebrikizumab including intact  antibody and light and heavy chain structure is considered adequately determined using several techniques and confirm the expected sequence.

Various techniques were used to determine the N- and C-terminal sequences of the LC and HC.

The oligosaccharide structure was studied and the oligosaccharide profiling was considered sufficient.

Charge and  size variants were analysed with  variety of techniques and considered sufficient to cover different forms of charged and size variant versions.

Biological activity is characterised and controlled by a cell-based assay which  measures the ability  of lebrikizumab to bind to IL-13.

Fc effector  functions studied demonstrated that no Fcγ receptor  binding or C1q binding is detected. Thus, no ADCC or CDC activity is expected.

Product-related  impurities/substances  as  well  as  process-related  impurities  have  been  identified. Impurities are characterised at sufficient level.

Control of mycoplasma and adventitious viruses are assessed.

Overall, the performed characterisation studies including identification of the impurities are considered relevant and cover a wide variety of physicochemical and biological characterisation studies.

## 2.4.2.3. Specification

The specifications for lebrikizumab active substance are based on the  quality of lebrikizumab used in toxicological  and  clinical  testing,  the  potential  risk  of  the  CQAs  to  the  patient,  the  stability  of lebrikizumab, the variability of the analytical methods, and ICH guidelines. The proposed release tests cover appearance, identity, quantity, purity/impurities, potency, general tests and microbial assurance. Overall, the set of quality attributes tested at release and at shelf-life can be considered acceptable.

## Analytical methods

The  analytical  methods  used  have been  adequately described. Non-compendial  methods  have  been appropriately validated in accordance with ICH guidelines.

Compendial analytical procedures were verified and confirmed suitable for their intended use according to the current Ph.Eur. requirements.

## Batch  analysis

Batch analysis data of the active substance were provided. The results are within  the specifications in place at the time of testing and confirm consistency of the manufacturing process.

<div style=\"page-break-after: always\"></div>

## Reference  materials

A  two-tiered  reference standard  (RS)  program for  lebrikizumab  is  in  use  which  includes  a  primary reference standard (PRS) and a secondary/working reference standard (WRS). Used analytical methods are the  same as those  used for active substance  or finished  product batch  release. The history and qualification of the reference standards used throughout development is described.

## Container closure

Two container closure systems are used for the storage of the active  substance: cryovessel  and  polymeric container. Sufficient results from extractable and leachables studies have been provided. However for the polymeric container, the on-going leachable studies continue to cover the proposed shelf-life of the active substance. The applicant is recommended to provide the results at the end of the shelf-life of the active substance when available (REC) .

## 2.4.2.4. Stability

Stability data are provided in support of a claimed shelf-life. The studies are conducted in accordance with the ICH Q5C and suitable study protocols are provided.

Data are provided for batches manufactured according to the commercial process and packaged in the two proposed container closure systems. All batches remained within specification over the course of the stability studies at the long term storage condition.

Accelerated and stress stability data was provided. In conclusion, the proposed drug substance shelf life is justified.

## 2.4.3. Finished Medicinal Product

## 2.4.3.1. Description of the product and pharmaceutical  development

Ebglyss,  or  lebrikizumab  injection,  250 mg/2 mL,  is  supplied  as  a  sterile,  non-pyrogenic  parenteral solution for subcutaneous administration. The finished product is contained in a 2.25 mL, Type I glass syringe barrel with a laminated bromobutyl elastomeric plunger. The container closure system filled with product is referred to as the semi-finished syringe (SFS). The SFS is assembled with device components to form one of two integral medicinal products, that is, either the pre-filled syringe with  needle safety device (PFS-NSD)  or the autoinjector  pre-filled pen (AI-PFP) presentation. The PFS-NSD  is  a needlebased injection system that enables the user to manually insert the needle and deliver the lebrikizumab finished  product.  The AI-PFP  is  a needle-based injection  system that,  when  activated,  automatically inserts the needle and delivers the lebrikizumab finished product.

All excipients (histidine, glacial acetic acid, sucrose, polysorbate 20, water for injections) are well known pharmaceutical ingredients and their quality is compliant with Ph. Eur. Standards. Excess  volume is filled into  each syringe to  enable delivery of 2  mL  in compliance with  United  States  Pharmacopoeia (USP) general chapter &lt;1151&gt; pharmaceutical dosage forms.

The primary packaging is a 2.25 mL Type-1 clear glass pre-filled syringe with small round flange, with a 27 gauge special thin wall x 12.7 mm stacked stainless steel needle, closed with a laminated bromobutyl elastomeric plunger and a rigid needle shield, to be assembled in a passive safety device, or a 2.25 mL Type-1 clear glass syringe in  an autoinjector  pre-filled pen with  extra-small round  flange, with  a 27 gauge special thin wall x 8 mm stacked stainless steel needle, and closed with a laminated bromobutyl elastomeric plunger and a rigid needle shield.

<div style=\"page-break-after: always\"></div>

The material complies with Ph. Eur. requirements. The container closure systems meet the applicable requirements of the standard International Organization for Standardization (ISO) 11040-4: 2015, Prefilled syringes - Part 4: Glass Barrels for Injectables. The choice of the container closure system has been validated by stability data and is adequate for the intended use of the product.

The finished presentations are medicinal products where the device part and the medicinal product form an integral product that is not reusable and where the action of the medicinal product is principal.

The SFS for PFS-NSD is assembled with commercially available syringe accessories to form the prefilled syringe with needle safety device (PFS-NSD).

The  container  closure studies  have included  analyses of  extractables and  leachables,  photostability, safety, compatibility and performance. The applicant provided a Notified Body Opinion for the PFS-NSD container closure and delivery device, in accordance with Article 117 of the Medical Device Regulation, confirming full compliance with the General Safety and Performance Requirements (GSPRs).

The  SFS for  AI-PFP is  assembled with  components  and subassemblies to  form an  autoinjector  (also referred to as Pre-filled Pen). The autoinjector is a needle-based injection system (NIS) with automated functions.  During  the  procedure, the  applicant  provided a Notified  Body Opinion  for  the autoinjector container closure and delivery device, in accordance with Article 117 of the Medical Device Regulation confirming full compliance with the relevant GSPRs, this to respond to a major objection (MO).

Both  presentations  (PFS-NSD  and  AI-PFP)  are  supported  by  extensive studies  for  protection,  light exposure, integrity  and  safety  of  container  closure  system  materials, sterilisation,  extractables and leachable  studies, compatibility, biocompatibility, usability, stability, needle and  needle  shield performance and shipping/transportation studies.

All  excipients are well  known  pharmaceutical ingredients  and their  quality  is  compliant  with  Ph.  Eur standards.  There  are  no  novel  excipients  used  in  the  finished  product  formulation.  The  selected formulation is further supported by formulation development studies.

Sufficient  process  characterisation  studies  were  performed  for  each  unit  operations  to  assess  the robustness of the finished product manufacturing process conducted at laboratory, pilot and commercial scales.

Compatibility of lebrikizumab bulk product with the SFS for PFS-NSD  and the SFS for AI-PFP has been demonstrated. Stability studies have been conducted to demonstrate product compatibility. A microbial hold  time  challenge  study  has  been  performed to  evaluate  the  impact  of  hold  times  on  microbial properties during active substance thaw and compounding. The provided data show that the hold times used for the proposed commercial process have no impact on microbial growth.

Based on the  provided data  the manufacturing  process development is  considered appropriately and sufficiently described.

## 2.4.3.2. Manufacture  of the product and process controls

Lebrikizumab product in SFS is manufactured and further assembled to PFS-NSD and AI-PFP.

Industrias  Farmacéuticas  Almirall, S.A.  Barcelona, Spain,  is  responsible  for final  EU  release. It  was confirmed that  all sites involved in manufacture and quality control of the finished product operate in accordance with EU GMP.

The manufacturing  process of the  finished product  consists of  the  following  steps: thawing  of  active substance, transfer of active substance into compounding vessel, mixing, bioburden reduction filtration, sterile filtration, filling and plunger insertion, visual inspection and assembly.

<div style=\"page-break-after: always\"></div>

The manufacturing process has been validated. It has been demonstrated that the manufacturing process is capable of producing the finished product of intended quality in a reproducible manner. The in-process controls  and  processing  time  limits  are  adequate.  The  process  validations  include  validation  of manufacturing  process steps for finished  product filled  into  2.25  mL syringes. Process validation  has included process design, process performance qualification, continued  process verification and quality system management of the control strategy.  Besides process validation also equipment  sterilisation, sterilising  filter  validation,  aseptic  process simulation  and  shipping  validation  were  performed.  The presented  data  demonstrate  that  the  manufacturing  process,  in-process,  and  product  controls  are appropriate to provide consistent finished product.

## 2.4.3.3. Product specification

The  release and  shelf  life  specifications  provided are  based  on  the  quality  of  lebrikizumab  used  in toxicological and clinical testing, the stability of lebrikizumab, the variability of the analytical methods used  to  analyse the  finished  product  and  ICH  guidelines.  These specifications  assure control  of  the finished product quality and device  functionality at release  and  during storage.  Parameters  tested  include appearance, quantity, identity, purity/impurities, potency and general tests including those required for a sterile product and device specific tests.

The specifications for the prefilled syringe with needle safety device (PFS-NSD) include appropriate tests for this type of delivery device.: appearance (visual inspection), extractable volume (Ph.Eur.), activation force (compression force) and functionality (visual inspection).

The  specifications  for  the  autoinjector  (AI-PFP)  include  appropriate  tests:  identity  (RP-HPLC),  dose accuracy (volume by weight), injection time (timing), visual/functional inspection (inspection).

## Analytical methods

The analytical methods used have been adequately described.  Non-compendial methods have been appropriately validated in accordance with ICH guidelines.

Compendial analytical procedures were verified and confirmed suitable for their intended use according to the current Ph.Eur. requirements.

## Characterisation  of impurities

The potential presence of elemental impurities in the finished product has been assessed on a riskbased approach in line with the ICH Q3D Guideline for Elemental Impurities. Studies comply with the expectations on ICH Guideline for Elemental Impurities Q3D. Based on the risk assessment, it can be concluded that it is not necessary to include any elemental impurity controls in the finished product specification. The information on the control of elemental impurities is satisfactory.

A risk evaluation concerning the presence of nitrosamine impurities in the finished product has been performed considering all suspected and actual root causes in line with the 'Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products' (EMA/409815/2020) and the 'Assessment report- Procedure under Article 5(3) of Regulation EC (No) 726/2004- Nitrosamine impurities in human medicinal products' (EMA/369136/2020).  Based on the information provided, it is accepted that no risk was identified on the possible presence of nitrosamine impurities in the active substance or the related finished product. Therefore, no additional control measures are deemed necessary.

<div style=\"page-break-after: always\"></div>

## Batch  analysis

Batch analysis data were provided for:

- Commercial scale batches of the semi-finished 2 mL SFS for PFS-NSD
- Assembled PFS-NSD process validation batches
- Commercial scale batches of the semi-finished 2 mL SFS for AI-PFP
- Assembled AI-PFP process validation batches

The results are within the specifications and confirm consistency of the manufacturing process.

In addition  to this,  batch analysis data for additional finished product  batches have been presented, corresponding to all lebrikizumab clinical batches made to date including active substance batches and their corresponding finished product batches. The results are within the specifications that were in place at the time of testing.

## Reference  materials

The reference standards for finished product are the same as used for active substance testing.

## Container closure system

Specifications,  drawings  with  dimensions  for  each  element  of  the  packaging  has  been  presented. Manufacturers of each component have been defined. The primary container closure components are received ready to use from the supplier.  The primary product container is a sterilised 2.25 mL Type I glass syringe, with a sterilised elastomeric plunger inserted after product filling. Sterilisation sites have been presented in the dossier.

The lebrikizumab semi-finished syringe (SFS) is  assembled with  syringe accessories, a needle safety device, a plunger rod and an add-on finger flange to form the pre-filled syringe  with needle  safety device (PFS-NSD).

The  lebrikizumab  semi-finished  syringe  (SFS)  is  assembled  with  the  autoinjector  components  and subassemblies to form the finished drug device combination product (AI-PFP).

The  materials  of  construction  for  each  syringe accessory are  described in  the  dossier.  The  syringe accessories are not sterilised and are not in contact with lebrikizumab product.

## 2.4.3.4. Stability of the product

A shelf life of 3 years is claimed for the PFS-NSD, and 2 years for the AI-PFP, when stored at 2-8°C in the original package in order to protected from light. After removal from the refrigerator, Ebglyss must be used within 7 days (when stored up to 30°C).

Stability data up to  36 months at  2-8°C are provided to support the proposed shelf-life. The stability studies were in general performed in accordance with ICH Q5C.

The  applicant  has  performed photostability  studies  which  demonstrated  that  the  finished  product  is sensitive to light exposure. Therefore, the finished product should be protected from light by secondary packaging.

The  primary  stability  data  and  supporting  stability  studies  at  long  term  and  accelerated conditions performed in accordance with ICH Q5C support a shelf-life of 36 months when stored at 2°C to 8°C for the PFS-NSD and a shelf-life of 24 months for the AI-PFP presentation when stored in the original carton protected from light at the long-term storage condition of 2°C to 8°C, with a patient use period of 7 days

<div style=\"page-break-after: always\"></div>

stored up to 30°C.   Studies supporting this  patient  use period was provided for PFS-NSD  and AI-PFP presentations.

## 2.4.3.5. Adventitious agents

Viral safety evaluation have been conducted in accordance with  ICH Q5A, as well as in other relevant guidelines. Appropriate testing has been conducted for cell banks and the unprocessed bulk harvest. The provided test results confirm the absence of adventitious agents in the cell banks. Viral clearance  studies were performed using qualified scale-down models. The overall combined log10 reduction values for the orthogonal reduction  unit  operations can  be considered satisfactory. The applicant's  assessment and conclusion  with  regard to  viral  safety can  be endorsed.  No  material  of animal  origin  is  used  in  the lebrikizumab manufacturing process and  based on  the  provided data the  TSE risk can be considered negligible.

## 2.4.4. Discussion on chemical, pharmaceutical and biological aspects

Information on development, manufacture and control of the active substance and finished product has been  presented  in  a  satisfactory manner.  The  results  of  tests  carried out  indicate  consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should  have a satisfactory and uniform performance in clinical use. During  the  procedure, in response to a Major Objection, the  applicant provided the notified body opinion for the AI-PFP, which confirms full compliance with the relevant GSPRs in Annex I of Regulation (EU) 2017/745.  Overall, the active substance has been extensively characterised using  state-of-art techniques.  The set of quality attributes tested at release and at shelf-life can be considered acceptable. The risk assessment related to the exposure of active substance to the light during its processing,  storage, and shipping was included in the dossier.

At the time of the CHMP opinion, there was a minor unresolved quality issue having no impact on the Benefit/Risk ratio of the product, which pertains to the need to provide results of leachable studies on polymeric container at the end of the shelf-life of the active substance when available. This point is put forward and agreed as recommendation for future quality development.

## 2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way. Data has been presented to give reassurance on viral/TSE safety.

## 2.4.6. Recommendation(s) for future quality development

In the context of the obligation of the MAHs to take due account of technical and scientific progress, the CHMP recommends the following point for investigation:

The applicant is recommended to provide results of leachables studies on the polymeric container at the end of the shelf-life of the active substance (24 months at NMT -65°C) to support the final conclusion on leachables characterisation.

<div style=\"page-break-after: always\"></div>

## 2.5. Non-clinical aspects

## 2.5.1. Introduction

The  non-clinical  programme for  lebrikizumab was  conducted  in  accordance with  the  ICH  guidelines S6(R1) and M3(R2). The pharmacology programme consisted of in vitro binding characterisation for IL13, and its blockade  of receptor  formation and signalling, and in vivo study in airway  inflammation model. No non-clinical efficacy  studies were conducted in non-human primates (NHP), as sole pharmacologically relevant  species.  Safety  pharmacology  endpoints  were  evaluated  in  repeat-dose  toxicity  studies. Pharmacokinetic (PK) and toxicokinetic (TK) program consisted of assessments of lebrikizumab following single intravenous (IV) and SC dosing in cynomolgus monkeys and assessment of formation of anti-drug antibodies (ADA; anti-lebrikizumab antibodies). Toxicology program consisted of single and repeat-dose toxicity studies, fertility and embryofetal  (EFD) development  and pre- and postnatal development  (PPND) studies in cynomolgus monkeys and ex vivo tissue cross-reactivity studies using cynomolgus monkey or human tissues. Carcinogenicity risk assessment was done by weight of evidence approach and no studies were conducted.

## 2.5.2. Pharmacology

## 2.5.2.1. Primary  pharmacodynamic  studies

The primary pharmacodynamic studies focused on in vitro IL-13  binding,  specificity and inhibition  of IL-13 -mediated signalling.

Lebrikizumab is an IgG4 isotype mAb with  modified Fc-region, which binds to  human IL-13 with  high affinity (31 pM) and neutralises the activity of IL-13. In addition to human IL-13, lebrikizumab binds to cynomolgus monkey IL13 (with KD &lt;0.67 pM), thus leaving NHPs as the sole  pharmacologically  relevant species. The accurate lebrikizumab binding affinity for cynomolgus monkey IL-13 could not be calculated due to slow off-rates being below the detection limits.

Lebrikizumab blocks the binding of IL-13 to IL-4R α preventing heterodimerisation of IL-13R α1/ IL-4R α, and thus inhibits the IL-13R α1/ IL-4R α STAT-dependent signalling pathway. Lebrikizumab does not block the binding of IL-13 to IL-13R α1 or IL-13R α2.

Lebrikizumab  inhibits  IL-13-induced  phosphorylation  of  STAT6,  the  primary  downstream  signalling mediator of the IL-13R α1/ IL-4R α receptor complex. Lebrikizumab inhibits IL-13-induced proliferation of Hodgkin lymphoma L-1236 and HDLM-2 cell lines in a dose-dependent manner.

Lebrikizumab is a IgG4 Mab with modified Fc, which has moderate binding affinity to Fc γ RI, low binding ability to Fc γ RIIIa, Fc γ RIIa and to C1q, and thus has a low effector function potential.

In an in vivo C57BL/6 mouse airway inflammation model, lebrikizumab reduced human IL-13-induced inflammatory reactions; reduced recruitment of inflammatory cells, eosinophils, IL-13R α2 expression in the lung and TGFβ1 levels in bronchoalveolar lavage fluid.

Serum IgE levels were measured retrospectively on the  serum samples collected in toxicology study from healthy female cynomolgus monkeys dosed weekly with 0.05,  1 or 25 mg/kg lebrikizumab IV for 9-months  (followed  by 8-month  recovery period). All animals  had detectable IgE  serum levels at all timepoints, but  levels  of  IgE  were  variable  between  animals.  In  lebrikizumab-treated  animals, approximately 25%-40% reduction of baseline corrected  serum IgE levels were recorded .  Maximum IgE reduction of 40% from pre-dose baseline levels was observed in the 25 mg/kg dose group on Day 29.

<div style=\"page-break-after: always\"></div>

Collectively, the pharmacology data support that  lebrikizumab is selective for IL-13, to which it binds with high affinity to block the formation of the IL-13R α1/ IL-4R α receptor complex and thereby inhibits IL-13-induced phosphorylation of STAT6 and downstream signalling.

## 2.5.2.2. Secondary  pharmacodynamic  studies

No secondary pharmacodynamic studies were conducted.

## 2.5.2.3. Safety pharmacology programme

Safety pharmacology endpoints  were incorporated  within  general repeat-dose toxicity  and  pre- and postnatal development and fertility studies of lebrikizumab in cynomolgus monkeys. Measurements were performed in compliance with ICH S6(R1) and S7A guidelines and according to GLP regulations. There were  no  indications  of  cardiovascular, respiratory, and  central  nervous  system  effects  attributed  to lebrikizumab in the toxicity studies. In addition, in vitro hERG ion channel current study was conducted, in which lebrikizumab induced no hERG inhibition at up to maximum concentration 6.0 mg/mL.

## 2.5.2.4. Pharmacodynamic  drug interactions

No secondary pharmacodynamic drug interaction studies were conducted.

## 2.5.3. Pharmacokinetics

The single-dose pharmacokinetics (PK) of lebrikizumab was evaluated in rats and cynomolgus monkeys, and  the  repeat-dose  toxicokinetics  (TK)  of  lebrikizumab  was  evaluated  in  monkeys.  In  rats,  PK parameters were evaluated after single SC administration of lebrikizumab derived from either Chinese hamster ovary (CHO) or murine myeloma (NS0) cells lines, and in cynomolgus monkeys after singe IV or repeated SC administration. TK was evaluated in monkeys as part of the repeat-dose toxicity studies after either IV or SC administration.

## Methods of analysis

For  the  quantification  of  free lebrikizumab (TNX-650)  or  anti-TNX-650  antibodies  in  the  cynomolgus monkey serum, an ELISA was used. The validation reports demonstrate that the assays were sensitive, selective and suitable for assessing the selected endpoints.

For assays S-1040 and S-1042 , the FDA assay  criteria  were used. EU acceptance  criteria (&lt;15% or 20%) are stricter than the FDA criteria (&lt;25%). Therefore, the EU criteria are not necessarily met. However, this is not considered as an issue in this data set.

## Absorption

Single-dose  PK  studies  were  performed  in  male  Sprague  Dawley  rats  with  5 mg/kg  SC  dose  of lebrikizumab and in cynomolgus monkeys with  1, 10 and 100 mg/kg IV dose of lebrikizumab. After a single IV administration, the Cmax  increased  in a dose-proportional  manner over the 100-fold dose range. The AUC0-inf was dose proportional over the 1 to 10 mg/kg dose levels but less than dose proportional at the  100 mg/kg.  Clearance rates  and  volume  of  distribution  were  low  (2.12  to  4.93 mL/day/kg and 59.0-85.0, respectively) and T1/2 9-25 days.

Repeat-dose TK studies were performed in male and female cynomolgus monkeys (weekly IV bolus or SC administration). The serum concentrations of lebrikizumab were analysed in the 6-week, 13-week and  9-month  general toxicity  studies  and  the  serum peak concentrations  and  AUC  values from  the

<div style=\"page-break-after: always\"></div>

13-week male fertility and 9-month female fertility studies. The dose levels 0.95 - 25 mg/kg bw were used in IV studies and 5-25 mg/kg in SC studies. With once weekly IV dosing, serum concentrations of lebrikizumab  were  dose-proportional  and  accumulation  was  low  to  moderate  (about  4-fold).  The clearance rates and volume of distribution were similar to the values collected from single-dose toxicity study. No sex differences were recorded. The TK data collected after SC administration was in line with the IV administration data. In the repeat-dose IV studies, treatment-emergent ADA were demonstrated in 2 monkeys (one at 1 mg/kg and one at 5 mg/kg dosing), and these animals were excluded from the analysis.

The  TK data  collected  from  IV  administration  DART-study  with  cynomolgus  monkeys  showed approximately  1.5-fold  accumulation  of  lebrikizumab  after  repeated  administration  and  T1/2 of approximately 19 days. 13 of 30 monkeys demonstrated treatment-emergent ADA (6 in the 0.05 mg/kg, 1 in the 1 mg/kg and 6 in the 25 mg/kg group). TK parameters were not estimated for 4/6 ADA-positive monkeys in  the  0.05 mg/kg  group  due  to  the  sample  concentrations  less than  the  LLOQ.  The data collected from SC administration male fertility study showed was comparative to the DART-study with female monkeys. One monkey in the high dose group demonstrated treatment-emergent ADA.

Serum TK of lebrikizumab was investigated in pregnant cynomolgus monkeys (SC administration once weekly; 15-150 mg/kg). Samples were collected from dams and fetuses. Dose proportional exposure as well as Cmax and AUC was observed in all groups. The mean fetal exposure was approximately 0.3. Seven monkeys demonstrated treatment-emergent anti-lebrikizumab antibodies and were excluded from the analysis. The offspring with detectable ADAs corresponded to dams with ADAs.

No bioavailability studies were conducted.

The type and extent of exposure data and TK parameters varied between toxicology studies and therefore the comparison of the results from different studies is challenging. However, taking the data together, the observed results are in line and no TK differences between sex nor in fertility/DART  studies were recorded.

ADA  were  observed  in  some  of  the  studies  with  no  clear  association  with  sex  or  lebrikizumab concentration or administration  route. The presence of ADAs did not seem to  neutralise the effects of lebrikizumab; however, the neutralizing ADA  assay was not performed to further investigate of ADAs had  an  effect  to  the  efficacy  of  lebrikizumab  as  described  in EMA  Guideline  on  immunogenicity assessment of monoclonal antibodies intended for in-vivo clinical use (EMA/CHMP/BMWP/86289/ 2010) . The Applicant has provided data on effects of chronic administration of lebrikizumab on serum total IgE from Study 07-1706 to demonstrate sustained activity, however, given the uncertainties with the data, it can be considered only as supporting information.

## Distribution

Formal tissue distribution and protein binding studies were not conducted with lebrikizumab.

## Metabolism and excretion

No  metabolism  and  excretion  studies  were  conducted  with  lebrikizumab.  No  renal  excretion  of lebrikizumab is anticipated due to its molecular size.

## Pharmacokinetic drug-interactions

Drug-drug interactions at the PK level are unlikely for biotechnology-derived substances as they do not metabolise via CYP P450 enzymes. It should  be noted  that  the mechanism of action  of lebrikizumab (cytokine secretion) may have an indirect effect on CYP450 activities.

The  absence  of  these  studies  in  animals  is  accepted,  however,  the  pharmacokinetic  drug-drug interactions (DDI) are assessed in the clinical AR.

<div style=\"page-break-after: always\"></div>

## Other Pharmacokinetic Studies

No other pharmacokinetic studies were conducted.

## 2.5.4. Toxicology

The toxicology program of lebrikizumab generally follows the principles given in ICH guideline S6 (R1) and ICH M3 (R2). Lebrikizumab binds only to human and cynomolgus monkey IL-13 target, thus leaving NHPs as a sole pharmacological relevant species to be used in toxicity testing.

Toxicology studies in cynomolgus monkeys were conducted using either CHO-cell-derived toxicology lots that  were  characterised using  contemporary analytical  methods  (13-week  male  fertility  and  PPND), similar to CHO  cell-derived clinical and commercial lots  or using NS0  cell-derived toxicology lots  that were characterised using older methods.

## 2.5.4.1. Single dose toxicity

There were no biological or toxicological differences between the individual animals and their pre-dose values. There were no apparent test  article-related effects on measured clinical pathology parameters due to a single intravenous  dose of lebrikizumab  in cynomolgus  monkeys.  The highest IV dose  100 mg/kg was the maximal non-lethal dose.

## 2.5.4.2. Repeat dose toxicity

GLP-compliant repeat-dose studies of 6 weeks, 13 weeks and 9 months in duration were conducted in cynomolgus monkeys to evaluate the toxicity and  TK of lebrikizumab. Monkeys of different ages and maturity (1 to 4.5 years)  were used, and IV  and SC routes of administration were evaluated. The highest dose across these studies was 25 mg/kg administered once weekly by bolus IV or SC injection and was both well tolerated and without adverse findings. There were no remarkable changes in peripheral blood immunophenotype (total  lymphocytes, mature T  cells,  helper T  cells, cytotoxic  T cells,  total  B  cells, NK cells, monocytes). At the  9-month necropsy, absolute and relative uterine weights were uniformly lower for lebrikizumab dose groups compared with  the  control group. No  abnormalities of the uterus were noted microscopically at  either the  3-  or 9-month  necropsy. There were no such  differences in uterine weights in a subsequent 9-month IV administration study in mature female monkeys suggesting contribution of variability in relative sexual maturity to observed difference in uterine weights.

## 2.5.4.3. Genotoxicity

In accordance with ICH S6(R1) no genotoxicity studies were conducted with lebrikizumab.

## 2.5.4.4. Carcinogenicity

Carcinogenicity studies with lebrikizumab were not conducted. The Applicant used weight-of-evidence based approach to assess the carcinogenicity risk of lebrikizumab. The structural and metabolic features of the mAb do not suggest potential for carcinogenicity. In repeat-dose toxicity studies in monkeys no evidence of carcinogenicity was observed. The totality of nonclinical and clinical evidence including other IL-13 inhibitors used for AD treatment does not suggest carcinogenicity risk of this group of compounds.

<div style=\"page-break-after: always\"></div>

## 2.5.4.5. Reproductive  and developmental toxicity

## Fertility and early embryonic development

The  main  purpose  of  the  male  fertility  study  was  to  investigate  the  effects  of  lebrikizumab  on spermatogenesis and fertility endpoints in sexually mature male monkeys during 13 weeks of dosing. This treatment period was sufficient to cover  at least 1 full spermatogenic  cycle including transit of sperm through  the  epididymis.  Monkeys were 4  to  7 years of age  at  study  start,  and sexual maturity  was confirmed by sperm evaluation. No effects on male reproductive endpoints were observed. Besides signs of reaction to injection in some animals there were no effects in several general toxicity endpoints that could be attributed to lebrikizumab. No ADA with effect on lebrikizumab exposure were observed.

The purpose of the female fertility study  was to investigate the  effects of lebrikizumab on menstrual cycling and related fertility  endpoints in sexually mature female monkeys during 9 months of dosing. Monkeys were 4.8 to 9.3 years of age at study start, and sexual maturity was confirmed by evidence of menses  and  ovulation,  assessed  by  vaginal  swabs,  and  reproductive  hormone  cycling  within  the 4 months  prior  to  dosing.  No  toxicity  and no  clear treatment-related  effects on  female reproductive endpoints  were observed. One high  dose group monkey developed serum polyclonal gammopathy of uncertain relationship to lebrikizumab. A subset of monkeys had microscopic tissue cysts present in the uterus, cervix,  parathyroid, thyroid and/or thymus for which a possible  relationship to lebrikizumab  could not  be excluded. None of the findings  were considered adverse as such cysts do not result in clinical signs or other detectable abnormalities when they occur incidentally in the cynomolgus monkey. Cysts in other affected glands occurred either in lebrikizumab-treated animals only (parathyroid, thymus) or at a higher incidence compared with control animals (thyroid). At the end of the treatment-free period, thymic cysts were present with increased incidence in animals given lebrikizumab, while parathyroid and thyroid  cysts  were  present  in  control  and  lebrikizumab-treated  animals  in  a  pattern  suggesting  an incidental effect.

## Embryo-fetal development

The purpose of the embryo-fetal development study was to assess the potential effects of lebrikizumab on  embryo-fetal  development when  administered to  pregnant  cynomolgus  monkeys throughout  the period of major organogenesis. Evaluated maternal parameters included serum chorionic gonadotrophic to confirm pregnancy, monitoring  of pregnancy status by ultrasound, clinical chemistry, haematology, urinalysis,  toxicokinetics  and  immunogenicity.  Cesarean  (C-)  sections  were  performed  on  GD  100. Placental  and  fetal  body  weights  and  measurements were  recorded. Fetuses  underwent  a  standard teratological evaluation consisting of external, organ/visceral, and skeletal examinations, which included organ weights  and long bone measurements. Lebrikizumab concentration in fetal cord blood was also measured. There was no maternal toxicity and no evidence of embryo-fetal toxicity or teratogenicity. Seven monkeys across the lebrikizumab treatment groups were ADA positive; however, only 2 animals, 1 in each of the low and high dose groups, had reduced serum concentrations consequently.

## Prenatal and postnatal development, including maternal function

The purpose of the prenatal and postnatal study was to assess the potential effects of lebrikizumab on pre- and postnatal development in cynomolgus monkeys. Lebrikizumab was administered to pregnant animals throughout gestation and their infant offspring were evaluated through approximately 6 months of age. Throughout gestation, ultrasound was used to monitor pregnancy status, including fetal viability and growth.  Evaluated maternal parameters also included clinical chemistry, haematology, urinalysis, serum  concentrations  of  lebrikizumab,  and  immunogenicity  throughout  gestation  and  through  to Lactation Day (LD) 180. Infants were evaluated from birth through Postnatal Day (PND) 180. In addition to  general health,  infants  were evaluated for growth,  morphological, functional,  and neurobehavioral development. Evaluated infant parameters also included skeletal examinations on PND7, immunological

<div style=\"page-break-after: always\"></div>

evaluations  on  PNDs  70  and  180,  clinical  chemistry  and  haematology,  serum  concentrations  of lebrikizumab and immunogenicity, and ECGs. The overall rate of embryo-fetal loss, including abortions, embryo-fetal death, and stillbirths  (18.75%  [3/16],  12.5% [2/16],  and 6.25%  [1/16]  in control, low, and high dose groups, respectively) was within  the historical background information and rate for this species and at the Testing Facility. Among surviving infants, there were no treatment-related changes in physical or functional development parameters. there were no immune system changes, as evaluated by immunophenotype and T-cell-dependent antibody  responses. At  the  terminal necropsy of infants, there were no gross findings  and no organ weight,  morphometric measurement, external, visceral or histopathology observations that were considered related to lebrikizumab.

## 2.5.4.6. Toxicokinetic  data

Lebrikizumab produced variable incidences of treatment-emergent ADA across studies; presence of ADA was associated with  reduced serum concentrations of lebrikizumab in some animals. Throughout  the 6-week study, serum trough concentrations of lebrikizumab showed that exposure increased in a doseproportional manner and accumulated about 4-fold across dose levels. Several animals had low levels of ADA with no appreciable impact on exposure. In a 9-month  study one monkey in each of the low and mid dose groups had a positive ADA titre  that  impacted their  serum lebrikizumab concentrations and AUC could not be determined for any dose. In 13-week study no lebrikizumab-treated monkey had a positive ADA titre. However, no AUC could be determined for male or female monkeys at dose levels of 5 and 25 mg/kg.

## 2.5.4.7. Local tolerance

Injection-site reactions were generally not observed across the lebrikizumab toxicology studies dosed either IV or SC. In the male fertility study, one high dose (25 mg/kg) group monkey had swelling in the area of SC dose administration for the majority of the dosing phase and a reaction to the injection could not be excluded. This clinical observation did not worsen with repeated dosing and was not associated with  a  histological  correlate.  Using  modified  Draize  scoring  and  microscopic  evaluation  no  dermal irritation was observed.

## 2.5.4.8. Other  toxicity studies

## Antigenicity

The repeat-dose general toxicity studies, fertility studies, EFD  and PPND studies each contained direct immunogenicity assessment. Validated ELISA methods were used for measuring anti-drug antibodies to lebrikizumab.  Immunogenicity  was  also  indirectly  assessed  via  analysis  of  lebrikizumab  serum concentrations using an antigen-capture ELISA.

## Immunotoxicity

Potential effects of lebrikizumab on the innate and humoral immune systems were evaluated in repeatdose studies in monkeys by means of routine haematology, peripheral blood immunophenotyping (total lymphocytes, mature T cells, helper T cells, cytotoxic T cells, total  B cells, NK  cells, monocytes) and evaluation of  lymphoid organs.  There were no  treatment-related  adverse effects identified  for these endpoints  in  any  study.  T-cell-dependent  antibody  (IgG  and  IgM)  response  to  Keyhole  limpet haemocyanin (KLH) immunisation  was performed at about  6 months of age in  the infant  offspring of lebrikizumab-treated monkeys. No  statistically  significant  differences were noted  in  response to  KLH between the control group and lebrikizumab groups.

<div style=\"page-break-after: always\"></div>

## Studies on impurities

Toxicology studies were conducted using either CHO cell-derived toxicology lots that were characterised using contemporary analytical methods (male fertility; PPND) or using NS0 cell-derived toxicology lots that  were characterised using older methods. Despite  the  differences in material source (NS0 versus CHO) and differences in  analytical methods  purity  and  impurity  levels were generally similar across toxicology lots. The potential toxicity of lebrikizumab impurities was evaluated repeat-dose toxicology studies  in  cynomolgus  monkeys. Specifications were justified  to  be acceptable  by providing  &gt;1 -fold margins of safety based on exposure at the NOAEL  in repeat-dose toxicity studies compared with the exposure to  maximal theoretical  levels of impurities  at  the  recommended clinical  dose regimen and widest DS/DP specifications.

Exposure margins were calculated based Cmax and Cav,ss values at NOAEL  (25 mg/kg IV QW) from 9-month chronic toxicity study and 9-month female fertility study. Exposure  data from  the female  fertility study were used for exposure multiples given limited toxicokinetic data from the chronic toxicity study. Exposure multiples, which were based on the most conservative % impurity in toxicology study batches and the widest  specifications across DS  and DP identified,  were calculated separately for purity, total HMWS, reduced purity,  non-reduced purity,  and  total  LMWS.  In all cases, exposure multiples,  based either on Cmax or Cav,ss, provided enough wide safety margins compared with the exposure to maximal theoretical levels of impurities at the recommended clinical dose regimen.

## 2.5.4.9  Other  studies

## Ex Vivo Tissue Cross-Reactivity

The tissue binding  specificity of lebrikizumab was evaluated in a comprehensive panel of human and cynomolgus  monkey tissues  in  separate  studies.  Lebrikizumab  was  applied  to  tissue  cryosections (3 human and 2 monkey donors/tissue, donors/tissue, where available) at concentrations of 5 µg/mL (optimal concentration) or 40 µg/mL,  based on prior method development. Lebrikizumab binding was assessed immunohistochemically  using  biotinylated  lebrikizumab  and  a  direct  avidin-biotin  complex immunoperoxidase staining procedure. No specific lebrikizumab staining was observed in any human or cynomolgus monkey tissues.

## 2.5.5. Ecotoxicity/environmental risk assessment

Lebrikizumab is a monoclonal antibody and it is classified as a protein. According to the 'Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use' (EMEA/CHMP/SWP/4447/00corr 2), proteins are included in products that are exempted from ERA. Due to its proteic nature and according to the abovementioned criteria of the EMA guideline, lebrikizumab is unlikely to  result in  a significant  risk to  the  environment. Therefore, ecotoxicological studies are not required for lebrikizumab.

## 2.5.6. Discussion on non-clinical aspects

## Pharmacology

## Pharmacodynamics

The  nonclinical  pharmacology  program  of  lebrikizumab  is  condensed  but  is  considered  adequate demonstrating the binding specificity to target IL-13 and principal mode of action. Lebrikizumab binds only to  human and cynomolgus monkey IL-13  target, thus  leaving NHPs  as a sole pharmacologically

<div style=\"page-break-after: always\"></div>

relevant  species.  No surrogates  were  developed  and used  in lebrikizumab  nonclinical studies. The batches (PUR25081, PUR15846, 3D9-1) used in the primary pharmacology studies could not be tracked and this required further clarification. Upon CHMP's  request, the applicant clarified, that  batches were by large from small scale preclinical research batches (from one batch used in Studies S-1043  and S-1044, no information  was  trackable).  The  batches  used  in  toxicology  studies  were  trackable  and  not  the development batches used in PD studies.  Considering that  the efficacy is demonstrated in the clinical trials, this issue is not pursued further by the CHMP.

In vitro studies show  that lebrikizumab inhibits  IL-13-induced phosphorylation of STAT6, the primary downstream signalling  mediator of the  IL-13R α1/ IL-4R α receptor complex and  inhibits  IL-13-induced proliferation of Hodgkin lymphoma L-1236 and HDLM-2  cell lines in a dose-dependent manner. In these assays, lebrikizumab (10 ng/mL) clearly inhibited the IL-13 -induced proliferation of TF-1 cells, but the inhibition  of IL-13-induced  phosphorylation of STAT6 (the primary downstream signalling  mediator of the  IL-13R α1/ IL-4R α receptor  complex)  was  barely  noticeable.  However,  the  inhibition  of  primary downstream signalling  of IL-13 was  shown under the  Quality data, where STAT6 signalling  reflecting luciferase activity is used as a potency assay and is not pursued further from a non-clinical viewpoint. In  conclusion,  lebrikizumab  binds  with  high  affinity  to  soluble  interleukin  IL-13  and  inhibits  IL-13 signalling through the IL-4 receptor alpha (IL-4R α)/ IL-13 receptor alpha 1 (IL-13R α1) pathway, thereby preventing the downstream effects of IL-13 with high selectivity.

Lebrikizumab  is  a  IgG4  Mab  with  modified  Fc,  which  has  low  binding  ability  to  Fc γ receptors  or components of the complement system and thus has a low effector function potential. No  description was provided under the  nonclinical pharmacodynamics regarding the  Fc-modification, and  no studies was included that characterise Fc-functions (or lack  of them, being a IgG4). However,  these studies were included under Quality module and demonstrated minimal binding  affinity to  Fc γ RIIIa, Fc γ RIIa and to C1q, and moderate binding affinity to Fc γ RI. No secondary pharmacodynamic studies were conducted, which is acceptable for a monoclonal antibody.

The only in vivo functionality  study was conducted in C57BL/6 mouse airway inflammation model. No disease  specific  animal  models  for  AD  were  used  to  verify in  vivo functionality  of  lebrikizumab. Nevertheless, this  issue is not pursued further as the AD and airway inflammation model share some similarities regarding the  IL-13  / STAT6 signalling  routes, and lack of binding  to  rodent target  limits further the studies in rodents. In addition, serum IgE levels  were measured retrospectively  on the serum samples collected in toxicology study from healthy female cynomolgus monkeys dosed weekly with 0.05, 1 or 25 mg/kg lebrigizumab IV for 9-months  (followed by 8-month recovery period). In lebrikizumabtreated  animals,  approximately 25%-40%  reduction  of  baseline corrected  serum IgE  levels were recorded, with  the  greatest  reduction  noted  at  D29.  Nevertheless,  considering  that  the  study  was conducted in healthy animals whose baseline IgE levels are expected to be low and large inter-animal variation in IgE levels throughout the study, the clinical relevance and the translation of these findings to AD cannot be confirmed, however these data can be considered supportive.

## Safety Pharmacology

There were no safety findings in CNS, respiratory and cardiovascular  systems  attributed to lebrikizumab.

## Pharmacokinetics

The PK/TK program performed with lebrikizumab in Sprague Dawley rats and cynomolgus monkeys was considered  acceptable  demonstrating  the  absorption  the  lebrikizumab after  single  and  repeat  dose exposure. The bioanalytical method is considered to be adequate for the measurement of lebrikizumab from the  serum  of cynomolgus monkeys in  PK and  TK  studies.  The ELISA  and ECLA  assays for the measurement of anti-IL-13  antibodies from the serum of cynomolgus monkeys are acceptable. In line with ICH S6, no distribution, metabolism or excretion was studied. For assays S-1040 and S-1042, the

<div style=\"page-break-after: always\"></div>

FDA assay criteria were used. EU acceptance criteria (&lt;15% or 20%) are stricter than the FDA criteria (&lt;25%). Therefore, the EU criteria are not necessarily met. However, this is not considered as an issue in this data set. The absence of other pharmacokinetic studies is accepted.

## Toxicology

The  Applicant  states  that  the  commonly  used  rodent  species  (mouse,  rat)  were  not  used  since lebrikizumab does not bind to rat or mouse IL-13. However, no information about binding to non-rodent species such as the dog or  pig IL-13 was given.  It is understood that the nonclinical development  program of lebrikizumab for the  present MAA for AD  was coordinated by the  previous Sponsor for a  different indication. However, considering the possible option to develop lebrikizumab for other indications in the future it is expected that the Applicant has studied these alternative species to assess replacement of monkeys in spirit of 3R principles.

The acute toxicity of lebrikizumab is low. There were  no apparent  test article-related effects  on measured clinical pathology parameters due to a single intravenous dose of lebrikizumab in cynomolgus monkeys. The highest IV dose 100 mg/kg was the maximal non-lethal dose.

GLP-compliant repeat-dose studies of 6 weeks, 13 weeks and 9 months in duration were conducted in cynomolgus monkeys to evaluate the toxicity and  TK of lebrikizumab. Monkeys of different ages and maturity (1 to 4.5 years)  were used, and IV  and SC routes of administration were evaluated. The highest dose across these studies was 25 mg/kg administered once weekly by bolus IV or SC injection and was both well tolerated and without adverse findings.

In humans, ocular disorders such as conjunctivitis and keratitis are quite frequently reported as adverse reactions with of IL-13 inhibitors including lebrikizumab. Conjunctivitis and keratitis were reported more frequently in patients treated with lebrikizumab (8.5 % and 0.6% respectively) compared to placebo in controlled clinical studies. Ophthalmological examinations  did not suggest any  ocular effects in long-term repeat-dose toxicity  studies  in  healthy  cynomolgus  monkeys. Differences  in  conjunctivitis  incidence across the different allergic diseases suggests that AD patients are predisposed to an increase in ocular disorders. In fact, these types of complications are well known in patients with  severe AD (Akinlade et al. 2019). Long-term toxicity studies were conducted in healthy cynomolgus monkeys, which would have lacked this  predisposition for ocular disorders. This aligns  with  the  data  that  ocular effects were not observed in monkeys administered lebrikizumab.

No consistent haematological findings, no alteration (reduction or increase) in lymphocyte subsets, and no histopathologic  changes in  lymphoid organs could  clearly be  seen across the  repeat-dose toxicity studies. However, some haematological parameters' changes (neutrophil increase, lymphocyte decrease) reached statistical significance following lebrikizumab treatment in males of 13-week (2.4-3.4 y old) and 9-month (2.5-4.5 y old) toxicity study, while no differences were seen in young males (1-2 y old) of the 6-week study  and  sexually mature monkeys  (4-7 y  old)  in  male  fertility  study.  On  the  other  hand, monocyte count and/or ratio was shown to be decreased on several occasions in dams of EFD and PPND study.  It  is  well  known  that  immune  system  function  is  age-  and  sex-  dependent.  While  the  e.g. immunophenotyping data for the offspring showed comparable means and standard deviations, the data for older animals were much more variable. The Applicant considered occasional numerical differences in  haematology  parameters,  including  some  that  were  statistically  significant,  sporadic/incidental, transient, and/or of a magnitude of change that is commonly observed in laboratory-housed monkeys undergoing  similar study  procedures. These differences were  considered not  related to  lebrikizumab treatment and not related to the age or gender of animals. Where differences were identified during the dosing phase of studies, they were inconsistent across  the studies conducted, often were present already at pretest, did not achieve statistical significance at all time points included in a study, and were typically small  changes  and/or  within  laboratory historical  control  ranges. On  the  other  hand,  regarding  the immunophenotyping data in offspring vs. in older animals, it is acknowledged that the variability may be

<div style=\"page-break-after: always\"></div>

attributed to the age  and sex  differences  as well as the differences  in the physiology of individual animals. It  can  be concluded  that  the  link between  lebrikizumab and  its  potential  effects on  immune-related endpoints in healthy animals may be complex to establish and may be complicated by the differences in the physiology of individual animals.

Although IL-13 functions in immune response, assessments of immunotoxicity and immunomodulation in monkeys administered lebrikizumab identified no remarkable or consistent changes, even if applied in the dose as high as 25 mg/kg/week (claimed to saturate circulating IL-13 levels) producing the exposure multiple of 17-20x when compared to human Cmax. The lebrikizumab toxicology studies were conducted using normal, healthy cynomolgus monkeys. Given the absence of disease, IL-13 is expected to be at low,  constitutive  levels and not  upregulated in  monkeys, which  is in  contrast  to the  diseased clinical population.  Nevertheless,  pharmacological  action  is  evident  by  the  effect  of  lebrikizumab  on  IgE pharmacodynamics in monkeys. It has been shown that autocrine IL-13 can drive IgE production from B cells and IL-13 receptor neutralisation can reduce IgE  levels. Although  IgE levels would have been lower in the normal monkey compared with a disease state-induced increase in IL-13, the site localised autocrine effect  of IL-13 on B  cells to drive IgE production would still have  been inhibited by lebrikizumab. The  Applicant  states  that  immunophenotype  and  TDAR  in  monkeys  have  proven  to  be  relatively insensitive  or  inconsistent  for demonstrating  desired pharmacology, whereas  these  immune  system endpoints were included in the toxicology studies to assess the potential for exaggerated pharmacology (gross effects)  that  could be  considered adverse, i.e.,  toxic.  It  is  agreed  that  despite  its  limitations monkey  is  the only  pharmacologically  relevant  model  to  characterise  the  potential  toxicity of lebrikizumab.

No genotoxicity studies were conducted with lebrikizumab which is acceptable. Carcinogenicity studies with  lebrikizumab were not  conducted. To support the lack of carcinogenicity risk for lebrikizumab the Lebrikizumab  Carcinogenicity  Risk  Assessment was  provided. The  totality  of  nonclinical  and  clinical evidence including other IL-13 inhibitors used for AD treatment does not suggest carcinogenicity risk of this group of compounds.

No significant findings were observed in reproductive and developmental toxicity studies in cynomolgus monkeys. In female fertility  study  a  subset  of monkeys had microscopic tissue  cysts  present in  the uterus, cervix,  parathyroid, thyroid and/or thymus for which a possible  relationship to lebrikizumab  could not  be excluded. Cysts in  other affected glands occurred either in  lebrikizumab-treated animals only (parathyroid, thymus) or at a higher incidence compared with control animals (thyroid). At the end of the  treatment-free  period,  thymic  cysts  were  present  with  increased  incidence  in  animals  given lebrikizumab,  while  parathyroid  and  thyroid  cysts  were  present  in  control  and  lebrikizumab-treated animals in a pattern suggesting an incidental effect. These cysts were interpreted as having an uncertain relationship with  test article because a) cysts in thymus are a well-documented and frequent common background incidental finding in cynomolgus monkeys, b) thymi of sexually mature monkeys undergo age-related thymic involution, a physiological  process  where  the thymus progressively  undergoes  various changes  including  loss  of  lymphocytes  and  presence  of  epithelial  remnants,  often  with  a  cystic appearance, c) the historical control data for cysts and involution in thymus in the age-matched control female and male cynomolgus monkeys from the conducting facility show that while the overall incidence of cysts in thymi in females and males are 3.89%  and 9.73%,  respectively, the individual studies can have incidences as high  as 50% and  80%,  respectively. Further,  when  combined with  the  finding  of thymic involution, which might encompass cystic changes, the overall combined incidence is 12.8% and 28.8%, with individual studies having incidences as high as 75% and 100%, respectively and d) Cysts in thymus were not present in the 9-month repeat dose toxicology study with 3-month interim sacrifice and the  13-week  repeat-dose toxicity  and local tolerability  study  in  both  sexes in  comparable doses groups that used sexually immature/peripubertal monkeys. Cysts in thymus were not considered adverse regardless of test article-relatedness because cysts in thymus did not result in clinical signs and/or other

<div style=\"page-break-after: always\"></div>

pathological changes or abnormalities that  adversely affected the quality of life of  these animals and because in  most tissues, occasional presence of cysts is not  considered adverse especially in thymus where there is little to no functional significance in adult animals.

Several deviations from ICH S6(R1) were noted in this procedure: the longest repeat dose toxicity study conducted with  monkeys was 9 months and also included 4 animals/sex/group. Increasing group sizes or  study  durations  is  not  required  and  will  generally not  generate more  informative  data  than  the standard 6 month 3/sex/group, control+3 design.

In addition, the applicant conducted fertility studies in males and females. A FEED study in NHP for mAbs is unusual and a rationale for this  study remains unclear, particularly since no untoward effects were noted in the pivotal RDT studies. An EFD  study is also unusual since IgG transfer is extremely limited in the  1st  and  2nd  trimester.  However,  retrospective  discussion  on  these  deviations  from  regulatory guidelines is not pursued.

In a 9-month study one monkey in each of the low and mid-dose groups had a positive ADA titre that impacted their serum lebrikizumab concentrations and AUC could not  be determined for any dose. In 13-week study no  lebrikizumab-treated monkey had a positive ADA  titre. However, no AUC could  be determined for male or female monkeys at dose levels of 5 and 25 mg/kg. The incidences of ADA positive responses were much higher in DART studies, when compared with general repeat-dose toxicity studies. The assay formats, ADA  positive criteria, and drug tolerance within  the  assays could account for the differences in  ADA  positive responses in  DART studies  compared to the  general repeat dose toxicity studies. Overall, lebrikizumab  exposures  were generally  dose-proportional in the various toxicity studies. While ADA analysis demonstrated a low to moderate rate of ADA detection, toxicokinetic determinations demonstrated continued exposure in most animals.

Validated ELISA methods were used for measuring anti-drug antibodies to lebrikizumab. Immunogenicity was also indirectly assessed via analysis of lebrikizumab serum concentrations using an antigen-capture ELISA.  The  applicant's  conclusion  that  in  most  cases  the  presence of  ADA  appeared not  to  impact lebrikizumab  exposure  in  monkeys  is  not  fully  endorsed.  However,  it  is  generally  accepted  that immunogenicity  of therapeutic  proteins  in  animals (NHPs  and  other  species) is not  predictive  of the immunogenicity in human.

Potential effects of lebrikizumab on the innate and humoral immune systems were evaluated in repeatdose studies in monkeys by means of routine haematology, peripheral blood immunophenotyping (total lymphocytes, mature T cells, helper T cells, cytotoxic T cells, total  B cells, NK  cells, monocytes) and evaluation of  lymphoid organs.  There were no  treatment-related  adverse effects identified  for these endpoints  in  any  study.  T-cell-dependent  antibody  (IgG  and  IgM)  response  to  keyhole  limpet haemocyanin (KLH)  immunisation  was performed at  about 6 months  of age in the  infant  offspring of lebrikizumab-treated monkeys. No  statistically  significant  differences were noted  in  response to  KLH between the control group and lebrikizumab groups.

Specifications of impurities in DS and DP are considered as toxicologically qualified.

No specific lebrikizumab staining was observed in any human or cynomolgus monkey tissues suggesting high specificity for IL-13.

The results of the toxicity studies are reflected in Section 5.3 of the SmPC 'Preclinical safety data'.

## Environmental risk assessment

The  active  substance  is  a  natural  substance,  the  use  of  which  will  not  alter  the  concentration  or distribution of the substance in the environment. Therefore, lebrikizumab is not expected to pose a risk to the environment.

<div style=\"page-break-after: always\"></div>

## 2.5.7. Conclusion on the non-clinical aspects

In conclusion, the applicant provided a comprehensive evaluation of pharmacologic, pharmacokinetic and toxicologic properties of lebrikizumab which supports the intended clinical use. Relevant information has been included in SmPC section 5.3.

## 2.6. Clinical aspects

## 2.6.1. Introduction

## GCP aspects

The clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the Community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular  overview of clinical studies

<div style=\"page-break-after: always\"></div>

Table 1: Efficacy and Safety Studies

<!-- image -->

| Study Identifier; Phase                     | Objective(s) of the Study                                                                                                                                                                         | Study Design and Type of Control                                                                                                                                       | Test Product(s); Dosage Regimen; Route of Administration                                                                                                                                                                                                                                                                                                                  | Number of Subjects                                                                                                                                                                                                                                                                    | Healthy Subjects or Diagnosis of Patients       | Durationof Treatment     | Study Status as of this report date; Type of Report   |
|---------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|--------------------------|-------------------------------------------------------|
| GS29735 (ARBAN)/ J2T-DM- KGAH; Phase 2;     | To evaluate the safety of lebrikizumab used as monotherapy compared with topical corticosteroids alone in patients with persistent moderate-to- severe ADthat is inadequately controlled with TCS | Randomised, open-label study of lebrikizumab monotherapy in adult patients (18-75 years of age) with persistent moderate- to-severe AD, inadequately controlledby TCS. | Lebrikizumab: 3 SC injections (3 doses of 125 mg/mL lebrikizumab, one Q4W) TCS: self- applied by patients during run-in period (Days -14 to -1) and treatment period (Day1 to Week 12): 2 times per dayto active skin lesions, and during safety follow-up period (Weeks 13 to 20): self- applied to active skin lesions as decided by the patient and study investigator | Randomised : 55 patients Lebrikizumab 125 mg Q4W: 28 patients TCS: 27 patients Completed: 43 patients Lebrikizumab 125 mg Q4W: 23 patients TCS: 20 patients                                                                                                                           | Patients with persistent moderate- to-severe AD | 12-week treatment period | Completed; Full CSR                                   |
| GS29250 (TREBLE)/ J2T-DM- KGAG a ; Phase 2; | To evaluate the efficacy of lebrikizumab used as adjunctive therapy with TCS, compared with TCS in patients with persistent moderate-to- severe AD                                                | Randomised, double-blind, placebo- controlled study of lebrikizumab in patients with persistent moderate- to-severeAD that is inadequately controlledby TCS.           | Group 1 : Lebrikizumab 250 mg SC single dose(Day 1) followed by 2 placebo doses (Weeks 4 and 8) for a total of 3 doses + TCS Group 2: lebrikizumab 125 mg SC single dose(Day 1) followed by 2 placebo doses                                                                                                                                                               | Randomised : 212 patients Lebrikizumab 250 mg single- dose group+TCS: 53 patients Lebrikizumab 125 mg single- dose group+TCS: 53 patients Lebrikizumab 125 mg Q4W group+TCS: 52 patients Placebo Q4W group+TCS: 54 patients Completed : 197 patients Lebrikizumab 250 mg single- dose | Patients with persistent moderate- to-severe AD | 12-week treatment period | Completed; Full CSR                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                                  |                                                                                                                                                                                                                |                                                                    | (Weeks 4 and 8) for a total of 3 doses + TCS Group 3 : lebrikizumab 125mgSC Q4W for a total of 3 doses + TCS Group 4 : placebo SCQ4W for a total of 3 doses + TCS                                                                                                                                                  | group+TCS: 53 patients Lebrikizumab 125 mg single- dose group+TCS: 49 patients Lebrikizumab 125 mg Q4W group+TCS: 48 patients Placebo Q4W group+TCS: 47 patients                                                                                                                                                                                                                                                                                                                                                                                                                           |                                      |                                                     |                     |
|--------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------|-----------------------------------------------------|---------------------|
| DRM06- AD01/ J2T-DM- KGAF; Phase 2b;             | • To evaluate the safety and efficacy of lebrikizumab compared with placebo in patients with moderate-to- severe AD. • To evaluate the dose- response of lebrikizumab in patients with moderate-to- severe AD. | Randomised, double-blind, placebo- controlled, dose-ranging trial. | Group 1 : Baseline loading dose of lebrikizumab 250 mg, followed by lebrikizumab 125 mg Q4W Group 2: Baseline loading dose of lebrikizumab 500 mg, followed by lebrikizumab 250 mg Q4W Group 3: Baseline and Week 2 loading doses of lebrikizumab 500 mg, followed by lebrikizumab 250 mg Q2W Group 4: Placebo Q2W | Randomised : 280 patients Lebrikizumab 125 mg Q4W (with a loading dose of 250 mg): 73 patients Lebrikizumab 250 mg Q4W (with a loading dose of 500 mg): 80 patients Lebrikizumab 250 mg Q2W (with a loading dose of 500mg given at baseline and Week 2): 75 patients Placebo Q2W: 52 patients Completed : 201 patients Lebrikizumab 125 mg Q4W (with a loading dose of 250 mg): 58 patients Lebrikizumab 250 mg Q4W (with a loading dose of 500 mg): 62 patients Lebrikizumab 250 mg Q2W (with a loading dose of 500mg given at baseline and Week 2): 58 patients Placebo Q2W: 23 patients | Patients with moderate- to-severe AD | 16-week treatment period                            | Completed; Full CSR |
| DRM06- AD04/ J2T-DM- KGAB (ADvocate 1); Phase 3; | To evaluate the safety and efficacy of lebrikizumab compared with placebo in adult and adolescent (≥12 to <18 years and weigh at least                                                                         | Randomised, double blind, placebo- controlled monotherapy trial.   | Induction Period: randomised 2:1 to: • Lebrikizumab: 500 mg lebrikizumab at baseline and Week 2 (loading dose; 2 PFS-                                                                                                                                                                                              | Enrolled: 424 patients Induction Period: • Lebrikizumab 250mg Q2W: 283 • Placebo:141                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Patients with moderate- to-severe AD | 16-week induction period 36-week maintenance period | Completed; Full CSR |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                                  | 40 kg) patients with moderate- to-severe AD.                                                                                                                                        |                                                                              | NSD)and 250 mg Q2W through Week 14 • Placebo: 4 mL (2 PFS-NSD) at baseline and Week 2 and 2 mL Q2W through Week 14 Maintenance Period: • randomised 2:2:1 to: Lebrikizumab 250 mg Q2W through Week 50 • Lebrikizumab 250mgQ4W: through Week 50 • Placebo Q2W Escape arm: lebrikizumab 250 mg as open-label treatment Q2W through Week 52                                                                                                                             | Enrolled: 445                                                                        |                                      |                                                     |                     |
|--------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|--------------------------------------|-----------------------------------------------------|---------------------|
| DRM06- AD05/ J2T-DM- KGAC (ADvocate 2); Phase 3; | To evaluate the safety and efficacy of lebrikizumab compared with placebo in adult and adolescent (≥12 to <18 years and weigh at least 40 kg) patients with moderate- to-severe AD. | Randomised, double blind, placebo- controlled monotherapy trial.             | Induction Period: randomised as 2:1 to: • Lebrikizumab: 500 mg lebrikizumab at baseline and Week 2 (loading dose; 2 PFS- NSD)and 250 mg Q2W through Week 14 • Placebo: 4 mL (2 PFS-NSD) at baseline and Week 2 and 2 mL Q2W through Week 14 Maintenance Period: • randomised 2:2:1 to: Lebrikizumab 250 mg Q2W through Week 50 • Lebrikizumab 250 mg Q4W through Week 50 • Placebo Q2W Escape arm: • lebrikizumab 250 mg as open-label treatment Q2W through Week 52 | patients Induction Period: • Lebrikizumab 250mg Q2W: 295 • Placebo:150               | Patients with moderate- to-severe AD | 16-week induction period 36-week maintenance period | Completed; Full CSR |
| DRM06- AD06/ J2T-DM- KGAD (ADhere); Phase 3;     | To evaluate the safety and efficacy of lebrikizumab when used in combination with TCS                                                                                               | Randomised, double blind, placebo- controlled TCS combination therapy trial. | Lebrikizumab 250 mg Q2W + TCS : 500 mg lebrikizumab administered at baseline and Week 2 (loading                                                                                                                                                                                                                                                                                                                                                                     | Randomised : 228 patients Lebrikizumab 250 mg Q2W: 145 patients Placebo: 66 patients | Patients with moderate- to-severe AD | 16-week treatment period                            | Completed; Full CSR |

<div style=\"page-break-after: always\"></div>

|                                                 | treatment compared with placebo, in adult and adolescent (12 to <18 years and weigh at least 40 kg) patients with moderate-to- severe AD.                                                                                                             |                                                                                       | dose) and 250 mg given Q2W through Week 14. TCS treatment was initiated at baseline and applied PRN. Placebo + TCS : 4 mL (2 PFS-NSD) administered at baseline and Week 2 and 2 mL given Q2W through Week 14. TCS treatment was initiated at baseline and applied PRN.      | Completed : 192 patients Lebrikizumab 250 mg Q2W: 134 patients Placebo: 58 patients                                                                          |                                                                                            |                                                     |                          |
|-------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|-----------------------------------------------------|--------------------------|
| DRM06- AD07/ J2T-DM- KGAA (ADjoin); Phase 3;    | To assess the long-term safety and efficacy of lebrikizumab in adult and adolescent (12 to <18 years and weigh at least 40 kg) patients with moderate-to- severe AD.                                                                                  | A long-term extension study                                                           | Two treatment regimens: 250 mg lebrikizumab, administered Q2W and 250 mg lebrikizumab, administered Q4W.                                                                                                                                                                    | Sample size is dependent on the number of patients who enter from a parent study (approximately 900 patients)+ approximately 100 patients from the addendum. | Patients with moderate- to-severe AD                                                       | 100 weeks                                           | Ongoing, Abbreviated CSR |
| DRM06- AD17/ J2T-DM- KGAE (ADore); Phase 3;     | To evaluate the safety and efficacy of lebrikizumab in adolescent patients (12 to <18 years and weigh at least 40 kg) with moderate-to- severe AD.                                                                                                    | Open-label, single-arm study                                                          | Lebrikizumab 250 mg Q2W : 500mg lebrikizumab administered at baseline and Week 2 (loading dose) and 250 mg given Q2W through Week 50                                                                                                                                        | Enrolled : 206 patients.                                                                                                                                     | Adolescent patients (12 to <18 years and weigh at least 40 kg) with moderate- to-severe AD | 52-week treatment period                            | Complete; Full CSR       |
| DRM06- AD18/ J2T-DM- KGAK (ADopt- VA); Phase 3; | To comparethe sero-responses to the Tdap and MCVbetween lebrikizumab- treated and placebo-treated participants with moderate- to-severe AD.                                                                                                           | Phase 3, randomised, double-blind, placebo- controlled, parallel- group trial.        | Lebrikizumab 250 mg Q2W : subcutaneous injection at Baseline and Week 2: 500- mg loading dose Weeks 4-14: 250 mg Q2W                                                                                                                                                        | Enrolled : 442 patients.                                                                                                                                     | Adult patients with moderate- to-severe AD                                                 | 16-week treatment period                            | Complete; Full CSR       |
| J2T-JE- KGAL, Phase 3                           | To test the hypothesis that lebrikizumab 250 mg Q2W or lebrikizumab 250mgQ4W is superior to placebo in reducing signs and symptoms of AD at Week 16 in Japanese participants with moderate- to-severe AD when used in combination with TCS treatment. | Randomised, double-blind, placebo- controlled, parallel- group TCS combination study, | Induction Period randomised in a 3:2:2 ratio to Group 1: Lebrikizumab 250mgQ2W SC (loading dose of 500mg given at baseline and Week 2) + TCS Group 2: Lebrikizumab 250mgQ4W SC (loading dose of 500mg given at baseline) + TCS Group 3: Placebo SC + TCS Maintenance period | Planned : approximately 280 patients                                                                                                                         | Japanese patients with moderate- to-severe AD                                              | 16-week treatment period 52 week maintenance period | Complete;                |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|              |                                                                                                                                                                                          |                                                                       | Group 1: responders re- randomised in a 1:1 ratio to lebrikizumab 250mgQ2W SC + TCS or lebrikizumab 250mgQ4W SC + TCS Group 2: Lebrikizumab 250mgQ4W SC + TCS Group 3: Placebo SC + TCS                                                                                               |                                      |                                      |                |         |
|--------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------|--------------------------------------|----------------|---------|
| J2T-AP- KGBQ | To evaluate the efficacy of lebrikizumab compared with placebo in patients not adequately controlled with cyclosporine or for whom cyclosporine is not medically advisableup to Week 16. | Randomised, double-blind, placebo- controlled, parallel- group study. | Induction Period either 250 mg lebrikizumab (loading dose of 500 mggiven at baseline and Week 2) or placebo through SC injection Q2W Maintenance Period Patients having achieved EASI 75: lebrikizumab 250 mg Q4W Patients not having achieved EASI 75: lebrikizumab 250 mg given Q2W | Planned : approximately 312 patients | Patients with moderate- to-severe AD | Up to 52 weeks | Ongoing |

Abbreviations: AD = atopic dermatitis; CSR = clinical study report; EASI 75 = 75% reduction from baseline in Eczema Area and Severity Index; MCV = meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (GlaxoSmithKline); PFS-NSD = prefilled syringe with needle safety device; PRN = as needed; Q2W= every 2 weeks; Q4W = every 4 weeks; SC = subcutaneous; TCS = topical corticosteroid; Tdap = tetanus, diphtheria, and pertussis.

a This study investigated changes in blood biomarkers in patients that received lebrikizumab.

<div style=\"page-break-after: always\"></div>

## 2.6.2. Clinical pharmacology

## 2.6.2.1. Pharmacokinetics

The applicant presented pharmacokinetic (PK) data in support of the application collected in 6 phase 1 studies in healthy volunteers, 1 phase  1 study in patients with mild asthma, 3 phase 2 studies in patients with AD, and 4 completed phase 3 studies in patients with AD (KGAB, KGAC, KGAD, and KGAE).

Anti-drug  antibodies  (ADAs)  did  not  have clinically  relevant effect on  exposure to  lebrikizumab, see Clinical safety - Immunological events of this report.

## Bioanalytical  methods

## Serum lebrikizumab concentration

ELISA based method was developed and validated for the quantification of lebrikizumab concentrations in human serum. The initial validated assay was used in one clinical study (KGBB).

Subsequently,  the  ELISA  method  was  validated  for  precision,  accuracy, selectivity,  and  short-term stability and used in studies KGAZ, KGBA and KGBF.

Thereafter, the ELISA method was validated  for method selectivity in atopic dermatitis, IP fibrosis and COPD. This method was used in studies KGAG, KGAH, and KGAY. The validation did not meet FDA current guidelines  and  the  method  was  partially  further  validated  in  terms  of  accuracy,  precision,  matrix selectivity, bench top stability at ambient room temperature, and freeze/thaw stability. The revalidated ELISA-assay was in principle validated according to ICH M10 Bioanalytical method validation guideline. It was used in clinical studies KGAA, KGAB, KGAC, KGAD, KGAE, KGAF, KGAM and KGBG.

## Anti-drug antibody and neutralising antibody assays

Both,  developed  ELISA  based  assays  to  characterise  anti-drug  antibodies  (ADAs)  and  neutralising antibodies (NAbs) against lebrikizumab included the validation in atopic dermatitis serum and to other disease indications. Later, both assays were validated  for parameters for the AD disease state.

For phase 3 AD studies Eli Lilly developed an  immunogenicity assay to screen  and to characterise the neutralizing ability of ADAs against lebrikizumab. The validation report was provided.

The ELISA based ADA and NAb methods used in phase 1 and 2 studies were acceptable in terms  of precision, selectivity, and stability but their sensitivity and drug tolerance was clearly lower compared to the  method used in phase 3 AD studies. Screening, confirmatory, titration  and neutralizing cut points of the  method were acceptable.

## Population PK analysis

PK of  lebrikizumab in  adult  and adolescent (12  to  &lt;18 years of  age weighing  ≥40 kg) subjects was characterised  using  population  PK  analysis.  The  dataset  included  lebrikizumab  concentrations  from 11 studies (four Phase 1 studies with dense PK sampling in healthy volunteers: KGAZ, KGAY, KGAM, and KGBA, and seven Phase 2 and 3 studies in  patients with  AD  with  sparse PK sampling: KGAG, KGAH, KGAF, KGAB, KGAC, KGAD, and KGAE). Intravenous administration  was used in only one small study (KGBA; see below for more information on study KGBA).

The  initial  PK  dataset  contained  8050  postbaseline  observations  from  2015 participants.  A  total  of 1190 observations were excluded from the  source data  to  form the  final analysis dataset.  The most common reasons for exclusion were samples from placebo-treated subjects (n=977)  and postbaseline

<div style=\"page-break-after: always\"></div>

samples below the limit of quantitation  from lebrikizumab-treated subjects (n=122).  The final dataset contained  6860  measurable  observations  from  1607  participants  (healthy  subjects,  n=281;  adult patients  with  AD,  n=1022;  adolescent patients  with  AD,  n=304).  The age distribution  for adolescent patients was evenly distributed across 12 to &lt;18 years of age. Approximately 20% and 2% of subjects had  mildly  (eGFR  60-89  mL/min)  and  moderately  (eGFR  30-59  mL/min)  impaired  renal  function, respectively. The SC injection site  locations most frequently used were arm and abdomen (51% and 37%, respectively), with thigh and multiple sites being less frequently used for dosing.

The base model was based on a published lebrikizumab population PK model in  healthy subjects and patients with asthma. It was a 2-compartment model with first-order absorption and linear elimination parameterised in terms of bioavailability (F), first order absorption rate constant (ka), clearance, (CL), central and peripheral volume of distribution (V2 and V3), and intercompartmental clearance (Q). Body weight based allometric exponents were included as fixed values of 0.8 on CL and Q, and 1.0 on V2 and V3. Interindividual variability (IIV) terms were included on ka, CL, V2, and F parameters, with omega blocks on CL-ka and ka-V2 terms and a logit transformation on F to restrict the estimate of bioavailability to between 0 and 1. Residual unexplained variability (RUV) was incorporated using a proportional and additive error structure. The goodness-of-fit (GOF) plots and pcVPC plots indicated that the base model adequately described the observed data.

An assessment of prespecified covariate effects (including  injection location) was conducted using the SCM procedure in  PsN  (forward  inclusion  p&lt;0.01,  backward elimination  p&lt;0.001).  Body weight  was formally tested on ka only because it was already included in the base model on clearance and volume parameters. Immunogenicity (ADA) was not tested as a covariate since the Week 52 data from the phase 3 studies were not available at the time of the population PK analysis. In the SCM, a total of 9 covariate effects were found to be statistically significant. These covariates were on CL (age, eGFR, and race), V2 (age, age category, disease state, and sex), and ka (disease state, race) parameters.  These 9 covariates were then evaluated stepwise to assess model diagnostics and to determine if these covariates reduced their respective OMEGA variance by at least 10%,  as prespecified in the analysis plan. Because these covariates did not result in notable improvements in parameter estimates, visible improvements in GOF plots, or reduction in variance of ≥10%,  they were considered not significant and were not retained in the final model. Forest plots and simulations (provided upon request) supported the conclusion that age, gender, race, eGFR,  and disease state  (AD  vs. healthy  subjects) had  no  clinically relevant effect on exposure to  lebrikizumab.  Hence,  the  base  model  and  the  final  model  were  the  same. The  model parameters are summarised in  Table  2.  Estimated  interindividual  variability (IIV) was  relatively low (around 24%) for CL and V2 after body weight was used as covariate for these parameters, but for ka and F the estimated IIV was moderate to high (45% and 119%, respectively). ETA-shrinkage for CL, ka, V2, and F were moderate to high: 24%, 48%, 45%, and 37%, respectively. The mean (SD) elimination half-life was 24.5 (5.4) days.

<div style=\"page-break-after: always\"></div>

Table 2: Pharmacokinetic  and Covariate  Parameters  in Population PK Model.

| Model Parameter (Unit)            | Population Estimate (%SEE)   | Interindividual Variability %CVa (%SEE)   | 95% Confidence Interval from Bootstrap Analysis   |
|-----------------------------------|------------------------------|-------------------------------------------|---------------------------------------------------|
| ka (1/day)                        | 0.303 (22.9)                 | 45.1 (14.1)                               | (0.249-0.355)                                     |
| F                                 | 0.861 (6)                    | 119 (33.3)                                | (0.805-0.915)                                     |
| CL (L/day)                        | 0.154 (6.62)                 | 24.7 (9)                                  | (0.144-0.165)                                     |
| V2 (L)                            | 3.86 (10.6)                  | 23.6 (38.1)                               | (3.31-4.36)                                       |
| Q (L/day)                         | 0.524 (19.1)                 | -                                         | (0.320-0.687)                                     |
| V3 (L)                            | 1.28 (47.9)                  | -                                         | (0.730-1.92)                                      |
| Covariates effects                |                              |                                           |                                                   |
| Covariate for body weight on CL b | 0.8 FIX                      | -                                         | -                                                 |
| Covariate for body weight on V2 c | 1 FIX                        | -                                         | -                                                 |
| Covariate for body weight on Q d  | 0.8 FIX                      | -                                         | -                                                 |
| Covariate for body weight on V2 e | 1 FIX                        | -                                         | -                                                 |
| Variance                          |                              |                                           |                                                   |
| Covariance for CL-ka f            | -                            | -0.057 (56.7)                             | -                                                 |
| Covariance for ka-V2 f            | -                            | -0.0384 (145)                             | -                                                 |
| Residual error g                  |                              |                                           |                                                   |
| Proportional                      | 0.0342 (7.22)                |                                           | (0.0300-0.0384)                                   |
| Additive (µg/mL)                  | 0.00307 (44)                 |                                           | (0.00120-0.00762)                                 |

CL = clearance after IV administration; CV = coefficient of variation; F = bioavailability; FIX = fixed;

ka = absorption rate constant; Q = intercompartmental clearance, SEE = standard error of estimate;

V2 = central volume of distribution; V3 = peripheral volume of distribution.

a   %CV = (SQRT(e^(OMEGA(N)) -1))*100%.

b CL = population CL*(WTE/70) 0.8 , where WTE is body weight at study entry and 70 is median body weight.

c V2 = population V2*(WTE/70) 1 , where WTE is body weight at study entry and 70 is median body weight.

d Q = population Q*(WTE/70) 0.8 , where WTE is body weight at study entry and 70 is median body weight.

e V3 = population V3*(WTE/70) 1 , where WTE is body weight at study entry and 70 is median body weight.

f Covariance between ω 2

.

g Reported as σ 2 .

## Absorption and bioavailability

Absorption and bioavailability of lebrikizumab was characterised in healthy volunteers.

Bioavailability of lebrikizumab was evaluated in one study (KGBA). It was a phase I, randomised, singledose, open-label, parallel group study in healthy volunteers conducted at one study site in the Hawaii in 2008.

Twenty of the  22 enrolled subjects (11 subjects/group, 12 males and 10 females, age 18 to 49 years, weight  39.9  to  96.8 kg)  completed the  study,  while  2  subjects withdrew  from  the  study  (both  from SC group). Each subject received a single dose of lebrikizumab (1 mg/kg) administered by SC injection or IV bolus infusion on day 1. Blood samples were taken on day 1 at pre-dose and 30 min post-dose and at  days  2,  4,  8,  11,  15,  22,  36,  57,  78  and  92,  and  at  early termination  as applicable.  The  initial lebrikizumab  concentration  dataset  contained  several anomalous  values  (e.g.,  measurable predose concentrations and  very low  concentrations compared with  other subjects at  the  same timepoint).  A subset of anomalous data that was considered most critical to the estimation of PK parameters was reassayed (a total of 18 samples; most results of the re-assays were markedly different than the initially reported values). Other anomalous data were excluded from the PK analysis; they included but were not

<div style=\"page-break-after: always\"></div>

limited  to  one  subject who  had  high  pre-dose concentration confirmed in  re-assay (the  subject was excluded from PK analysis) and three subjects with embedded zero concentration values (the embedded zero values were excluded from PK analysis).

The reported exposure parameters and SC bioavailability results are presented in Table 3. After a subcutaneous dose of 250 mg lebrikizumab, peak serum concentrations were achieved approximately 7 to 8 days post dose. The absolute bioavailability was estimated at 86% based on a population PK analysis.

Table 3: Lebrikizumab Exposure Parameters  and Statistical Analysis (SC Injection relative  to IV Infusion) - Study KGBA.

| Parameter (Units)     | SC injection (Group 2)   | SC injection (Group 2)   | IV Infusion (Group 1)   | IV Infusion (Group 1)   | SC/IV (Ratio of Geometric Means,   | 90% Ci d      |
|-----------------------|--------------------------|--------------------------|-------------------------|-------------------------|------------------------------------|---------------|
|                       | N a                      | LS means b               | N a                     | LS means b              | %)c                                |               |
| AUC 0-t (ng  hr/mL)  | 11                       | 6229081                  | 10                      | 7797469                 | 79.89                              | 66.23, 96.36  |
| AUC 0- ∞ (ng  hr/mL) | 9                        | 7275319                  | 10                      | 8534570                 | 85.25                              | 69.51, 104.54 |
| Cmax (ng/mL)          | 11                       | 8506                     | 10                      | 19836                   | 42.88                              | 37.35, 49.23  |

a In Group 1 (IV infusion), 1 participant was excluded from PK analysis due to anomalous predose value. One participant from Group 1 (IV infusion) and 2 participants from Group 2 (SC injection) were not included for assessment of bioavailability based on AUC0-∞ values due to difficulties in estimating the terminal elimination. b Geometric means calculated by transforming the natural log means back to the linear scale.

c Ratio of parameter means (expressed as a percent), transformed back to the linear scale.

d 90% CI for ratio of parameter means (expressed as a percent), transformed back to the linear scale.

PK similarity between pre-filled syringe with needle safety device (PFS-NSD) and autoinjector (AI) was evaluated in study KGBG. It was a phase 1, multi-site, randomised, parallel-design, open-label, 2-arm, single-dose study conducted in 4 study sites in the USA in 2021-2022.

Eligible subjects were stratified into 1 of 3 weight categories (less than 70.0 kg, 70.0 to 80.0 kg, greater than 80.0 kg), randomised 1:1 to  delivery device (either PFS-NSD  [reference] or AI [test]), and subrandomised 1:1:1 to injection site (arm, thigh,  or abdomen). A total of 242 subjects were randomised. One subject was identified as a screen  failure after the randomisation and did not receive  the study drug. Two-hundred and forty-one subjects ((PFS-NSD  = 122, AI = 119; 104 men and 137 women; aged 21 to 65 years, weights 48.3 to 116.5 kg) received one dose of study treatment per the study design. Six subjects prematurely discontinued from the study resulting in 235 participants that completed the study; three discontinued subjects were included in assessment of Cmax. PK blood samples were taken at predose and days 3, 5, 8, 11, 15, 22, 29, 43, 57, 71, 85, and 99.

The statistical analysis showed that  2-ml (125 mg/ml)  lebrikizumab AI had comparable PK with 2-mL (125 mg/mL) lebrikizumab PFS-NSD (reference) as the 90% CIs of the geometric least squares means ratios for lebrikizumab AUC0-t, AUC0-∞ , and Cmax were all completely contained within  the pre-specified confidence limits of 0.80 and 1.25 (Table 4). Based on a comparison of descriptive statistics, injectionsite location  did not  appear to impact  lebrikizumab systemic exposure (AUC0-t, AUC0-∞ , and Cmax) for either device.

<div style=\"page-break-after: always\"></div>

Table 4: Statistical Analysis of the PK Parameters  of Lebrikizumab (Study KGBG)

| Parameter                | Treatment                                         |   n |   Geometric LS Mean | Ratio of Geometric LS Mean (Test:Reference) (90% CI)   |
|--------------------------|---------------------------------------------------|-----|---------------------|--------------------------------------------------------|
| AUC(0-t) ( µ g . day/mL) | 2-mL (125 mg/mL) lebrikizumab PFS-NSD (Reference) | 117 |              1262   | 1.09 (1.03, 1.14)                                      |
|                          | 2-mL (125 mg/mL) lebrikizumab AI (Test)           | 117 |              1370   | 1.09 (1.03, 1.14)                                      |
| AUC(0- ∞) ( µ g .        | 2-mL (125 mg/mL) lebrikizumab PFS-NSD (Reference) | 106 |              1357   | 1.07 (1.02, 1.14)                                      |
| day/mL)                  | 2-mL (125 mg/mL) lebrikizumab AI (Test)           | 100 |              1458   | 1.07 (1.02, 1.14)                                      |
| C max ( µ g/mL)          | 2-mL (125 mg/mL) lebrikizumab PFS-NSD (Reference) | 120 |                38.6 | 1.09 (1.03, 1.16)                                      |
| C max ( µ g/mL)          | 2-mL (125 mg/mL) lebrikizumab AI (Test)           | 118 |                42.2 | 1.09 (1.03, 1.16)                                      |

PK  similarity  following  administration  of  2  x  1 mL  SC  injections  or  a  single  2 mL  SC  injection  was evaluated in  study  KGAM. It  was a  phase 1,  single-centre, randomised, 2-arm,  parallel group study conducted in one study site in the  USA in  2018-2019.  Study drug was administered in  the abdomen, upper arm, or thigh.  If the subject was to receive two 1-mL injections, the injections were to be given one after the other in the same body region and same body side (both in the left arm, both in the right abdomen, etc.); the two injections were to be ≥10 cm from one another.

Subjects were stratified by albumin level (&lt;4.3 mg/dL, ≥4.3 mg/dL) at screening then randomised 1:1. A total of 41 subjects (19 males  and 22 females)  were randomised  and 38 subjects completed the study. PK blood samples were collected at baseline (pre-dose), and on days 2, 4, 6, 8, 11, 15, 29, 43, 57, 71, 85 and 99.

The statistical analysis (Table 5) showed that the exposure parameters (AUC0-t, AUC0-∞ , and Cmax) were comparable, although similarity was not formally demonstrated for AUC0-∞ and Cmax because the upper and lower limits of 90% CIs, respectively, were outside the pre-specified confidence limit (0.80 to 1.25).

Table 5: Statistical Analysis of the PK Parameters  of Lebrikizumab (Study KGAM)

| Parameter (Units)      | LebrikizumabTwo 1-mL Injections   | LebrikizumabTwo 1-mL Injections   | LebrikizumabOne2-mL Injection   | LebrikizumabOne2-mL Injection   | Least Square GMR (90% CI)   |
|------------------------|-----------------------------------|-----------------------------------|---------------------------------|---------------------------------|-----------------------------|
|                        | N                                 | GeometricMeans (CV%)              | N                               | GeometricMeans (CV%)            |                             |
| AUC 0-t (day . ng/mL)  | 18                                | 1460000 (19.8)                    | 20                              | 1510000 (24.2)                  | 1.03 (0.91 - 1.16)          |
| AUC 0- ∞ (day . ng/mL) | 7                                 | 1530000 (30.4)                    | 8                               | 1560000 (24.1)                  | 1.02 (0.80 - 1.30)          |
| C max (ng/mL)          | 19                                | 47900 (49.4)                      | 20                              | 42500 (21.2)                    | 0.89 (0.73 - 1.08)          |

Comparable PK and exposure (AUC0-t, AUC0-∞ , and Cmax) parameters between a 125 mg/mL formulation of lebrikizumab administered SC by a needle and syringe and a 37.5 mg/mL formulation of lebrikizumab administered SC by a pre-filled syringe with needle safety device (PFS-NSD) was demonstrated in study KGAY.  Detailed  information  is  omitted  because  the  37.5 mg/mL  formulation  was  terminated  for development and used only in this study.

## Distribution and elimination

The central and peripheral volume of distribution  estimates for a typical subject (weight  70 kg) were 3.86 L and 1.28 L, respectively,  in the population PK analysis.  This indicates a total volume  of distribution at steady state of 5.14 L. Body weight based allometric exponents were included in the population PK

<div style=\"page-break-after: always\"></div>

model as fixed value of 1.0 on the central and peripheral Vd, indicating larger Vd in subjects with higher body  weight. Similar results were  reported  in individual clinical pharmacology  studies using noncompartmental analysis. Binding to plasma proteins and distribution  to erythrocytes has not  been investigated.

No studies on metabolism and excretion of lebrikizumab were conducted. In the population PK analysis, the CL for a typical subject was 0.154 L/day and mean elimination half-life was approximately 24.5 days (SD  5.4 days). Body weight  based allometric exponents were included in the  population PK model as fixed value of 0.8  on clearance parameters, indicating  higher clearance in  subjects with  higher  body weight. Similar  results were reported  in individual clinical pharmacology  studies using noncompartmental analysis.

## Dose proportionality and time dependencies

Study  KGBB  was  a  randomised,  double-blind,  placebo-controlled,  dose-escalation  study  in  healthy volunteers. The objectives were to determine the safety, tolerability, and PK of lebrikizumab in healthy subjects. The study was conducted in 2006-2007 at one clinical study site in the USA. Five dose cohorts of 8 subjects each received single IV bolus infusion of lebrikizumab (6 subjects) or placebo (2 subjects) as  a  bolus  infusion.  Lebrikizumab  doses  were  0.1 mg/kg,  0.3 mg/kg,  1.0  mg/kg,  3.0  mg/kg,  and 5.0 mg/kg. The early phosphate formulation was used in the study. Blood samples for PK were collected at predose (Day 1), and 15 minutes and 1, 2, 4, and 24 hours, and on Days 3, 5, 8, 15, 22, 29, 36, 43, 57, 78, and 92 postdose.

The time-concentration curve for one subject (randomised to lebrikizumab 0.3 mg/kg) was indicative of SC dosing, and this subject's data were  excluded from the PK analysis. The PK parameters by dose group are summarised in  Table 6. Lebrikizumab Cmax and AUC increased in approximately dose-proportional manner across the 0.1- to 5.0-mg/kg dose range used in this study.

Table 6: Lebrikizumab Mean (SD) PK Parameters  by Dose (Study KGBB)

| Parameter (Units)          | 0.1 mg/kg, N=6   | 0.3 mg/kg, N=5   | 1.0 mg/kg, N=6   | 3.0 mg/kg, N=6   | 5.0 mg/kg, N=6   |
|----------------------------|------------------|------------------|------------------|------------------|------------------|
| Cmax (ng/mL)               | 2788 (289)       | 9070 (871)       | 30675 (7721)     | 92300 (15507)    | 142433 (20538)   |
| AUC0-last (day·ng/mL)      | 51423 (5040)     | 204090 (19645)   | 575111 (48160)   | 1766282 (578161) | 3158958 (616744) |
| AUC0- ∞ (day·ng/mL)        | 55561 (6517)     | 227809 (21131)   | 621196 (54902)   | 1927488 (672053) | 3491756 (761033) |
| Cmax / Dose (kg/mL)        | 0.028 (0.003)    | 0.030 (0.003)    | 0.031 (0.008)    | 0.031 (0.005)    | 0.028 (0.003)    |
| AUC0- ∞ / Dose (day·kg/mL) | 0.556 (0.065)    | 0.759 (0.070)    | 0.621 (0.055)    | 0.642 (0.224)    | 0.698 (0.152)    |
| t ½ (day)                  | 25.1 (3.3)       | 28.8 (2.6)       | 25.0 (3.8)       | 23.3 (6.8)       | 27.2 (3.6)       |

AUC0-last = area under the concentration-time curve determined using all time points at which measurable drug concentration were observed; AUC0-∞ = area under the concentration-time curve extrapolated to infinity; Cmax = maximum observed serum concentration; SD = standard deviation; t½ = terminal elimination half-life.

Study KGBF was a randomised, double-blind, placebo-controlled, dose escalation study that evaluated the safety,  tolerability, PK, and immunogenicity of four IV doses (0.3 mg/kg, 1.0 mg/kg, and 3.0 mg/kg) of lebrikizumab administered Q4W in patients with mild, intermittent asthma. The primary objective was to  evaluate  the  safety  and  tolerability  of  multiple  doses  of  lebrikizumab in  patients;  the  secondary objective was to  characterise the PK and immunogenicity. The study was conducted in  2007-2009  at seven study sites in the USA. The early phosphate formulation was used in the study. Blood samples for PK were collected at predose and 30 minutes post dose on study drug administration Days 0, 28, 56, and 84. In addition, PK samples were collected on Days 1, 3, 7, 14, 85, 91, 112, 140, 168, and 196.

<div style=\"page-break-after: always\"></div>

Of the 37  patients  randomised to lebrikizumab, 33 completed the  study and were included in the  PK population. The PK parameters by dose group are summarised in Table 7. Following multiple (4) doses, lebrikizumab Cmax and AUC increased in a dose-proportional manner and clearance was similar across the 0.3- to 3.0-mg/kg dose range used in this study.

Table 7: Lebrikizumab Mean (SD) PK Parameters by Dose following  Multiple-dose Administration (Study KGBF)

| Parameter (Units)                                                                                                                                                                                     | 0.3 mg/kg, N=10                                                                                                                                                                                       | 1.0 mg/kg, N=12                                                                                                                                                                                       | 3.0 mg/kg, N=11                                                                                                                                                                                       |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Cmax (µg/mL)                                                                                                                                                                                          | 13.5 (7.01)                                                                                                                                                                                           | 40.6 (6.71)                                                                                                                                                                                           | 99.9 (22.0)                                                                                                                                                                                           |
| AUC0- ∞ (day·µg/mL)                                                                                                                                                                                   | 748 (140)                                                                                                                                                                                             | 2340 (496)                                                                                                                                                                                            | 6560 (1470)                                                                                                                                                                                           |
| Clearance (mL/day/kg)                                                                                                                                                                                 | 1.65 (0.270)                                                                                                                                                                                          | 1.78 (0.399)                                                                                                                                                                                          | 1.92 (0.462)                                                                                                                                                                                          |
| Terminal half-life (day)                                                                                                                                                                              | 22.4 (3.84)                                                                                                                                                                                           | 21.7 (3.82)                                                                                                                                                                                           | 25.2 (9.36)                                                                                                                                                                                           |
| Vss (mL/kg)                                                                                                                                                                                           | 117 (17.3)                                                                                                                                                                                            | 116 (25.7)                                                                                                                                                                                            | 132 (28.7)                                                                                                                                                                                            |
| AUC0- ∞ = area under the serum concentration-time curve extrapolated to infinity; Cmax = maximum observed serum concentration; SD = standard deviation; Vss = volume of distribution at steady state. | AUC0- ∞ = area under the serum concentration-time curve extrapolated to infinity; Cmax = maximum observed serum concentration; SD = standard deviation; Vss = volume of distribution at steady state. | AUC0- ∞ = area under the serum concentration-time curve extrapolated to infinity; Cmax = maximum observed serum concentration; SD = standard deviation; Vss = volume of distribution at steady state. | AUC0- ∞ = area under the serum concentration-time curve extrapolated to infinity; Cmax = maximum observed serum concentration; SD = standard deviation; Vss = volume of distribution at steady state. |

Study KGAZ was a randomised, double-blind, placebo-controlled, parallel group study that evaluated the safety, tolerability, and PK following single SC dose administration of lebrikizumab in healthy Japanese and Caucasian subjects. The primary objective was to investigate the safety, tolerability, and PK of SC lebrikizumab in Japanese subjects, and the secondary objective was to compare the safety, tolerability, and PK between healthy Japanese and Caucasian subjects. The study was conducted in 2011-2012 at one study site in Hawaii. The commercial formulation was used in the study. Blood samples for PK were collected at predose, 4 and 12 hours postdose on Day 1, and on Days 2, 5, 8, 15, 29, 50, 71, 99, and Day 120 (or early termination).

A  total  of  21 Japanese  and  21 Caucasian  participants  were  randomly  assigned  to  lebrikizumab (7 Japanese and 7 Caucasian to each lebrikizumab dose group). Two Caucasian subjects randomised to 125 mg lebrikizumab withdrew  from the study, one of them had sufficiently PK observations and was included in the PK analyses.

The PK parameters are presented in Table  8 . In Japanese subjects, dose normalised Cmax and AUC values were comparable and the CL/F was similar across the 125- to  375-mg dose range used in this study. In Caucasian subjects, dose normalised AUC0-inf values were comparable, but dose normalised Cmax and AUC0-t were increased in the 375 mg dose qroup. Statistical analysis using the power model to assess dose proportionality showed that  the slope estimate (90% CI) was 1.08  (0.85,  1.32),  0.99 (0.79, 1.19), and 0.98 (0.77, 1.18) in Japanese subjects and 1.39 (1.25, 1.53), 1.17 (1.01, 1.32), and 1.13  (0.97,  1.29)  for  Caucasian  subjects  for  Cmax,  AUC0-t,  and  AUC0-∞ adjusted  for  weight, respectively.

<div style=\"page-break-after: always\"></div>

Table 8: Lebrikizumab Mean (SD) PK Parameters  by Dose (Study KGBZ)

|                           | Japanese          | Japanese          | Japanese          | Caucasian         | Caucasian         | Caucasian        |
|---------------------------|-------------------|-------------------|-------------------|-------------------|-------------------|------------------|
| Parameter (Units)         | 125 mg, N=7       | 250 mg, N=7       | 375 mg, N=7       | 125 mg, N=6       | 250 mg, N=7       | 375 mg, N=7      |
| Cmax (µg/mL)              | 15.3 (4.37)       | 29.0 (7.99)       | 47.2 (8.28)       | 14.2 (3.85)       | 27.9 (8.74)       | 61.0 (11.9)      |
| DN Cmax (µg/mL/mg)        | 0.122 (0.0350)    | 0.116 (0.0319)    | 0.126 (0.0221)    | 0.114 (0.0308)    | 0.112 (0.0350)    | 0.163 (0.0317)   |
| AUC0-t (µg·day/mL)        | 622 (125)         | 1180 (306)        | 1760 (294)        | 733 (218)         | 1260 (438)        | 2430 (465)       |
| DN AUC0-t (µg·day/mL/mg)  | 4.97 (1.00)       | 4.70 (1.23)       | 4.69 (0.784)      | 5.86 (1.74)       | 5.04 (1.75)       | 6.47 (1.24)      |
| AUC0- ∞ (µg·day/mL)       | 643 (134)         | 1210 (324)        | 1790 (297)        | 802 (245)         | 1300 (462)        | 2550 (507)       |
| DN AUC0- ∞ (µg·day/mL/mg) | 5.15 (1.07)       | 4.86 (1.30)       | 4.78 (0.792)      | 6.42 (1.96)       | 5.22 (1.85)       | 6.81 (1.35)      |
| tmax (day) a              | 4.00 (1.00, 14.0) | 6.00 (4.00, 14.0) | 6.96 (6.94, 7.95) | 7.00 (4.00, 14.0) | 6.00 (4.00, 14.0) | 6.98 (3.98,7.19) |
| CL/F (mL/day/kg)          | 3.37 (0.628)      | 3.43 (1.36)       | 3.12 (0.344)      | 2.52 (0.509)      | 2.78 (0.869)      | 2.20 (0.133)     |
| t 1/2 (day)               | 23.1 (2.48)       | 21.3 (5.61)       | 20.4 (1.61)       | 31.6 (2.99)       | 22.2 (3.37)       | 28.3 (5.06)      |
| Vz/F (mL/kg)              | 112 (22.7)        | 98.0 (14.2)       | 91.1 (8.55)       | 115 (23.6)        | 86.9 (20.0)       | 90.0 (17.4)      |

AUC0-∞ = area under the concentration-time curve extrapolated to infinity; AUC0-t = area under the concentration-time curve from time 0 to the last measurable concentration; Cmax = maximum observed serum concentration; CL/F = apparent clearance after SC administration; DN = dose normalised; SD = standard deviation; t1/2 = terminal elimination half-life; tmax = time of maximum observed serum concentration; Vz/F = apparent volume of distribution at the terminal phase after SC administration.

Dedicated time dependency studies were not conducted. No indication of time-dependent clearance was found in the population PK analysis.

## PK in target population

The proposed dosing regimen, which was used in the pivotal phase 3 studies, consists of an induction phase  (500 mg  SC  at  weeks 0  and  2,  followed  by 250 mg  SC Q2W  up  to  week 16),  followed  by a maintenance phase (250 mg SC Q4W). Exposure to lebrikizumab will  be highest  during the  induction phase  and,  based  on  simulations  using  the  final  population  PK  model,  the  steady  state  average concentration (Cavg,ss) will be approximately 50% lower during the maintenance phase compared with the induction phase (Figure 1 and Table 9).

<div style=\"page-break-after: always\"></div>

Figure  1:  Virtual  patient  simulations to 52 weeks:  Loading/induction doses up to Week  16, then lebrikizumab 250 mg Q2W versus 250 mg Q4W in maintenance period.

<!-- image -->

Q2W = every 2 weeks; Q4W = every 4 weeks.

a Simulated patients received 500 mg loading doses at Weeks 0 and 2, followed by 250 mg Q2W dosing until Week 16. At Week 16, 1 group remained on 250 mg Q2W and 1 group reduced their dose to 250 mg Q4W for remainder of maintenance period to Week 52.

N = 500 participants for each dose group in maintenance period. Lines represent medians and shaded areas represent 5 th and 95 th   percentiles of simulated values at each time point.

Table  9:  Observed  and  Simulated  Lebrikizumab  Concentrations  Following Phase  3  Dosing Regimens, Reported as Median (5th Percentile,  95th Percentile).

| Dosing Regimen      | 500 mg Loading Dose at Weeks 0 and 2, 250 mg Q2WWeeks 4 to 16, and 250 mg Q2Wor 250 mg Q4WStarting at Week 16   | 500 mg Loading Dose at Weeks 0 and 2, 250 mg Q2WWeeks 4 to 16, and 250 mg Q2Wor 250 mg Q4WStarting at Week 16          | 500 mg Loading Dose at Weeks 0 and 2, 250 mg Q2WWeeks 4 to 16, and 250 mg Q2Wor 250 mg Q4WStarting at Week 16          | 500 mg Loading Dose at Weeks 0 and 2, 250 mg Q2WWeeks 4 to 16, and 250 mg Q2Wor 250 mg Q4WStarting at Week 16          |
|---------------------|-----------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|
| Population          | Observed data: Phase 3 Study Participants (N = 796)                                                             | Simulations of 500 Virtual Participants Based on Body Weight Distribution of Phase 3 Adolescent and Adult Participants | Simulations of 500 Virtual Participants Based on Body Weight Distribution of Phase 3 Adolescent and Adult Participants | Simulations of 500 Virtual Participants Based on Body Weight Distribution of Phase 3 Adolescent and Adult Participants |
| PK Parameter        | 250 mg Q2W Week 16                                                                                              | 250 mg Q2W Week 16                                                                                                     | 250 mg Q2W Week 52                                                                                                     | 250 mg Q4W Week 52                                                                                                     |
| C max,ss (µg/mL)    | NA                                                                                                              | 109 (61.6-177)                                                                                                         | 108 (61.7-182)                                                                                                         | 62.6 (38.2-106)                                                                                                        |
| C avg,ss (µg/mL)    | NA                                                                                                              | 100 (56.3-167)                                                                                                         | 99.9 (56.1-175)                                                                                                        | 51.1 (29.4-86.5)                                                                                                       |
| C trough,ss (µg/mL) | 94.4 (32.6-152)                                                                                                 | 86.4 (46.4-153)                                                                                                        | 86.6 (46.0-159)                                                                                                        | 36.1 (17.6-67.9)                                                                                                       |

Cavg,ss = average concentration over a dosing interval at steady state; Cmax,ss = maximum concentration over a dosing interval at steady state; Ctrough,ss = minimum concentration over a dosing interval at steady state;

NA = not applicable; Q2W = every 2 weeks; Q4W = every 4 weeks.

Following  the  500 mg  loading doses at  week 0  and week 2, steady-state serum concentrations were achieved with the first 250 mg Q2W dose at week 4.Based on a population pharmacokinetic (PK) analysis, the predicted steady-state trough concentrations (Ctrough,ss) following lebrikizumab 250 mg Q2W and Q4W subcutaneous dosing in patients  with  atopic dermatitis (median and 5th  - 95th  percentile) were 87 (46-159) µg/mL and 36 (18-68) µg/mL, respectively.

<div style=\"page-break-after: always\"></div>

## Special populations

Dedicated  studies  in  special  populations  were  not  conducted.  Potential  effects  of  intrinsic  factors [including age, weight, gender, race, markers of renal and hepatic function, and disease state (patients with AD vs healthy subjects)] on PK parameters were tested in population PK analysis.

Exposure is inversely correlated with body weight (Figure 2 and Table 10). Interindividual variability in observed serum lebrikizumab levels can be  partly, but  not  entirely, attributed  to  differences in  body weight.

Figure  2: Observed  lebrikizumab  Week  16 predose concentrations  by baseline body weight: all Phase 3 participants (adults and adolescents).

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table  10: Simulated Lebrikizumab Exposure Parameters  at Week  52 by Regimen and Weight Category.

| Simulations of 500 Virtual Participants in Each Maintenance Period Regimen Based on Body Weight Distributions of Phase 3 Adolescent and Adult Participants. Concentrations Are Expressed as Median (5 th , 95 th )   | Simulations of 500 Virtual Participants in Each Maintenance Period Regimen Based on Body Weight Distributions of Phase 3 Adolescent and Adult Participants. Concentrations Are Expressed as Median (5 th , 95 th )   | Simulations of 500 Virtual Participants in Each Maintenance Period Regimen Based on Body Weight Distributions of Phase 3 Adolescent and Adult Participants. Concentrations Are Expressed as Median (5 th , 95 th )   | Simulations of 500 Virtual Participants in Each Maintenance Period Regimen Based on Body Weight Distributions of Phase 3 Adolescent and Adult Participants. Concentrations Are Expressed as Median (5 th , 95 th )   | Simulations of 500 Virtual Participants in Each Maintenance Period Regimen Based on Body Weight Distributions of Phase 3 Adolescent and Adult Participants. Concentrations Are Expressed as Median (5 th , 95 th )   | Simulations of 500 Virtual Participants in Each Maintenance Period Regimen Based on Body Weight Distributions of Phase 3 Adolescent and Adult Participants. Concentrations Are Expressed as Median (5 th , 95 th )   | Simulations of 500 Virtual Participants in Each Maintenance Period Regimen Based on Body Weight Distributions of Phase 3 Adolescent and Adult Participants. Concentrations Are Expressed as Median (5 th , 95 th )   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Dosing Regimen                                                                                                                                                                                                       | 500 mg Loading Dose at Weeks 0 and 2, 250 250 mg Q2Wor 250 mg Q4WStarting 16                                                                                                                                         | 500 mg Loading Dose at Weeks 0 and 2, 250 250 mg Q2Wor 250 mg Q4WStarting 16                                                                                                                                         | 500 mg Loading Dose at Weeks 0 and 2, 250 250 mg Q2Wor 250 mg Q4WStarting 16                                                                                                                                         |                                                                                                                                                                                                                      | Week                                                                                                                                                                                                                 |                                                                                                                                                                                                                      |
| Maintenance Regimen                                                                                                                                                                                                  | Q2W                                                                                                                                                                                                                  | Q2W                                                                                                                                                                                                                  | Q2W                                                                                                                                                                                                                  | Q4 W                                                                                                                                                                                                                 | Q4 W                                                                                                                                                                                                                 | Q4 W                                                                                                                                                                                                                 |
| Body Weight Category                                                                                                                                                                                                 | <60 kg                                                                                                                                                                                                               | 60-100 kg                                                                                                                                                                                                            | >100 kg                                                                                                                                                                                                              | <60 kg                                                                                                                                                                                                               | 60-100 kg                                                                                                                                                                                                            | >100 kg                                                                                                                                                                                                              |
| N (%) a                                                                                                                                                                                                              | 130 (26)                                                                                                                                                                                                             | 317 (63)                                                                                                                                                                                                             | 53 (11)                                                                                                                                                                                                              | 151 (30)                                                                                                                                                                                                             | 293 (59)                                                                                                                                                                                                             | 56 (11)                                                                                                                                                                                                              |
| C max,ss (µg/mL)                                                                                                                                                                                                     | 142 (97.2-217)                                                                                                                                                                                                       | 104 (64.8-156)                                                                                                                                                                                                       | 70.1 (49.2-96.5)                                                                                                                                                                                                     | 80.3 (57.3-127)                                                                                                                                                                                                      | 58.7 (39.9- 90.3)                                                                                                                                                                                                    | 43.6 (29.7- 58.7)                                                                                                                                                                                                    |
| C avg,ss (µg/mL)                                                                                                                                                                                                     | 132 (86.2-206)                                                                                                                                                                                                       | 96.8 (57.8-148)                                                                                                                                                                                                      | 64.1 (44.6-91.5)                                                                                                                                                                                                     | 64.0 (39.6-107)                                                                                                                                                                                                      | 47.7 (29.9- 77.6)                                                                                                                                                                                                    | 36.4 (23.3- 51.0)                                                                                                                                                                                                    |
| C trough,ss (µg/mL)                                                                                                                                                                                                  | 117 (67.9-188)                                                                                                                                                                                                       | 83.8 (48.3-133)                                                                                                                                                                                                      | 56.3 (35.7-84.0)                                                                                                                                                                                                     | 43.0 (22.2- 81.8)                                                                                                                                                                                                    | 33.8 (17.3- 61.0)                                                                                                                                                                                                    | 25.4 (14.8- 40.7)                                                                                                                                                                                                    |

Cavg,ss = average concentration over a dosing interval at steady state; Cmax,ss = maximum concentration over a dosing interval at steady state; Ctrough,ss = minimum concentration over a dosing interval at steady state; N = number of participants; Q2W = every 2 weeks; Q4W = every 4 weeks.

The predicted mean steady state exposure in adolescents (12 to &lt;18 years of age weighing ≥40 kg) with AD was approximately 20% higher compared with  adults, which was attributed to the lower body weight distribution in adolescents.

Age (range: 12 to 93 years), gender, race, and markers of renal and hepatic function were considered not to have meaningful effect on PK. The number of 65-74  years old, 7584 years old, and ≥85  years old subjects in the PK dataset were 71, 17, and 3, respectively.

## Pharmacokinetic  interaction  studies

No formal studies have been conducted to examine the effect of lebrikizumab on the PK of other drugs. Monoclonal antibodies are not anticipated to directly impact the PK of other drugs. Published literature (Davis et al. 2018) indicates that blockade of the IL-4 α receptor (thus blocking IL-13 activity) was not associated with changes in CYP3A, CYP2C19, CYP2C9, CYP1A2, or CYP2D6 activity following 4 weeks of treatment in patients with AD. Based on these data, it is unlikely that lebrikizumab (an anti-IL-13 mAb) will have an effect on the PK of other drugs due to potential drug-disease interactions.

## 2.6.2.2. Pharmacodynamics

## Mechanism of action

Lebrikizumab is an immunoglobulin (IgG4) monoclonal antibody that binds with high affinity to interleukin (IL)-13 and selectively inhibits IL-13 signalling through the IL-4 receptor alpha (IL-4R α)/ IL-13 receptor alpha 1 (IL-13R α1 ) heterodimer, thereby inhibiting the downstream effects of IL-13. Inhibition of IL-13 signalling is expected to be of benefit in diseases in which IL-13 is a key contributor to the disease pathogenesis. Lebrikizumab does not prevent the binding of IL-13 to the IL-13 receptor alpha 2 (IL-13R α2 or decoy receptor), which allows the internalisation of IL-13 into the cell.

<div style=\"page-break-after: always\"></div>

## Primary  and Secondary  pharmacology

Limited pharmacodynamic data were collected in the clinical program, mainly clinical efficacy endpoints were used in the proof-of-concept and dose finding studies. PD biomarker data were not evaluated in phase 3 studies in patients with AD.

Study KGAG was a preliminary Phase 2 study to evaluate the efficacy of lebrikizumab plus TCS vs. TCS alone in moderate to severe AD. A total of 212 patients were  randomised 1:1:1:1, 209 of whom received study drug (and TCS) as follows: lebrikizumab 250 mg SC single-dose, lebrikizumab 125 mg SC singledose, lebrikizumab 125 mg SC at weeks 0, 4, and 8, placebo. The 12-week treatment period was followed by an  8-week safety follow-up  period. Changes  in  candidate biomarkers in  patients  with  AD  [serum periostin, IgE, CCL-13 (monocyte chemotactic protein-4), CCL-18 (pulmonary and activation-regulated chemokine), and peripheral blood eosinophils] were evaluated as an exploratory objective in the study.

Lebrikizumab (combined with TCS) decreased the levels of CCL-13, CCL-18, and periostin compared to placebo (TCS only). Median reduction from baseline (%) to week 1 was 25.7-33.2% and 52.3-58.4%, for CCL-13  and CCL-18,  respectively, in the  lebrikizumab arms compared to  3.4% and  12.1%  in the placebo arm (Table 11). The percent reductions from baseline were generally sustained through the 12week treatment  period in the lebrikizumab arms. Median  reduction from baseline (%)  to week 1 was 8.3-10.6% for periostin in the lebrikizumab arms compared to 1.4% in the placebo arm. Serum periostin levels continued to gradually decline during the study in all lebrikizumab treatment arms (Table 11).

Peripheral blood eosinophils tended to increase above baseline levels in lebrikizumab-treated patients (Figure  3).  Between-subject variability in  serum IgE levels was high.  Overall, a gradual  reduction in median serum total IgE occurred in both the placebo and lebrikizumab arms during the treatment phase, with  the decline continuing  throughout  the safety follow-up period. At the end of the safety follow-up period (Week 20),  the  median decrease in  IgE  levels from baseline  was  28.7%,  37.3%,  40.0%  and 25.6%  in  lebrikizumab  250 mg  single  dose,  125 mg  single  dose,  125 mg  Q4W  and  placebo  arms, respectively.

Overall, the responses were comparable in each lebrikizumab dose groups, i.e., no dose-response was observed for these PD biomarkers.

Table 11: Serum CCL-13, CCL-18, and Periostin Median Concentrations (Study KGAG).

|                   | 250 mg SC single dose   | 125 mg SC single dose   | 125 mg SC at weeks 0, 4, and 8   | Placebo           |
|-------------------|-------------------------|-------------------------|----------------------------------|-------------------|
| CCL-13 (ng/l)     | CCL-13 (ng/l)           | CCL-13 (ng/l)           | CCL-13 (ng/l)                    | CCL-13 (ng/l)     |
| Baseline          | 240.4                   | 272.2                   | 280.0                            | 243.0             |
| Week 1            | 169.1                   | 186.7                   | 189.9                            | 235.1             |
| Week 4            | 158.2                   | 178.5                   | 193.5                            | 226.6             |
| Week 12           | 145.2                   | 192.7                   | 181.9                            | 229.0             |
| Week 20           | 154.5                   | 192.9                   | 154.4                            | 219.4             |
| CCL-18 (ng/ml)    | CCL-18 (ng/ml)          | CCL-18 (ng/ml)          | CCL-18 (ng/ml)                   | CCL-18 (ng/ml)    |
| Baseline          | 214.7                   | 260.5                   | 232.1                            | 250.4             |
| Week 1            | 90.3                    | 118.4                   | 118.7                            | 234.4             |
| Week 4            | 73.0                    | 86.4                    | 91.5                             | 171.1             |
| Week 12           | 79.1                    | 100.0                   | 83.7                             | 160.9             |
| Week 20           | 106.1                   | 114.7                   | 82.0                             | 155.4             |
| Periostin (ng/ml) | Periostin (ng/ml)       | Periostin (ng/ml)       | Periostin (ng/ml)                | Periostin (ng/ml) |
| Baseline          | 67.6                    | 61.1                    | 64.2                             | 66.6              |
| Week 1            | 64.2                    | 55.6                    | 54.6                             | 68.5              |
| Week 4            | 58.9                    | 58.5                    | 55.3                             | 68.2              |
| Week 12           | 54.2                    | 54.6                    | 50.1                             | 64.9              |
| Week 20           | 57.8                    | 58.1                    | 47.3                             | 67.0              |

<div style=\"page-break-after: always\"></div>

Figure 3: Median (Q1-Q3)  absolute change from baseline in eosinophils over 20 weeks (Study KGAG).

<!-- image -->

The  effect  of  lebrikizumab  on  serum  PD  biomarkers  was  also  evaluated  in  randomised,  placebocontrolled, double-blind phase 3 studies KGAN and KGAO in patients with asthma. In these two studies, serum levels of CCL-13, CCL-17, periostin, and IgE decreased in patients treated with lebrikizumab.

Lebrikizumab induced  no  hERG  inhibition in  vitro at  test  concentrations  up  to  6.0  mg/mL,  which  is markedly higher than clinical exposure (Table 9).

## Relationship between plasma concentration  and effect

Exposure-response (E-R)  model  was  developed including  efficacy  data  (EASI)  up  to  Week 16  from 5 randomised, double-blind, placebo-controlled Phase 2 and Phase 3 trials in patients with AD:  KGAF, KGAG (data up to week 12), KGAB, KGAC and KGAD.

A placebo model was developed first. Exploratory graphical analyses indicated response to placebo and use  of  topical  corticosteroids  (TCS)  appeared  to  improve  the  response,  as  expected.  The  placebo response was  described by an indirect  effect model, including  a TCS effect on  Kout and study  effects (Phase 2 vs Phase 3) on baseline EASI. Other structures (direct effect, asymptotic, linear model) were explored, but indirect  effect was most predictive (lowest  OFV). The logit fractional placebo effect was found to be most stable and was used in all models.

Lebrikizumab  treatment  data  were  added  to  the  placebo model  using  the  individual  EBEs  from  the population  PK  model.  Treatment  effect,  linear,  Emax  and  sigmoidal  Emax  drug  effect  models  were evaluated; the inhibitory Emax model provided the best fit. The TCS effect on Kout was re-evaluated with

<div style=\"page-break-after: always\"></div>

the addition  of lebrikizumab-treated patients.  A time-varying effect was added to  the model ( Δ OFV 13.7), then rewritten by expanding the TCS effect on Kout described in the placebo model.

Different implementations of random effects models were also assessed. The off-diagonal block from the placebo model was removed and rearranged to include correlation between the individual estimated EASI baseline and placebo effect, which improved model fit. Switching IIV from Emax to EC50 provided a lower condition number. Lastly, allowing estimation of Kout showed strong improvement in the model fit. This final structural model was carried forward for the evaluation of patient covariate effects.

Covariates of interest were explored graphically. Potential trends in continuous body weight were seen versus Kout and EC50. Age and body weight  were tested as covariates on Emax and EC50 but were not found to be significant. Study effect on estimated population baseline EASI score was re-evaluated as a covariate effect. With  the addition of the  treatment data, the study  effect was re-stratified into  three groups: KGAG (mean baseline 25.4), KGAF and KGAD (mean baseline 26.8),  KGAB and KGAC (mean baseline 29.0).  This  adjustment in the  baseline effect was significant  and allowed the  model to more accurately identify responders relative to each group.

The final model comprised an indirect effect, including a time varying TCS  effect on Kout  and study effects on baseline EASI (Figure 4 and Table 12).

Figure  4:  The  final  exposure-response  model  for  lebrikizumab  in  atopic  dermatitis.  Effect compartment represents the EASI score.

<!-- image -->

CL = clearance after IV administration; Cp = drug concentration; EC50 = drug concentration that produces 50% of maximum effect; Edrug = drug effect; Emax = maximum effect; Epbo = placebo effect; Kin = zero-order constant for production of response; Kout = first-order rate constant for loss of response; Q = intercompartmental clearance; SC = subcutaneous; TCS = topical corticosteroid; Vc = volume of distribution of central compartment; Vp = volume of distribution of peripheral compartment.

<div style=\"page-break-after: always\"></div>

Table 12: Parameter  Estimates of the Final Exposure-Response Model

| Param   | Alias                             |   Estimate | Relative SE (%)   | 95% CI            |
|---------|-----------------------------------|------------|-------------------|-------------------|
| 01      | Baseline EASI (KGAG)              |    23.9    | 3.1               | (22.4 - 25.3)     |
| 02      | Baseline EASI (KGAF,KGAD)         |    26.8    | 1.9               | (25.8 - 27.8)     |
| 03      | Kout (1/d)                        |     0.0523 |                   | (0.0489 - 0.0559) |
| 04      | Placebo Effect (Fixed)            |     0.702  |                   |                   |
| 05      | TCS on Kout (unitless multiplier) |     1.08   |                   | (1.06 - 1.10)     |
| 06      | sigmaE                            |     0.468  |                   | (0.463 - 0.474)   |
| 07      | Emax                              |     0.831  |                   | (0.761 - 0.883)   |
| 08      | EC50 (ug/mL)                      |    16.5    |                   | (9.84 - 27.6)     |
| 0g      | Baseline EASI (KGAB,KGAC)         |    29.5    | 0.5               | (29.3 - 29.8)     |
| W1.1    | w20                               |     1.74   | 8.4               | (1.45 - 2.03)     |
| W2.1    | WEo,Kout                          |    -0.0599 | 82.5              | (-0.157 - 0.0370) |
| W2.2    | wkout                             |     0.34   | 8.2               | (0.285 - 0.395)   |
| w3.2    | kout,Epbo                         |     0.086  | 81.8              | (-0.0519 - 0.224) |
| W3.3    |                                   |     2.46   | 7.9               | (2.08 - 2.84)     |
| W5.5    | WEC50 2                           |     4.96   | 32.2              | (1.83 - 8.09)     |

Parameter values for the final PK-PDmodel. EASI: Eczema Area and Severity Index; TCS: topical corticosteroid; E0: individual baseline EASI estimate; Epbo: placebo effect; sigmaE: individual variability on baseline; w2: variance of the IIV of parameter X, IIV is derived from variance according to /w2 · 100. m x,y : covariance of the IIV of parameters X and Y.

Shrinkage in ETA1 (estimated individual baseline, E0), ETA2 (Kout), ETA3 (Epbo), and ETA4 (EC50) were 12.9%, 32.1%, 24.9% and 53.6%, respectively. Due to high shrinkage values the model evaluation and predictive  performance  relied  mostly  on  VPC.  Logit-transformed  EASI  scores were  reasonably well described by the final model, with good agreement between predicted and observed data through week 12 (KGAG) and week 16 (all other studies) (Figure 5).  The percentage change from baseline (%CFB) EASI score was  reasonably well  described for those  with  typical  (median) and good  (95 th  percentile) response but the model underpredicted the response for those with poor response (5 th  percentile).

<div style=\"page-break-after: always\"></div>

Figure 5: Prediction-corrected  VPC of EASI Score over Time by Study.

<!-- image -->

A response curve over time for patients with and without  TCS is provided in Figure 6 for the prediction of percentage of patients achieving EASI-75 and EASI-90 response. The phase 3 dose regimen shows the highest predicted proportion of patients achieving reduction in EASI scores, compared to the lower phase 2 dose regimens (single loading dose of 500 mg or 250 mg followed by 250 mg Q4W or 125 mg Q4W).

<div style=\"page-break-after: always\"></div>

Figure 6: Predicted  percent  of EASI-75 (Top) and EASI-90 (Bottom) responders over time by dose.

<!-- image -->

Regimen refers to the loading dose followed by the treatment regimen. 500/250 mg Q2W: two loading doses of 500 mg Q2W followed by 250 mg Q2W; 500/250 mg Q4W: single loading dose of 500 mg followed by 250 mg Q4W; 250/125 mg Q2W: single loading dose of 250 mg followed by 125 mg Q4W.

## 2.6.3. Discussion on clinical pharmacology

## Bioanalytical  methods

## Serum lebrikizumab concentrations

The  ELISA  method  was  validated  For  performance  of  calibration  standards,  precision,  accuracy, selectivity, and short-term stability of the assay were acceptable. The Genentech method was used in studies  KGAZ,  KGBA, and  KGBF.  Bioanalysis  of  lebrikizumab  samples  in  these  clinical  studies  met precision and accuracy acceptance criteria and the performance of calibration standards was acceptable.

Subsequently,  the  ELISA assay was  validated according to  ICH  M10  Bioanalytical  method validation guideline. The partial re-validation was done with different lebrikizumab batch than the validation  and these methods  were shown  to be  comparable. The revalidated method  showed acceptable accuracy,

<div style=\"page-break-after: always\"></div>

precision, selectivity,  stability and parallelism  and was used in clinical studies KGAA,  KGAB,  KGAC,  KGAD, KGAE, KGAF, KGAM and KGBG. The  bioanalytical  reports of  these  clinical  studies  indicated  that  the sample analysis was reliable within  the  given accuracy and precision ranges. The reasons for repeat analysis were acceptable and the required criteria for incurred method analysis was met.

## ADA and NAb

In phase 1 and 2 studies, ELISA based methods were utilised  to characterise ADAs and NAbs against lebrikizumab. For phase 3 clinical trials Eli Lilly developed an  immunogenicity assay for the detection of ADAs and NAbs in the healthy and AD serum samples.

The original ELISA based ADA and NAb methods were acceptable in terms of precision, selectivity, and stability  but  their  sensitivity  and  drug  tolerance  was  lower  compared  to  the  immunogenicity  assay method. Therefore, it is difficult to compare the prevalence and incidence of ADAs and NAbs in phase 1 and 2 vs. phase 3 studies. Assessment of the ADA/NAb assays is focused on the immunogenicity assay method that was used in the pivotal studies in target population. Screening, confirmatory, titration and neutralizing  cut  points  immunogenicity  assay  method  were  determined  in  an  acceptable  manner. ADA/NAb bioanalytical reports for studies KGAA, KGAB, KGAC, KGAD and KGAE were provided and were within the given accuracy and precision ranges.

## PD biomarkers

Candidate PD biomarkers were determined in two phase 2 AD studies, one of which was a small openlabel study, and two asthma studies. No validation reports for the PD biomarker bioanalytical methods were provided in  the dossier. This  is not  pursued  because the  candidate PD  biomarker data are not considered essential for the application.

## Bioanalytical methods used in clinical study KGAK

In clinical study KGAK two bioanalytical methods for the determination of bactericidal antibody (SBA) against Neisseria meningitidis serogroup C and tetanus Toxoid IgG in human serum were utilised. SBA method  was  validated  in  terms  of  precision,  accuracy,  linearity,  specificity  and  stability  (ambient temperature and freeze/thaw) and was considered acceptable. Only high-level summary of the validation results for anti-tetanus  Toxoid IgG Enzyme Immunoassay method was provided but according to the summary the  validation  seems  to  be  appropriate.  The  bioanalytical  report  of  clinical  study  KGAK regarding SBA was provided but only contained information about control performance which, however, seems to  be acceptable. The Applicant committed to provide the final bioanalytical report for tetanus toxoid IgG by the end of November 2023.

## Population PK analysis

The dataset included in the original population PK analysis includes only data from Induction period (up to week 16) and not from maintenance period of the phase 3 studies. The Applicant provided updated population PK analysis with data from maintenance period (from weeks 16 to 52) included; the majority of the new data were trough concentrations at steady state. The model estimates from the original and the updated datasets parameters were similar and had overlapping 95% CI.

The  model development strategy  was  generally appropriate;  the  fixed allometric  exponent (0.8)  for clearance parameters differs slightly from the more  commonly used exponent 0.75, but it is unlikely that this would significantly affect the parameter estimates and applicability of the model. Most of the THETA parameters were estimated  with  good  precision (low  standard  error of estimate)  but  ETA shrinkage values were high (24% to 48%), probably due to sparse sampling in majority of subjects and low number of subjects with IV administration. The pcVPC plots indicated that the base model adequately described the observed data.

<div style=\"page-break-after: always\"></div>

Only linear (dose-independent) CL  was tested in  model development. This  is acceptable because the model adequately described  the  observed data  and  non-compartmental  analyses of  several studies indicated that clearance of lebrikizumab is similar over the investigated dose range.

The  estimate for  SC bioavailability  (0.861,  or  86.1%)  is  larger than  that  usually reported for  mAbs (typically ~60-70%)  and  the  interindividual  variability of  the  estimate was  high  (CV% of  119).  This estimate  is  based  on  little  data  following  IV  administration,  which  are  from  one  study  (KGBA). Supplementary  information  was  provided  upon  request,  including  additional  PK  data  following  IV administration in patients with asthma. These data supported the initial estimate for SC bioavailability.

A total of 9 covariates were statistically significant in the SCM but not considered relevant based on the definitions pre-specified in the analysis plan (age, eGFR, and race on CL;  age, age category, disease state,  and  sex  on  V2;  disease  state  and  race  on  ka.  Forest  plots  and  simulations  (supplementary information provided upon request) supported the conclusion that age, gender, race, eGFR, and disease state (AD vs. healthy subjects) had no clinically relevant effect on exposure to lebrikizumab.

## Absorption and bioavailability

Four  studies  (KGBA,  KGAY,  KGAM,  and  KGBG)  in  healthy  subjects  were  carried  out  to  evaluate bioavailability  of  lebrikizumab after  SC  administration  and  PK  similarity  of  different  formulations  or devices. The general problem in  these studies was that  the study sampling periods were too short to optimal characterise the whole PK profile, and the PK sampling could have been more frequent around the tmax.

In study KGBA the PK of lebrikizumab following SC and IV administration was evaluated, and the absolute SC bioavailability was estimated. According to the clinical study report there were numerous anomalous values  in  lebrikizumab  concentrations, which were  attributed to suspected  problems  with the bioanalytical  assay.    Supplementary  information  was  provided  upon  request,  including  sensitivity analysis for study  KGBA and additional  PK data  following  IV administration  in  patients  with  asthma. These data supported the initial estimate for SC bioavailability.

PK similarity was established between the PFS-NSD  and the AI devices in study KGBG. The geometric means for the primary PK parameters (i.e., Cmax, AUC0-tlast and AUC0-∞ ) were slightly higher with AI than with PFS-NSD and the 90% CIs were above 1 (not including the unity in the range). The differences are not considered clinically relevant.

The KGAM study showed overall comparable total  exposure (AUC)  of 250 mg  doses administered by 2 injections x 1 mL and a single injection of 2 mL. The geometric mean Cmax was 11% lower following the  single  injection  of  2 mL,  suggesting  that  absorption  is  slightly  more rapid  following  2  separate injections.  Results of study KGAM have no impact on the benefit/risk profile because both applied drug products  (PFS-NSD  and  AI) contain  250 mg  of  lebrikizumab in  2 mL  solution  (125 mg/mL,  which  is administered as a single injection. This method of administration was used in the pivotal phase 3 studies.

In study KGAY, the studied histidine formulations 37.5 mg/mL by a PFS-NSD and 125 mg/mL by a needle and syringe were shown to have similar PK. Results of study KGAY have little  significance because the 37.5 mg/mL formulation was terminated for development and used only in this study.

The proposed method of administration (section 4.2 of the SmPC) is SC injection into the thigh, abdomen, or upper arm. This is acceptable; results of the population PK analysis and study KGBG indicate that no clinically meaningful difference in exposure is expected between the three injection sites. This has been adequately reflected in SmPC section 5.2.

<div style=\"page-break-after: always\"></div>

## Distribution and elimination

The  PK  of  lebrikizumab  in  adult  and  adolescent populations  was  characterised using  population  PK analysis. The estimated total volume of distribution  and clearance for a 70-kg subject at steady state were  5.14 L and  0.154 L/day,  respectively,  and  the estimated mean  elimination half-life  was approximately  24.5  days  (SD  5.4 days).  Comparable  values  were  reported  in  individual  clinical pharmacology studies using noncompartmental analysis. These values are similar to those reported for several mAb drug products.

Metabolism and excretion pathways, binding to plasma proteins, and distribution to erythrocytes were not investigated. This is acceptable because lebrikizumab is a large protein.

## Dose proportionality and time dependencies

Formal statistical assessment of dose proportionality was not conducted in studies KGBB and KGBF, but dose  normalised AUC  values suggested  no  meaningful  deviation  from  dose  proportionality  in  these studies. In study KGAZ, statistical analysis to assess dose  proportionality was conducted using the power model for exposure parameters (Cmax, AUC0-t, and AUC0-∞ adjusted for weight).  In Japanese subjects, the  90%  CI  of  the  slope  estimate  of  each parameter  contained  1.0  indicating  dose proportionality, whereas in Caucasian subjects the slope estimate (90% CI) was 1.39 (1.25, 1.53), 1.17 (1.01, 1.32), and 1.13 (0.97, 1.29) for weight-adjusted Cmax,  AUC0-t,  and AUC0-∞ ,  respectively,  indicating slightly more than dose proportional increase in exposure, especially for Cmax. In addition, sparse PK sampling data from studies KGAF and KGAG indicated dose proportionality (data shown in Clinical AR). The dose was not tested as a covariate on PK parameters in population PK analysis and time-dependent clearance was not evaluated, but linear clearance adequately described the observed data. Based on the overall data, the Applicant's conclusion of dose proportional PK is acceptable. This information has been adequately reflected in SmPC section 5.2.

## PK in target population

The proposed dose regimen (induction phase: 500 mg SC at weeks 0 and 2 followed by 250 mg SC Q2W up  to  week 16,  followed by  maintenance phase  250 mg  SC Q4W),  was used  in  the  pivotal  phase 3 studies; a more frequent maintenance phase regimen (250 mg Q2W) was also tested in them. Using the proposed regimen, exposure to lebrikizumab is highest during the first 16 weeks and the steady state average concentration (Cavg,ss) is  approximately 50%  lower during  the maintenance phase compared with the induction phase.

## Special populations

Dedicated studies in special populations (e.g., patients with impaired renal and hepatic function) were not  conducted,  which  is  acceptable because lebrikizumab  is  a  large  protein  and  is  not  expected to undergo  significant  renal  or  hepatic  elimination.  Potential  effects  of  intrinsic  factors  [including  age, weight,  gender, race, markers of renal and  hepatic function,  and disease state (patients  with  AD  vs healthy  subjects)]  on  PK  parameters were  tested  in  population  PK  analysis.  Exposure  is  inversely correlat ed with body weight. The predicted mean steady state exposure in adolescents (12 to &lt;18 years of age weighing ≥40 kg) with  AD was approximately 20% higher compared with  adults, which can be attributed to the lower body weight distribution in adolescents.  The Applicant did not yet have clinical data on PK, efficacy, and safety of lebrikizumab in subjects weighing &lt; 40 kg. The other aforementioned subject characteristics  were considered  not to have  meaningful effect on PK  in the population PK analysis. Based on the  population PK analysis, dose adjustment in  special populations  is not warranted. These issues are reflected in sections 4.1 and 4.2 of the SmPC.

<div style=\"page-break-after: always\"></div>

## PK drug interactions

Monoclonal antibodies are not anticipated to directly impact the PK of other drugs. Published literature indicate  that  blockade of  the  IL-4 α receptor  (thus  blocking  IL-13  activity)  was  not  associated with changes in CYP3A, CYP2C19, CYP2C9, CYP1A2, or CYP2D6 activity in patients with  AD. Hence, PK drug interactions are not expected  for lebrikizumab in the target population and the corresponding  information in section 4.5 of the SmPC is acceptable.

## Pharmacodynamics

Pharmacodynamic endpoints have limited value for the current application. Nevertheless, they do provide some limited  evidence that  the  use of lebrikizumab can modulate  the  IL-13  pathway.  Mainly clinical efficacy endpoints were used in the proof-of-concept and dose finding studies.

Changes  in  candidate  biomarkers  in  patients  with  AD  [serum  periostin,  IgE,  CCL-13  (monocyte chemotactic protein-4), CCL-18 (pulmonary and activation-regulated chemokine), and peripheral blood eosinophils] were evaluated as an exploratory objective in one randomised double-blind phase 2 study (KGAG).  The  results  indicated  that  treatment  with  lebrikizumab  (plus  TCS)  was  associated  with decreased CCL-13, CCL-18,  and periostin levels, and increased peripheral blood eosinophils compared with  placebo (plus  TCS).  Serum IgE levels decreased similarly in  lebrikizumab- and  placebo-treated patients. No dose-response association was observed for any of the biomarkers (lebrikizumab 125 mg single  dose  vs. 250 mg  single  dose vs.  125 mg  three  doses Q4W).  In  addition,  PD  biomarker data including  CCL-17  were evaluated in patients  with  asthma  in two  phase 3 studies  (KGAN and KGAO). Overall, the results indicate that  treatment with  lebrikizumab was associated with  decreased levels of serum periostin, CCL-13, CCL-17, CCL-18, and IgE, although the between-subject variability was very high for IgE.

During  the  assessment, the  Applicant  provided  the  results  of  a  randomised, double-blind,  placebocontrolled study to assess the  impact of lebrikizumab on vaccine immune responses in adult patients with moderate-to-severe AD [Study J2T-MC-KGAK (KGAK)]. The vaccines used in the study were Tdap (Diphtheria and  Tetanus  Toxoids  and  Acellular  Pertussis  Vaccine  Adsorbed;  Sanofi),  and  MCV (Meningococcal (Groups A, C, Y, and W-135)  Oligosaccharide Diphtheria  CRM197  Conjugate Vaccine; GlaxoSmithKline). The results are reflected in section 4.5 of the SmPC.

An exposure-response (E-R) analysis was conducted by the Applicant. The dataset included efficacy data (observed EASI) up to Week 16 from 5 randomised, double-blind, placebo-controlled Phase 2 and Phase 3 trials: KGAF, KGAG (data up to week 12), KGAB, KGAC and KGAD. Exposure was based on individual empirical Bayesian estimates from a population PK model. Approximately 10.0% (n=131) of subjects in the dataset were adolescents  (12 to &lt;18 years of age). Because the proposed posology was investigated in the pivotal phase 3 trials, the E-R model is considered as supportive information. Model development was overall acceptable, although some details were not sufficiently presented. The E-R model was built using up to 16 weeks efficacy data (i.e., induction  phase), and it was able to adequately describe the EASI  response from  week  0  to  week  16.  However, supplementary  information  provided  during  the assessment indicated that the E-R model could not accurately describe the observed clinical efficacy  from week 16 to week 52 in studies KGAB and KGAC. Given the low impact of the E-R model for the marketing authorisation application these issues are not further pursued by the CHMP.

## 2.6.4. Conclusions on clinical pharmacology

The PK profile of lebrikizumab has been adequately characterised although it relies mostly on population PK analysis. The final proposed dosing regimen is acceptable. Appropriate information relevant for the prescribers and patients has been included in the SmPC and package leaflet.

<div style=\"page-break-after: always\"></div>

## 2.6.5. Clinical efficacy

The pivotal Phase 3 studies in AD are shown in Table 13.

Table 13: Pivotal Phase 3 Studies in AD

|                            | StudyKGAB                                                                          | StudyKGAB                                                                          | Study KGAC                                                        | Study KGAC                                                        | Study KGAD                        |
|----------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|-----------------------------------|
| N                          | 424                                                                                | 424                                                                                | 427                                                               | 427                                                               | 211                               |
| Participants               | Adults and adolescentsa                                                            | Adults and adolescentsa                                                            | Adults and adolescentsa                                           | Adults and adolescentsa                                           | Adults and adolescentsa           |
| Monotherapy or combination | Monotherapy                                                                        | Monotherapy                                                                        | Monotherapy                                                       | Monotherapy                                                       | Combination w/ TCS                |
| Treatment periods          | Induction (0-16W)                                                                  | Maintenance (16-52W)                                                               | Induction (0-16W)                                                 | Maintenance (16-52W)                                              | Induction (0-16W)                 |
| Treatment                  | PBO Q2W LEB 250mgQ2Wb                                                              | PBO Q2W LEB 250mg Q2Wc LEB 250mg Q4Wc                                              | PBO Q2W LEB 250mg Q2wb                                            | PBO Q2W LEB 250mg Q2Wc LEB 250mg Q4Wc                             | PBO Q2W +TCS LEB 250mg Q2Wb + TCS |
| Randomization ratio        | 1:2                                                                                | 1:2:2d                                                                             | 1:2                                                               | 1:2:2d                                                            | 1:2                               |
| Location of study          | Australia,Canada,Estonia. France.Latvia,Lithuanian. Poland, Spain, South Korea, US | Australia,Canada,Estonia. France.Latvia,Lithuanian. Poland, Spain, South Korea, US | Bulgaria, Canada, Germany. Mexico, Singapore, Taiwan, Ukraine, US | Bulgaria, Canada, Germany. Mexico, Singapore, Taiwan, Ukraine, US | Canada, Germany. Poland. US       |
| Study status               | Completed                                                                          | Completed                                                                          | Completed                                                         | Completed                                                         | Completed                         |

Abbreviations:EASI75=atleast75%improvementfromBaselineinEczemaAreaandSeverityIndexscore;IGA =Investigator's Global Assessment;LEB=lebrikizumab;N=number of participants included in efficacy analyses; PBO =placebo;Q2W= every 2 weeks;Q4W= every 4 weeks;TCS= topical corticosteroid;US = United States;W =week;w/=with.

- a Adults(218years);Adolescents(12 to&lt;18years weighing40kg)
- b Participants randomly assigned to lebrikizumab 250 mg Q2W at Baseline received 500-mg loading doses at Week 0 and Week 2.
- C Participantswhoreceivedplaceboduring the first16weeksof the study andwhowerererandomized to lebrikizumabtreatment,receivedloading dosesof500mg atWeeks16 and 18ifrandomized totheLEB 250mgQ2W arm,oratonlyWeek16if randomized to the250mgQ4Warm.
- P OnlyparticipantswhoachievedanIGAof0or1orEASI75atWeek16anddidnotuserescue treatment beforeWeek16werererandomizedatthestartofthemaintenancephase.Allotherparticipantswere treatedwithLEB250mgQ2wduring themaintenancephase.

## 2.6.5.1. Dose response study

The selection of doses into the pivotal Phase 3 studies was based on Phase 2b dose-ranging study KGAF. The study included patients ≥18 years with chronic AD that had been present for ≥1 year. Patients had moderate-tosevere  AD, defined  by EASI  score  ≥16, an IGA  score  ≥3, and ≥10% BSA of  AD involvement. Patients  were  to  have  a  history  of  inadequate  response  to  treatment  with  topical  medications  or determination that topical treatments were medically inadvisable.

The patients participated in the study up to a maximum of approximately 36 weeks, including screening period (up to approximately 4 weeks), a treatment period (baseline through Week 16), and a follow-up period (through Week 32).

Altogether 280 patients were enrolled; 73, 80, and 75 patients to the lebrikizumab 125 mg Q4W (with 250 mg loading dose at week 0), 250 mg Q4W (with 500 mg loading dose at week 0), and 250 mg Q2W (with 500 mg loading dose at weeks 0 and 2) groups, respectively, and 52 patients to the placebo group.

<div style=\"page-break-after: always\"></div>

All 280 randomised patients were included in the  mITT population defined as all randomised patients who received at least 1 dose  of study drug. The primary  and key secondary  endpoints are shown in Table 14.

Table 14: Primary and Key Secondary  Endpoints for Study KGAF at Week  16

|                                                                                                      | PBO N=52                                                                                             | LEB 125mg Q4W N=73                                                                                   | LEB 250mg Q4W N=80                                                                                   | LEB 250mg Q2W N=75                                                                                   |
|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|
| Loading dose                                                                                         |                                                                                                      | 250mg Wo                                                                                             | 500mg W0                                                                                             | 500mg W0 + W2                                                                                        |
| Primary Endpoint: EASI percentage change from Baseline at Week 16                                    | Primary Endpoint: EASI percentage change from Baseline at Week 16                                    | Primary Endpoint: EASI percentage change from Baseline at Week 16                                    | Primary Endpoint: EASI percentage change from Baseline at Week 16                                    | Primary Endpoint: EASI percentage change from Baseline at Week 16                                    |
| LS Mean (LSSD)a. b p-Value vs. placeboa                                                              | -41.1 (56.5)                                                                                         | -62.3 (37.3) .0165                                                                                   | -69.2 (38.3) .0022                                                                                   | -72.1 (37.2) .0005                                                                                   |
| Proportion ofparticipants withIGA 0,1 and≥2-pointreductionfromBaseline toWeek 16                     | Proportion ofparticipants withIGA 0,1 and≥2-pointreductionfromBaseline toWeek 16                     | Proportion ofparticipants withIGA 0,1 and≥2-pointreductionfromBaseline toWeek 16                     | Proportion ofparticipants withIGA 0,1 and≥2-pointreductionfromBaseline toWeek 16                     | Proportion ofparticipants withIGA 0,1 and≥2-pointreductionfromBaseline toWeek 16                     |
| Participants with response (%)b                                                                      | 15.3                                                                                                 | 26.6                                                                                                 | 33.7                                                                                                 | 44.6                                                                                                 |
| p-Value vs. placeboc                                                                                 |                                                                                                      | .1917                                                                                                | .0392                                                                                                | .0023                                                                                                |
| Proportion of participants with EASI 75 at Week 16                                                   | Proportion of participants with EASI 75 at Week 16                                                   | Proportion of participants with EASI 75 at Week 16                                                   | Proportion of participants with EASI 75 at Week 16                                                   | Proportion of participants with EASI 75 at Week 16                                                   |
| Participants with response (%)b                                                                      | 24.3                                                                                                 | 43.3                                                                                                 | 56.1                                                                                                 | 60.6                                                                                                 |
| p-Value vs.placeboc                                                                                  |                                                                                                      | .061                                                                                                 | .0021                                                                                                | .0005                                                                                                |
| Proportion ofparticipantswithEASI 90 at Week16                                                       | Proportion ofparticipantswithEASI 90 at Week16                                                       | Proportion ofparticipantswithEASI 90 at Week16                                                       | Proportion ofparticipantswithEASI 90 at Week16                                                       | Proportion ofparticipantswithEASI 90 at Week16                                                       |
| Participants with response (%)b                                                                      | 11.4                                                                                                 | 26.1                                                                                                 | 36.1                                                                                                 | 44.0                                                                                                 |
| p-Value vs. placeboc                                                                                 |                                                                                                      | .0800                                                                                                | .0062                                                                                                | .0006                                                                                                |
| Proportion of participants with Pruritus NRS 4-point or greater improvement from Baseline to Week 16 | Proportion of participants with Pruritus NRS 4-point or greater improvement from Baseline to Week 16 | Proportion of participants with Pruritus NRS 4-point or greater improvement from Baseline to Week 16 | Proportion of participants with Pruritus NRS 4-point or greater improvement from Baseline to Week 16 | Proportion of participants with Pruritus NRS 4-point or greater improvement from Baseline to Week 16 |
| Participants with response n/N (%)                                                                   | 6/22 (27.3)                                                                                          | 23/55 (41.8)                                                                                         | 27/57 (47.4)                                                                                         | 35/50 (70.0)                                                                                         |
| p-Value vs. placebod                                                                                 |                                                                                                      | .2371                                                                                                | .1067                                                                                                | .0008                                                                                                |

Abbreviations:ANCOVA=analysis ofcovariance;EASI=EczemaAreaandSeverityIndex;EASI75=75% reduction from Baseline in EASI; EASI 90 = 90% reduction from Baseline in EASI; IGA = Investigator's Global Assessment;IGA 0.1 =IGA score of 0 or 1, with a 2-point or greater reduction from Baseline;LEB = lebrikizumab; LS = least square; LSSD = least square standard deviation; MCMC = Markov Chain Monte Carlo; N =number of participants in the analysispopulation; n=number of participants inthe specified category;NRS = numeric rating scale; PBO = placebo; Q2W = every 2 weeks; Q4W = every 4 weeks.

- LS mean, SD, contrast p-values from an ANCOVA with a factor of treatment group and corresponding baseline EASI as a covariate. Values were adjusted for multiple imputation.
- missing baseline value were not included in the analyses.
- p-Value from pairwise Cochran-Mantel-Haenszel tests.Values were adjusted for multiple imputations.
- p-Value from pairwise Cochran-Mantel-Haenszel tests. No imputations were made for missing data.

In terms of lebrikizumab doses in the pivotal studies, the data from the 16-week Phase 2b study KGAF supported selection of the lebrikizumab 250 mg Q2W (with the 500  mg loading doses at weeks 0 and week 2) as the induction dose (weeks 0-16) for the Phase 3 studies.

## 2.6.5.2. Main studies

KGAB and KGAC studies had an identical title: 'a randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of lebrikizumab in patients with moderate-to-severe atopic dermatitis'

KGAD was  titled:  'a  randomized, double-blind,  placebo-controlled trial  to  evaluate the  efficacy and safety of lebrikizumab when used in combination with topical corticosteroid treatment in patients with moderate-to severe atopic dermatitis'

KGAB and KGAC studies had identical design and therefore the studies are described together.

<div style=\"page-break-after: always\"></div>

## Methods

## KGAB and KGAC studies

KGAB and  KGAC studies  were randomised,  double-blind,  placebo-controlled, parallel-group  studies designed to confirm the safety and efficacy of lebrikizumab in adults and adolescents (12 to less than 18 years of age that weighted at least 40 kg) with moderate-to-severe AD.

Both  studies  had a  screening period 30  to  7 days before the  baseline visit  (day 1)  and  a 16-week induction treatment  period followed by a 36-week long-term maintenance treatment  period up to 52 weeks of total  treatment. Patients who terminated early from the study or did not enroll in the long-term extension study (KGAA), underwent a follow-up visit approximately 12 weeks after the last study drug injection.

During  the  16-week  induction  period,  the  patients  were  randomised (2:1)  to  receive lebrikizumab 250 mg  Q2W  (loading  dose  of  500  mg  given  at  baseline  and  week  2)  or  placebo  Q2W.  Patients considered to have responded to treatment were defined as having an IGA score of 0 or 1, or at least a 75% reduction in  EASI (EASI 75  from baseline to Week 16,  and not  receiving any rescue treatment during  the  induction  period). After completion of the  Week 16  visit,  patients  who responded to  the lebrikizumab treatment were randomly reassigned (2:2:1) to lebrikizumab 250 mg Q2W, lebrikizumab 250 mg Q4W or placebo.

Patients who did not achieve an IGA of 0 or 1 nor an EASI 75  at Week 16 or who received topical or systemic rescue therapy between baseline to Week 16 were assigned to an Escape Arm and received open-label  lebrikizumab 250 mg  Q2W  through  Week 52.  Patients  who  had  received placebo  during Induction Period initiated lebrikizumab 250 mg Q2W after loading doses.

Following re-randomisation at Week 16, patients not maintaining an EASI 50 response at Weeks 24, 32, 40, or 48 were assigned to an Escape Arm and received open-label lebrikizumab 250 mg Q2W through Week 52.

Patients who did not achieve an EASI 50 response in the Escape Arm after 8 weeks of treatment were terminated from the study.

Figure 7: Study design of KGAB and KGAC studies

<!-- image -->

Abbreviations:D/C=discontinue;EASI=EczemaAreaandSeverityIndex;EASI50=50%reductioninEASI;LEB =lebrikizumab;n=number of participants;Q2w= every 2weeks;Q4w= every 4 weeks.

<div style=\"page-break-after: always\"></div>

## KGAD study

KGAD study  was  a  randomised, double  blind,  placebo-controlled, parallel-group study  designed  to evaluate the  safety and efficacy of lebrikizumab + TCS compared with  placebo +  TCS in  adults  and adolescents (12 to less than 18 years  of age  that weighted at least 40 kg) with moderate-to-severe  AD.

The study had a screening period 30 to 7 days before the baseline visit (day 1) and 16-week treatment period. After completion of the Week 16 visit, patients were offered the option to continue treatment in a separate long-term extension study (KGAA). Patients who terminated early or chose not to enter the long-term extension study, underwent a safety follow-up approximately 12 weeks after the last study drug injection.

Figure 8: Study design of KGAD study

<!-- image -->

Abbreviations: AD = atopic dermatitis; EASI= Eczema Area and Severity Index; EASI 75 = 75% reduction in EASI; IGA = Investigator's Global Assessment; LD = loading dose ; LEB = lebrikizumab; LTE = longterm extension; PBO = placebo; TCS = topical corticosteroid.

- a Use of TCS was required at baseline but could be used, tapered, stopped, and resumed as needed after that.
- c 500 mg loading dose at W0 and W2.
- b A total of 228 participants with moderate-to-severe AD, including 53 adolescent participants.
- d Participants who completed Study KGAD had the option to enroll in Study KGAA long-term extension.
- Otherwise, participants entered a safety follow-up period for 12 weeks after their last dose.
- e ≤30-day screening period.
- 8 FDA primary endpoint.
- f IGA (0,1) with ≥2-point improvement from baseline.
- h EMA co-primary endpoint.

## Study Participants

## KGAB and KGAC studies

The study population consisted of adult and adolescent patients with  moderate-to-severe AD who had inadequate response to treatment with topical medications or for whom topical treatment was otherwise medically inadvisable.

The eligibility criteria for the KGAB and KGAC studies were identical.

## Inclusion criteria

Patients were to meet all the following criteria to be eligible for the study:

1. Adults and adolescents (≥12 to &lt;18 years of age and weighing ≥40 kg).

<div style=\"page-break-after: always\"></div>

2. Chronic AD (according to American Academy of Dermatology Consensus Criteria) that has been present for ≥1 year before the screening visit.
3. Eczema Area and Severity Index (EASI) score ≥16 at the baseline visit.
4. Investigator Global Assessment (IGA) score ≥3 (scale of 0 to 4) at the baseline visit.
5. ≥10% body surface area (BSA) of AD involvement at the baseline visit.
6. History  of  inadequate response to  treatment  with  topical  medications; or  determination  that topical treatments are otherwise medically inadvisable.
7. Apply a stable dose of non-medicated topical moisturise r at least twice daily for ≥7 days prior to the baseline visit.
8. Completed electronic  diary entries  for pruritus  and  sleep-loss for  a minimum  of  4  of  7 days preceding randomisation.
9. Willing and able to comply with all clinic visits and study-related procedures and questionnaires.
10. For  women  of  childbearing  potential:  agree  to  remain  abstinent  (refrain  from  heterosexual intercourse) or use a highly effective contraceptive method during the treatment period and for at least 18 weeks after the last dose of lebrikizumab or placebo.
11. Male patients must agree to use an effective barrier method of contraception during the study and for a minimum of 18 weeks following the  last dose of study drug if sexually active with a female of child bearing potential
12. Provide signed informed consent/assent.

## Exclusion criteria

Patients meeting any of the criteria below were to be excluded from the study:

1. Participation in a prior lebrikizumab clinical study.
2. History of anaphylaxis as defined by the Sampson criteria (Sampson, 2006).
3. Treatment with  topical  corticosteroids, calcineurin inhibitors  or phosphodiesterase-4 inhibitors such as crisaborole within 1 week prior to the baseline visit.
4. Prior treatment with dupilumab or tralokinumab.
5. Treatment with any of the following agents within 4 weeks prior to the baseline visit:
- a. Immunosuppressive/immunomodulating drugs (e.g., systemic corticosteroids, cyclosporine,  mycophenolate-mofetil,  IFNγ, Janus  kinase  inhibitors, azathioprine, methotrexate, etc.)
- b. Phototherapy and photochemotherapy (PUVA) for AD.
6. Treatment with the following prior to the baseline visit:
- a. An investigational  drug within  8 weeks or within  5  half-lives (if known),  whichever is longer.
- b. B Cell-depleting biologics, including rituximab, within 6 months.
- c. Other biologics within 5 half-lives (if known) or 16 weeks, whichever is longer.
7. Use of prescription moisturisers within 7 days of the baseline visit.

<div style=\"page-break-after: always\"></div>

8. Regular use  (more  than  2  visits  per  week)  of  a  tanning  booth/parlor  within  4 weeks of  the screening visit.
9. Treatment with a live (attenuated) vaccine  within 12 weeks  of the baseline visit or  planned during the study.
10. Uncontrolled  chronic disease that  might  require bursts  of oral corticosteroids, e.g.,  comorbid severe  uncontrolled  asthma  (defined  by  an  ACQ5 score ≥1.5 or a history of ≥2 asthma exacerbations within the last 12 months requiring systemic [oral and/or parenteral] corticosteroid treatment or hospitalisation for &gt; 24 hours).
11. Active  chronic  or  acute  infection  requiring  treatment  with  systemic  antibiotics,  antivirals, antiparasitics,  antiprotozoals,  or  antifungals  within  2 weeks  before  the  baseline  visit,  or superficial skin infections within 1 week before the baseline visit.

NOTE: patients may be rescreened after infection resolves.

12. Evidence of active acute or chronic hepatitis (as defined by the Department of Health &amp; Human Services Centers for Disease Control and Prevention) or known liver cirrhosis.
13. Diagnosed active endoparasitic infections or at high risk of these infections.
14. Known or suspected history of immunosuppression, including history of invasive opportunistic infections (e.g., tuberculosis [TB], histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, and aspergillosis) despite infection resolution: or unusually frequent, recurrent, or prolonged infections, per the Investigator's judgment.
15. History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening.
16. In  the  Investigator's opinion,  any  clinically significant  laboratory results  from  the  chemistry, haematology or urinalysis tests obtained at the screening visit.
17. Presence of skin comorbidities that may interfere with study assessments.
18. History of malignancy, including  mycosis fungoides, within  5 years before the  screening visit, except completely treated in situ carcinoma of the cervix, completely treated and resolved nonmetastatic squamous or basal cell carcinoma of the skin.
19. Severe concomitant  illness(es) that  in the Investigator's judgment would  adversely affect the patient's  participation  in  the  study.  Any other  medical or  psychological  condition  that  in  the opinion of the  Investigator may suggest  a new and/or insufficiently  understood disease, may present an unreasonable risk to the study patient because of his/her participation in this clinical trial, may make patient's participation unreliable, or may interfere with study assessments.
20. Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.

## KGAD study

The eligibility criteria for the KGAD study were identical to the criteria in the KGAB and KGAC studies (see above), except for the following:

- Concerning  the  inclusion  criteria  'History  of  inadequate  response to  treatment  with  topical medications; or determination that topical treatments are otherwise medically inadvisable', the wording  'or  determination  that  topical  treatments  are  otherwise  medically  inadvisable' was removed, as TCS use was required in the study (per Amendment 1, dated 13 May 2020).

<div style=\"page-break-after: always\"></div>

- Whereas patients with prior treatment with dupilumab or tralokinumab were excluded from the KGAB and KGAC studies (exclusion criteria no. 4), patients with prior dupilumab treatment could enroll  into  the  KGAD  study  after  appropriate  washout  (patients  with  prior  treatment  with dupilumab within 8 weeks were to be excluded).
- Patients  that  had  had  an  important  side  effect  to  TCS  (e.g.,  intolerance  to  treatment, hypersensitivity reactions, significant  skin atrophy, and systemic effects), as assessed by the investigator or treating physician that would prevent further use, were to be excluded, as TCS was required in the study (criterion added per Amendment 1, dated 13 May 2020).

## Treatments

In each of the pivotal studies (KGAB, KGAC and KGAD), the study drug (lebrikizumab and placebo) was supplied as a sterile prefilled syringe with  a preassembled needle safety device. Each prefilled syringe was intended for a single 2-mL dose (250 mg) administered subcutaneously.

## KGAB and KGAC studies

The treatment schemes in the KGAB and KGAC studies were identical.

## Induction period

During the 16-week induction period, the patients received lebrikizumab 250 mg Q2W (loading dose of 500 mg given at baseline and week 2) or placebo Q2W. All study drug injections were administered in the clinic.

## Use of rescue therapy  in the Induction Period

Use of topical or systemic treatments for AD was prohibited during the induction period, unless used as a rescue therapy. Patients  who experienced intolerable AD  symptoms and required rescue treatment could be started on topical treatments, such as TCS,  and still continue study drug, but were  then assigned to  the Escape  Arm at  Week 16.  If  patients  required  systemic  rescue  treatments,  such  as  oral corticosteroids, phototherapy,  and  cyclosporine, study  drug  was  discontinued,  though  patients  could enter the escape arm after a washout period equal to 5 or more half-lives of the medication.

## Maintenance  Period

During  the 36-week maintenance period, the patients  were assigned to  either maintenance  blinded period or maintenance  escape  period based on  their  response to  treatment  during  the  induction period. Because treatments were administered between visits as well as at visits, patients were trained and instructed to self-administer study drug at home.

## Maintenance  Blinded Period

After completion of the Week-16 visit, patients who completed the induction period and achieved an IGA 0,1 or EASI 75  response, without  the use of rescue therapy, entered the maintenance blinded period and  received  lebrikizumab  250 mg  Q2W,  lebrikizumab  250 mg  Q4W  or  placebo.  Responders  who received placebo during the  first 16 weeks of study and who were randomised to  lebrikizumab arms, received a loading dose of lebrikizumab of either 500 mg at week 16 or 500 mg given at week 16 and 18 based on the active treatment group assigned in the maintenance period.

## Maintenance  Escape Period

The maintenance escape period included patients who achieved neither IGA 0,1 nor EASI 75 at Week 16, received topical or systemic rescue therapy from baseline to week 16, or did not maintain an EASI 50 response at Week 24, 32, 40, or 48 following rerandomisation to the maintenance blinded period.

<div style=\"page-break-after: always\"></div>

All patients received open-label lebrikizumab 250 mg Q2W through week 52.

Patients in the Escape Arm received blinded loading doses based on their prior treatment assignment:

- Patients assigned to the lebrikizumab treatment group in the Induction Period who then entered the Escape Arm received 2 injections at Week 16 and Week 18, i.e. 1 lebrikizumab injection (250 mg) and 1 placebo injection.
- Patients  assigned to  the  placebo treatment  group  in  the  Induction  Period who  then  entered  the Escape Arm received 2 lebrikizumab injections (500 mg) at Week 16 and Week 18
- Patients who did not achieve an EASI 50 response after 8 weeks of treatment were terminated from the study.

## Use of rescue therapy  in the Maintenance  Period

Intermittent use of topical rescue medications for AD was permitted. Patients who required short-term systemic treatment for symptoms of AD were assessed on a case-by-case basis and discussed with the medical monitor prior to initiating treatment.

## Topical moisturiser

All patients were  to use  nonmedicated  topical  moisturiser daily  during the 7 days  preceding randomisation and throughout the study.

## KGAD study

## Treatment  period

During the 16-week treatment period, the patients received lebrikizumab 250 mg Q2W (loading dose of 500 mg given at baseline and week 2) + TCS or placebo Q2W + TCS.

## Concomitant topical treatment

All patients were instructed to use TCS for AD symptoms starting at the Baseline visit (Day 1).  Patients were provided with  a mid-potency TCS (triamcinolone acetonide 0.1% cream) and a low potency TCS (hydrocortisone 1% cream) for use on sensitive skin areas. Patients were allowed to taper or stop TCS use as needed. If AD lesions returned or a patient  experienced AD exacerbation, TCS treatment could be resumed at the patient's discretion. Low potency TCI use was permitted for use on sensitive areas only, but they were not supplied by the study site. All use of TCS and TCI was recorded daily by the patient using an electronic diary.

## Rescue treatment

Add-on rescue therapies were permitted when a patient experienced clinical worsening of symptoms that were  intolerable,  including  high  potency  TCS  or  systemic  treatments,  such  as  oral  corticosteroids, phototherapy,  and  cyclosporin.  Study  drug  was  discontinued  for  patients  receiving systemic  rescue treatment,  but  patients  were still  required to  attend  all  study visits  and  be assessed for safety and efficacy according to the schedule of events, even when rescue medication was initiated.

## Topical moisturiser

All patients were  to use  nonmedicated  topical  moisturiser daily  during the 7 days  preceding randomisation. Nonmedicated moisturisers were to be used during the study. The patient could continue her/his current over-the-counter moisturiser regimen, if approved by the Investigator.

<div style=\"page-break-after: always\"></div>

## Objectives

## KGAB and KGAC studies

KGAB and KGAC were identical studies in design, with the objective to evaluate the safety and efficacy of lebrikizumab compared with placebo in patients with moderate-to-severe AD.

## KGAD study

The objective of the KGAD study was to evaluate the safety and efficacy of lebrikizumab in combination with TCS compared with placebo in patients with moderate-to-severe AD.

## Outcomes/endpoints

## KGAB and KGAC studies

## Primary  endpoint

Co-primary endpoint:

- Percentage of  patients  with  an  IGA score of  0  or 1  and a  reduction  ≥2 points  from baseline  to Week 16.
- Percentage of patients achieving EASI75 (≥75% reduction from Baseline in EASI score) at Week 16

## Key secondary  endpoints specific for induction period

- Percentage of patients achieving EASI-90 at Week 16
- Percentage of patients achieving EASI-90 at Week 4
- Percentage change in EASI score from Baseline to Week 16
- Percentage change in Pruritus NRS score from Baseline to Week 16
- Percentage of patients with a Pruritus NRS of ≥4 -points at Baseline  who achieve  a ≥4 -point reduction from Baseline to Week 16
- Percentage of patients with a Pruritus NRS of ≥4 -points at Baseline  who achieve  a ≥4 -point reduction from Baseline to Week 4
- Percentage of patients with a Pruritus NRS of ≥4 -points at Baseline  who achieve  a ≥4 -point reduction from Baseline to Week 2
- Change from baseline in DLQI total score at Week 16
- Percentage of patients  with  a  DLQI  total  score of ≥4 -points  at  Baseline who  achieve a  ≥4 -point improvement from baseline to Week 16
- Change from Baseline in Sleep-loss score at Week 16
- Percentage of  patients  with  a  Sleeploss  score  ≥2 points  at  Baseline who  achieve a  ≥2  points reduction from Baseline at Week 16

## Key secondary  endpoints specific for maintenance  period

- Percentage of patients from those re-randomised having achieved EASI-75 at Week 16 who continue to exhibit EASI-75 at Week 52 (EASI-75 calculated relative to baseline EASI score)
- Percentage  of  patients  from  those  rerandomised having achieved IGA 0 or 1 and a ≥2 -point improvement from Baseline at Week 16 who continue to exhibit an IGA 0 or 1 and a ≥2 -point improvement from Baseline at Week 52
- Percentage of patients from those with a Pruritus NRS of ≥4 -points at baseline re-randomised having achieved ≥4 -point  reduction from baseline at Week 16 who continue to exhibit ≥4 -point  reduction from baseline at Week 52

<div style=\"page-break-after: always\"></div>

- Percentage change in EASI score from Baseline at Week 52 in the subset of patients who were rerandomised at Week 16

## KGAD study

## Primary  endpoint

Co-primary endpoint was identical to the KGAB and KGAC studies:

- Percentage of patients  with  an IGA score of 0 or 1 and a reduction ≥2 points from baseline to Week 16.
- Percentage of patients achieving EASI75 (≥75% reduction from Baseline in EASI score) at Week 16

## Key secondary  endpoints

- Percentage of patients achieving EASI-90 at Week 16
- Percentage change in Pruritus NRS score from Baseline to Week 16
- Percentage of patients with a Pruritus NRS of ≥4 -points at Baseline who achieve a ≥4 -point reduction from Baseline to Week 16
- Percentage change in EASI score from Baseline to Week 16
- Change from baseline in DLQI at Week 16
- Percentage of patients with a DLQI total score of ≥4 -points at baseline who achieve ≥4 -point improvement in DLQI from baseline to Week 16
- Change from Baseline in Sleep-loss score at Week 16
- Percentage of patients with a Pruritus NRS score of ≥4 points at Baseline who achieve both EASI -75 and a ≥4 -point reduction in NRS score from Baseline at Week 16

## Sample size

## KGAB and KGAC studies

In the Phase 2b dose-range finding study (KGAF), the proportion of patients who achieved an IGA score of 0 or 1 at Week 16 using the rescue medication non-response sensitivity analysis was approximately 34.7%  for lebrikizumab 250  mg Q2W  versus 7.7%  for placebo,  and the  proportion  of  patients  who achieved an  EASI-75 at  Week 16  using  the rescue medication non-response sensitivity  analysis was approximately 48.0% for lebrikizumab 250 mg Q2W versus 11.5% for placebo. A sample size of 96 for lebrikizumab 250 mg  Q2W versus 48 for placebo had more than  95%  power to detect  a statistically significant  difference  based  on  a  two-group  continuity  corrected  chi-square  test  with  a  two-sided significance level of 0.05 for each of the co-primary endpoints, which imply and overall power of at least 90%. However, to ensure sufficient safety information was collected and to ensure sufficient responders for the Maintenance Period, the sample size was increased to 400 in total with a randomisation ratio of 2:1 lebrikizumab:placebo.

## KGAD study

Approximately  225  patients  were  to  be  randomised  at  a  2:1  ratio  to  lebrikizumab  or  placebo (150 patients:75 patients). The assumed IGA score of 0 or 1 at Week 16 response rates were 38% for lebrikizumab 250  mg  Q2W  and  13%  for  placebo. The  assumed EASI  75  response rate  at  Week 16 response rates  were 58% for  lebrikizumab 250  mg  Q2W  and 20%  for placebo. The assumptions  for lebrikizumab were based on the dose-range finding Phase 2b study (KGAF), the proportion of patients

<div style=\"page-break-after: always\"></div>

who achieved an IGA score of 0 or 1 and proportion of patients who achieved EASI75 response at Week 16  using  the  rescue  medication  non-response  sensitivity  analysis,  adjusting  for  the  allowed  use  of TCS/TCI. The placebo response rates were based on the review of historical TCS clinical studies in atopic dermatitis. This study had power &gt;95% for testing  superiority of lebrikizumab to placebo based on a two-sided Fisher's exact test with alpha of 0.05.

## Randomisation and blinding (masking)

## KGAB, KGAC and KGAD studies

All patients  were randomly allocated to  receive the  study treatment  using an  electronic data  capture (EDC) system at the Baseline visit. The allocation to treatment was prospectively  stratified by geographic region (US versus EU versus rest of world), age (adolescent patients 12 to &lt;18 years versus adults ≥18 years) and disease severity (IGA 3  versus 4).  At  the Baseline visit (Day  1), once a  patient was considered eligible to  participate in the study, demographic and stratification information was entered into the EDC system to receive a medication number assigning a kit to a patient.

During the Maintenance Period in KGAB and KGAC studies, the EDC was used to re-randomise a patient to a maintenance treatment based on the IGA or EASI score at Week 16 and rescue therapy usage during induction period.

The  Sponsor  or  designee,  the  Investigator,  study-site  personnel,  and  the  patient  were  blinded  to treatment  assignment.  The  integrity  of  the  clinical  study  was  to  be  maintained  by  observing  the treatment blind. If knowledge of a patient's treatment assignment was required for the patient's clinical care and/or safety, the Investigator consulted with the Sponsor's medical monitor prior to breaking the blind.

Placebo solution was identical in appearance and content to the active solution except for lebrikizumab. All study drug (lebrikizumab and placebo) were supplied as a sterile PFS-NSD.  Each pre-filled syringe was used to deliver a single 2-mL dose (250 mg) administered subcutaneously.

Appropriate combination of active and placebo injections was given to maintain blinding.

## Statistical methods

## Induction Treatment  Periods in Studies KGAB, KGAC, and KGAD

## Primary  and supportive estimands for Induction Periods

Three types of prespecified estimands were used to address different clinical questions of interest and ICEs for the  Induction Period. Two types of  ICEs were considered for the Induction  Period, including initiation of  rescue  medication,  as  defined  for  the individual  study,  and  permanent  treatment discontinuation. All estimands of the Induction Period were defined for the patient population as defined by the protocol inclusion or exclusion criteria. The primary estimand was a hybrid estimand combining composite strategy and hypothetical strategy to handle ICEs depending on their causes. The primary estimand was used for all primary and key secondary endpoints. Two supportive estimands were also used, 1 for all categorical endpoints and 1 for all continuous endpoints (Table 15).

As per the SAPs, the primary estimand is a hybrid estimand representing the primary clinical question of interest: 'What is the difference between treatment conditions, i.e., Lebrikizumab vs Placebo, in the target  patient  population,  in  successful responses or  means after 16  weeks achieved without  use  of rescue medication and if all patients continued with treatment except those who discontinued due to lack of efficacy?'

<div style=\"page-break-after: always\"></div>

For the primary and key secondary analyses conducted relative to the primary estimand, patients who received topical  rescue medications (any  TCS, TCI,  or  crisaborole for  Study  KGAB and Study  KGAC patients or only high-potency TCS for  Study KGAD patients) or  systemic rescue  therapies or discontinued treatment due to lack of efficacy had values set to their baseline value subsequent to this time through Week 16 which, when dichotomised, implies non-response; data after treatment discontinuation due to any other reasons were treated as missing, and all the missing data were imputed with the MCMC-MI method.  The MCMC-MI  method  takes into  account  each patient's  own  data  trajectory and  leverages information from other patients within the same treatment (including the afore-mentioned imputed data according  patients'  baseline  values)  to  impute  plausible  values  for  the  missing  data:  Twenty-five imputations  were  conducted  within  each  treatment  group  independently  so  the  pattern  of  missing observations in one treatment group cannot influence missing value imputation  in another. IGA scores were rounded to (0, 1, 2, 3, or 4) from the continuous values generated by the MCMC algorithm after which IGA (0,1) response derived based on the rounded values. For derivation of an EASI-75 and EASI90 response, no rounding will be performed.

Table 15: Description of Primary and Supportive Estimands

|                                                            | AnalysisStrategyforIntercurrentEvents   | AnalysisStrategyforIntercurrentEvents   | AnalysisStrategyforIntercurrentEvents   | AnalysisStrategyforIntercurrentEvents   |                                                                        |
|------------------------------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|------------------------------------------------------------------------|
|                                                            | ICE: Medication                         | ICE:Treatment Discontinuation           | ICE:Treatment Discontinuation           | ICE:Treatment Discontinuation           | Missing Data                                                           |
| Estimand                                                   | Used Rescue                             | Due to Lack of Efficacy                 | Due to Adverse Event                    | Due to Any Other Reasous                | Imputation Method                                                      |
| Primaryestimand (hybrid)                                   | Composite: Set to baseline              | Composite: Set to baseline              | Hypothetical: Set to missing            | Hypothetical: Set to missing            | Primary analysis: MCMC-MI Sensitivity analysis: Tipping point analysis |
| Supportiveestimand for categorical endpoints(composite)    | Composite: Set to nonresponder          | Composite: Set to nonresponder          | Composite: Set to nonresponder          | Composite: Set to nonresponder          | NRI                                                                    |
| Supportiveestimand for continuous endpoints (hypothetical) | Hypothetical: Set to missing            | Hypothetical: Set to missing            | Hypothetical: Set to missing            | Hypothetical: Set to missing            | MMRM, LOCF                                                             |
| Additional FDA- requested estimand (hybrid)                | Composite: Set to baseline              | Composite: Set to baseline              | Composite: Set to baseline              | Treatment policy: Observed              | MCMC-MI                                                                |

Abbreviations: ICE =intercurrent event; LOCF =last observation carried forward; MCMC-MI =Markov Chain Monte Carlo multiple imputation; MMRM = mixed model repeated measures; NRI = nonresponder imputation.

In D120  LoQ, a set  of supplementary analyses was requested in accordance with  ITT principle,  i.e., treatment policy estimand for which observed data are used regardless of any intercurrent events. Any data that  remained missing was imputed using MCMC-MI  even if the  Applicant was requested to use imputation  strategy  that  considers what  is  known  about  the  subjects'  status  with  respect  to  these intercurrent  events.  The results  of  these  supplementary analyses are  presented for  the  co-primary endpoints and also for DLQI because of the considerable impact of the analysis strategy on the results. For the pivotal Phase 3 studies, a prespecified graphical multiple testing approach was implemented to control the overall Type I error rate at 2-sided alpha of 0.05 for all primary and key secondary endpoints in the  16-week treatment  periods. The primary and  key secondary endpoints for the  pivotal Phase 3 studies differed between US and EU based on regulator requests. The graphical testing scheme used for Study KGAB and Study KGAC for EMA is provided in Figure 9. The graphical testing scheme for Study KGAD FOR EMA is provided in Figure 10.

<div style=\"page-break-after: always\"></div>

Figure 9: Graphical approach to control type 1 error for induction period in studies KGAB and KGAC

<!-- image -->

The  CSR's  report  observed  results  excluding  data  collected  after  rescue  medication  or  treatment discontinuation. In addition, in line with the estimand definitions (Table 15), for dichotomised endpoints, response rates and, for quantitative endpoints, LS means were presented following data handling/imputation  rules  as  specified  below.  Treatment  effect  estimates  were,  for  dichotomised endpoints, based on stratified difference in the proportion of responders and, for quantitative endpoints, based on an ANCOVA model as further specified below.

## Analysis models

For  the  dichotomised  endpoints,  Cochran-Mantel-Haenszel  (CMH)  test  was  used  for  testing  the  null hypothesis of no treatment effect, stratified by randomisation strata: geographic region (US versus EU versus rest of world), age (adolescent patients 12 to &lt;18 versus adults &gt;=18 years) and disease severity (IGA 3 versus 4). The difference in the proportion of responders was also estimated with stratification by  the  randomisation  strata.  The  confidence  intervals  were  calculated  using  Mantel-Haenszel-Sato method. [NB: In the study reports, the above-mentioned stratified analyses are referred to as CMH test and common risk difference 'adjusted' by geographic region (US versus EU versus rest of world), age (adolescent versus adult), and disease severity (IGA 3 versus 4).]

For the quantitative endpoints, an ANCOVA model was applied including  treatment, geographic region (US vs EU vs rest of the world), age group (adolescent patients 12 to &lt;18 versus  adults &gt;=18 years) and baseline IGA score (3,4) as fixed factors and baseline value as covariate. The analysis results were combined across all multiply imputed datasets using SAS procedure MIANALYZE. In response to D120 LoQ, the Applicant clarified that for estimation of treatment-arm specific LS means, the default covariate weights of the respective SAS procedure were used. These imply a target population where a third  of patients are from each region, half are adolescents and half have IGA of 3.

<div style=\"page-break-after: always\"></div>

Figure 10: Study KGAD graphical testing scheme

<!-- image -->

Abbreviations: CFB = change from Baseline; DLQI = Dermatology Life Quality Index; DLQI-4 = 4-point or greater improvement from Baseline in DLQI among participants with baseline score of 4 or more; EASI = Eczema Area and Severity Index; EASI 90 = 90% improvement from Baseline in EASI; IGA = Investigator's Global Assessment; IGA 0,1 = IGA score of 0 or 1, with a 2-point or greater reduction from Baseline; NRS = numeric rating scale; PCFB = percentage change from Baseline; Pruritus NRS-4 = baseline score of 4 or more; W = week.

## Maintenance  Periods in Study KGAB and Study KGAC

## Primary  and supportive estimands for Maintenance  Periods

Four types of estimands were used to address different clinical questions of interest and ICEs for the Maintenance  Period.  These  four  estimands  were  defined  for  the  Maintenance  Populations  in  the Maintenance Blinded Period (Table 16).

The maintenance primary estimand was used for all key secondary endpoints for the Maintenance Period. Three secondary maintenance estimands were also used:

- a hybrid estimand for all key and other secondary endpoints
- a composite estimand for all key and other secondary categorical endpoints, and
- a hypothetical estimand for all key and other secondary continuous endpoints

Three types of ICEs were used to estimate the treatment effects for Maintenance Period, including

- initiation of rescue medication
- permanent treatment discontinuation, and
- transfer to escape arm.

<div style=\"page-break-after: always\"></div>

For the Maintenance Week 16 Escape Population, results were reported for efficacy analyses performed using observed values at each time point,  with no imputation for missing values. In addition, a hybrid estimand  considering  permanent  treatment  discontinuation  as  the  only  ICE  is  also  reported  as  a supportive analysis.

Table 16: Analysis of Primary and Supportive Estimands for Maintenance Period of Study KGAB and Study KGAC

| Maintenance Estimand                                                    | AnalysisStrategyforIntercurrentEvents   | AnalysisStrategyforIntercurrentEvents   | AnalysisStrategyforIntercurrentEvents   | AnalysisStrategyforIntercurrentEvents   | AnalysisStrategyforIntercurrentEvents   | Missing Data Imputation Method   |
|-------------------------------------------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|----------------------------------|
|                                                                         | ICE: Rescue Medication                  | ICE: Rescue Medication                  | ICE:Treatment Discontinuation           | ICE:Treatment Discontinuation           | ICE: Transfer to                        |                                  |
|                                                                         | Topical Rescue Medication               | Systemic Rescue Medication              | Due to Lack of Efficacy                 | Due to Any Other Reasons                | Escape Arm                              |                                  |
| Maintenance primary estimand (hybrid)                                   | Hypothetical: Set to missing            | Composite: Set to baseline              | Composite: Set to baseline              | Hypothetical: Set to missing            | Composite: Set to baseline              | MCMC-MI                          |
| Maintenance supportive estimand (hybrid)                                | Treatment policy: As observed           | Composite: Set to baseline              | Composite: Set to baseline              | Hypothetical: Set to missing            | Composite: Set to baseline              | MCMC-MI                          |
| Maintenance supportive estimandfor categorical endpoints (composite)    | Composite: Set to nonresponder          | Composite: Set to nonresponder          | Composite: Set to nonresponder          | Composite: Set to nonresponder          | Composite: Set to nonresponder          | NRI                              |
| Maintenance supportive estimand for continuous endpoints (hypothetical) | Hypothetical: Set to missing            | Hypothetical: Set to missing            | Hypothetical: Set to missing            | Hypothetical: Set to missing            | Hypothetical: Set to missing            | LOCF                             |

Abbreviations: ICE = intercurrent event; LOCF = last observation carried forward; MCMC-MI = Markov Chain Monte Carlo multiple imputation; MMRM = mixed model repeated measures; NRI = nonresponder imputation.

## Multiplicity control for Maintenance  Period

For  the  Maintenance  Period  of  Study  KGAB  and  Study  KGAC,  a  multiplicity  testing  scheme  was implemented which  used alpha control with  a  family-wise error rate at 0.05.  The hierarchical testing scheme is provided in Table 16.

<div style=\"page-break-after: always\"></div>

Table 17: Hierarchy for Key Secondary Endpoints at Week 52

| Lebrikizumab 250mgQ2W Maintenance Therapy                                                                                                                                                                                                                   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Percentage of patients from those rerandomized to Q2W maintenance therapy having achieved EASI 75 at Week 16 who continue to exhibit EASI 75 at Week 52 (EASI 75 calculated relative to Baseline EASI)                                                      |
| Percentage of patients from those rerandomized to Q2W maintenance therapy having achieved IGA 0 or 1 and a ≥2-point improvement from Baseline at Week 16 who continue to exhibit an IGA 0 or 1 and a ≥2-point improvementfromBaseline atWeek52              |
| Percentage of patients from those with a Pruritus NRS of ≥4 points at Baseline and rerandomized to Q2W maintenance therapy having achieved ≥4-point reduction from Baseline at Week 16 who continue to report ≥4- point reduction from Baseline at Week 52. |
| Lebrikizumab250mgQ4W MaintenanceTherapy                                                                                                                                                                                                                     |
| Percentage of patients from those rerandomized to Q4W maintenance therapy having achieved EASI 75 at Week 16 who continue to exhibit EASI 75 at Week 52 (EASI 75 calculated relative to Baseline EASI)                                                      |
| Percentage of patients from those rerandomized to Q4W maintenance therapy having achieved IGA 0 or 1 and a ≥2-point improvement from Baseline at Week 16 who continue to exhibit an IGA 0 or 1 and a ≥2-point improvement from Baseline at Week 52.         |
| Percentage ofpatients from those with a Pruritus NRS of ≥4 points at Baseline and rerandomized to Q4W maintenance therapy having achieved ≥4-point reduction from Baseline at Week 16 who continue to report ≥4- point reduction from Baseline at Week 52.  |
| Lebrikizumab 250mgQ2W MaintenanceTherapy                                                                                                                                                                                                                    |
| Percentage change in EASI from Baseline at Week 52 for those patients rerandomized to Q2W maintenance therapy at Week 16.                                                                                                                                   |
| Lebrikizumab250mgQ4W MaintenanceTherapy                                                                                                                                                                                                                     |
| Percentage change in EASI from Baseline at Week 52 for those patients rerandomized to Q4W maintenance therapy at Week 16.                                                                                                                                   |

Abbreviations: EASI = Eczema Area and Severity Index; EASI 75 = 75% improvement from Baseline in EASI; IGA = Investigator's Global Assessment; IGA 0.1 = IGA score of 0 or 1, with a 2-point or greater reduction from Baseline; NRS = numeric rating scale; Q2W = every 2 weeks; Q4W = every 4 weeks.

## Use of Study KGAB and Study KGAC Pooled Data

Data  from Study KGAB and  Study KGAC were pooled where applicable. This  pooled analysis set was prespecified in the integrated efficacy analysis plan. Study KGAB and Study KGAC had identical study designs, which enabled the creation of these pooled populations.

## Subgroup analyses

Subpopulation  analyses  were  performed  to  examine  how  patient  baseline  demographic,  disease characteristics,  or  treatment  history  affects  response  to  treatment  with  lebrikizumab.  All  subgroup analyses were performed on data pooled from Study KGAB and Study KGAC.

## Induction Period

Subgroup analyses for the Induction Period were conducted using the Pooled Induction set, which is the combination of patients from Study KGAB and Study KGAC. Subgroup analyses were conducted relative to primary estimand (hybrid), comparing the lebrikizumab 250 mg Q2W treatment group to placebo.

Effect modification by subgroups on odds ratio scale was evaluated using logistic regression including a treatment by subgroup interaction term. Treatment group differences in responder rates were evaluated within each subgroup using the Cochran-Mantel-Haenszel (CMH) test stratified by study (KGAB, KGAC; but  not  by  randomisation strata  within  study)  regardless of  whether the  interaction  was  statistically significant.

## Maintenance Period

Subgroup analyses for the Maintenance Period were conducted in the Pooled Maintenance Primary Set, which  is  the  combination  of  patients  from  Study  KGAB  and  Study  KGAC. Subgroup  analyses were

<div style=\"page-break-after: always\"></div>

conducted  relative  to  maintenance  primary  estimand  (hybrid),  comparing  the  treatment  group  rerandomised to lebrikizumab 250 mg Q4W to those re-randomised to placebo (lebrikizumab withdrawal) and the treatment group re-randomised to lebrikizumab 250 mg Q2W to those re-randomised to placebo (lebrikizumab withdrawal).

## Analyses for Efficacy Outcomes for Study KGAD Patients in Study KGAA

Descriptive statistics were used to summarise  the efficacy  results from  Study KGAA.  The efficacy  analyses were  conducted  relative to  the  primary  estimand  as  defined  in  the  study.  No  statistical  tests  were performed.

## Primary and supportive estimands of efficacy objectives

Three types of estimands were used to  handle missing data in analyses of Study KGAA. The primary estimand was used for all efficacy endpoints. Two supportive estimands were also used for all efficacy endpoints. Table 18 summarises the primary and supportive estimands used in the Study KGAA analyses.

Treatment discontinuation, whether due to lack of efficacy  or any other reason,  was the only intercurrent event considered in the estimation of the treatment effect in Study KGAA.

Table 18: Estimands Used in Analyses of Efficacy Endpoints for Study KGAD Patients in Study KGAA

|                             | ICE: Treatment Discontinuation   | ICE: Treatment Discontinuation   |                               |
|-----------------------------|----------------------------------|----------------------------------|-------------------------------|
| Estimand                    | DuetoLackofEfficacy              | DuetoAnyOther Reasons            | Missing DataImputation Method |
| Composite: Set to baseline  | Hypothetical: Set to missing     | MCMC-MI                          | Primary                       |
| Asobserved                  | As observed                      | As observed analysis             | Supportive                    |
| Hypothetical: Set tomissing | Hypothetical:                    | LOCF Set tomissing               | Supportive                    |

Abbreviations:ICE =intercurrent event;LOCF =last observation carry forward; MCMC-MI=Markoy Chain Monte Carlo multiple imputation.

## Results

## Participant  flow

## Induction period (0 to 16 weeks)

KGAB: A  total  of  536  patients  entered  the  study,  and  424  patients  were  randomly  assigned  to  a treatment group. A total of 383 patients completed the Week 16 Induction Period, including 85.1%  of patients receiving placebo and 92.9% of patients in the lebrikizumab treatment group.

KGAC: A  total  of  606  patients  entered  the  study,  and  445  patients  were  randomly  assigned  to  a treatment  group.  Following  findings  of a  site  audit,  data  from all 18  patients  at  a specific site  were excluded, creating an mITT Population of 427 patients. A total of 389 patients completed the Week 16 Induction Period, including 89% of patients receiving placebo and 92.2% of patients in the lebrikizumab treatment group.

KGAD: A total of 312 patients entered the study. A total of 228 patients were randomly assigned to a treatment  group.  Following  findings  of a  site  audit,  data  from all 17  patients  at  a specific site  were excluded, creating a mITT population  of 211.  A  total  of 192  patients  completed the  16 Week study, including 87.9% in placebo + TCS group and 92.4% in the lebrikizumab treatment group (Table 19).

<div style=\"page-break-after: always\"></div>

Table 19: Treatment Disposition for Induction Period

|                                         | StudyKGAB N=424   | StudyKGAB N=424   | StudyKGAC N=427   | StudyKGAC N=427   | Study KGAD N=211   | Study KGAD N=211    |
|-----------------------------------------|-------------------|-------------------|-------------------|-------------------|--------------------|---------------------|
| Treatment Disposition, n (%)            | PBO               | LEB 250mg Q2W     | PBO               | LEB 250mg Q2W     | PBO + TCS          | LEB 250mg Q2W + TCS |
|                                         | N=141             | N=283             | N =146            | N=281             | N=66               | N=145               |
| Completed W16                           | 120 (85.1)        | 263 (92.9)        | 130 (89.0)        | 259 (92.2)        | 58 (87.9)          | 134 (92.4)          |
| Rerandomized to Maintenance Populationa | 24 (17.0)         | 157 (55.5)        | 22 (15.1)         | 134 (47.7)        | NA                 | NA                  |
| Enrolled in Escape Arm at Week 16b      | 96 (68.1)         | 106 (37.5)        | 108 (74.0)        | 125 (44.5)        | NA                 | NA                  |
| DiscontinuedpriortoW16                  | 21 (14.9)         | 20 (7.1)          | 16 (11.0)         | 22 (7.8)          | 8 (12.1)           | 11 (7.6)            |
| Reasonfordiscontinuation prior to W16   |                   |                   |                   |                   |                    |                     |
| Adverse event                           | 1 (0.7)           | 2 (0.7)           | 4 (2.7)           | 6 (2.1)           | 0 (0.0)            | 3 (2.1)             |
| Duetoepidemic/pandemic                  | 1 (0.7)           | 2 (0.7)           | 1(0.7)            | 4 (1.4)           | 1 (1.5)            | 1 (0.7)             |
| Lack of efficacy                        | 7 (5.0)           | 2 (0.7)           | 4 (2.7)           | 1 (0.4)           | 1 (1.5)            | 3 (2.1)             |
| Lost to follow-up                       | 1 (0.7)           | 4 (1.4)           | 2 (1.4)           | 0 (0.0)           | 0 (0.0)            | 0 (0.0)             |
| Other                                   | 0 (0.0)           | 1 (0.4)           | 0 (0.0)           | 1 (0.4)           | 0 (0.0)            | 0 (0.0)             |
| Physician decision                      | 0 (0.0)           | 0 (0.0)           | 0 (0.0)           | 0 (0.0)           | 1 (1.5)            | 0 (0.0)             |
| Protocol deviation                      | 5 (3.5)           | 6 (2.1)           | 0 (0.0)           | 6 (2.1)           | 2 (3.0)            | 2 (1.4)             |
| Withdrawal by participant               | 6 (4.3)           | 3 (1.1)           | 5 (3.4)           | 4 (1.4)           | 3 (4.5)            | 2 (1.4)             |

Abbreviations: CSR = clinical study report; LEB = lebrikizumab; N = number of participants in the analysis population; n = number of participants in the specified category; PBO = placebo; Q2W = every 2 weeks; TCS = topical corticosteroids; W16 = Week 16.

Seven participants in Study KGAB and 3 participants in Study KGAC were erroneously rerandomized at Week 16.

Arm at Week 16.

## Maintenance  blinded Period (16 to 52 weeks)

KGAB: Of the lebrikizumab-treated and placebo-treated patients from the Induction Period, 181 (42.7%) entered the Maintenance Blinded Period as induction responders. Of these patients randomly reassigned at  Week 16,  87.5%  from the  Induction  placebo group  (21 of  24 patients),  and 79.0% from the Induction lebrikizumab group (124  of 157 patients)  completed treatment at Week 52 (Figure 11).

KGAC: Of the lebrikizumab-treated and placebo-treated patients from the Induction Period, 156 patients (36.5%)  entered the Maintenance Blinded Period as induction responders. Of these patients randomly reassigned at Week 16, 86.4% from the induction placebo group (19 of 22 patients), and 85.1% from the induction lebrikizumab group (114 of 134 patients) completed treatment at Week 52 (Figure 12).

<div style=\"page-break-after: always\"></div>

Figure 11: Disposition during the maintenance blinded period (KGAB)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 12: Disposition during the maintenance blinded period (KGAC)

<!-- image -->

Note: 3 participants who did not meet the definition of responder at Week 16 were randomly assigned to the Maintenance Primary Population.101ebrikizumab-treatedparticipants and 4 placebo-treatedparticipants who achieved EASI 75 during theInduction Period without rescue medication use were incorrectly assigned to the Escape Arm at W16.

## Maintenance  Escape Period

KGAB: Of the 202 patients who entered the Escape Arm at Week 16, 154 patients (76.2%) completed treatment at Week 52.

KGAC: Of the 233 patients who entered the Escape Arm at Week 16, 168 patients (72.1%) completed treatment at Week 52 (Table 20).

<div style=\"page-break-after: always\"></div>

Table 20: Patient Dispositions After Entering Maintenance Escape Arms of Study KGAB and Study KGAC at Week 16 (Maintenance Week 16 Escape Population)

| Study Disposition, n (%)                           | StudyKGAB (N =202)     | StudyKGAB (N =202)      | Study KGAC (N =233)     | Study KGAC (N =233)     | PooledStudiesKGABand KGAC (N = 435)   | PooledStudiesKGABand KGAC (N = 435)   |
|----------------------------------------------------|------------------------|-------------------------|-------------------------|-------------------------|---------------------------------------|---------------------------------------|
| Induction Period/Mainte nance Period Treatment     | PBO/LEB 250mg Q2W N=96 | LEB/LEB 250mg Q2W N=106 | PBO/LEB 250mg Q2W N=108 | LEB/LEB 250mg Q2W N=125 | PBO/LEB 250mg Q2W N=204               | LEB/LEB 250mg Q2W N=231               |
| Completed treatment through W52                    | 77 (80.2)              | 77 (72.6)               | 85 (78.7)               | 83 (66.4)               | 162 (79.4)                            | 160 (69.3)                            |
| Discontinued treatment                             | 19 (19.8)              | 29 (27.4)               | 23 (21.3)               | 42 (33.6)               | 42 (20.6)                             | 71 (30.7)                             |
| Reason for treatment discontinuation Adverse event | 1 (1.0)                | 4 (3.8)                 | 3 (2.8)                 | 3 (2.4)                 | 4 (2.0)                               | 7 (3.0)                               |
| Lack of efficacy                                   | 11 (11.5)              | 17 (16.0)               | 16 (14.8)               | 27 (21.6)               | 27 (13.2)                             | 44 (19.0)                             |
| Lost to follow-up                                  | 1 (1.0)                | 2 (1.9)                 | 0 (0.0)                 | 1 (0.8)                 | 1 (0.5)                               | 3 (1.3)                               |
| Physician decision                                 | 1 (1.0)                | 1 (0.9)                 | 0 (0.0)                 | 0 (0.0)                 | 1 (0.5)                               | 1 (0.4)                               |
| Pregnancy                                          | 0 (0.0)                | 1 (0.9)                 | 0 (0.0)                 | 0 (0.0)                 | 0 (0.0)                               | 1 (0.4)                               |
| Withdrawal by patient                              | 5 (5.2)                | 2 (1.9)                 | 4 (3.7)                 | 9 (7.2)                 | 9 (4.4)                               | 11 (4.8)                              |
| Other                                              | 0 (0.0)                | 2 (1.9)                 | 0 (0.0)                 | 2 (1.6)                 | 0 (0.0)                               | 4 (1.7)                               |

Abbreviations: CSR = clinical study report; LEB = lebrikizumab; LEB/LEB 250mg Q2W = lebrikizumab 250 mg Q2W treatment during Induction Period and lebrikizumab 250 mg Q2W treatment during Maintenance Period; N placebo; PBO/LEB 250 mg Q2W = placebo treatment during Induction Period and lebrikizumab 250 mg Q2W treatment duringMaintenancePeriod;Q2W=every 2weeks;W52=Week52.

## Recruitment

## KGAB study

Date of first subject first visit: 24 September 2019

Date of last subject last visit: 3 May 2022

Data lock point 1 (week 16 DBL): 19 July 2021

Data lock point 2 (week 52 DBL): 29 April 2022

## KGAC study

Date of first subject first visit: 29 October 2019

Date of last subject last visit: 28 April 2022

Data lock point 1 (week 16 DBL): 6 August 2021

Data lock point 2 (week 52 DBL): 3 May 2022

## KGAD study

Date of first subject first visit: 3 February 2020

Date of last subject last visit: 16 September 2021

<div style=\"page-break-after: always\"></div>

Data lock point 1 (week 16 DBL): 13 September 2021 Data lock point 2 (final DBL): 16 December 2021

## Conduct of the study

## Site exclusion

Following primary outcome database lock, a site audit triggered by statistically implausible data at one study site resulted in a critical finding. The site audit revealed GCP noncompliance with protocol entry criteria and the  associated efficacy data  was considered unreliable. The site  was closed for all active lebrikizumab studies. As a result, the patients from the affected study site with the critical finding were excluded from the modified intent-to-treat (mITT) population and the Modified Safety population for the KGAC and KGAD  studies.  In  total,  35  patients  were  excluded,  18  from  Study  KGAC  and  17  from Study KGAD. According to the Applicant, due to the unreliable baseline AD values, any efficacy analyses performed on the data of these patients would lead to inconclusive and unreliable  results. For this reason, efficacy analyses in this population were not performed.

## Protocol amendments

## KGAB and KGAC studies

The following substantial changes were made to studies KGAB and KGAC.

Amendment 1 (dated 16 October 2019):

- Clarification of primary, co-primary, and secondary endpoints  to be analysed for the FDA and EMA.
- Updated inclusion criterion 10 for contraceptive use after the last dose of study drug (increased from 17 to 18 weeks).
- Added  inclusion  criterion  11  to  require  male  participants  to  use  an  effective  method  of contraception if sexually active with a female of child-bearing potential.
- Other minor clarifications and editorial changes.

Amendment 2 (dated 20 May 2020):

- Added hormone testing for adolescent participants.
- Removed requirement for TB screening serology at screening visit.
- Added PK sample at Week 4 and at the safety follow-up visit.
- Clarifications on analysis timing, study procedures, and protocol wording.

## KGAD study

## Amendment 1

- Added hormone testing for adolescent participants
- Removed requirement for TB screening serology at screening visit
- Added PK sample at Week 4
- Added PK and ADA sample at follow-up visit
- Clarifications on analysis timing, study procedures, and protocol wording, including
- Clarified inclusion criterion [6] to reflect that use of topical corticosteroids is necessary
- Inclusion criterion [10] was modified to require  'highly-effective' contraceptive measures

<div style=\"page-break-after: always\"></div>

## Protocol deviations

Important  protocol  deviations  included  those  that  might  have  meaningful  effects  on  the  accuracy, completeness, or reliability of study data or those that could affect the rights, safety, or well-being of a study participant.

## KGAB and KGAC studies

In KGAB study, altogether 69 patients (16.3% of the total ITT population) and 33 patients (8.6% of the total Maintenance Population) were identified to have at least 1 important protocol deviation during the induction and maintenance periods, respectively.

In  KGAC study,  69  patients  (15.5%  of  the  total  ITT  Population)  and  32  patients  (7.9%  of  the  total Maintenance  Population),  were  identified  to  have  at  least  1  important  protocol  deviation  during  the induction and maintenance periods, respectively.

## KGAD study

Altogether, 120  patients  (52.6%  of the  ITT population),  were identified to  have at least 1  important protocol deviation (Table 21).

Table 21: Summary of Important Protocol Deviations by Category (ITT Population) (KGAD)

| Protocol Deviation Category                                 | PBO+TCS (N = 75) n (%)   | LEB250mgQ2W+ TCS (N = 153) n (%)   | Total (N =228) n (%)   |
|-------------------------------------------------------------|--------------------------|------------------------------------|------------------------|
| Participantswith≥limportantprotocol deviation               | 41 (54.7)                | 79 (51.6)                          | 120 (52.6)             |
| Studyprocedure/Missingsafety assessments                    | 23 (30.7)                | 50 (32.7)                          | 73 (32.0)              |
| Inclusion/Exclusion                                         | 12 (16.0)                | 16 (10.5)                          | 28 (12.3)              |
| Studyprocedure/sitestaff authorization, delegation,training | 3 (4.0)                  | 15 (9.8)                           | 18 (7.9)               |
| Informed consent form/other                                 | 3 (4.0)                  | 7 (4.6)                            | 10 (4.4)               |
| Studyprocedure/missedprocedures                             | 2 (2.7)                  | 7 (4.6)                            | 9 (3.9)                |
| IP/IP dosing                                                | 2 (2.7)                  | 1 (0.7)                            | 3 (1.3)                |
| Studyprocedure/missingefficacyassessments                   | 0                        | 1 (0.7)                            | 1 (0.4)                |

Abbreviations:ITT=intent-to-treat;IP=investigational product;LEB=lebrikizumab;N=number of participants in the analysispopulation; n=number of participants in thespecified category;PBO=placebo;Q2W=every 2 weeks; TCS = topical corticosteroids.

<div style=\"page-break-after: always\"></div>

## Baseline data

## Demographic and other baseline characteristics

## KGAB study

The mean age of patients  was 35.5  years, with  13%  of the population made up of adolescents aged 12 years to less than 18 years. The mean duration of time since AD onset was 22.6 years, and similar percentages of females and males were included. The majority of patients were White (68.2%), followed by Asian (16.5%) and Black or African American (11.6%) (Table 22).

Table 22: Summary Baseline Characteristics (Induction Period, ITT Population)

| Attribute                                    | PBO (N = 141)   | LEB 250mg Q2W (N=283)   | Total (N = 424)   |
|----------------------------------------------|-----------------|-------------------------|-------------------|
| Age (years), mean (SD)                       | 34.2 (16.4)     | 36.1 (17.8)             | 35.5 (17.3)       |
| Adolescents (12 to <18 years: ≥40 kg), n (%) | 18 (12.8)       | 37 (13.1)               | 55 (13.0)         |
| Adults (18 years), n (%)                     | 123 (87.2)      | 246 (86.9)              | 369 (87.0)        |
| Female, n (%)                                | 73 (51.8)       | 141 (49.8)              | 214 (50.5)        |
| Male, n (%)                                  | 68 (48.2)       | 142 (50.2)              | 210 (49.5)        |
| Race, n (%)                                  |                 |                         |                   |
| American Indian or Alaska Native             | 0               | 7 (2.5)                 | 7 (1.7)           |
| Asian                                        | 31 (22.0)       | 39 (13.8)               | 70 (16.5)         |
| Black or AfricanAmerican                     | 16 (11.3)       | 33 (11.7)               | 49 (11.6)         |
| NativeHawaiian or OtherPacific Islander      | 0               | 2 (0.7)                 | 2 (0.5)           |
| White                                        | 93 (66.0)       | 196 (69.3)              | 289 (68.2)        |
| Multiple                                     | 1 (0.7)         | 4 (1.4)                 | 5 (1.2)           |
| Other                                        | 0               | 1 (0.4)                 | 1 (0.2)           |
| Not reported                                 | 0               | 1 (0.4)                 | 1 (0.2)           |
| Duration since AD onset (years), mean (SD)   | 23.8 (15.4)     | 22.0 (14.9)             | 22.6 (15.0)       |
| Weight (kg), mean (SD)                       | 79.0 (22.7)     | 77.0 (19.7)             | 77.7 (20.8)       |
| <60 kg, n (%)                                | 31 (22.0)       | 60 (21.3)               | 91 (21.5)         |
| ≥60 to <100 kg, n (%)                        | 93 (66.0)       | 188 (66.7)              | 281 (66.4)        |
| ≥100 kg. n (%)                               | 17 (12.1)       | 34 (12.1)               | 51 (12.1)         |
| Body mass index (kg/m2), mean (SD)           | 27.8 (7.2)      | 26.6 (5.8)              | 27.0 (6.4)        |
| Country, n (%)                               |                 |                         |                   |
| Australia                                    | 13 (9.2)        | 26 (9.2)                | 39 (9.2)          |
| Canada                                       | 7 (5.0)         | 16 (5.7)                | 23 (5.4)          |
| Estonia                                      | 4 (2.8)         | 4 (1.4)                 | 8 (1.9)           |
| France                                       | 0               | 7 (2.5)                 | 7 (1.7)           |
| Latvia                                       | 6 (4.3)         | 5 (1.8)                 | 11 (2.6)          |
| Lithuania                                    | 7 (5.0)         | 11 (3.9)                | 18 (4.2)          |
| Poland                                       | 25 (17.7)       | 56 (19.8)               | 81 (19.1)         |
| Spain                                        | 4 (2.8)         | 9 (3.2)                 | 13 (3.1)          |
| South Korea                                  | 13 (9.2)        | 21 (7.4)                | 34 (8.0)          |
| US                                           | 62 (44.0)       | 128 (45.2)              | 190 (44.8)        |

Abbreviations: AD = atopic dermatitis; LEB = 1ebrikizumab; ITT = intent to treat; N = number of participants in the analysis population; n = number of participants in the specified category; PBO = placebo; Q2W = every 2 weeks; SD = standard deviation.

<div style=\"page-break-after: always\"></div>

## KGAC study

The mean age of patients  was 36.2 years, with  11% of the population made up of adolescents, aged 12 years to less than 18 years. The mean duration of time since AD onset was 20.5 years, and similar percentages of females and males were included. The majority of patients were white (59.3%), followed by Asian (28.6%), and Black or African American (8.2%) (Table 23).

Table 23: Summary of Baseline Characteristics (Induction Period, mITT Population)

| Attribute                                    | PBO (N =146)   | LEB 250 mg Q2W (N = 281)   | Total (N = 427)   |
|----------------------------------------------|----------------|----------------------------|-------------------|
| Age (years), mean (SD)                       | 35.3 (17.2)    | 36.6 (16.8)                | 36.2 (16.9)       |
| Adolescents (12 to ≤18 years; ≥40 kg), n (%) | 17 (11.6)      | 30 (10.7)                  | 47 (11.0)         |
| Adults (≥18 years). n (%)                    | 129 (88.4)     | 251 (89.3)                 | 380 (89.0)        |
| Female, n (%)                                | 75 (51.4)      | 136 (48.4)                 | 211 (49.4)        |
| Male, n (%)                                  | 71 (48.6)      | 145 (51.6)                 | 216 (50.6)        |
| Race, n (%)                                  |                |                            |                   |
| AmericanIndianorAlaskaNative                 | 2 (1.4)        | 3 (1.1)                    | 5 (1.2)           |
| Asian                                        | 44 (30.1)      | 78 (27.8)                  | 122 (28.6)        |
| Black or Afican American                     | 10 (6.8)       | 25 (8.9)                   | 35 (8.2)          |
| Native Hawaiian or Other Pacific Islander    | 1 (0.7)        | 2 (0.7)                    | 3 (0.7)           |
| White                                        | 85 (58.2)      | 168 (59.8)                 | 253 (59.3)        |
| Multiple                                     | 3 (2.1)        | 4 (1.4)                    | 7 (1.6)           |
| Other                                        | 1 (0.7)        | 1 (0.4)                    | 2 (0.5)           |
| Duration since AD onset (years), mean (SD)   | 20.1 (14.1)    | 20.8 (15.2)                | 20.5 (14.8)       |
| Weight (kg), mean (SD)                       | 76 (21.1)      | 76.7 (20.5)                | 76.5 (20.7)       |
| <60 kg, n (%)                                | 32 (22.1)      | 57 (20.3)                  | 89 (20.9)         |
| ≥60 to <100 kg. n (%)                        | 100 (69.0)     | 188 (66.9)                 | 288 (67.6)        |
| ≥100 kg. n (%)                               | 13 (9.0)       | 36 (12.8)                  | 49 (11.5)         |
| Body mass index (kg/m2), mean (SD)           | 26.3 (6.3)     | 26.7 (6.6)                 | 26.5 (6.5)        |
| Country, n (%)                               |                |                            |                   |
| Bulgaria                                     | 7 (4.8)        | 15 (5.3)                   | 22 (5.2)          |
| Canada                                       | 16 (11.0)      | 42 (14.9)                  | 58 (13.6)         |
| Germany                                      | 28 (19.2)      | 53 (18.9)                  | 81 (19.0)         |
| Mexico                                       | 3 (2.1)        | 6 (2.1)                    | 9 (2.1)           |
| Singapore                                    | 8 (5.5)        | 11 (3.9)                   | 19 (4.4)          |
| Taiwan (Province of China)                   | 21 (14.4)      | 39 (13.9)                  | 60 (14.1)         |
| Ukraine                                      | 3 (2.1)        | 8 (2.8)                    | 11 (2.6)          |
| US                                           | 60 (41.1)      | 107 (38.1)                 | 167 (39.1)        |

<div style=\"page-break-after: always\"></div>

## KGAD study

The mean age of patients was 37.2 years, with 21.8% of the population made up of adolescents, aged 12 years to  less than18  years. The mean  duration  of time  since  AD  onset  was 21.1  years, and  the population was divided nearly evenly between females and males. The majority of patients were white (61.6%), followed by Asian (14.7%), and Black or African American (13.3%) (Table 24).

Table 24: Summary of Baseline Characteristics (mITT Population)

| Attribute                                   | PBO + TCS (N =66)   | LEB 250 mg Q2W + TCS (N = 145)   | (N = 211)   |
|---------------------------------------------|---------------------|----------------------------------|-------------|
| Age (years), mean (SD)                      | 36.7 (17.9)         | 37.5 (19.9)                      | 37.2 (19.3) |
| Adolescents (12 to <18 years; ≥40kg), n (%) | 14 (21.2)           | 32 (22.1)                        | 46 (21.8)   |
| Adults (≥18 years), n (%)                   | 52 (78.8)           | 113 (77.9)                       | 165 (78.2)  |
| Female, n (%)                               | 33 (50.0)           | 70 (48.3)                        | 103 (48.8)  |
| Race, n (%)                                 |                     |                                  |             |
| AmericanIndianorAlaskaNative                | 2 (3.0)             | 5 (3.4)                          | 7 (3.3)     |
| Asian                                       | 13 (19.7)           | 18 (12.4)                        | 31 (14.7)   |
| Black or African American                   | 9 (13.6)            | 19 (13.1)                        | 28 (13.3)   |
| NativeHawaiianorOtherPacificIslander        | 0                   | 3 (2.1)                          | 3 (1.4)     |
| White                                       | 40 (60.6)           | 90 (62.1)                        | 130 (61.6)  |
| Multiple                                    | 1 (1.5)             | 8 (5.5)                          | 9 (4.3)     |
| Other                                       | 1 (1.5)             | 2 (1.4)                          | 3 (1.4)     |
| Duration since AD onset (years), mean (SD)  | 21.2 (13.9)         | 21.0 (17.4)                      | 21.1 (16.3) |
| Weight (kg), mean (SD)                      | 79.8 (24.4)         | 74.6 (23.3)                      | 76.2 (23.7) |
| <60 kg, n (%)                               | 15 (22.7)           | 44 (30.3)                        | 59 (28.0)   |
| 60 to <100 kg, n (%)                        | 37 (56.1)           | 81 (55.9)                        | 118 (55.9)  |
| ≥100 kg, n (%)                              | 14 (21.2)           | 20 (13.8)                        | 34 (16.1)   |
| Body mass index (kg/m?), mean (SD)          | 27.9 (7.5)          | 26.5 (7.2)                       | 26.9 (7.3)  |
| Country, n (%)                              |                     |                                  |             |
| Canada                                      | 8 (12.1)            | 14 (9.7)                         | 22 (10.4)   |
| Germany                                     | 2 (3.0)             | 9 (6.2)                          | 11 (5.2)    |
| Poland                                      | 8 (12.1)            | 19 (13.1)                        | 27 (12.8)   |
| US                                          | 48 (72.7)           | 103 (71.0)                       | 151 (71.6)  |

Abbreviations:AD= atopic dermatitis;LEB=lebrikizumab; mITT =modified intent-to-treat; N=number of participants in the analysis population; n = number of participants in the specified category; PBO = placebo; Q2W = every 2 weeks; SD = standard deviation; TCS = topical corticosteroids.

<div style=\"page-break-after: always\"></div>

## Baseline disease characteristics

## KGAB study

At Baseline, 40.3% of patients had severe AD, based on their IGA score, and the rest of the patients had moderate AD. The mean EASI was 29.6 and mean Pruritus NRS score was 7.3 (Table 25).

Table 25: Summary of Baseline Disease Characteristics (Induction Period, ITT Population)

| Baseline Attribute                     | PBO (N = 141)   | LEB 250mg Q2W (N = 283)   | Total (N =424)   |
|----------------------------------------|-----------------|---------------------------|------------------|
| IGA score, n (%)                       |                 |                           |                  |
| 3,moderate                             | 83 (58.9)       | 170 (60.1)                | 253 (59.7)       |
| 4, severe                              | 58 (41.1)       | 113 (39.9)                | 171 (40.3)       |
| EASI, mean (SD)                        | 31.0 (12.9)     | 28.8 (11.3)               | 29.6 (11.9)      |
| Pruritus NRS, mean (SD)                | 7.3 (1.7)       | 7.2 (1.9)                 | 7.3 (1.8)        |
| 24, n/Nx (%)                           | 130 (95.6)      | 263 (94.9)                | 393 (95.2)       |
| Sleep-Loss Scale score, mean (SD)      | 2.3 (1.0)       | 2.3 (1.0)                 | 2.3 (1.0)        |
| ≥2, n/Nx (%)                           | 91 (66.9)       | 195 (70.7)                | 286 (69.4)       |
| DLQI, mean (SD)                        | 15.7 (7.2)      | 15.3 (7.4)                | 15.4 (7.3)       |
| POEM, mean (SD)                        | 20.5 (6.3)      | 20.9 (5.9)                | 20.8 (6.0)       |
| PROMIS Anxiety score, mean (SD)        |                 |                           |                  |
| Adolescents (12 to <18 years; ≥40 kg). | 53.6 (12.7)     | 52.0 (9.4)                | 52.5 (10.5)      |
| Adults (≥18 years)                     | 54.3 (9.3)      | 52.9 (10.1)               | 53.4 (9.9)       |
| PROMIS Depression score, mean (SD)     |                 |                           |                  |
| Adolescents (12 to <18 years; ≥40 kg)  | 55.8 (13.8)     | 52.5 (9.8)                | 53.6 (11.2)      |
| Adults (≥18 years)                     | 50.0 (9.2)      | 49.8 (10.0)               | 49.9 (9.7)       |
| EQ-5 D VAS Score, mean (SD)            | 67.0 (22.2)     | 68.2 (22.0)               | 67.8 (22.1)      |

Abbreviations: DLQI = Dermatology Life Quality Index; EASI = Eczema Area and Severity Index; EQ-5 D =

European Quality of Life-5 Dimensions; IGA = Investigator Global Assessment; ITT = intent to treat; LEB = lebrikizumab; N = number of participants in the analysis population; n = number of participants in the specified NRS = numeric rating scale; PBO = placebo; POEM = Patient Oriented Eczema Measure; PROMIS = PatientReported Outcomes Measurement Information System; Q2W = every 2 weeks; SD = standard deviation; VAS = visual analog scale.

<div style=\"page-break-after: always\"></div>

## KGAC study

At baseline, 36.8% of patients had severe AD, based on their IGA score, and the rest of the patients had moderate AD. The mean EASI was 29.7 and mean Pruritus NRS score was 7.1 (Table 26).

Table 26: Summary of Baseline Disease Characteristics (Induction Period, mITT Population)

| Baseline Attribute                    | PBO (N = 146)   | LEB 250 mg Q2W (N = 281)   | Total (N = 427)   |
|---------------------------------------|-----------------|----------------------------|-------------------|
| IGA score, n (%)                      |                 |                            |                   |
| 3, moderate                           | 95 (65.1)       | 175 (62.3)                 | 270 (63.2)        |
| 4, severe                             | 51 (34.9)       | 106 (37.7)                 | 157 (36.8)        |
| EASI, mean (SD)                       | 29.6 (10.8)     | 29.7 (12.0)                | 29.7 (11.6)       |
| Pruritus NRS, mean (SD)               | 7.2 (1.9)       | 7.1 (1.9)                  | 7.1 (1.9)         |
| 24. n/Nx (%)                          | 134 (93.7)      | 253 (94.1)                 | 387 (93.9)        |
| Sleep-Loss Scale score, mean (SD)     | 2.2 (0.9)       | 2.2 (0.9)                  | 2.2 (0.9)         |
| ≥2, n/Nx (%)                          | 97 (67.8)       | 161 (60.1)                 | 258 (62.8)        |
| POEM, mean (SD)                       | 21.4 (5.6)      | 20.4 (5.6)                 | 20.8 (5.6)        |
| DLQI, mean (SD)                       | 15.9 (7.6)      | 15.4 (7.0)                 | 15.5 (7.2)        |
| PROMIS Anxiety score, mean (SD)       |                 |                            |                   |
| Adolescents (12 to <18 years; ≥40 kg) | 52.2 (13.3)     | 49.9 (11.5)                | 50.8 (12.1)       |
| Adults (18 years)                     | 55 (10.4)       | 54.4 (8.9)                 | 54.6 (9.5)        |
| PROMIS Depression score, mean (SD)    |                 |                            |                   |
| Adolescents (12 to <18 years; ≥ 40kg) | 52.9 (11.7)     | 49.6 (11.2)                | 50.8 (11.4)       |
| Adults (218 years)                    | 51.2 (10.4)     | 51.3 (9.2)                 | 51.2 (9.6)        |
| EQ-5D VAS score, mean (SD)            | 68.6 (21.6)     | 66.7 (20.7)                | 67.4 (21.0)       |

Abbreviations: DLQI = Dermatology Life Quality Index; EASI = Eczema Area and Severity Index; IGA = Investigator's Global Assessment; LEB = lebrikizumab; mITT = modified intent-to-treat; N = number of participants in the analysis population; n = number of participants in the specified category; NRS = numeric rating scale; Nx = number of participants in the analysis population with nonmissing data for the specified endpoint; PBO = placebo; POEM = Patient Oriented Eczema Measure; PROMIS = Patient-Reported Outcomes Measurement Information System; Q2W = every 2 weeks; SD = standard deviation; VAS = visual analog scale.

<div style=\"page-break-after: always\"></div>

## KGAD study

At baseline, 30.8% of patients had severe AD, based on their IGA score, and the rest of the patients had moderate AD. The mean EASI was 27.3 and mean pruritus NRS score was 7.1 (Table 27).

Table 27: Summary of Baseline Disease Characteristics

| BaselineAttribute                     | PBO +TCS N=66   | LEB 250 mg Q2W + TCS N=145   | Total N=211    |
|---------------------------------------|-----------------|------------------------------|----------------|
| IGA Score, n/N (%)                    |                 |                              |                |
| 3,moderate                            | 48/66 (72.7)    | 98/145 (67.6)                | 146/211 (69.2) |
| 4, severe                             | 18/66 (27.3)    | 47/145 (32.4)                | 65/211 (30.8)  |
| EASI, mean (SD)                       | 26.4 (10.6)     | 27.7 (11.1)                  | 27.3 (10.9)    |
| SCORAD\",mean (SD)                     | 63.4 (11.1)     | 64.8 (11.8)                  | 64.3 (11.6)    |
| %BSA affected,mean (SD)               | 38.2 (20.8)     | 40.4 (21.9)                  | 39.7 (21.5)    |
| Pruritus NRSb, mean (SD)              | 6.8 (2.0)       | 7.3 (1.8)                    | 7.1 (1.9)      |
| ≥4, n/Nx (%)                          | 57/63 (90.5)    | 130/139 (93.5)               | 187/202 (92.6) |
| Sleep-loss scoreb, mean (SD)          | 1.9 (0.9)       | 2.1 (0.9)                    | 2.0 (0.9)      |
| ≥2, n/Nx (%)                          | 34/63 (54.0)    | 88/139 (63.3)                | 122/202 (60.4) |
| POEM, mean (SD)                       | 19.5 (6.2)      | 19.5 (6.4)                   | 19.5 (6.3)     |
| DLQI,mean (SD)                        | 13.5 (7.5)      | 14.9 (7.2)                   | 14.4 (7.3)     |
| CDLQI,mean (SD)                       | 10.7 (6.4)      | 11.8 (7.2)                   | 11.5 (6.9)     |
| PROMISdAnxiety Score,mean (SD)        |                 |                              |                |
| Adolescents (12 to ≤18 years; ≥40kg). | 49.6 (12.5)     | 48.1 (11.9)                  | 48.5 (12.0)    |
| Adults (≥18 years)                    | 50.8 (8.1)      | 52.4 (9.4)                   | 51.9 (9.0)     |
| PROMISdDepressionScore,mean (SD)      |                 |                              |                |
| Adolescents (12 to ≤18 years; ≥40kg). | 50.5 (15.1)     | 48.2 (9.8)                   | 48.9 (11.5)    |
| Adults (≥18 years)                    | 47.0 (8.6)      | 48.9 (8.9)                   | 48.3 (8.8)     |

Abbreviations: AD = atopic dermatitis; BSA = body surface area; CDLQI = Children Dermatology Life Quality Index; DLQI = Dermatology Life Quality Index; EASI = Eczema Area and Severity Index; IGA = Investigator's Global Assessment for AD; LEB = lebrikizumab; N = number of participants in the analysis population; n = number of participants in the specified category; Nx = number of participants in the analysis population with non-missing data for specified endpoint; NRS = numeric rating scale; PBO = placebo; POEM =Patient-Oriented Eczema Measure;PROMIS=Patient-Reported Outcomes Measurement InformationSystem;Q2W=every 2 weeks;SCORAD=SCORing Atopic Dermatitis;SD=standard deviation;TCS=topical corticosteroids.

- a Mean value at baseline was calculated from number of participants with non-missing data (SCORAD: PBO N = 65,LEBN=140;POEM:PBON=64,LEBN=135.
- b The number of participants with non-missing data for mean and score calculations of Pruritus NRS and Sleep-loss was PBO N=63,LEB N=139.
- Adult participants with non-missing data at Baseline for the DLQI were PBO N = 51, LEB N = 109. Adolescent
- d Adult participants with non-missing data at baseline for PROMIS were PBO N = 44, LEB N = 101. Adolescent

## Previous AD treatments

## KGAB study

The most common prior therapies used, reported by 10% of patients or more, were topical corticosteroids (96.9%) and topical calcineurin inhibitors (43.4%). Prior systemic  treatment use  was reported by 49.3%, mainly systemic corticosteroids (41.5%) and cyclosporine (15.1%). Prior phototherapy was reported by 15.1% of the patients. (Table 28).

<div style=\"page-break-after: always\"></div>

Table 28: Summary of AD Treatment History at Baseline (ITT Population)

| Prior Therapy                                     | PBO (N =141) n (%)   | LEB 250mg Q2W (N =283) n (%)   | Total (N =424) n (%)   |
|---------------------------------------------------|----------------------|--------------------------------|------------------------|
| None                                              | 3 (2.1)              | 4 (1.4)                        | 7 (1.7)                |
| Topicalcorticosteroids                            | 136 (96.5)           | 275 (97.2)                     | 411 (96.9)             |
| Topical calcineurininhibitor's                    | 65 (46.1)            | 119 (42.0)                     | 184 (43.4)             |
| Systemic treatment                                | 79 (56.0)            | 130 (45.9)                     | 209 (49.3)             |
| Systemic corticosteroids                          | 70 (49.6)            | 106 (37.5)                     | 176 (41.5)             |
| Cyclosporine                                      | 25 (17.7)            | 39 (13.8)                      | 64 (15.1)              |
| Mycophenolate-mofetil                             | 3 (2.1)              | 4 (1.4)                        | 7 (1.7)                |
| IFN-gamma                                         | 0                    | 1 (0.4)                        | 1 (0.2)                |
| Janus kinase inhibitors                           | 9 (6.4)              | 16 (5.7)                       | 25 (5.9)               |
| Azathioprine                                      | 6 (4.3)              | 6 (2.1)                        | 12 (2.8)               |
| Methotrexate                                      | 9 (6.4)              | 12 (4.2)                       | 21 (5.0)               |
| Phototherapy                                      | 32 (22.7)            | 35 (12.4)                      | 67 (15.8)              |
| Photochemotherapy                                 | 3 (2.1)              | 9 (3.2)                        | 12 (2.8)               |
| Other biologics (e.g., cell- depleting biologics) | 6 (4.3)              | 10 (3.5)                       | 16 (3.8)               |
| Other nonbiologic medication/treatment            | 22 (15.6)            | 35 (12.4)                      | 57 (13.4)              |

## KGAC study

The most  common prior therapies, reported by 10%  or more of patients  were topical corticosteroids (98.8%) and topical calcineurin inhibitors (36.1%). Prior systemic  treatment use  was reported by 46.4%, mainly systemic corticosteroids (37.7%) and cyclosporine (10.5%). Prior phototherapy was reported by 23.7% of the patients (Table 29).

Table 29: Summary of AD Treatment History at Baseline (mITT Population)

| Prior therapy                                  | PBO (N =146) n (%)   | LEB 250 mg Q2W (N = 281) n (%)   | Total (N = 427) n (%)   |
|------------------------------------------------|----------------------|----------------------------------|-------------------------|
| None                                           | 2 (1.4)              | 2 (0.7)                          | 4 (0.9)                 |
| Topical corticosteroids                        | 144 (98.6)           | 278 (98.9)                       | 422 (98.8)              |
| Topical calcineurininhibitor's                 | 55 (37.7)            | 99 (35.2)                        | 154 (36.1)              |
| Systemic treatment                             | 62 (42.5)            | 136 (48.4)                       | 198 (46.4)              |
| Systemic corticosteroids                       | 49 (33.6)            | 112 (39.9)                       | 161 (37.7)              |
| Cyclosporine                                   | 19 (13.0)            | 26 (9.3)                         | 45 (10.5)               |
| Mycophenolate-mofetil                          | 0                    | 0                                | 0                       |
| IFN-gamma                                      | 0                    | 0                                | 0                       |
| Janus kinase inhibitors                        | 8 (5.5)              | 19 (6.8)                         | 27 (6.3)                |
| Azathioprine                                   | 12 (8.2)             | 13 (4.6)                         | 25 (5.9)                |
| Methotrexate                                   | 18 (12.3)            | 31 (11.0)                        | 49 (11.5)               |
| Phototherapy                                   | 35 (24.0)            | 66 (23.5)                        | 101 (23.7)              |
| Photochemotherapy (PUVA)                       | 1 (0.7)              | 6 (2.1)                          | 7 (1.6)                 |
| Other biologics (eg, cell depleting biologics) | 6 (4.1)              | 10 (3.6)                         | 16 (3.7)                |
| Othernon-biologicmedication/treatment          | 9 (6.2)              | 17 (6.0)                         | 26 (6.1)                |

<div style=\"page-break-after: always\"></div>

## KGAD study

All  patients  had  previously used  TCS, and  33.6%  had  used topical  calcineurin  inhibitors.  Altogether 47.4% of patients had  previously  used some  systemic  treatment, most  commonly  systemic corticosteroids (29.9%), phototherapy (18.0%) dupilumab (13.7%) and cyclosporine (10.4%) (Table 30).

Table 30: Summary of AD Treatment History at Baseline

| Prior therapy                           | PBO + TCS (N = 66) n (%)   | LEB 250 mg Q2W + TCS (N = 145) n (%)   | Total (N =211) n (%)   |
|-----------------------------------------|----------------------------|----------------------------------------|------------------------|
| None                                    | 0                          | 0                                      | 0                      |
| Topical corticosteroids                 | 66 (100)                   | 145 (100)                              | 211 (100)              |
| Topical calcineurin inhibitors          | 23 (34.8)                  | 48 (33.1)                              | 71 (33.6)              |
| Systemictreatment                       | 34 (51.5)                  | 66 (45.5)                              | 100 (47.4)             |
| Systemic corticosteroids                | 22 (33.3)                  | 41 (28.3)                              | 63 (29.9)              |
| Phototherapy                            | 14 (21.2)                  | 24 (16.6)                              | 38 (18.0)              |
| Dupilumab                               | 9 (13.6)                   | 20 (13.8)                              | 29 (13.7)              |
| Cyclosporine                            | 4 (6.1)                    | 18 (12.4)                              | 22 (10.4)              |
| Methotrexate                            | 6 (9.1)                    | 13 (9.0)                               | 19 (9.0)               |
| Janus kinase inhibitors                 | 4 (6.1)                    | 5 (3.4)                                | 9 (4.3)                |
| Photochemotherapy (PUVA)                | 2 (3.0)                    | 3 (2.1)                                | 5 (2.4)                |
| Mycophenolate-mofetil                   | 0                          | 4 (2.8)                                | 4 (1.9)                |
| Tralokinumab                            | 1 (1.5)                    | 1 (0.7)                                | 2 (0.9)                |
| Other biologics                         | 5 (7.6)                    | 16 (11.0)                              | 21 (10.0)              |
| Other non-biologic medication/treatment | 5 (7.0)                    | 16 (11.0)                              | 21 (10.0)              |

## Numbers analysed

## KGAB and KGAC studies

In the KGAB study, the ITT  population included 424  patients in lebrikizumab 250 mg Q2W (n=283) and  placebo  (n=141)  groups.  The Maintenance Primary  Population included  157  patients  in lebrikizumab 250 mg Q2W (n=62), lebrikizumab 250 Q4W (n=63) and placebo (n=32) groups.

In the KGAC study, the mITT population included 427 patients in lebrikizumab 250 mg Q2W (n=281) and placebo (n=146) groups. The Modified Maintenance  Primary  Population (mMPP) included 134 patients  in  lebrikizumab  250  mg  Q2W  (n=51),  lebrikizumab 250  Q4W  (n=55)  and  placebo (n=28) groups.

## KGAD study

The mITT population included 211 patients in lebrikizumab 250 mg Q2W (n=145) and placebo (n=66) groups.

## Outcomes and estimation

## Study KGAB, KGAC and KGAD Induction Period Results

## Coprimary endpoint: IGA 0 or 1 with ≥2 -Point reduction at week 16

A significantly greater percentage of patients achieved an IGA 0,1 with ≥2 points reduction (IGA 0,1) at week 16 in the  lebrikizumab group compared to placebo in  all pivotal  Phase 3  studies  based on the primary analysis of the 'hybrid' estimand. In KGAB and KGAC, 43.1% and 33.2% of patients treated

<div style=\"page-break-after: always\"></div>

with lebrikizumab and 12.7% and 10.8%  of patients treated with  placebo achieved IGA 0,1. In KGAD, 41.2% of patients treated with lebrikizumab + TCS and 22.1% of patients treated with placebo + TCS achieved IGA 0,1. The treatment difference between lebrikizumab and placebo was 29.7% and 21.9% in KGAB and KGAC, respectively, and 18.3% in KGAD where TCS was used (Table 31).

The supportive 'composite' estimand yielded similar results to the primary analysis. In KGAB and KGAC, 41.0% and 31.3% of patients treated with lebrikizumab and 11.3% and 9.6% of patients treated with placebo achieved IGA 0,1  (p&lt;0.001  in both studies). In KGAD, 39.3% and 19.7% of patients treated with lebrikizumab + TCS and placebo + TCS, respectively, achieved IGA 0,1 (p=0.006).

Table 31: IGA 0 or 1 with ≥2 -Point Reduction at Week 16 Primary Estimand (Hybrid) with MCMC-MI

|                         | Study KGAB        | Study KGAB          | StudyKGAC         | StudyKGAC           | Study KGAD       | Study KGAD                |
|-------------------------|-------------------|---------------------|-------------------|---------------------|------------------|---------------------------|
|                         | PBO N=141         | LEB 250mg Q2W N=283 | PBO N=146         | LEB 250mg Q2W N=281 | PBO + TCS N=66   | LEB 250mg Q2W + ICS N=145 |
| IGA 0,1 response, n (%) | 18 (12.7)         | 122 (43.1)          | 16 (10.8)         | 93 (33.2)           | 15 (22.1)        | 60 (41.2)                 |
| DifffromPBO (95% CI)    | 29.7 (21.6, 37.8) | 29.7 (21.6, 37.8)   | 21.9 (14.2, 29.6) | 21.9 (14.2, 29.6)   | 18.3 (5.1, 31.5) | 18.3 (5.1, 31.5)          |
| p-valuevs.PBOa          | <.001             | <.001               | <.001             | <.001               | .011             | .011                      |

Abbreviations: CSR = clinical study report; CI = confidence interval; Diff = difference; IGA = Investigator's Global Assessment; IGA 0,1 = IGA score of 0 or 1, with a 2-point or greater reduction from Baseline; LEB = lebrikizumab; MCMC-MI =Markov Chain Monte Carlo multiple imputation; N =number of participants in the analysis population; n = number of participants in the specified category; NA = not applicable; PBO = placebo; Q2W =every 2 weeks; TCS =topical corticosteroids.

Cochran-Mantel-Haenszel test adjusted by geographic region (US versus EU versus rest of world), age (adolescent versus adult), and disease severity (IGA 3 versus 4).

Figure 13 shows the IGA 0,1 responses by visit throughout the 16-week induction period.

A supplementary post  hoc analysis that  used all  observed data regardless of any intercurrent events yielded similar results to the primary analysis. In KGAB and KGAC, 45.6% and 36.6% of patients treated with lebrikizumab and 14.2% and 12 .6% of patients treated with placebo achieved IGA 0,1 (p&lt;0.001 in both  studies).  In  KGAD,  43.5%  and  22.2%  of  patients  treated  with  lebrikizumab  +  TCS  and placebo + TCS, respectively, achieved IGA 0,1 (p=0.004).

<div style=\"page-break-after: always\"></div>

Figure 13: Proportion of patients achieving IGA 0 or 1, with a ≥2 -point improvement from Baseline through Week 16. Primary estimand (hybrid) with MCMC-MI.

<!-- image -->

## Coprimary endpoint: EASI 75 (≥75% reduction from Baseline in EASI score) at Week 16

A significantly greater percentage of patients achieved EASI 75 at week 16 in the lebrikizumab-treated group compared to the placebo-treated group in all pivotal Phase 3 studies based  on the primary  analysis of the 'hybrid' estimand.

In KGAB and KGAC, 58.8% and 52.1% of patients treated with lebrikizumab and 16.2% and 18.1%  of patients treated with placebo achieved EASI 75. In KGAD, 69.5% of patients treated with lebrikizumab + TCS and 42.2% of patients treated with placebo + TCS achieved EASI 75. The treatment difference between lebrikizumab and placebo was 42.0% and 33.3% in KGAB and KGAC, respectively, and 26.4% in KGAD where TCS was used (Table 32).

<div style=\"page-break-after: always\"></div>

The supportive 'composite' estimand yielded similar results to the primary analysis. In KGAB and KGAC, 56.5% and 50.2% of patients treated with lebrikizumab and 14.2% and 17.1% of patients treated with placebo achieved EASI 75 (p&lt;0.001 in both studies). In KGAD, 66.9% and 39.4% of patients treated with lebrikizumab + TCS and placebo + TCS, respectively, achieved EASI 75 (p&lt;0.001).

A supplementary post  hoc analysis that  used all  observed data regardless of any intercurrent events yielded similar results to the primary analysis. In KGAB and KGAC, 63.1% and 59.9% of patients treated with lebrikizumab and 20.6% and 26.7% of patients treated with placebo achieved EASI 75 (p&lt;0.001 in both studies). In KGAD, 72.6% and 42.5%  of patients treated with lebrikizumab + TCS and placebo + TCS, respectively, achieved EASI 75 (p &lt; 0.001).

Table 32: Percentage of Patients Achieving EASI 75 and EASI 90 at Week 16 Primary Estimand (Hybrid) with MCMC-MI

|                                | Study KGAB        | Study KGAB          | Study KGAC        | Study KGAC          | Study KGAD        | Study KGAD                |
|--------------------------------|-------------------|---------------------|-------------------|---------------------|-------------------|---------------------------|
|                                | PBO N=141         | LEB 250mg Q2W N=283 | PBO N =146        | LEB 250mg Q2W N=281 | PBO + TCS N=66    | LEB 250mg Q2W + TCS N=145 |
| EASI75                         |                   |                     |                   |                     |                   |                           |
| Response, n (%)                | 23 (16.2)         | 166 (58.8)          | 26 (18.1)         | 146 (52.1)          | 28 (42.2)         | 101 (69.5)                |
| Difference Vs.PBO, % (95% CI)  | 42.0 (33.3, 50.6) | 42.0 (33.3, 50.6)   | 33.3 (24.4, 42.2) | 33.3 (24.4, 42.2)   | 26.4 (12.1, 40.8) | 26.4 (12.1, 40.8)         |
| p-value vs. PBOa               | <.001             | <.001               | <.001             | <.001               | <.001             | <.001                     |
| EASI90                         |                   |                     |                   |                     |                   |                           |
| Response, n (%)                | 13 (9.0)          | 108 (38.3)          | 14 (9.5)          | 86 (30.7)           | 14 (21.7)         | 60 (41.2)                 |
| Difference vs. PBO, % (95% CI) | 28.8 (21.3, 36.3) | 28.8 (21.3, 36.3)   | 20.7 (13.3, 28.1) | 20.7 (13.3, 28.1)   | 18.9 (6.1, 31.7)  | 18.9 (6.1, 31.7)          |
| p-value vs. PBOa               | <.001             | <.001               | <.001             | <.001               | .008              | .008                      |

Abbreviations: CSR = clinical study report; CI = confidence interval; EASI = Eczema Area and Severity Index; EASI75=75%improvementfromBaselineinEASI;EASI90=90%improvement fromBaselineinEASI; IGA = Investigator's Global Assessment; LEB = lebrikizumab; MCMC-MI =Markov Chain Monte Carlo multiple imputation; N = number of participants in the analysis population; n = number of participants in the specified category; PBO = placebo; Q2W = every 2 weeks; TCS = topical corticosteroids.

Cochran-Mantel-Haenszel test adjusted by geographic region (US versus EU versus rest of world), age (adolescent versus adult), and disease severity (IGA 3 versus 4).

Figure 14 shows the EASI 75 responses by visit throughout the 16-week induction period.

<div style=\"page-break-after: always\"></div>

Figure 14: Proportion of patients achieving EASI 75 through Week 16. Primary estimand (hybrid) with MCMC-MI.

## a)KGAB

<!-- image -->

Week

## C)KGAD

<!-- image -->

Abbreviations: EASI =Eczema Area and Severity Index; EASI 75 = 75% reduction from Baseline in EASI; LEB = lebrikizumab; MCMC-MI = Markov Chain Monte Carlo multiple imputation; PBO =placebo; Q2W = every 2 weeks; TCS = topical corticosteroids.

<!-- formula-not-decoded -->

## Key secondary  endpoints:

## Percentage  of patients achieving EASI90 at Week  16

As shown in Table 32, a significantly greater percentage of patients achieved EASI 90 at Week 16 in the lebrikizumab-treated group compared to the placebo-treated group in all Phase 3 studies.

In KGAB and KGAC, 38.3% and 30.7% of patients treated with  lebrikizumab and 9.0%  and 9.5%  of patients treated with placebo achieved EASI 90. In KGAD, 41.2% of patients treated with lebrikizumab + TCS and 21.7% of patients treated with placebo + TCS achieved EASI 90. The treatment difference between lebrikizumab and placebo was 28.8% and 20.7% in KGAB and KGAC, respectively, and 18.9% in KGAD where TCS was used.

<!-- image -->

<div style=\"page-break-after: always\"></div>

In KGAB and KGAC, Percentage  of patients achieving EASI90 at Week 4 , was also listed as a Major secondary endpoint. In KGAB study, 12.4% vs. 1.6% of the patients in lebrikizumab and placebo groups, respectively, achieved EASI 90 at Week 4 resulting in a treatment difference of 10.7% (p&lt;0.001). In KGAC study, 6.3% vs. 1.5% of the patients in lebrikizumab and placebo groups, respectively, achieved EASI 90 at Week 4 with a treatment difference of 4.9% (p=0.023).

## Percentage  change  in EASI score from Baseline to Week 16

In  KGAB  and  KGAC,  the  percentage  change  (LSM)  in  EASI  score  was  -64.31%  and  -61.5%  in lebrikizumab groups and -26.01% and 28.0% in placebo groups at Week 16 (p&lt;0.001 in both studies). In KGAD, the corresponding change was -76.8% in lebrikizumab + TCS group and -53.1% in placebo + TCS group (p&lt;0.001). The decrease in EASI score with lebrikizumab reached statistical significance vs. placebo from week 2 onwards in KGAB and KGAC studies, and from week 4 onwards in KGAD study.

## Percentage  of patients with a Pruritus NRS of ≥4 -points at Baseline who achieve  a ≥4 -point reduction from Baseline to Week  16

In KGAB and KGAC, 45.9% and 39.8% of patients treated with lebrikizumab and 13.0% and 11.5%  of patients treated with placebo achieved a ≥4 reduction in NRS at Week 16 (p&lt;0.001). In KGAD, 50.6% of patients treated with lebrikizumab + TCS and 31.9% of patients treated with placebo + TCS achieved a ≥4 reduction in NRS at  Week 16 (p&lt;0.017).  The treatment difference between lebrikizumab and placebo was 32.9% and 28.3% in KGAB and KGAC, respectively, and 19.2% in KGAD where TCS was used. A statistically significant difference between lebrikizumab vs. placebo was reached from 2 weeks onwards in KGAB study and from 4 week onwards in KGAC and KGAD studies.

## Percentage  change  in Pruritus NRS score from Baseline to Week  16

In KGAB and KGAC, the percentage change (LSM)  in  Pruritus NRS Score was -45.5%  and -36.6%  in lebrikizumab groups and -15.1% and 9.0% in placebo groups at Week 16 (p&lt;0.001 in both studies). In KGAD, the corresponding change was -50.7% in  lebrikizumab + TCS group and -35.5%  in placebo + TCS  group  (p&lt;0.017).  A  statistically  significant  reduction  between  lebrikizumab  vs.  placebo  was observed in  Pruritus NRS  score from 1  week onwards in KGAB and KGAC studies and  from 6 weeks onwards in KGAD study.

## Percentage  of patients  with a DLQI  total  score  of ≥4 -points at Baseline  who achieve  a ≥4 -point improvement from baseline to Week  16 and Change from baseline in DLQI total score at Week  16

As shown in Table 33 , a significantly greater percentage of patients with a baseline DLQI of ≥4 reported a ≥4 -point  reduction at Week 16 in lebrikizumab group compared to placebo group. The mean change from baseline in DLQI was also significantly greater  in lebrikizumab-treated  vs. placebo-treated patients.

<div style=\"page-break-after: always\"></div>

Table 33: Proportion of Patients with a 4-Point or Greater Improvement in DLQI and DLQI Mean Change from Baseline at Week  16 Primary Estimand (Hybrid) with MCMC-MI

|                                                                | Study KGAB                                                     | Study KGAB                                                     | Study KGAC                                                     | Study KGAC                                                     | Study KGAD                                                     | Study KGAD                                                     |
|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|
|                                                                | PBO                                                            | LEB 250mg Q2W                                                  | PBO                                                            | LEB 250mg Q2W                                                  | PBO + TCS                                                      | LEB 250mgQ2W + TCS                                             |
| Percentage of participants with 4-point or greater improvement | Percentage of participants with 4-point or greater improvement | Percentage of participants with 4-point or greater improvement | Percentage of participants with 4-point or greater improvement | Percentage of participants with 4-point or greater improvement | Percentage of participants with 4-point or greater improvement | Percentage of participants with 4-point or greater improvement |
| Participants with DLQI ≥4 at BLa, N                            | 116                                                            | 226                                                            | 115                                                            | 215                                                            | 48                                                             | 105                                                            |
| Response, n (%)                                                | 39 (33.8)                                                      | 171 (75.6)                                                     | 39 (33.6)                                                      | 143 (66.3)                                                     | 28 (58.7)                                                      | 81 (77.4)                                                      |
| Diff vs. PBO, % (95% CI)b                                      | 41.8 (31.2, 52.3)                                              | 41.8 (31.2, 52.3)                                              | 33.0 (22.2, 43.8)                                              | 33.0 (22.2, 43.8)                                              | 17.2 (0.1, 34.3)                                               | 17.2 (0.1, 34.3)                                               |
| p-value vs. PBOb                                               | <.001                                                          | <.001                                                          | <.001                                                          | <.001                                                          | .036                                                           | .036                                                           |
| Mean change from Baseline in DLQI                              | Mean change from Baseline in DLQI                              | Mean change from Baseline in DLQI                              | Mean change from Baseline in DLQI                              | Mean change from Baseline in DLQI                              | Mean change from Baseline in DLQI                              | Mean change from Baseline in DLQI                              |
| Nc                                                             | 121                                                            | 239                                                            | 118                                                            | 218                                                            | 51                                                             | 109                                                            |
| Baseline DLQI (SD)                                             | 15.7 (7.2)                                                     | 15.3 (7.4)                                                     | 15.9 (7.6)                                                     | 15.4 (7.0)                                                     | 13.5 (7.5)                                                     | 14.9 (7.2)                                                     |
| LSM change (SE)                                                | -2.9 (1.1)                                                     | -8.7 (1.1)                                                     | -2.4 (1.2)                                                     | -7.3 (1.2)                                                     | -6.5 (1.9)                                                     | -9.8 (1.8)                                                     |
| LSM Diff vs. PBO (SE)d                                         | -5.8                                                           | (0.68)                                                         | -4.9                                                           | (0.71)                                                         | -3.3                                                           | (1.0)                                                          |
| p-value vs. PBOd                                               | <.001                                                          | <.001                                                          | <.001                                                          | <.001                                                          | .001                                                           | .001                                                           |

- Abbreviations: ANCOVA = analysis of covariance; BL = baseline; CI = confidence interval; CSR = clinical study report; Diff = difference; DLQI = Dermatology Life Quality Index; IGA = Investigator's Global Assessment; LEB = lebrikizumab; LSM = least standard mean; MCMC-MI = Markov Chain Monte Carlo multiple imputation; N = number of participants in the analysis population; n = number of participants in the specified category; PBO = placebo; Q2W = every 2 weeks; SD = standard deviation; SE = standard error; TCS = topical corticosteroids.
- DLQI 4-point improvement response was analyzed in participants with a Baseline DLQI score of 4 or more.
- Cochran-Mantel-Haenszel test adjusted by geographic region (US versus EU versus rest of world), age (adolescent versus adult), and disease severity (IGA 3 versus 4).
- Change from Baseline in DLQI analyzed in participants with nonmissing DLQI baseline values.
- d (adolescent participants 12 to &lt;18 versus adults ≥18 years) and baseline IGA score (3,4) as fixed factors and baseline value as covariate.

In a supplementary post hoc analysis that used all observed data regardless of any intercurrent events, smaller treatment  effect on DLQI  ≥4 -point  improvement rates  was  observed as  compared  with  the primary analysis. In KGAB and KGAC, 84.7% and 80.9% of patients treated with lebrikizumab and 56.5% and 61.9%  of patients  treated with  placebo achieved DLQI  ≥4 -point  improvement (p&lt;0.001  in  both studies). The corresponding results in KGAD were 83.6% and 63.9% for lebrikizumab + TCS and placebo + TCS, respectively (p=0.025).

Change from Baseline in Sleep-loss Scale score at Week  16 and Percentage  of patients with a Sleeploss score ≥2 points at Baseline who achieve  a ≥2 points reduction from Baseline  at Week 16 (Major secondary endpoint only in KGAB and KGAC Studies)

Patients in lebrikizumab-treated group  reported significantly greater  reductions in Sleep-Loss  Scale  Score compared to placebo. Further, the proportion of patients with SleepLoss  Scale Score  ≥2 at baseline who had ≥2 -point reduction at Week 16 was greater in lebrikizumab group vs. placebo group in all Phase 3 studies (Table 34).

<div style=\"page-break-after: always\"></div>

Table 34: Proportion of Patients with a 2-Point or Greater Reduction in Sleep-Loss Scale Score and Mean Change from Baseline in Sleep-Loss Scale Score at Week  16 Primary Estimand (Hybrid) with MCMC-MI

|                                                              | StudyKGAB                                                    | StudyKGAB                                                    | Study KGAC                                                   | Study KGAC                                                   | Study KGAD                                                   | Study KGAD                                                   |
|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|
|                                                              | PBO                                                          | LEB 250mg Q2W                                                | PBO                                                          | LEB 250mg Q2W                                                | PBO + TCS                                                    | LEB 250mg Q2W + TCS                                          |
| Percentage of participants with 2-point or greater reduction | Percentage of participants with 2-point or greater reduction | Percentage of participants with 2-point or greater reduction | Percentage of participants with 2-point or greater reduction | Percentage of participants with 2-point or greater reduction | Percentage of participants with 2-point or greater reduction | Percentage of participants with 2-point or greater reduction |
| Participants with score ≥2 at BLa, N                         | 91                                                           | 195                                                          | 97                                                           | 161                                                          | 34                                                           | 88                                                           |
| Response, n (%)                                              | 4 (4.7)                                                      | 76 (39.0)                                                    | 8 (8.2)                                                      | 45 (28.0)                                                    | 6 (18.4)                                                     | 30 (34.5)                                                    |
| Diff vs. PBO, % (95% CI)b                                    | 34.6 (26.2, 43.0)                                            | 34.6 (26.2, 43.0)                                            | 18.9 (9.6, 28.1)                                             | 18.9 (9.6, 28.1)                                             | 20.8 (2.1, 39.5)                                             | 20.8 (2.1, 39.5)                                             |
| p-value vs. PBOb                                             | <.001                                                        | <.001                                                        | <.001                                                        | <.001                                                        | .048                                                         | .048                                                         |
| Mean change from Baseline in Sleep-Loss Scale score          | Mean change from Baseline in Sleep-Loss Scale score          | Mean change from Baseline in Sleep-Loss Scale score          | Mean change from Baseline in Sleep-Loss Scale score          | Mean change from Baseline in Sleep-Loss Scale score          | Mean change from Baseline in Sleep-Loss Scale score          | Mean change from Baseline in Sleep-Loss Scale score          |
| Nc                                                           | 136                                                          | 276                                                          | 143                                                          | 268                                                          | 63                                                           | 139                                                          |
| Baseline score (SD)                                          | 2.3 (1.0)                                                    | 2.3 (1.0)                                                    | 2.2 (0.9)                                                    | 2.2 (0.9)                                                    | 1.9 (0.9)                                                    | 2.1 (0.9)                                                    |
| LSM change (SE)                                              | -0.38 (0.1)                                                  | -1.13 (0.1)                                                  | -0.35 (0.1)                                                  | -1.05 (0.1)                                                  | -0.80 (0.1)                                                  | -1.10 (0.1)                                                  |
| LSM Diff vs. PBO (SE)d                                       | -0.75 (0.1)                                                  | -0.75 (0.1)                                                  | -0.70 (0.1)                                                  | -0.70 (0.1)                                                  | -0.30 (0.1)                                                  | -0.30 (0.1)                                                  |
| p-value vs. PBOd                                             | <.001                                                        | <.001                                                        | <.001                                                        | <.001                                                        | .025                                                         | .025                                                         |

- Abbreviations: ANCOVA = analysis of covariance; BL = baseline; CI = confidence interval; CSR = clinical study report; IGA = Investigator's Global Assessment; LEB = lebrikizumab; LSM = least-standard mean; MCMCMI = Markov Chain Monte Carlo multiple imputation; N = number of participants in the analysis population; n = number of participants in the specified category; PBO = placebo; Q2W = every 2 weeks; SD = standard deviation; SE = standard error; TCS = topical corticosteroids.
- Sleep-Loss Scale score 2-point improvement response was analyzed in participants with a Baseline score of 2 or more.
- b Cochran-Mantel-Haenszel test adjusted by geographic region (US versus EU versus rest of world), age (adolescent versus adult), and disease severity (IGA 3 versus 4).
- Change from Baseline in Sleep-Loss Scale score was analyzed in participants with nonmissing baseline values.
- d The ANCOVA model includes treatment, geographic region (US versus EU versus rest of the world), age group (adolescent participants 12 to &lt;18 versus adults ≥18 years) and baseline IGA score (3.4) as fixed factors and baseline value as covariate.

Percentage  of patients with a Pruritus NRS score of ≥4 points at Baseline who achieve  both EASI75 and a ≥4 -point reduction in NRS score from Baseline  at Week  16 (Major  secondary endpoint only in KGAD Study)

Lebrikizumab + TCS resulted in statistically significant improvement compared with  placebo + TCS in percentage of patients experiencing both EASI 75 and a 4-point reduction in NRS score from baseline to Week 16 among patients with a score of ≥4 at baseline .

## Other  secondary endpoints:

KGAB, KGAC and KGAD studies had several secondary endpoints. Selected secondary endpoints have been presented in the Summary of Clinical Efficacy SCE by the Applicant and shown below.

Lebrikizumab-treated  patients  had  a  statistically  significantly  greater  reduction  in  Patient-Oriented Eczema Measure (POEM), than placebo-treated patients in Phase 3 studies (Table 35).

<div style=\"page-break-after: always\"></div>

Table 35: Total Change from Baseline in POEM at Week  16 Supportive Estimand (Hypothetical) with MMRM

|                         | Study KGAB   | Study KGAB    | Study KGAC   | Study KGAC    | Study KGAD   | Study KGAD          |
|-------------------------|--------------|---------------|--------------|---------------|--------------|---------------------|
|                         | PBO          | LEB 250mg Q2W | PBO          | LEB 250mg Q2W | PBO + TCS    | LEB 250mg Q2W + TCS |
| eN                      | 133          | 275           | 141          | 266           | 64           | 135                 |
| Baseline score (SD)     | 20.5 (6.3)   | 20.9 (5.9)    | 21.4 (5.6)   | 20.4 (5.6)    | 19.5 (6.2)   | 19.5 (6.4)          |
| LSM, (SE)               | -3.9 (0.7)   | -11.3 (0.5)   | -3.5 (0.8)   | -9.5 (0.5)    | -6.2 (1.0)   | -10.2 (0.7)         |
| LSM diff vs. PBO, (SE)b | -7.3 (0.8)   | -7.3 (0.8)    | -6.0 (0.9)   | -6.0 (0.9)    | -4.0 (1.1)   | -4.0 (1.1)          |
| p-value vs. PBOb        | <.001        | <.001         | <.001        | <.001         | <.001        | <.001               |

- Abbreviations: CSR = clinical study report; diff = difference; LEB = lebrikizumab; LSM = least square mean; MMRM = mixed model repeated measures; N = number of participants in the analysis population; PBO = placebo; POEM = Patient-Oriented Eczema Measure; Q2W = every 2 weeks; SD = standard deviation; SE = standard error; TCS = topical corticosteroids.
- a Change from Baseline in POEM score was analyzed in participants with nonmissing baseline values.
- The MMRM model includes treatment, baseline value, visit, the interaction of the baseline value-by-visit, the interaction of treatment by-visit, geographic region, age group, baseline IGA score.

In patient-reported outcome measures (PROMIS) in anxiety and depression in adults, KGAB and KGAC showed statistically significant improvements in lebrikizumab  groups  vs. placebo.  In KGAD, the difference was smaller and did not reach statistical significance (Table 36).

<div style=\"page-break-after: always\"></div>

Table 36: Change from Baseline in PROMIS Scores at Week 16 Supportive Estimand (Hypothetical) with LOCF (Adult Patients)

|                         | Study KGAB   | Study KGAB           | Study KGAC   | Study KGAC           | Study KGAD     | Study KGAD                 |
|-------------------------|--------------|----------------------|--------------|----------------------|----------------|----------------------------|
|                         | PBO N =122   | LEB 250 mg Q2W N=244 | PBO N= 128   | LEB 250 mg Q2W N=246 | PBO + TCS N=52 | LEB 250 mg Q2W + TCS N=113 |
| Anxiety                 |              |                      |              |                      |                |                            |
| Baseline score (SD)     | 54.3 (9.3)   | 52.9 (10.1)          | 55.0 (10.4)  | 54.4 (8.9)           | 50.8 (8.2)     | 52.4 (9.4)                 |
| LSM, (SE)               | -0.6 (0.7)   | -3.9 (0.5)           | -0.5 (0.6)   | -3.2 (0.4)           | -1.1 (1.4)     | -1.9 (1.0)                 |
| LSM diff vs. PBOa, (SE) | -3.3 (0.8)   | -3.3 (0.8)           | -2.7 (0.7)   | -2.7 (0.7)           | -0.8 (1.4)     | -0.8 (1.4)                 |
| p-value vs.PBOa         | <.001        | <.001                | <.001        | <.001                | .571           | .571                       |
| Depression              |              |                      |              |                      |                |                            |
| Baseline score (SD)     | 50.0 (9.2)   | 49.8 (10.0)          | 51.2 (10.4)  | 51.3 (9.2)           | 47.2 (8.6)     | 48.9 (8.9)                 |
| LSM, (SE)               | -0.4 (0.6)   | -3.1 (0.4)           | 0.2 (0.5)    | -2.6 (0.4)           | -1.2 (1.1)     | -1.4 (0.8)                 |
| LSM diff vs. PBOa, (SE) | -2.7 (0.7)   | -2.7 (0.7)           | -2.8 (0.7)   | -2.8 (0.7)           | -0.2 (1.1)     | -0.2 (1.1)                 |
| p-value vs. PBOa        | <.001        | <.001                | <.001        | <.001                | .882           | .882                       |

Abbreviations: ANCOVA = analysis of covariance; CSR = clinical study report; diff = difference; LEB =

lebrikizumab; LOCF = last observation carried forward; LSM = least standard mean; N = number of participants in the analysis population; PBO = placebo; PROMIS = Patient-Reported Outcomes Measurement Information System; Q2W = every 2 weeks; SD = standard definition; SE = standard error; TCS = topical corticosteroids.

The ANCOVA model includes treatment, geographic region (US versus EU versus rest of the world) and baseline IGA score (3,4) as fixed factors and baseline value as covariate.

## Study KGAB and KGAC Maintenance  Period Results

## Key secondary  endpoints specific for maintenance  period:

## Percentage  of patients from those re-randomised  having achieved  EASI-75 at Week  16 who continue to exhibit EASI-75 at Week  52 (EASI-75 calculated  relative  to baseline EASI score)

Lebrikizumab-responders who were re-randomised to treatment with lebrikizumab maintained EASI 75 response at  Week 52  at  numerically higher  rates  compared with  those  who  were re-randomised to placebo (lebrikizumab withdrawal) (Table 37). Among patients in the pooled population, maintenance of EASI 75  was higher at Week 52 for patients re-randomised to lebrikizumab 250 mg Q4W (81.7%)  or lebrikizumab  250  mg  Q2W  (78.4%)  compared  to  those  re-randomised  to  placebo  (lebrikizumab withdrawal) (66.4%).

Overall, the rates of maintenance of EASI 75 at Week 52 and throughout the Maintenance Period were similar for patients re-randomised to either lebrikizumab 250 mg Q4W or Q2W, although in Study KGAC the  percentage  of  patients  maintaining  EASI  75  was  numerically  higher  in  the  group  treated  with lebrikizumab Q4W compared with Q2W.

<div style=\"page-break-after: always\"></div>

Table 37: Percentage of Patients Maintaining EASI 75 at Week 52 Maintenance  Primary Estimand (Hybrid) with MCMC-MI LEB-Responders

|                                    | StudyKGAB                 | StudyKGAB          | StudyKGAB           | StudyKGAC                 | StudyKGAC            | StudyKGAC          | PooledStudiesKGABandKGAC   | PooledStudiesKGABandKGAC   | PooledStudiesKGABandKGAC   |
|------------------------------------|---------------------------|--------------------|---------------------|---------------------------|----------------------|--------------------|----------------------------|----------------------------|----------------------------|
| Maintenance Period Rerandomization | PBO (LEB Withdrawal) N=32 | LEB 250mg Q4W N=63 | LEB 250mg Q2W N =62 | PBO (LEB Withdrawal) N=28 | LEB 250mg Q4W N = 55 | LEB 250mg Q2W N=51 | PBO (LEB Withdrawal) N=60  | LEB 250mg Q4W N=118        | LEB 250mg Q2W N=113        |
| EASI75 Responders at W16 (Nx)      | 30                        | 62                 | 61                  | 27                        | 53                   | 51                 | 57                         | 115                        | 112                        |
| Maintained ResponseatW52, n (%)    | 18 (61.3)                 | 49 (79.2)          | 48 (79.2)           | 19 (72.0)                 | 45 (84.7)            | 39 (77.4)          | 38 (66.4)                  | 94 (81.7)                  | 88 (78.4)                  |
| Diff vs. PBO, % (95% CI)           |                           | 17.9 (-2.3,38.1)   | 17.5 (-4.5, 39.5)   |                           | 12.8 (-9.5, 35.1)    | 4.8 (-17.8, 27.3)  |                            | 15.5 (0.3, 30.8)           | 11.6 (-4.5, 27.6)          |
| p-value vs.PBOa                    |                           | .072               | .107                |                           | .238                 | .612               |                            | .038                       | .147                       |

Percentage  of patients from those rerandomised having achieved IGA 0 or 1 and a ≥2 -point improvement from Baseline at Week 16 who continue to exhibit an IGA 0 or 1 and a ≥2 -point improvement from Baseline at Week 52

Lebrikizumab-responders who were re-randomised to treatment with  lebrikizumab maintained IGA 0,1 response  at  Week  52  at  higher  rates  compared  to  those  who  were  re-randomised  to  placebo (lebrikizumab withdrawal) (Table 38). Among patients in the pooled population, maintenance of IGA 0,1 was higher at Week 52 for patients re-randomised to lebrikizumab 250 mg Q4W (76.9%) or lebrikizumab 250 mg Q2W (71.2%) compared to those re-randomised to placebo (lebrikizumab withdrawal) (47.9%).

Overall,  the rates of maintenance of IGA  0,1 response  were similar for patients treated with lebrikizumab 250 mg Q4W or Q2W, although in Study KGAC the percentage of patients maintaining IGA 0,1 response was numerically higher in the group treated with lebrikizumab Q4W compared with Q2W.

Table 38: Percentage of Patients Maintaining IGA 0, 1 at Week  52 Maintenance  Primary Estimand (Hybrid) with MCMC-MI LEB-Responders with IGA 0,1 at Week 16

|                                     | StudyKGAB                 | StudyKGAB         | StudyKGAB           | StudyKGAC                 | StudyKGAC         | StudyKGAC          | PooledStudiesKGABandKGAC   | PooledStudiesKGABandKGAC   | PooledStudiesKGABandKGAC   |
|-------------------------------------|---------------------------|-------------------|---------------------|---------------------------|-------------------|--------------------|----------------------------|----------------------------|----------------------------|
| Maintenance Period Rerandomization  | PBO (LEB Withdrawal) N=32 | LEB250mg Q4W N=63 | LEB 250mg Q2W N =62 | PBO (LEB Withdrawal) N=28 | LEB250mg Q4W N=55 | LEB250mg Q2W N=51  | PBO (LEB Withdrawal) N =60 | LEB 250mg Q4W N=118        | LEB250mg Q2W N=113         |
| W16 LEB-responder's withIGA 0,1(Nx) | 22                        | 45                | 45                  | 16                        | 32                | 32                 | 38                         | 77                         | 77                         |
| Maintained Response at W52, n (%)   | 10 (46.5)                 | 33 (74.2)         | 34 (75.8)           | 8 (49.8)                  | 26 (80.6)         | 21 (64.6)          | 18 (47.9)                  | 59 (76.9)                  | 55 (71.2)                  |
| Diff vs. PBO, % (95% CI)            |                           | 28.0 (2.8, 53.2)  | 29.0 (4.6, 53.3)    |                           | 32.6 (2.6, 62.5)  | 13.4 (-17.5, 44.3) |                            | 29.9 (10.5, 49.3)          | 22.6 (3.2,42.0)            |
| p-value vs. PBOa                    |                           | .030              | .020                |                           | .034              | .407               |                            | .003                       | .022                       |

Percentage  of patients from those with a Pruritus  NRS of ≥4 -points at baseline re-randomised having achieved  ≥4 -point reduction from baseline at Week  16 who continue to exhibit ≥4 -point reduction from baseline at Week  52

<div style=\"page-break-after: always\"></div>

Lebrikizumab-responders who were re-randomised to treatment with lebrikizumab maintained Pruritus NRS 4-point improvement at Week 52 at numerically higher rates compared with  those who were rerandomised to placebo (lebrikizumab withdrawal) (Table 39). Among patients in the pooled population, approximately 85% of  patients  treated with  lebrikizumab  250  mg,  either  Q4W  or  Q2W,  maintained Pruritus NRS 4-point improvement at Week 52, whereas 66.3% of patients in the placebo (lebrikizumab withdrawal) group maintained this response at Week 52.

Overall, the rates of maintenance of Pruritus NRS 4-point improvement were similar for patients treated with either lebrikizumab 250 mg Q4W or Q2W.

Table 39: Percentage of Patients Maintaining Pruritus NRS 4-Point Improvement at Week  52 Maintenance Primary Estimand (Hybrid) with MCMC-MI Week 16 LEB-Responders

|                                                          | StudyKGAB                 | StudyKGAB          | StudyKGAB            | StudyKGAC                | StudyKGAC          | StudyKGAC          | PooledStudiesKGABandKGAC   | PooledStudiesKGABandKGAC   | PooledStudiesKGABandKGAC   |
|----------------------------------------------------------|---------------------------|--------------------|----------------------|--------------------------|--------------------|--------------------|----------------------------|----------------------------|----------------------------|
| Maintenance Period                                       | PBO (LEB Withdrawal) N=32 | LEB250mg Q4W N =63 | LEB250mg Q21W N = 62 | PBO(LEB Withdrawal) N=28 | LEB250mg Q4W N=55  | LEB250mg Q21W N=51 | PBO(LEB Withdrawal) N =60  | LEB250mg Q4W N=118         | LEB250mg Q21W N =113       |
| Participantswith PruritusNRS4-pt Improvement at W16 (Nx) | 17                        | 29                 | 38                   | 11                       | 36                 | 23                 | 28                         | 65                         | 61                         |
| Maintained Response at W52,n (%)                         | 11 (65.4)                 | 23 (80.4)          | 31 (81.2)            | 7 (67.6)                 | 32 (88.1)          | 21 (90.3)          | 19 (66.3)                  | 55 (84.7)                  | 52 (84.6)                  |
| Diff vs.PBO, % (95% CI)                                  |                           | 15.8 (-12.2, 43.8) | 16.6 (-9.4, 42.7)    |                          | 20.3 (-11.4, 52.0) | 20.4 (-10.6, 51.4) |                            | 17.7 (-3.1, 38.6)          | 18.1 (-1.7, 37.9)          |
| p-value vs.PBOa                                          |                           | .268               | .193                 |                          | .159               | .165               |                            | .077                       | .058                       |

## Percentage  change in EASI score from Baseline at Week 52 in the subset of patients who were re-randomised  at Week  16

Lebrikizumab  responders who  were  randomly  reassigned  to  lebrikizumab Q4W  or  Q2W  maintained numerically  higher  mean  percentage  improvement from  Baseline  in  EASI response  up  to  Week  52 compared with responders who were randomly reassigned to placebo (lebrikizumab withdrawal) (Table 40 and Table 41).

Table 40: Percentage change in EASI from Baseline at Week  52 in the subset of patients who were randomly reassigned at Week 16 (Study KGAB)

| Percentage Change in EASIfrom Baseline                    | PBO (LEB Withdrawal) N=32                                 | LEBRes/LEB 250mg Q4W N =62                                | LEBRes/LEB 250mg Q2W N=61                                 |
|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|
| Maintenanceprimaryestimand( (Hybrid): ANCOVA with MCMC-MI | Maintenanceprimaryestimand( (Hybrid): ANCOVA with MCMC-MI | Maintenanceprimaryestimand( (Hybrid): ANCOVA with MCMC-MI | Maintenanceprimaryestimand( (Hybrid): ANCOVA with MCMC-MI |
| LSM (SE)                                                  | -60.67 (6.3)                                              | -79.44 (4.5)                                              | -77.93 (4.5)                                              |
| p-value vs.PBO                                            | NA                                                        | .012                                                      | .025                                                      |

<div style=\"page-break-after: always\"></div>

Table 41: Percentage change in EASI from Baseline at Week  52 in the subset of patients who were randomly reassigned at Week 16 (Study KGAC)

| Percentage Change in EASIfrom Baseline         | PBO (LEB Withdrawal) N=28                      | LEBRes/LEB 250mg Q4W N =55                     | LEBRes/LEB 250mgQ2W N=51                       |
|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|
| Primary estimand (Hybrid): ANCOVA with MCMC-MI | Primary estimand (Hybrid): ANCOVA with MCMC-MI | Primary estimand (Hybrid): ANCOVA with MCMC-MI | Primary estimand (Hybrid): ANCOVA with MCMC-MI |
| LSM (SE)                                       | -72.9 (6.3)                                    | -87.6 (4.4)                                    | -77.2 (4.4)                                    |
| p-Value vs. PBO                                | NA                                             | 0.057                                          | 0.575                                          |

For the abovementioned endpoints for Maintenance Period (EASI 75;  IGA 0, 1; Pruritus NRS ≥4 -Point Improvement and EASI percent change from baseline) the results remained consistent when analysed according to  the Maintenance  Supportive Estimand  (hybrid), i.e.,  including data  regardless of topical rescue medication use.

## Other  Secondary  Endpoints Specific for Maintenance  Period

Among lebrikizumab-responders with  EASI 75  at Week 16,  proportions of patients achieving EASI 90 increased from Week 16 to Week 52 for groups re-randomised to treatment with lebrikizumab 250 mg Q4W or Q2W, while proportions of patients  achieving EASI 90 decreased in groups re-randomised to placebo (lebrikizumab withdrawal). In the pooled population, 66.4% of patients treated Q4W and 64.0% of patients treated Q2W achieved EASI 90 at Week 52, compared with 41.9% of patients in the placebo (lebrikizumab withdrawal) group.

Table 42: Percentage of Patients with EASI 90 at Week  16 and Week  52 Maintenance Primary Estimand (Hybrid) with MCMC-MI Week 16 LEB-Responders

|                                               | Study KGAB                | Study KGAB        | Study KGAB         | Study KGAC               | Study KGAC         | Study KGAC         | Pooled Studies KGAB and KGAC   | Pooled Studies KGAB and KGAC   | Pooled Studies KGAB and KGAC   |
|-----------------------------------------------|---------------------------|-------------------|--------------------|--------------------------|--------------------|--------------------|--------------------------------|--------------------------------|--------------------------------|
| Maintenance Period Rerandomization            | PBO (LEB Withdrawal) N=32 | LEB250mg Q4W N=63 | LEB 250mg Q2W N=62 | PBO(LEB Withdrawal) N=28 | LEB 250mg Q4W N=55 | LEB 250mg Q2W N=51 | PBO (LEB Withdrawal) N=60      | LEB 250mg Q4W N=118            | LEB 250mg Q2W N=113            |
| EASI 75Responder's at W16, Nxa                | 30                        | 62                | 61                 | 27                       | 53                 | 51                 | 57                             | 115                            | 112                            |
| EASI75 Responders withEASI90atW16,n (%)       | 21 (70.0)                 | 39 (62.9)         | 40 (65.6)          | 15 (55.6)                | 30 (56.6)          | 29 (56.9)          | 36 (63.2)                      | 69 (60.0)                      | 69 (61.6)                      |
| EASI 75 Responders with EASI 90 at W52, n (%) | 14 (45.2)                 | 41 (66.6)         | 40 (66.1)          | 10 (38.2)                | 35 (66.2)          | 31 (61.5)          | 24 (41.9)                      | 76 (66.4)                      | 72 (64.0)                      |
| Diff vs. PBO, % (95% CI                       |                           | 21.4 (-1.2, 44.1) | 20.2 (-2.9, 43.2)  |                          | 28.5 (4.4, 52.7)   | 23.3 (-1.0, 47.6)  |                                | 24.8 (8.4, 41.1)               | 21.6 (4.9, 38.4)               |
| p-value vs. PBOb                              |                           | .064              | .088               |                          | .024               | .064               |                                | .004                           | .012                           |

## Study KGAB and KGAC Maintenance  Week 16 Escape Population Results

Among patients  who  were  treated  with  lebrikizumab 250  mg  Q2W  during  the  Induction  Period and remained on lebrikizumab 250 mg Q2W through Week 52, 64 (40.0%) patients achieved IGA 0,1, 123 (76.9%) patients achieved EASI 75 and 76 (47.5%) patients achieved EASI 90.

Among patients who received placebo during the Induction Period, transitioned to lebrikizumab 250 mg Q2W treatment at Week 16, and remained on lebrikizumab 250 mg Q2W treatment through Week 52, 84 (52.5%) patients achieved IGA 0,1, 135 (83.9%) patients achieved EASI 75 and 98 (60.9%) patients achieved EASI 90.

<div style=\"page-break-after: always\"></div>

## Rescue medications

## KGAB study

The most commonly used rescue treatment during both the Induction and Maintenance Blinded Periods was TCS (Table 43  and Table 44).  During  the Induction Period, 29.8%  of the patients in  the placebo group vs. 8.5% in the lebrikizumab group used TCS.

Table 43: Summary of AD Rescue therapy Induction Period (ITT Population)

| ADTreatment                       | PBO (N = 141) n (%)   | LEB 250mg Q2W (N = 283) n (%)   | Total (N = 424) n (%)   |
|-----------------------------------|-----------------------|---------------------------------|-------------------------|
| Subjects with≥l rescue medication | 47 (33.3)             | 31 (11.0)                       | 78 (18.4)               |
| Topical treatment                 | 44 (31.2)             | 27 (9.5)                        | 71 (16.7)               |
| Topicalcorticosteroids            | 42 (29.8)             | 24 (8.5)                        | 66 (15.6)               |
| Low-moderatepotency               | 38 (27.0)             | 20 (7.1)                        | 58 (13.7)               |
| Highpotency                       | 15 (10.6)             | 6 (2.1)                         | 21 (5.0)                |
| Topicalcalcineurininhibitor       | 9 (6.4)               | 4 (1.4)                         | 13 (3.1)                |
| Systemictreatment                 | 11 (7.8)              | 7 (2.5)                         | 18 (4.2)                |
| Systemic corticosteroids          | 9 (6.4)               | 6 (2.1)                         | 15 (3.5)                |
| Immunosuppressant                 | 1 (0.7)               | 2 (0.7)                         | 3 (0.7)                 |
| Biologics                         | 1 (0.7)               | 0                               | 1 (0.2)                 |
| Phototherapy                      | 0                     | 0                               | 0                       |

## Time to use of rescue therapy

Patients randomised to lebrikizumab 250 mg Q2W demonstrated a 73% reduction in the risk of initiating rescue therapy during the Induction Period compared to patients given placebo in Study KGAB (hazard ratio: 0.27, 95% CI: 0.17 to 0.42)

Table 44: Summary of AD Rescue therapy Maintenance Blinded Period (Maintenance  Primary Population)

| AD Treatment                      | PBO (LEB Withdrawal) (N = 32) n (%)   | LEB 250mg Q4W (N = 63) n (%)   | LEB 250mg Q2W (N = 62) n (%)   | Total (N = 157) n (%)   |
|-----------------------------------|---------------------------------------|--------------------------------|--------------------------------|-------------------------|
| Subjects with≥l rescue medication | 5 (15.6)                              | 11 (17.5)                      | 6 (9.7)                        | 22 (14.0)               |
| Topical treatment                 | 5 (15.6)                              | 9 (14.3)                       | 6 (9.7)                        | 20 (12.7)               |
| Topical corticosteroids           | 3 (9.4)                               | 8 (12.7)                       | 5 (8.1)                        | 16 (10.2)               |
| Low-ModeratePotency               | 2 (6.3)                               | 6 (9.5)                        | 2 (3.2)                        | 10 (6.4)                |
| High potency                      | 2 (6.3)                               | 3 (4.8)                        | 3 (4.8)                        | 8 (5.1)                 |
| Topical calcineurin inhibitor     | 2 (6.3)                               | 1 (1.6)                        | 2 (3.2)                        | 5 (3.2)                 |
| Systemic treatment                | 0                                     | 2 (3.2)                        | 0                              | 2 (1.3)                 |
| Systemic corticosteroids          | 0                                     | 2 (3.2)                        | 0                              | 2 (1.3)                 |
| Immunosuppressant                 | 0                                     | 0                              | 0                              | 0                       |
| Biologics                         | 0                                     | 0                              | 0                              | 0                       |
| Phototherapy                      | 0                                     | 0                              | 0                              | 0                       |

Abbreviations: AD = atopic dermatitis; LEB = lebrikizumab; N = number of participants in the analysis population; = number of participants in the specified category; PBO = placebo; Q2W = every 2 weeks; Q4W = every 4 weeks.

<div style=\"page-break-after: always\"></div>

In the Week 16 escape arm of the KGAB study (Week 16 to 52), any rescue therapy was used by:

- 40.6% of patients entering the escape arm from the Induction Period placebo arm (PBO/LEB), and
- 24.5% of those entering from the Induction Period lebrikizumab 250 mg Q2W arm (LEB/LEB)

Topical  rescue therapy  was  used  by  35.4%  (PBO/LEB)  and  23.6%  (LEB/LEB),  and  systemic rescue therapy by 5.2% (PBO/LEB) and 2.8% (LEB/LEB), respectively.

## KGAC study

The most commonly used rescue treatment during both the Induction and Maintenance Blinded Periods was TCS (Table 45 and Table 46). During the Induction Period, 37% of the patients in the placebo group vs. 16.7% in the lebrikizumab group used TCS.

Table 45: Summary of AD Rescue therapy Induction Period (mITT Population)

| AD treatment                          | PBO (N = 146) n (%)   | LEB 250 mg Q2W (N = 281) n (%)   | Total (N = 427) n (%)   |
|---------------------------------------|-----------------------|----------------------------------|-------------------------|
| Participants with≥l rescue medication | 58 (39.7)             | 52 (18.5)                        | 110 (25.8)              |
| Topical treatment                     | 54 (37.0)             | 48 (17.1)                        | 102 (23.9)              |
| Topical corticosteroids               | 54 (37.0)             | 47 (16.7)                        | 101 (23.7)              |
| Low-moderatepotency                   | 24 (16.4)             | 27 (9.6)                         | 51 (11.9)               |
| High potency                          | 36 (24.7)             | 25 (8.9)                         | 61 (14.3)               |
| Topical calcineurin inhibitor         | 6 (4.1)               | 8 (2.8)                          | 14 (3.3)                |
| Systemic treatment                    | 9 (6.2)               | 8 (2.8)                          | 17 (4.0)                |
| Systemic corticosteroids              | 8 (5.5)               | 7 (2.5)                          | 15 (3.5)                |
| Immunosuppressant                     | 2 (1.4)               | 2 (0.7)                          | 4 (0.9)                 |
| Biologics                             | 0                     | 1 (0.4)                          | 1 (0.2)                 |
| Phototherapy or photochemotherapy     | 0                     | 0                                | 0                       |

Abbreviations: AD = atopic dermatitis; LEB = lebrikizumab; mITT = modified intent to treat; N = number of participants in the analysis population; n = number of participants in the specified category; PBO = placebo; Q2W = every 2 weeks.

## Time to first use of rescue therapy

Patients randomised to lebrikizumab 250 mg Q2W demonstrated a 65% reduction in the risk of initiating rescue therapy during the Induction Period compared to patients given placebo in Study KGAC (hazard ratio: 0.35, 95% CI: 0.24 to 0.52).

<div style=\"page-break-after: always\"></div>

Table 46: Summary of AD Rescue therapy Maintenance Blinded Period (Modified Maintenance Primary Population)

| AD treatment                           | PBO (LEB Withdrawal) (N = 28) n (%)   | LEB 250 mg Q4W (N = 55) n (%)   | LEB 250 mg Q2W (N = 51) n (%)   | Total (N =134) n (%)   |
|----------------------------------------|---------------------------------------|---------------------------------|---------------------------------|------------------------|
| Participants with ≥l rescue medication | 6 (21.4)                              | 8 (14.5)                        | 8 (15.7)                        | 22 (16.4)              |
| Topical treatment                      | 6 (21.4)                              | 7 (12.7)                        | 7 (13.7)                        | 20 (14.9)              |
| Topical corticosteroids                | 5 (17.9)                              | 6 (10.9)                        | 6 (11.8)                        | 17 (12.7)              |
| Low-moderatepotency                    | 1 (3.6)                               | 3 (5.5)                         | 4 (7.8)                         | 8 (6.0)                |
| High potency                           | 4 (14.3)                              | 3 (5.5)                         | 2 (3.9)                         | 9 (6.7)                |
| Topical calcineurin inhibitor          | 1 (3.6)                               | 1 (1.8)                         | 2 (3.9)                         | 4 (3.0)                |
| Systemic treatment                     | 0                                     | 1 (1.8)                         | 2 (3.9)                         | 3 (2.2)                |
| Systemic corticosteroids               | 0                                     | 1 (1.8)                         | 1 (2.0)                         | 2 (1.5)                |
| Immunosuppressant                      | 0                                     | 0                               | 1 (2.0)                         | 1 (0.7)                |
| Biologics                              | 0                                     | 0                               | 0                               | 0                      |
| Phototherapy or photochemotherapy      | 0                                     | 0                               | 0                               | 0                      |

Abbreviations: AD = atopic dermatitis; LEB = lebrikizumab; N = number of participants in the analysis population; n = number of participants in the specified category; PB0 = placebo; Q2W = every 2 weeks; Q4W = every 4 weeks.

In the Week 16 Escape Arm of the KGAC study (Week 16 to 52), any rescue therapy was used by

- 43.5% of patients entering the escape arm from the Induction Period placebo arm (PBO/LEB), and
- 32% of those entering from the Induction Period lebrikizumab 250 mg Q2W arm (LEB/LEB)

Topical rescue therapy was used by 40.7% (PBO/LEB) and 32% (LEB/LEB), and systemic rescue therapy by 3.7% (PBO/LEB) and 2.4% (LEB/LEB), respectively.

## KGAD study

In Study KGAD, which allowed use of low-to-mid-potency TCS and TCI by all patients, smaller proportions of patients in either treatment group used rescue therapy compared to the monotherapy studies. A total of 7 (10.6%) placebo-treated patients required 1 or more rescue therapies during the study, and rescue therapy was used by 6 (4.1%) lebrikizumab-treated patients (Table 47).

<div style=\"page-break-after: always\"></div>

Table 47: Summary of Type of Rescue Medication Used

|                                       | PBO + TCS (N =66) n (%)   | LEB 250 mg Q2W + TCS (N =145) n (%)   |
|---------------------------------------|---------------------------|---------------------------------------|
| Participantswith ≥l AD rescue therapy | 7 (10.6)                  | 6 (4.1)                               |
| High potency TCS                      | 3 (4.5)                   | 2 (1.4)                               |
| Betamethasone                         | 1 (1.5)                   | 1 (0.7)                               |
| Clobetasol                            | 1 (1.5)                   | 1 (0.7)                               |
| Mometasone                            | 1 (1.5)                   | 0                                     |
| Prednicarbate                         | 1 (1.5)                   | 0                                     |
| Systemic therapy                      | 5 (7.6)                   | 5 (3.4)                               |
| Oral corticosteroids                  | 4 (6.1)                   | 5 (3.4)                               |
| Prednisone                            | 2 (3.0)                   | 3 (2.1)                               |
| Dexamethasone                         | 0                         | 1 (0.7)                               |
| Methylprednisolone;lidocaine          | 0                         | 1 (0.7)                               |
| Prednisolone                          | 1 (1.5)                   | 0                                     |
| Triamcinolone                         | 1 (1.5)                   | 0                                     |
| Immunosuppressant                     | 1 (1.5)                   | 1 (0.7)                               |
| Ciclosporine                          | 1 (1.5)                   | 0                                     |
| Methotrexate                          | 0                         | 1 (0.7)                               |

Abbreviations: AD = atopic dermatitis; LEB = lebrikizumab; N = number of participants in the analysis population; n = number of participants in the specified category; PBO = placebo; Q2W = every 2 weeks; TCS = topical corticosteroids.

## Concomitant topical treatment  for AD in KGAD study

## Topical corticosteroids

All patients in Study KGAD were required to use TCS at the start of the trial. Patients were allowed to taper, stop, and restart use as needed throughout the 16 weeks of the trial. Data from both the CRFs and patient diaries showed percentages of TCS use close to 100%. The 2 most commonly used TCS were triamcinolone and hydrocortisone, which were the products supplied by the study sites (Table 48).

## Topical calcineurin inhibitors

TCI were permitted for use on sensitive areas only, but they were not supplied by the study sites. While case report form data showed similar rates of use between treatment groups, patient diary data indicated that a greater percentage of lebrikizumab-treated patients used TCI (Table 48).

<div style=\"page-break-after: always\"></div>

Table 48: Summary of Concomitant Topical Treatment for AD

| ADTreatment                                                | PBO + TCS (N =66) n (%)   | LEB250mgQ2W+ TCS (N = 145) n (%)   | Total (N =211) n (%)   |
|------------------------------------------------------------|---------------------------|------------------------------------|------------------------|
| Participants using topical therapy (case report form data) | 64 (97.0)                 | 140 (96.6)                         | 204 (96.7)             |
| Mild or moderate topical corticosteroids                   | 64 (97.0)                 | 140 (96.6)                         | 204 (96.7)             |
| Triamcinolone                                              | 61 (92.4)                 | 130 (89.7)                         | 191 (90.5)             |
| Hydrocortisone                                             | 46 (69.7)                 | 99 (68.3)                          | 145 (68.7)             |
| Desonide                                                   | 0                         | 1 (0.7)                            | 1 (0.5)                |
| Topical calcineurin inhibitors                             | 3 (4.5)                   | 5 (3.4)                            | 8 (3.8)                |
| Tacrolimus                                                 | 3 (4.5)                   | 3 (2.1)                            | 6 (2.8)                |
| Pimecrolimus                                               | 0                         | 3 (2.1)                            | 3 (1.4)                |
| Crisaborole                                                | 0                         | 0                                  | 0                      |
| Participants with ≥l AD treatment (Participant Diary Data) | 66 (100)                  | 144 (99.3)                         | 210 (99.5)             |
| Topicalcorticosteroids                                     | 62 (93.9)                 | 140 (96.6)                         | 202 (95.7)             |
| Triamcinolone acetonide cream 0.1%                         | 53 (80.3)                 | 124 (85.5)                         | 177 (83.9)             |
| Hydrocortisone1% cream                                     | 47 (71.2)                 | 103 (71.0)                         | 150 (71.1)             |
| Other TCS                                                  | 13 (19.7)                 | 31 (21.4)                          | 44 (20.9)              |
| Topical calcineurininhibitors                              | 23 (34.8)                 | 67 (46.2)                          | 90 (42.7)              |
| Pimecrolimus 1%                                            | 13 (19.7)                 | 27 (18.6)                          | 40 (19.0)              |
| Tacrolimus 0.03%                                           | 7 (10.6)                  | 14 (9.7)                           | 21 (10.0)              |
| Tacrolimus 0.1%                                            | 21 (31.8)                 | 33 (22.8)                          | 54 (25.6)              |
| Other TCI                                                  | 12 (18.2)                 | 42 (29.0)                          | 54 (25.6)              |

Abbreviations: AD = atopic dermatitis; LEB = lebrikizumab; N = number of participants in the analysis population; n = number of participants in the specified category; PBO = placebo; Q2W = every 2 weeks; TCI = topical calcineurin inhibitor; TCS = topical corticosteroids.

## Ancillary analyses

## Subgroup Analysis - Induction period

Subgroup analyses of pooled data from the Induction Periods of Study KGAB and Study KGAC are shown in Figure 15. Subgroup analyses were conducted relative to primary estimand (hybrid), comparing the lebrikizumab 250 mg Q2W treatment group to placebo.

<div style=\"page-break-after: always\"></div>

Figure 15: Subgroup analysis of pooled data from the Induction Periods of Study KGAB and Study KGAC at Week 16.

a) IGA 0,1

<!-- image -->

RiskDifference vs.PBO(95% CI)

Abbreviations: CI = confidence interval; CSE = clinical summary of efficacy; EASI = Eczema Area and Severity Index; EASI 75 = 75% reduction from Baseline in EASI; EASI 90 = 90% reduction from Baseline in EASI; IGA = Investigator's Global Assessment; IGA 0,1 = IGA score of 0 or 1, with a 2-point or greater reduction from Baseline; n = number of participants in the specified category; NRS = numeric rating scale; PBO = placebo; Pruritus NRS 4-point Improvement = improvement of 4 or more points in Pruritus NRS among participants with a baseline score of at least 4. Note: Risk differences adjusted for study factor (KGAB versus KGAC).

Figure 16 shows the subgroup analysis in KGAD study. According to the Applicant, if any group within the subgroup made up less than 10% of the total population, the subgroup was not included in the figure due to large variability.

<div style=\"page-break-after: always\"></div>

Figure 16: Subgroup analysis of data from Study KGAD at Week 16.

a)IGA0,1

<!-- image -->

Abbreviations: CI = confidence interval; EASI = Eczema Area and Severity Index; EASI 75 = 75% reduction in EASI; EASI 90 = 90% reduction in EASI; IGA = Investigator's Global Assessment; IGA 0,1 = IGA score of 0 or 1, with a 2-point or greater reduction from Baseline; n = number of participants in the specified category; NRS = numeric rating scale; PBO = placebo; Pruritus NRS 4-point Improvement = improvement of 4 or more points in Pruritus NRS among participants with a baseline score of at least 4.

## Subgroup Analysis - Maintenance  period

Subgroup analyses of pooled data  from the  Maintenance  Period of Study  KGAB and Study  KGAC are shown  in  Figure  17.  Subgroup  analyses were  conducted  relative  to  maintenance  primary estimand (hybrid),  comparing  the  treatment  group  re-randomised to  lebrikizumab 250  mg  Q4W  to  those  rerandomised  to placebo  (lebrikizumab withdrawal) and  the treatment group  re-randomised  to lebrikizumab 250 mg Q2W to those re-randomised to placebo (lebrikizumab withdrawal).

<div style=\"page-break-after: always\"></div>

Figure 17: Subgroup analyses of pooled data from the Maintenance Periods of Study KGAB and Study KGAC at Week 52 for proportion of patients maintaining response. Populations with respective responses at Week  16.

a)IGA0.1

<!-- image -->

66.478.481.7

<!-- image -->

Abbreviations: CI = confidence interval; CSE = clinical summary ofefficacy; EASI = Eczema Area and Severity Index; EASI 75 = 75% improvement from Baseline in EASI; IGA = Investigator*s Global Assessment; IGA 0.1 = IGA score of 0 or 1, with a 2-point or greater reduction from Baseline; LEB = lebrikizumab; MCMC-MI = Markov Chain Monte Carlo multiple imputation; NRS = numeric rating scale; PBO = placebo; Pruritus NRS 4-point Improvement = improvement of 4 or more points in Pruritus NRS among participants with a baseline score of at least 4; Q2W = every 2 weeks; Q4W = every 4 weeks.

## Efficacy in adolescent population

The results for the adolescent population from the pivotal Phase 3 studies KGAB, KGAC and KGAD and shown in Table 49. The efficacy results for adolescents at Week 52 in studies KGAB and KGAC are shown in Table 50.

<div style=\"page-break-after: always\"></div>

Table 49: Adolescent Results at Week 16 across Studies (MCMC-MI)

|                                      | Study KGAB Week 16   | Study KGAB Week 16       | Study KGAC Week 16   | Study KGAC Week 16        | Study KGAD Week 16   | Study KGAD Week 16              |
|--------------------------------------|----------------------|--------------------------|----------------------|---------------------------|----------------------|---------------------------------|
|                                      | PBO N=18  (%)        | LEB 250 mg Q2W N=37  (%) | PBO N=17  (%)        | LEB 250 mg Q2W N=30 n (%) | PBO + TCS N=14 n (%) | LEB 250 mg Q2W + TCS N=32 n (%) |
| IGA 0 or 1a                          | 4 (22.2)             | 18 (48.6)                | 1 (5.9)              | 13 (44.1)**               | 4 (28.6)             | 18 (57.3)                       |
| EASI 75b                             | 4 (22.2)             | 23 (62.2)**              | 2 (12.0)             | 19 (61.7)**               | 8 (57.1)             | 28 (88.0)*                      |
| EASI90b                              | 3 (16.7)             | 17 (45.9)*               | 1 (6.1)              | 10 (34.3)*                | 4 (28.6)             | 18 (55.1)                       |
| Pruritus NRS ( 4-point improvement)c | 4 (22.8)             | 17 (54.3)*               | 0 (0.3)              | 11 (42.1)d                | 2 (13.8)             | 11 (45.8)                       |

Abbreviations: EASI = Eczema Area and Severity Index; EASI 75 = at least 75% improvement from baseline in EASI; EASI 90 = at least 90% improvement from baseline in EASI; IGA = Investigator's Global Assessment, KGAB = J2T-DM-KGAB; KGAC =J2T-DM-KGAC; KGAD =J2T-DM-KGAD; LEB =lebrikizumab; N= number of participants in adolescent subgroup; n = number of participants in specified category; Q2W = every 2 weeks; TCS = topical corticosteroid.

- At Week 16, participants with IGA 0 or 1 (\"clear\" or *almost clear\") with a reduction of ≥2 points from Baseline on a 0 to 4 IGA scale.
- b At Week 16, participants with a 75% or 90% reduction in EASI from Baseline to Week 16.
- The percentage is calculated relative to the number of participants with a baseline Pruritus NRS ≥4. (KGAB Ns: PB0=17, LEB=31; KGAC Ns: PB0=13, LEB=25; KGAD Ns: PB0=11; LEB=24)
- Adolescent participants with baseline Pruritus NRS ≥4 made up less than 10% of the total population for Study KGAC; therefore, only summary statistics were prepared for this outcome.

p&lt;.05; **p&lt;.01 versus placebo

Table 50: Adolescent Results for Study KGAB and Study KGAC at Week 52 (MCMC-MI)

|                                                 | Placebo (LEB Withdrawal)   | Lebrikizumab 250 mg Q4W   | Lebrikizumab 250 mg Q2W   |
|-------------------------------------------------|----------------------------|---------------------------|---------------------------|
| IGA 0 or 1a                                     |                            |                           |                           |
| Adolescent participants with response at W16, N | 6                          | 15                        | 7                         |
| Participants maintaining response at W52, n (%) | 2 (40.7)                   | 10 (63.7)                 | 3 (49.1)                  |
| EASI 75 b                                       |                            |                           |                           |
| Adolescent participants with response at W16, N | 8                          | 16                        | 13                        |
| Participants maintaining response at W52, n (%) | 4 (53.0)                   | 15 (92.8)*                | 11 (82.2)                 |
| Pruritus NRS ( 4-point improvement). (          |                            |                           |                           |
| Adolescent participants with response at W16, N | 2                          | 8                         | 8                         |
| Participants maintaining response at W52, n (%) | 1 (50.0)                   | 7 (91.0)                  | 5 (68.0)                  |

Abbreviations: EASI = Eczema Area and Severity Index; EASI 75 = atleast 75% improvement from baseline in EASI; IGA = Investigator's Global Assessment; KGAB = J2T-DM-KGAB; KGAC = J2T-DM-KGAC; LEB = lebrikizumab; N = number of participants in adolescent subgroup; n = number of participants in specified category; NRS = Numeric Rating Scale; Q2W = every 2 weeks; Q4W = every 4 weeks; W = Week.

- At Week 52. participants with IGA 0 or 1 with a ≥2-point improvement from Baseline at Week 16 who continued to exhibit IGA 0 or 1 with a ≥2-point improvement at Week 52.
- At Week 52, participants who achieved EASI 75 response at Week 16 and continued to exhibit EASI 75 at Week 52.
- The percentage is calculated relative to the number of participants with a baseline Pruritus NRS ≥4.
- p&lt;.05

In study KGAE, the adolescent patients  achieved IGA 0,1 response at rates of 46.3%  at Week 16 and 62.6% at Week 52, and EASI 75 response at rates of 73.2% at Week 16 and 81.9% at Week 52 (see section 3.3.4.4).

<div style=\"page-break-after: always\"></div>

## 2.6.5.3. Summary of main efficacy results

The following tables summarise the efficacy results from the  main studies supporting the  present application. These summaries should be read in conjunction with the discussion on clinical efficacy  as well as the benefit risk assessment (see later sections).

Table 51: Summary of Efficacy for Study KGAB

| Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS   | Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study Identifier                                                                                                                                                        | J2T-DM-KGAB; DRM06-AD04                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | J2T-DM-KGAB; DRM06-AD04                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Design                                                                                                                                                                  | Phase 3, randomised, double-blind, placebo-controlled, parallel-group study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Phase 3, randomised, double-blind, placebo-controlled, parallel-group study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Design                                                                                                                                                                  | Duration of Induction Period Duration of Maintenance Period                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 16 weeks 36 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Treatment Groups                                                                                                                                                        | The study comprises 2 treatment periods: • Induction: Participants were randomly assigned 2:1 to LEB 500-mg loading dose at baseline and Week 2 then 250 mg or PBO Q2W. • Maintenance: Participants who were LEB responders were randomly assigned 2:2:1 to LEB 250 mg Q2W, LEB 250 mg Q4W, or PBO (LEB withdrawal). • Participants who achieved neither IGA 0,1 nor EASI 75 at Week 16 or who received rescue therapy from baseline to Week 16 were assigned to an escape arm and received LEB 250 mg Q2W (following blinded 500-mg loading dose at Weeks 16 and 18 for participants who received PBO during Induction) as an open-label treatment through Week 52. | The study comprises 2 treatment periods: • Induction: Participants were randomly assigned 2:1 to LEB 500-mg loading dose at baseline and Week 2 then 250 mg or PBO Q2W. • Maintenance: Participants who were LEB responders were randomly assigned 2:2:1 to LEB 250 mg Q2W, LEB 250 mg Q4W, or PBO (LEB withdrawal). • Participants who achieved neither IGA 0,1 nor EASI 75 at Week 16 or who received rescue therapy from baseline to Week 16 were assigned to an escape arm and received LEB 250 mg Q2W (following blinded 500-mg loading dose at Weeks 16 and 18 for participants who received PBO during Induction) as an open-label treatment through Week 52. |
| Hypothesis                                                                                                                                                              | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Induction Period                                                                                                                                                        | LEB Q2W subcutaneous injection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Randomised N = 283 LEB 500-mg at baseline and at Week 2 (loading dose), and LEB 250 mg Q2W from Week 4 through Week 14.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Induction Period                                                                                                                                                        | PBO Q2W subcutaneous injection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Randomised N = 141 4-mL PBO at baseline and at Week 2, and 2-mL PBO Q2W from Week 4 through Week 14.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Maintenance Period                                                                                                                                                      | Maintenance Primary population (LEB responders)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Randomised N = 157 • LEB 250 mg Q2W (N = 62) • LEB 250 mg Q4W (N = 63) • PBO (LEB withdrawal) (N = 32)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Maintenance Period                                                                                                                                                      | Maintenance Week 16 escape population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Assigned N = 202 Open-label LEB 250 mg Q2W through Week 52                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|                  | Participants who achieved neither IGA 0,1 nor EASI 75 at Week 16 or used any rescue medication during the Induction Period   | Participants who achieved neither IGA 0,1 nor EASI 75 at Week 16 or used any rescue medication during the Induction Period   | • LEB 250 mg Q2W to LEB 250 mg Q2W (N = 106) • PBO to LEB 250 mg Q2W (N = 96)                                                             |
|------------------|------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| Endpoints        | Coprimary endpoint                                                                                                           | IGA 0,1                                                                                                                      | Percentage of participants with an IGA 0,1 and a reduction of ≥2 points from baseline to Week 16                                          |
| Induction Period | Coprimary endpoint                                                                                                           | EASI 75                                                                                                                      | Percentage of participants achieving EASI 75 (≥75% reduction from baseline in EASI) at Week 16                                            |
| Induction Period | Major secondary endpoint                                                                                                     | EASI 90, W16                                                                                                                 | Percentage of participants achieving EASI 90 (≥90% reduction from baseline in EASI) at Week 16                                            |
| Induction Period | Major secondary endpoint                                                                                                     | EASI 90, W4                                                                                                                  | Percentage of participants achieving EASI 90 at Week 4                                                                                    |
| Induction Period | Major secondary endpoint                                                                                                     | EASI PCFB                                                                                                                    | Percentage change in EASI from baseline to Week 16                                                                                        |
| Induction Period | Major secondary endpoint                                                                                                     | Pruritus NRS PCFB                                                                                                            | Percentage change in pruritus NRS score from baseline to Week 16                                                                          |
| Induction Period | Major secondary endpoint                                                                                                     | Pruritus NRS 4 - point improvement, W16                                                                                      | Percentage of participants with a pruritus NRS of ≥4 points at baseline who achieved a ≥4 -point reduction from baseline to Week 16       |
| Induction Period | Major secondary endpoint                                                                                                     | Pruritus NRS 4 - point improvement, W4                                                                                       | Percentage of participants with a pruritus NRS of ≥4 points at baseline who achieved a ≥4 -point reduction from baseline to Week 4        |
| Induction Period | Major secondary endpoint                                                                                                     | Pruritus NRS 4 - point improvement, W2                                                                                       | Percentage of participants with a pruritus NRS of ≥4 points at baseline who achieved a ≥4 -point reduction from baseline to Week 2        |
| Induction Period | Major secondary endpoint                                                                                                     | DLQI CFB                                                                                                                     | CFB in DLQI total score at Week 16                                                                                                        |
| Induction Period | Major secondary endpoint                                                                                                     | DLQI 4-point improvement                                                                                                     | Percentage of participants with a DLQI total score of ≥4 points at baseline who achieved a ≥4 -point improvement from baseline to Week 16 |
|                  | Major secondary endpoint                                                                                                     | Sleep-Loss CFB                                                                                                               | CFB in Sleep-Loss score at Week 16                                                                                                        |
|                  | Major secondary endpoint                                                                                                     | Sleep-Loss, 2 - point improvement                                                                                            | Percentage of participants with a Sleep-Loss score ≥2 points at baseline who achieve a ≥2 -points reduction from baseline at Week 16      |
|                  | Other endpoint                                                                                                               | POEM                                                                                                                         | CFB in POEM at Week 16                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| Endpoints Maintenance                                        | Major secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | EASI 75                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Percentage of participants from those randomly reassigned having achieved EASI 75 at Week 16 who continue to exhibit EASI 75 at Week 52 (EASI 75 calculated relative to baseline EASI)                                                                                                                                                                                                                                                                                                         | Percentage of participants from those randomly reassigned having achieved EASI 75 at Week 16 who continue to exhibit EASI 75 at Week 52 (EASI 75 calculated relative to baseline EASI)                                                                                                                                                                                                                                                                                                         |
|--------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Endpoints Maintenance                                        | Major secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | IGA 0,1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Percentage of participants from those randomly reassigned having achieved IGA 0,1 and a ≥2 -point improvement from baseline at Week 16 who continue to exhibit IGA 0,1 and a ≥2 -point improvement from baseline at Week 52                                                                                                                                                                                                                                                                    | Percentage of participants from those randomly reassigned having achieved IGA 0,1 and a ≥2 -point improvement from baseline at Week 16 who continue to exhibit IGA 0,1 and a ≥2 -point improvement from baseline at Week 52                                                                                                                                                                                                                                                                    |
| Endpoints Maintenance                                        | Major secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Pruritus 4-point improvement                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Percentage of participants from those with a pruritus NRS of ≥4 -points at baseline randomly reassigned having achieved ≥4 -point reduction from baseline at Week 16 who continue to exhibit ≥4 -point reduction from baseline at Week 52                                                                                                                                                                                                                                                      | Percentage of participants from those with a pruritus NRS of ≥4 -points at baseline randomly reassigned having achieved ≥4 -point reduction from baseline at Week 16 who continue to exhibit ≥4 -point reduction from baseline at Week 52                                                                                                                                                                                                                                                      |
| Endpoints Maintenance                                        | Major secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | EASI PCFB                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Percentage change in EASI from baseline at Week 52 in the subset of participants who were randomly reassigned at Week 16                                                                                                                                                                                                                                                                                                                                                                       | Percentage change in EASI from baseline at Week 52 in the subset of participants who were randomly reassigned at Week 16                                                                                                                                                                                                                                                                                                                                                                       |
| Endpoints Maintenance                                        | Other endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | EASI 90                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Percentage of participants with EASI 90 at Week 52 in the subset of participants who achieved EASI 75 and randomly reassigned at Week 16 (EASI 90 calculated relative to baseline EASI)                                                                                                                                                                                                                                                                                                        | Percentage of participants with EASI 90 at Week 52 in the subset of participants who achieved EASI 75 and randomly reassigned at Week 16 (EASI 90 calculated relative to baseline EASI)                                                                                                                                                                                                                                                                                                        |
| Endpoints                                                    | Other endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | IGA 0,1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Percentage of participants with IGA 0,1 and a ≥2 -point improvement at Week 52                                                                                                                                                                                                                                                                                                                                                                                                                 | Percentage of participants with IGA 0,1 and a ≥2 -point improvement at Week 52                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Maintenance Week 16                                          | Other endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | EASI 75                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Percentage of participants with EASI 75 at Week 52 (EASI 75 calculated relative to baseline EASI)                                                                                                                                                                                                                                                                                                                                                                                              | Percentage of participants with EASI 75 at Week 52 (EASI 75 calculated relative to baseline EASI)                                                                                                                                                                                                                                                                                                                                                                                              |
| Escape Population                                            | Other endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | EASI 90                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Percentage of participants with EASI 90 at Week 52 (EASI 90 calculated relative to baseline EASI)                                                                                                                                                                                                                                                                                                                                                                                              | Percentage of participants with EASI 90 at Week 52 (EASI 90 calculated relative to baseline EASI)                                                                                                                                                                                                                                                                                                                                                                                              |
| Escape Population                                            | Other endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Pruritus NRS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Percentage of participants with a pruritus NRS of ≥4 points at baseline with ≥4 -point reduction at Week 52                                                                                                                                                                                                                                                                                                                                                                                    | Percentage of participants with a pruritus NRS of ≥4 points at baseline with ≥4 -point reduction at Week 52                                                                                                                                                                                                                                                                                                                                                                                    |
| Multiplicity Adjustment                                      | Two families for alpha control were defined: 1 for induction and 1 for maintenance with each family-wise error rate at 0.05. For all primary and key secondary endpoints for Induction Period, a prespecified graphical multiple testing approach was implemented to control the overall Type I error rate at 2-sided alpha of 0.05. For all maintenance key secondary endpoints, a hierarchal testing scheme with a prespecified order was implemented with a family-wise error rate at 0.05. | Two families for alpha control were defined: 1 for induction and 1 for maintenance with each family-wise error rate at 0.05. For all primary and key secondary endpoints for Induction Period, a prespecified graphical multiple testing approach was implemented to control the overall Type I error rate at 2-sided alpha of 0.05. For all maintenance key secondary endpoints, a hierarchal testing scheme with a prespecified order was implemented with a family-wise error rate at 0.05. | Two families for alpha control were defined: 1 for induction and 1 for maintenance with each family-wise error rate at 0.05. For all primary and key secondary endpoints for Induction Period, a prespecified graphical multiple testing approach was implemented to control the overall Type I error rate at 2-sided alpha of 0.05. For all maintenance key secondary endpoints, a hierarchal testing scheme with a prespecified order was implemented with a family-wise error rate at 0.05. | Two families for alpha control were defined: 1 for induction and 1 for maintenance with each family-wise error rate at 0.05. For all primary and key secondary endpoints for Induction Period, a prespecified graphical multiple testing approach was implemented to control the overall Type I error rate at 2-sided alpha of 0.05. For all maintenance key secondary endpoints, a hierarchal testing scheme with a prespecified order was implemented with a family-wise error rate at 0.05. |
| Database Lock                                                | 29 April 2022                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 29 April 2022                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 29 April 2022                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 29 April 2022                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Induction Period - Results and Analysis - IGA 0,1 at Week 16 | Induction Period - Results and Analysis - IGA 0,1 at Week 16                                                                                                                                                                                                                                                                                                                                                                                                                                   | Induction Period - Results and Analysis - IGA 0,1 at Week 16                                                                                                                                                                                                                                                                                                                                                                                                                                   | Induction Period - Results and Analysis - IGA 0,1 at Week 16                                                                                                                                                                                                                                                                                                                                                                                                                                   | Induction Period - Results and Analysis - IGA 0,1 at Week 16                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Analysis Description                                         | Coprimary endpoint: Percentage of participants with an IGA 0,1 and a reduction of ≥2 points from baseline to Week 16                                                                                                                                                                                                                                                                                                                                                                           | Coprimary endpoint: Percentage of participants with an IGA 0,1 and a reduction of ≥2 points from baseline to Week 16                                                                                                                                                                                                                                                                                                                                                                           | Coprimary endpoint: Percentage of participants with an IGA 0,1 and a reduction of ≥2 points from baseline to Week 16                                                                                                                                                                                                                                                                                                                                                                           | Coprimary endpoint: Percentage of participants with an IGA 0,1 and a reduction of ≥2 points from baseline to Week 16                                                                                                                                                                                                                                                                                                                                                                           |
| Statistical Model                                            | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|                                                              | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | PBO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | LEB 250 mg Q2W                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                                                              | Number of participants (Nx)                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Number of participants (Nx)                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 141                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 283                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| Descriptive Statistics and Estimate Variability              | Response, n (%)                                                                                                          | 18 (12.7)                                                                                                                | 18 (12.7)                                                                                                                | 122 (43.1)                                                                                                               |
|--------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|
| Effect Estimate per Comparison                               | Comparison groups                                                                                                        | Comparison groups                                                                                                        | LEB 250 mg Q2W versus PBO                                                                                                | LEB 250 mg Q2W versus PBO                                                                                                |
| Effect Estimate per Comparison                               | Common risk difference (95% CI)                                                                                          | Common risk difference (95% CI)                                                                                          | 29.7 (21.6, 37.8)                                                                                                        | 29.7 (21.6, 37.8)                                                                                                        |
| Effect Estimate per Comparison                               | p-value                                                                                                                  | p-value                                                                                                                  | <.001                                                                                                                    | <.001                                                                                                                    |
| Induction Period - Results and Analysis - EASI 75 at Week 16 | Induction Period - Results and Analysis - EASI 75 at Week 16                                                             | Induction Period - Results and Analysis - EASI 75 at Week 16                                                             | Induction Period - Results and Analysis - EASI 75 at Week 16                                                             | Induction Period - Results and Analysis - EASI 75 at Week 16                                                             |
| Analysis Description                                         | Coprimary endpoint: Percentage of participants achieving EASI 75 (≥75% reduction from baseline in EASI) at Week 16       | Coprimary endpoint: Percentage of participants achieving EASI 75 (≥75% reduction from baseline in EASI) at Week 16       | Coprimary endpoint: Percentage of participants achieving EASI 75 (≥75% reduction from baseline in EASI) at Week 16       | Coprimary endpoint: Percentage of participants achieving EASI 75 (≥75% reduction from baseline in EASI) at Week 16       |
| Statistical Model                                            | Primary estimand (hybrid): CMH with MCMC-MI a                                                                            | Primary estimand (hybrid): CMH with MCMC-MI a                                                                            | Primary estimand (hybrid): CMH with MCMC-MI a                                                                            | Primary estimand (hybrid): CMH with MCMC-MI a                                                                            |
| Descriptive Statistics and Estimate Variability              | Treatment group                                                                                                          | PBO                                                                                                                      | PBO                                                                                                                      | LEB 250 mg Q2W                                                                                                           |
| Descriptive Statistics and Estimate Variability              | Number of participants (Nx)                                                                                              | 141                                                                                                                      | 141                                                                                                                      | 283                                                                                                                      |
| Descriptive Statistics and Estimate Variability              | Response, n (%)                                                                                                          | 23 (16.2)                                                                                                                | 23 (16.2)                                                                                                                | 166 (58.8)                                                                                                               |
| Effect Estimate per Comparison                               | Comparison groups                                                                                                        | Comparison groups                                                                                                        | LEB 250 mg Q2W versus PBO                                                                                                | LEB 250 mg Q2W versus PBO                                                                                                |
| Effect Estimate per Comparison                               | Common risk difference (95% CI)                                                                                          | Common risk difference (95% CI)                                                                                          | 42.0 (33.3, 50.6)                                                                                                        | 42.0 (33.3, 50.6)                                                                                                        |
| Effect Estimate per Comparison                               | p-value                                                                                                                  | p-value                                                                                                                  | <.001                                                                                                                    | <.001                                                                                                                    |
| Induction Period - Results and Analysis - EASI 90 at Week 16 | Induction Period - Results and Analysis - EASI 90 at Week 16                                                             | Induction Period - Results and Analysis - EASI 90 at Week 16                                                             | Induction Period - Results and Analysis - EASI 90 at Week 16                                                             | Induction Period - Results and Analysis - EASI 90 at Week 16                                                             |
| Analysis Description                                         | Major secondary endpoint: Percentage of participants achieving EASI 90 (≥90% reduction from baseline in EASI) at Week 16 | Major secondary endpoint: Percentage of participants achieving EASI 90 (≥90% reduction from baseline in EASI) at Week 16 | Major secondary endpoint: Percentage of participants achieving EASI 90 (≥90% reduction from baseline in EASI) at Week 16 | Major secondary endpoint: Percentage of participants achieving EASI 90 (≥90% reduction from baseline in EASI) at Week 16 |
| Statistical Model                                            | Primary estimand (hybrid): CMH with MCMC-MI a                                                                            | Primary estimand (hybrid): CMH with MCMC-MI a                                                                            | Primary estimand (hybrid): CMH with MCMC-MI a                                                                            | Primary estimand (hybrid): CMH with MCMC-MI a                                                                            |
| Descriptive Statistics and Estimate Variability              | Treatment group                                                                                                          | PBO                                                                                                                      | PBO                                                                                                                      | LEB 250 mg Q2W                                                                                                           |
| Descriptive Statistics and Estimate Variability              | Number of participants (Nx)                                                                                              | 141                                                                                                                      | 141                                                                                                                      | 283                                                                                                                      |
| Descriptive Statistics and Estimate Variability              | Response, n (%)                                                                                                          | 13 (9.0)                                                                                                                 | 13 (9.0)                                                                                                                 | 108 (38.3)                                                                                                               |
| Effect Estimate per Comparison                               | Comparison groups                                                                                                        | Comparison groups                                                                                                        | LEB 250 mg Q2W versus PBO                                                                                                | LEB 250 mg Q2W versus PBO                                                                                                |
| Effect Estimate per Comparison                               | Common risk difference (95% CI)                                                                                          | Common risk difference (95% CI)                                                                                          | 28.8 (21.3, 36.3)                                                                                                        | 28.8 (21.3, 36.3)                                                                                                        |
| Effect Estimate per Comparison                               | p-value                                                                                                                  | p-value                                                                                                                  | <.001                                                                                                                    | <.001                                                                                                                    |
| Induction Period - Results and Analysis - EASI 90 at Week 4  | Induction Period - Results and Analysis - EASI 90 at Week 4                                                              | Induction Period - Results and Analysis - EASI 90 at Week 4                                                              | Induction Period - Results and Analysis - EASI 90 at Week 4                                                              | Induction Period - Results and Analysis - EASI 90 at Week 4                                                              |
| Analysis Description                                         | Major secondary endpoint: Percentage of participants achieving EASI 90 at Week 4                                         | Major secondary endpoint: Percentage of participants achieving EASI 90 at Week 4                                         | Major secondary endpoint: Percentage of participants achieving EASI 90 at Week 4                                         | Major secondary endpoint: Percentage of participants achieving EASI 90 at Week 4                                         |
| Statistical Model                                            | Primary estimand (hybrid): CMH with MCMC-MI a                                                                            | Primary estimand (hybrid): CMH with MCMC-MI a                                                                            | Primary estimand (hybrid): CMH with MCMC-MI a                                                                            | Primary estimand (hybrid): CMH with MCMC-MI a                                                                            |
|                                                              | Treatment group                                                                                                          | PBO                                                                                                                      | PBO                                                                                                                      | LEB 250 mg Q2W                                                                                                           |

<div style=\"page-break-after: always\"></div>

| Descriptive Statistics and Estimate                                                    | Number of participants (Nx)                                                                                                                                  | 141                                                                                                                                                          | 283                                                                                                                                                          |
|----------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variability Effect                                                                     | Response, n (%) 2 (1.6)                                                                                                                                      | Response, n (%) 2 (1.6)                                                                                                                                      | 35 (12.4)                                                                                                                                                    |
| Estimate per Comparison                                                                | Comparison groups                                                                                                                                            | Comparison groups                                                                                                                                            | LEB 250 mg Q2W versus PBO                                                                                                                                    |
| Estimate per Comparison                                                                | Common risk difference (95% CI)                                                                                                                              | Common risk difference (95% CI)                                                                                                                              | 10.7 (6.2, 15.2)                                                                                                                                             |
| Estimate per Comparison                                                                | p-value                                                                                                                                                      | p-value                                                                                                                                                      | <.001                                                                                                                                                        |
| Induction Period - Results and Analysis - EASI PCFB                                    | Induction Period - Results and Analysis - EASI PCFB                                                                                                          | Induction Period - Results and Analysis - EASI PCFB                                                                                                          | Induction Period - Results and Analysis - EASI PCFB                                                                                                          |
| Analysis Description                                                                   | Major secondary endpoint: Percentage change in EASI from baseline to Week 16                                                                                 | Major secondary endpoint: Percentage change in EASI from baseline to Week 16                                                                                 | Major secondary endpoint: Percentage change in EASI from baseline to Week 16                                                                                 |
| Statistical Model                                                                      | Primary estimand (hybrid): ANCOVA with MCMC-MI b                                                                                                             | Primary estimand (hybrid): ANCOVA with MCMC-MI b                                                                                                             | Primary estimand (hybrid): ANCOVA with MCMC-MI b                                                                                                             |
| Descriptive Statistics and Estimate                                                    | Treatment group                                                                                                                                              | PBO                                                                                                                                                          | LEB 250 mg Q2W                                                                                                                                               |
| Descriptive Statistics and Estimate                                                    | Number of participants (Nx)                                                                                                                                  | 141                                                                                                                                                          | 283                                                                                                                                                          |
| Variability                                                                            | LSM (SE)                                                                                                                                                     | - 26.0 (4.0)                                                                                                                                                 | - 64.3 (3.2)                                                                                                                                                 |
| Effect Estimate per Comparison                                                         | Comparison groups                                                                                                                                            | Comparison groups                                                                                                                                            | LEB 250 mg Q2W versus PBO                                                                                                                                    |
| Effect Estimate per Comparison                                                         | LSM difference (95% CI)                                                                                                                                      | LSM difference (95% CI)                                                                                                                                      | - 38.3 ( - 46.4, - 30.2)                                                                                                                                     |
| Effect Estimate per Comparison                                                         | p-value                                                                                                                                                      | p-value                                                                                                                                                      | <.001                                                                                                                                                        |
| Induction Period - Results and Analysis -Pruritus NRS PCFB                             | Induction Period - Results and Analysis -Pruritus NRS PCFB                                                                                                   | Induction Period - Results and Analysis -Pruritus NRS PCFB                                                                                                   | Induction Period - Results and Analysis -Pruritus NRS PCFB                                                                                                   |
| Analysis Description                                                                   | Major secondary endpoint: Percentage change in pruritus NRS score from baseline to Week 16                                                                   | Major secondary endpoint: Percentage change in pruritus NRS score from baseline to Week 16                                                                   | Major secondary endpoint: Percentage change in pruritus NRS score from baseline to Week 16                                                                   |
| Statistical Model                                                                      | Primary estimand (hybrid): ANCOVA with MCMC-MI b                                                                                                             | Primary estimand (hybrid): ANCOVA with MCMC-MI b                                                                                                             | Primary estimand (hybrid): ANCOVA with MCMC-MI b                                                                                                             |
| Descriptive Statistics and Estimate Variability                                        | Treatment group                                                                                                                                              | PBO                                                                                                                                                          | LEB 250 mg Q2W                                                                                                                                               |
| Descriptive Statistics and Estimate Variability                                        | Number of participants with baseline Pruritis NRS score greater than 0 (Nx)                                                                                  | 136                                                                                                                                                          | 276                                                                                                                                                          |
| Descriptive Statistics and Estimate Variability                                        | LSM (SE)                                                                                                                                                     | - 15.1 (3.8)                                                                                                                                                 | - 45.5 (3.1)                                                                                                                                                 |
| Effect Estimate per Comparison                                                         | Comparison groups                                                                                                                                            | Comparison groups                                                                                                                                            | LEB 250 mg Q2W versus PBO                                                                                                                                    |
| Effect Estimate per Comparison                                                         | LSM difference (95% CI)                                                                                                                                      | LSM difference (95% CI)                                                                                                                                      | -30.4 (-38.1, -22.7)                                                                                                                                         |
| Effect Estimate per Comparison                                                         | p-value                                                                                                                                                      | p-value                                                                                                                                                      | <.001                                                                                                                                                        |
| Induction Period - Results and Analysis - Pruritus NRS 4-Point Iimprovement at Week 16 | Induction Period - Results and Analysis - Pruritus NRS 4-Point Iimprovement at Week 16                                                                       | Induction Period - Results and Analysis - Pruritus NRS 4-Point Iimprovement at Week 16                                                                       | Induction Period - Results and Analysis - Pruritus NRS 4-Point Iimprovement at Week 16                                                                       |
| Analysis Description                                                                   | Major secondary endpoint: Percentage of participants with a pruritus NRS of ≥4 points at baseline who achieve a ≥4 -point reduction from baseline to Week 16 | Major secondary endpoint: Percentage of participants with a pruritus NRS of ≥4 points at baseline who achieve a ≥4 -point reduction from baseline to Week 16 | Major secondary endpoint: Percentage of participants with a pruritus NRS of ≥4 points at baseline who achieve a ≥4 -point reduction from baseline to Week 16 |
| Statistical Model                                                                      | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                |

<div style=\"page-break-after: always\"></div>

| Descriptive Statistics and Estimate Variability                                      | Treatment group                                                                                                                                             | PBO                                                                                                                                                         | PBO                                                                                                                                                         | LEB 250 mg Q2W                                                                                                                                              |
|--------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Descriptive Statistics and Estimate Variability                                      | Number of participants with baseline pruritus NRS score ≥4 (Nx)                                                                                             | 130                                                                                                                                                         | 130                                                                                                                                                         | 263                                                                                                                                                         |
| Descriptive Statistics and Estimate Variability                                      | Response, n (%)                                                                                                                                             | 17 (13.0)                                                                                                                                                   | 17 (13.0)                                                                                                                                                   | 121 (45.9)                                                                                                                                                  |
| Effect Estimate per Comparison                                                       | Comparison groups                                                                                                                                           | Comparison groups                                                                                                                                           | LEB 250 mg Q2W versus PBO                                                                                                                                   | LEB 250 mg Q2W versus PBO                                                                                                                                   |
| Effect Estimate per Comparison                                                       | Common risk difference (95% CI)                                                                                                                             | Common risk difference (95% CI)                                                                                                                             | 32.9 (24.6, 41.3)                                                                                                                                           | 32.9 (24.6, 41.3)                                                                                                                                           |
| Effect Estimate per Comparison                                                       | p-value                                                                                                                                                     | p-value                                                                                                                                                     | <.001                                                                                                                                                       | <.001                                                                                                                                                       |
| Induction Period - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 4 | Induction Period - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 4                                                                        | Induction Period - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 4                                                                        | Induction Period - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 4                                                                        | Induction Period - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 4                                                                        |
| Analysis Description                                                                 | Major secondary endpoint: Percentage of participants with a pruritus NRS of ≥4 points at baseline who achieve a ≥4 -point reduction from baseline to Week 4 | Major secondary endpoint: Percentage of participants with a pruritus NRS of ≥4 points at baseline who achieve a ≥4 -point reduction from baseline to Week 4 | Major secondary endpoint: Percentage of participants with a pruritus NRS of ≥4 points at baseline who achieve a ≥4 -point reduction from baseline to Week 4 | Major secondary endpoint: Percentage of participants with a pruritus NRS of ≥4 points at baseline who achieve a ≥4 -point reduction from baseline to Week 4 |
| Statistical Model                                                                    | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                               | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                               | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                               | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                               |
| Descriptive Statistics and Estimate Variability                                      | Treatment group                                                                                                                                             | PBO                                                                                                                                                         | PBO                                                                                                                                                         | LEB 250 mg Q2W                                                                                                                                              |
| Descriptive Statistics and Estimate Variability                                      | Number of participants with baseline pruritus NRS score ≥4 (Nx)                                                                                             | 130                                                                                                                                                         | 130                                                                                                                                                         | 263                                                                                                                                                         |
| Descriptive Statistics and Estimate Variability                                      | Response, n (%)                                                                                                                                             | 3 (2.3)                                                                                                                                                     | 3 (2.3)                                                                                                                                                     | 56 (21.5)                                                                                                                                                   |
| Effect Estimate per Comparison                                                       | Comparison groups                                                                                                                                           | Comparison groups                                                                                                                                           | LEB 250 mg Q2W versus PBO                                                                                                                                   | LEB 250 mg Q2W versus PBO                                                                                                                                   |
| Effect Estimate per Comparison                                                       | Common risk difference (95% CI)                                                                                                                             | Common risk difference (95% CI)                                                                                                                             | 19.3 (13.7, 25.0)                                                                                                                                           | 19.3 (13.7, 25.0)                                                                                                                                           |
| Effect Estimate per Comparison                                                       | p-value                                                                                                                                                     | p-value                                                                                                                                                     | <.001                                                                                                                                                       | <.001                                                                                                                                                       |
| Induction Period - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 2 | Induction Period - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 2                                                                        | Induction Period - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 2                                                                        | Induction Period - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 2                                                                        | Induction Period - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 2                                                                        |
| Analysis Description                                                                 | Major secondary endpoint: Percentage of participants with a pruritus NRS of ≥4 points at baseline who achieve a ≥4 -point reduction from baseline to Week 2 | Major secondary endpoint: Percentage of participants with a pruritus NRS of ≥4 points at baseline who achieve a ≥4 -point reduction from baseline to Week 2 | Major secondary endpoint: Percentage of participants with a pruritus NRS of ≥4 points at baseline who achieve a ≥4 -point reduction from baseline to Week 2 | Major secondary endpoint: Percentage of participants with a pruritus NRS of ≥4 points at baseline who achieve a ≥4 -point reduction from baseline to Week 2 |
| Statistical Model                                                                    | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                               | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                               | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                               | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                               |
| Descriptive Statistics and Estimate Variability                                      | Treatment group                                                                                                                                             | PBO                                                                                                                                                         | PBO                                                                                                                                                         | LEB 250 mg Q2W                                                                                                                                              |
| Descriptive Statistics and Estimate Variability                                      | Number of participants with baseline pruritus NRS score ≥4 (Nx)                                                                                             | 130                                                                                                                                                         | 130                                                                                                                                                         | 263                                                                                                                                                         |
| Descriptive Statistics and Estimate Variability                                      | Response, n (%)                                                                                                                                             | 1 (0.9)                                                                                                                                                     | 1 (0.9)                                                                                                                                                     | 16 (6.1)                                                                                                                                                    |
| Effect Estimate per Comparison                                                       | Comparison groups                                                                                                                                           | Comparison groups                                                                                                                                           | LEB 250 mg Q2W versus PBO                                                                                                                                   | LEB 250 mg Q2W versus PBO                                                                                                                                   |
| Effect Estimate per Comparison                                                       | Common risk difference (95% CI)                                                                                                                             | Common risk difference (95% CI)                                                                                                                             | 5.3 (1.9, 8.6)                                                                                                                                              | 5.3 (1.9, 8.6)                                                                                                                                              |
| Effect Estimate per Comparison                                                       | p-value                                                                                                                                                     | p-value                                                                                                                                                     | .017                                                                                                                                                        | .017                                                                                                                                                        |
| Induction Period - Results and Analysis - DLQI CFB                                   | Induction Period - Results and Analysis - DLQI CFB                                                                                                          | Induction Period - Results and Analysis - DLQI CFB                                                                                                          | Induction Period - Results and Analysis - DLQI CFB                                                                                                          | Induction Period - Results and Analysis - DLQI CFB                                                                                                          |
| Analysis Description                                                                 | Major secondary endpoint: CFB in DLQI total score at Week 16                                                                                                | Major secondary endpoint: CFB in DLQI total score at Week 16                                                                                                | Major secondary endpoint: CFB in DLQI total score at Week 16                                                                                                | Major secondary endpoint: CFB in DLQI total score at Week 16                                                                                                |

<div style=\"page-break-after: always\"></div>

| Statistical Model                                                                               | Primary estimand (hybrid): ANCOVA with MCMC-MI b                                                                                                                   | Primary estimand (hybrid): ANCOVA with MCMC-MI b                                                                                                                   | Primary estimand (hybrid): ANCOVA with MCMC-MI b                                                                                                                   | Primary estimand (hybrid): ANCOVA with MCMC-MI b                                                                                                                   |
|-------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Descriptive Statistics and Estimate Variability                                                 | Treatment group                                                                                                                                                    | PBO                                                                                                                                                                | PBO                                                                                                                                                                | LEB 250 mg Q2W                                                                                                                                                     |
| Descriptive Statistics and Estimate Variability                                                 | Number of participants with non- missing baseline DLQI score (Nx)                                                                                                  | 121                                                                                                                                                                | 121                                                                                                                                                                | 239                                                                                                                                                                |
| Descriptive Statistics and Estimate Variability                                                 | LSM (SE)                                                                                                                                                           | -2.9 (1.1)                                                                                                                                                         | -2.9 (1.1)                                                                                                                                                         | -8.7 (1.1)                                                                                                                                                         |
| Effect Estimate per Comparison                                                                  | Comparison groups                                                                                                                                                  | Comparison groups                                                                                                                                                  | LEB 250 mg Q2W versus PBO                                                                                                                                          | LEB 250 mg Q2W versus PBO                                                                                                                                          |
| Effect Estimate per Comparison                                                                  | LSM difference (95% CI)                                                                                                                                            | LSM difference (95% CI)                                                                                                                                            | -5.8 (-7.1, -4.5)                                                                                                                                                  | -5.8 (-7.1, -4.5)                                                                                                                                                  |
| Effect Estimate per Comparison                                                                  | p-value                                                                                                                                                            | p-value                                                                                                                                                            | <.001                                                                                                                                                              | <.001                                                                                                                                                              |
| Induction Period - Results and Analysis - DLQI 4-Point Improvement at Week 16                   | Induction Period - Results and Analysis - DLQI 4-Point Improvement at Week 16                                                                                      | Induction Period - Results and Analysis - DLQI 4-Point Improvement at Week 16                                                                                      | Induction Period - Results and Analysis - DLQI 4-Point Improvement at Week 16                                                                                      | Induction Period - Results and Analysis - DLQI 4-Point Improvement at Week 16                                                                                      |
| Analysis Description                                                                            | Major secondary endpoint: Percentage of participants with a DLQI total score of ≥4 points at baseline who achieve a ≥4 -point improvement from baseline to Week 16 | Major secondary endpoint: Percentage of participants with a DLQI total score of ≥4 points at baseline who achieve a ≥4 -point improvement from baseline to Week 16 | Major secondary endpoint: Percentage of participants with a DLQI total score of ≥4 points at baseline who achieve a ≥4 -point improvement from baseline to Week 16 | Major secondary endpoint: Percentage of participants with a DLQI total score of ≥4 points at baseline who achieve a ≥4 -point improvement from baseline to Week 16 |
| Statistical Model                                                                               | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                      | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                      | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                      | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                      |
| Descriptive Statistics and Estimate Variability                                                 | Treatment group                                                                                                                                                    | PBO                                                                                                                                                                | PBO                                                                                                                                                                | LEB 250 mg Q2W                                                                                                                                                     |
| Descriptive Statistics and Estimate Variability                                                 | Number of participants with baseline DLQI score of at least 4 (Nx)                                                                                                 | 116                                                                                                                                                                | 116                                                                                                                                                                | 226                                                                                                                                                                |
| Descriptive Statistics and Estimate Variability                                                 | Response, n (%)                                                                                                                                                    | 39 (33.8)                                                                                                                                                          | 39 (33.8)                                                                                                                                                          | 171 (75.6)                                                                                                                                                         |
| Effect Estimate per Comparison                                                                  | Comparison groups                                                                                                                                                  | Comparison groups                                                                                                                                                  | LEB 250 mg Q2W versus PBO                                                                                                                                          | LEB 250 mg Q2W versus PBO                                                                                                                                          |
| Effect Estimate per Comparison                                                                  | Common risk difference (95% CI)                                                                                                                                    | Common risk difference (95% CI)                                                                                                                                    | 41.8 (31.2, 52.3)                                                                                                                                                  | 41.8 (31.2, 52.3)                                                                                                                                                  |
| Effect Estimate per Comparison                                                                  | p-value                                                                                                                                                            | p-value                                                                                                                                                            | <.001                                                                                                                                                              | <.001                                                                                                                                                              |
| Induction Period - Results and Analysis - Sleep-Loss Scale Score CFB                            | Induction Period - Results and Analysis - Sleep-Loss Scale Score CFB                                                                                               | Induction Period - Results and Analysis - Sleep-Loss Scale Score CFB                                                                                               | Induction Period - Results and Analysis - Sleep-Loss Scale Score CFB                                                                                               | Induction Period - Results and Analysis - Sleep-Loss Scale Score CFB                                                                                               |
| Analysis Description                                                                            | Major secondary endpoint: CFB in Sleep-Loss score at Week 16                                                                                                       | Major secondary endpoint: CFB in Sleep-Loss score at Week 16                                                                                                       | Major secondary endpoint: CFB in Sleep-Loss score at Week 16                                                                                                       | Major secondary endpoint: CFB in Sleep-Loss score at Week 16                                                                                                       |
| Statistical Model                                                                               | Primary estimand (hybrid): ANCOVA with MCMC-MI b                                                                                                                   | Primary estimand (hybrid): ANCOVA with MCMC-MI b                                                                                                                   | Primary estimand (hybrid): ANCOVA with MCMC-MI b                                                                                                                   | Primary estimand (hybrid): ANCOVA with MCMC-MI b                                                                                                                   |
| Descriptive Statistics and Estimate Variability                                                 | Treatment group                                                                                                                                                    | PBO                                                                                                                                                                | PBO                                                                                                                                                                | LEB 250 mg Q2W                                                                                                                                                     |
| Descriptive Statistics and Estimate Variability                                                 | Number of participants with non- missing baseline Sleep-Loss scale score (Nx)                                                                                      | 136                                                                                                                                                                | 136                                                                                                                                                                | 276                                                                                                                                                                |
| Descriptive Statistics and Estimate Variability                                                 | LSM (SE)                                                                                                                                                           | -0.4 (0.1)                                                                                                                                                         | -0.4 (0.1)                                                                                                                                                         | -1.1 (0.1)                                                                                                                                                         |
| Effect Estimate per Comparison                                                                  | Comparison groups                                                                                                                                                  | Comparison groups                                                                                                                                                  | LEB 250 mg Q2W versus PBO                                                                                                                                          | LEB 250 mg Q2W versus PBO                                                                                                                                          |
| Effect Estimate per Comparison                                                                  | LSM difference (95% CI)                                                                                                                                            | LSM difference (95% CI)                                                                                                                                            | -0.8 (-0.9, -0.6)                                                                                                                                                  | -0.8 (-0.9, -0.6)                                                                                                                                                  |
| Effect Estimate per Comparison                                                                  | p-value                                                                                                                                                            | p-value                                                                                                                                                            | <.001                                                                                                                                                              | <.001                                                                                                                                                              |
| Induction Period - Results and Analysis - Sleep-Loss Scale Score 2-Point Improvement at Week 16 | Induction Period - Results and Analysis - Sleep-Loss Scale Score 2-Point Improvement at Week 16                                                                    | Induction Period - Results and Analysis - Sleep-Loss Scale Score 2-Point Improvement at Week 16                                                                    | Induction Period - Results and Analysis - Sleep-Loss Scale Score 2-Point Improvement at Week 16                                                                    | Induction Period - Results and Analysis - Sleep-Loss Scale Score 2-Point Improvement at Week 16                                                                    |

<div style=\"page-break-after: always\"></div>

| Analysis Description                                           | Major secondary endpoint: Percentage of participants with a Sleep- Loss scale score of ≥2 points at baseline who achieve a ≥2 -point reduction from baseline at Week 16                                                          | Major secondary endpoint: Percentage of participants with a Sleep- Loss scale score of ≥2 points at baseline who achieve a ≥2 -point reduction from baseline at Week 16                                                          | Major secondary endpoint: Percentage of participants with a Sleep- Loss scale score of ≥2 points at baseline who achieve a ≥2 -point reduction from baseline at Week 16                                                          | Major secondary endpoint: Percentage of participants with a Sleep- Loss scale score of ≥2 points at baseline who achieve a ≥2 -point reduction from baseline at Week 16                                                          | Major secondary endpoint: Percentage of participants with a Sleep- Loss scale score of ≥2 points at baseline who achieve a ≥2 -point reduction from baseline at Week 16                                                          |
|----------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Statistical Model                                              | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                                                                                    | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                                                                                    | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                                                                                    | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                                                                                    | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                                                                                    |
| Descriptive Statistics and Estimate Variability                | Treatment group                                                                                                                                                                                                                  | Treatment group                                                                                                                                                                                                                  | PBO                                                                                                                                                                                                                              | PBO                                                                                                                                                                                                                              | LEB 250 mg Q2W                                                                                                                                                                                                                   |
|                                                                | Number of participants with baseline Sleep-Loss score of at least 2 (Nx)                                                                                                                                                         | Number of participants with baseline Sleep-Loss score of at least 2 (Nx)                                                                                                                                                         | 91                                                                                                                                                                                                                               | 91                                                                                                                                                                                                                               | 195                                                                                                                                                                                                                              |
|                                                                | Response, n (%) 4                                                                                                                                                                                                                | Response, n (%) 4                                                                                                                                                                                                                | (4.7)                                                                                                                                                                                                                            | (4.7)                                                                                                                                                                                                                            | 76 (39.0)                                                                                                                                                                                                                        |
| Effect Estimate per Comparison                                 | Comparison groups                                                                                                                                                                                                                | Comparison groups                                                                                                                                                                                                                | Comparison groups                                                                                                                                                                                                                | LEB 250 mg Q2W versus PBO                                                                                                                                                                                                        | LEB 250 mg Q2W versus PBO                                                                                                                                                                                                        |
| Effect Estimate per Comparison                                 | Common risk difference (95% CI)                                                                                                                                                                                                  | Common risk difference (95% CI)                                                                                                                                                                                                  | Common risk difference (95% CI)                                                                                                                                                                                                  | 34.6 (26.2, 43.0)                                                                                                                                                                                                                | 34.6 (26.2, 43.0)                                                                                                                                                                                                                |
| Effect Estimate per Comparison                                 | p-value                                                                                                                                                                                                                          | p-value                                                                                                                                                                                                                          | p-value                                                                                                                                                                                                                          | <.001                                                                                                                                                                                                                            | <.001                                                                                                                                                                                                                            |
| Induction Period - Results and Analysis - POEM CFB             | Induction Period - Results and Analysis - POEM CFB                                                                                                                                                                               | Induction Period - Results and Analysis - POEM CFB                                                                                                                                                                               | Induction Period - Results and Analysis - POEM CFB                                                                                                                                                                               | Induction Period - Results and Analysis - POEM CFB                                                                                                                                                                               | Induction Period - Results and Analysis - POEM CFB                                                                                                                                                                               |
| Analysis Description                                           | Other endpoint: CFB in POEM at Week 16                                                                                                                                                                                           | Other endpoint: CFB in POEM at Week 16                                                                                                                                                                                           | Other endpoint: CFB in POEM at Week 16                                                                                                                                                                                           | Other endpoint: CFB in POEM at Week 16                                                                                                                                                                                           | Other endpoint: CFB in POEM at Week 16                                                                                                                                                                                           |
| Statistical Model                                              | Supportive estimand for continuous endpoints (hypothetical): MMRM c                                                                                                                                                              | Supportive estimand for continuous endpoints (hypothetical): MMRM c                                                                                                                                                              | Supportive estimand for continuous endpoints (hypothetical): MMRM c                                                                                                                                                              | Supportive estimand for continuous endpoints (hypothetical): MMRM c                                                                                                                                                              | Supportive estimand for continuous endpoints (hypothetical): MMRM c                                                                                                                                                              |
| Descriptive Statistics and Estimate Variability                | Treatment group                                                                                                                                                                                                                  | PBO                                                                                                                                                                                                                              | PBO                                                                                                                                                                                                                              | LEB 250 mg Q2W                                                                                                                                                                                                                   | LEB 250 mg Q2W                                                                                                                                                                                                                   |
| Descriptive Statistics and Estimate Variability                | Number of participants (Nx)                                                                                                                                                                                                      | 133                                                                                                                                                                                                                              | 133                                                                                                                                                                                                                              | 275                                                                                                                                                                                                                              | 275                                                                                                                                                                                                                              |
| Descriptive Statistics and Estimate Variability                | LSM (SE)                                                                                                                                                                                                                         | -3.9 (0.7)                                                                                                                                                                                                                       | -3.9 (0.7)                                                                                                                                                                                                                       | -11.3 (0.5)                                                                                                                                                                                                                      | -11.3 (0.5)                                                                                                                                                                                                                      |
| Effect Estimate per Comparison                                 | Comparison groups                                                                                                                                                                                                                | Comparison groups                                                                                                                                                                                                                | Comparison groups                                                                                                                                                                                                                | LEB 250 mg Q2W versus PBO                                                                                                                                                                                                        | LEB 250 mg Q2W versus PBO                                                                                                                                                                                                        |
| Effect Estimate per Comparison                                 | LSM difference (SE)                                                                                                                                                                                                              | LSM difference (SE)                                                                                                                                                                                                              | LSM difference (SE)                                                                                                                                                                                                              | -7.3 (0.8)                                                                                                                                                                                                                       | -7.3 (0.8)                                                                                                                                                                                                                       |
| Effect Estimate per Comparison                                 | p-value                                                                                                                                                                                                                          | p-value                                                                                                                                                                                                                          | p-value                                                                                                                                                                                                                          | <.001                                                                                                                                                                                                                            | <.001                                                                                                                                                                                                                            |
| Maintenance Period - Results and Analysis - EASI 75 at Week 52 | Maintenance Period - Results and Analysis - EASI 75 at Week 52                                                                                                                                                                   | Maintenance Period - Results and Analysis - EASI 75 at Week 52                                                                                                                                                                   | Maintenance Period - Results and Analysis - EASI 75 at Week 52                                                                                                                                                                   | Maintenance Period - Results and Analysis - EASI 75 at Week 52                                                                                                                                                                   | Maintenance Period - Results and Analysis - EASI 75 at Week 52                                                                                                                                                                   |
| Analysis Description                                           | Maintenance major secondary endpoint: Percentage of participants from those randomly reassigned, having achieved EASI 75 at Week 16 who continue to exhibit EASI 75 at Week 52 (EASI calculated relative to baseline EASI score) | Maintenance major secondary endpoint: Percentage of participants from those randomly reassigned, having achieved EASI 75 at Week 16 who continue to exhibit EASI 75 at Week 52 (EASI calculated relative to baseline EASI score) | Maintenance major secondary endpoint: Percentage of participants from those randomly reassigned, having achieved EASI 75 at Week 16 who continue to exhibit EASI 75 at Week 52 (EASI calculated relative to baseline EASI score) | Maintenance major secondary endpoint: Percentage of participants from those randomly reassigned, having achieved EASI 75 at Week 16 who continue to exhibit EASI 75 at Week 52 (EASI calculated relative to baseline EASI score) | Maintenance major secondary endpoint: Percentage of participants from those randomly reassigned, having achieved EASI 75 at Week 16 who continue to exhibit EASI 75 at Week 52 (EASI calculated relative to baseline EASI score) |
| Statistical Model                                              | Maintenance primary estimand (hybrid): CMH with MCMC-MI d                                                                                                                                                                        | Maintenance primary estimand (hybrid): CMH with MCMC-MI d                                                                                                                                                                        | Maintenance primary estimand (hybrid): CMH with MCMC-MI d                                                                                                                                                                        | Maintenance primary estimand (hybrid): CMH with MCMC-MI d                                                                                                                                                                        | Maintenance primary estimand (hybrid): CMH with MCMC-MI d                                                                                                                                                                        |
| Descriptive Statistics and Estimate Variability                | Treatment group                                                                                                                                                                                                                  | PBO (LEB withdrawal)                                                                                                                                                                                                             | LEB 250 mg Q4W                                                                                                                                                                                                                   | LEB 250 mg Q4W                                                                                                                                                                                                                   | LEB 250 mg Q2W                                                                                                                                                                                                                   |
| Descriptive Statistics and Estimate Variability                | Participants with EASI 75 at Week 16 (Nx)                                                                                                                                                                                        | 30                                                                                                                                                                                                                               | 62                                                                                                                                                                                                                               | 62                                                                                                                                                                                                                               | 61                                                                                                                                                                                                                               |
| Descriptive Statistics and Estimate Variability                | Maintained response at Week 52, n (%)                                                                                                                                                                                            | 18 (61.3)                                                                                                                                                                                                                        | 49 (79.2)                                                                                                                                                                                                                        | 49 (79.2)                                                                                                                                                                                                                        | 48 (79.2)                                                                                                                                                                                                                        |
| Descriptive Statistics and Estimate Variability                | Comparison groups                                                                                                                                                                                                                | LEB 250 mg Q4W vs PBO                                                                                                                                                                                                            | LEB 250 mg Q4W vs PBO                                                                                                                                                                                                            | LEB 250 mg Q2W vs PBO                                                                                                                                                                                                            | LEB 250 mg Q2W vs PBO                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| Effect Estimate per Comparison                                                          | Common risk difference n, (95% CI)                                                                                                                                                                                                                                                       | 17.9 (-2.3, 38.1)                                                                                                                                                                                                                                                                        | 17.9 (-2.3, 38.1)                                                                                                                                                                                                                                                                        | 17.5 (-4.5, 39.5)                                                                                                                                                                                                                                                                        | 17.5 (-4.5, 39.5)                                                                                                                                                                                                                                                                        |
|-----------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Effect Estimate per Comparison                                                          | p-value                                                                                                                                                                                                                                                                                  | .072                                                                                                                                                                                                                                                                                     | .072                                                                                                                                                                                                                                                                                     | .107                                                                                                                                                                                                                                                                                     | .107                                                                                                                                                                                                                                                                                     |
| Maintenance Period - Results and Analysis - IGA 0,1 at Week 52                          | Maintenance Period - Results and Analysis - IGA 0,1 at Week 52                                                                                                                                                                                                                           | Maintenance Period - Results and Analysis - IGA 0,1 at Week 52                                                                                                                                                                                                                           | Maintenance Period - Results and Analysis - IGA 0,1 at Week 52                                                                                                                                                                                                                           | Maintenance Period - Results and Analysis - IGA 0,1 at Week 52                                                                                                                                                                                                                           | Maintenance Period - Results and Analysis - IGA 0,1 at Week 52                                                                                                                                                                                                                           |
| Analysis Description                                                                    | Maintenance major secondary endpoint: Percentage of participants from those randomly reassigned, having achieved IGA 0,1 and a >2 -point improvement from baseline at Week 16 who continue to exhibit an IGA 0,1 and a >2 -point improvement from baseline at Week 52                    | Maintenance major secondary endpoint: Percentage of participants from those randomly reassigned, having achieved IGA 0,1 and a >2 -point improvement from baseline at Week 16 who continue to exhibit an IGA 0,1 and a >2 -point improvement from baseline at Week 52                    | Maintenance major secondary endpoint: Percentage of participants from those randomly reassigned, having achieved IGA 0,1 and a >2 -point improvement from baseline at Week 16 who continue to exhibit an IGA 0,1 and a >2 -point improvement from baseline at Week 52                    | Maintenance major secondary endpoint: Percentage of participants from those randomly reassigned, having achieved IGA 0,1 and a >2 -point improvement from baseline at Week 16 who continue to exhibit an IGA 0,1 and a >2 -point improvement from baseline at Week 52                    | Maintenance major secondary endpoint: Percentage of participants from those randomly reassigned, having achieved IGA 0,1 and a >2 -point improvement from baseline at Week 16 who continue to exhibit an IGA 0,1 and a >2 -point improvement from baseline at Week 52                    |
| Statistical Model                                                                       | Maintenance primary estimand (hybrid): CMH with MCMC-MI d                                                                                                                                                                                                                                | Maintenance primary estimand (hybrid): CMH with MCMC-MI d                                                                                                                                                                                                                                | Maintenance primary estimand (hybrid): CMH with MCMC-MI d                                                                                                                                                                                                                                | Maintenance primary estimand (hybrid): CMH with MCMC-MI d                                                                                                                                                                                                                                | Maintenance primary estimand (hybrid): CMH with MCMC-MI d                                                                                                                                                                                                                                |
| Descriptive Statistics and Estimate Variability                                         | Treatment group                                                                                                                                                                                                                                                                          | PBO (LEB withdrawal)                                                                                                                                                                                                                                                                     | LEB 250 mg Q4W                                                                                                                                                                                                                                                                           | LEB 250 mg Q4W                                                                                                                                                                                                                                                                           | LEB 250 mg Q2W                                                                                                                                                                                                                                                                           |
| Descriptive Statistics and Estimate Variability                                         | Participants with IGA 0,1 at W16 (Nx)                                                                                                                                                                                                                                                    | 22                                                                                                                                                                                                                                                                                       | 45                                                                                                                                                                                                                                                                                       | 45                                                                                                                                                                                                                                                                                       | 45                                                                                                                                                                                                                                                                                       |
| Descriptive Statistics and Estimate Variability                                         | Maintained response at Week 52, n (%)                                                                                                                                                                                                                                                    | 10 (46.5)                                                                                                                                                                                                                                                                                | 33 (74.2)                                                                                                                                                                                                                                                                                | 33 (74.2)                                                                                                                                                                                                                                                                                | 34 (75.8)                                                                                                                                                                                                                                                                                |
| Effect Estimate per Comparison                                                          | Comparison groups                                                                                                                                                                                                                                                                        | LEB 250 mg Q4W vs PBO                                                                                                                                                                                                                                                                    | LEB 250 mg Q4W vs PBO                                                                                                                                                                                                                                                                    | LEB 250 mg Q2W vs PBO                                                                                                                                                                                                                                                                    | LEB 250 mg Q2W vs PBO                                                                                                                                                                                                                                                                    |
| Effect Estimate per Comparison                                                          | Common risk difference n, (95% CI)                                                                                                                                                                                                                                                       | 28.0 (2.8, 53.2)                                                                                                                                                                                                                                                                         | 28.0 (2.8, 53.2)                                                                                                                                                                                                                                                                         | 29.0 (4.6, 53.3)                                                                                                                                                                                                                                                                         | 29.0 (4.6, 53.3)                                                                                                                                                                                                                                                                         |
| Effect Estimate per Comparison                                                          | p-value                                                                                                                                                                                                                                                                                  | .030                                                                                                                                                                                                                                                                                     | .030                                                                                                                                                                                                                                                                                     | .020                                                                                                                                                                                                                                                                                     | .020                                                                                                                                                                                                                                                                                     |
| Maintenance Period - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 52 | Maintenance Period - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 52                                                                                                                                                                                                  | Maintenance Period - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 52                                                                                                                                                                                                  | Maintenance Period - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 52                                                                                                                                                                                                  | Maintenance Period - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 52                                                                                                                                                                                                  | Maintenance Period - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 52                                                                                                                                                                                                  |
| Analysis Description                                                                    | Maintenance major secondary endpoint: Percentage of participants from those with a pruritus NRS of > 4 points at baseline who were randomly reassigned having achieved > 4-point reduction from baseline at Week 16 who continue to exhibit > 4-point reduction from baseline at Week 52 | Maintenance major secondary endpoint: Percentage of participants from those with a pruritus NRS of > 4 points at baseline who were randomly reassigned having achieved > 4-point reduction from baseline at Week 16 who continue to exhibit > 4-point reduction from baseline at Week 52 | Maintenance major secondary endpoint: Percentage of participants from those with a pruritus NRS of > 4 points at baseline who were randomly reassigned having achieved > 4-point reduction from baseline at Week 16 who continue to exhibit > 4-point reduction from baseline at Week 52 | Maintenance major secondary endpoint: Percentage of participants from those with a pruritus NRS of > 4 points at baseline who were randomly reassigned having achieved > 4-point reduction from baseline at Week 16 who continue to exhibit > 4-point reduction from baseline at Week 52 | Maintenance major secondary endpoint: Percentage of participants from those with a pruritus NRS of > 4 points at baseline who were randomly reassigned having achieved > 4-point reduction from baseline at Week 16 who continue to exhibit > 4-point reduction from baseline at Week 52 |
| Statistical Model                                                                       | Maintenance primary estimand (hybrid): CMH with MCMC-MI d                                                                                                                                                                                                                                | Maintenance primary estimand (hybrid): CMH with MCMC-MI d                                                                                                                                                                                                                                | Maintenance primary estimand (hybrid): CMH with MCMC-MI d                                                                                                                                                                                                                                | Maintenance primary estimand (hybrid): CMH with MCMC-MI d                                                                                                                                                                                                                                | Maintenance primary estimand (hybrid): CMH with MCMC-MI d                                                                                                                                                                                                                                |
| Descriptive Statistics and Estimate Variability                                         | Treatment group                                                                                                                                                                                                                                                                          | PBO (LEB withdrawal)                                                                                                                                                                                                                                                                     | LEB 250 mg Q4W                                                                                                                                                                                                                                                                           | LEB 250 mg Q4W                                                                                                                                                                                                                                                                           | LEB 250 mg Q2W                                                                                                                                                                                                                                                                           |
| Descriptive Statistics and Estimate Variability                                         | Participants with pruritus NRS 4-point improvement at W16 (Nx)                                                                                                                                                                                                                           | 17                                                                                                                                                                                                                                                                                       | 29                                                                                                                                                                                                                                                                                       | 29                                                                                                                                                                                                                                                                                       | 38                                                                                                                                                                                                                                                                                       |
| Descriptive Statistics and Estimate Variability                                         | Maintained response at Week 52, n (%)                                                                                                                                                                                                                                                    | 11 (65.4)                                                                                                                                                                                                                                                                                | 23 (80.4)                                                                                                                                                                                                                                                                                | 23 (80.4)                                                                                                                                                                                                                                                                                | 31 (81.2)                                                                                                                                                                                                                                                                                |
| Effect Estimate per Comparison                                                          | Comparison groups                                                                                                                                                                                                                                                                        | LEB 250 mg Q4W vs PBO                                                                                                                                                                                                                                                                    | LEB 250 mg Q4W vs PBO                                                                                                                                                                                                                                                                    | LEB 250 mg Q2W vs PBO                                                                                                                                                                                                                                                                    | LEB 250 mg Q2W vs PBO                                                                                                                                                                                                                                                                    |
| Effect Estimate per Comparison                                                          | Common risk difference n, (95% CI)                                                                                                                                                                                                                                                       | 15.8 (-12.2, 43.8)                                                                                                                                                                                                                                                                       | 15.8 (-12.2, 43.8)                                                                                                                                                                                                                                                                       | 16.6 (-9.4, 42.7)                                                                                                                                                                                                                                                                        | 16.6 (-9.4, 42.7)                                                                                                                                                                                                                                                                        |
| Effect Estimate per Comparison                                                          | p-value                                                                                                                                                                                                                                                                                  | .268                                                                                                                                                                                                                                                                                     | .268                                                                                                                                                                                                                                                                                     | .193                                                                                                                                                                                                                                                                                     | .193                                                                                                                                                                                                                                                                                     |
| Maintenance Period - Results and Analysis - EASI PCFB                                   | Maintenance Period - Results and Analysis - EASI PCFB                                                                                                                                                                                                                                    | Maintenance Period - Results and Analysis - EASI PCFB                                                                                                                                                                                                                                    | Maintenance Period - Results and Analysis - EASI PCFB                                                                                                                                                                                                                                    | Maintenance Period - Results and Analysis - EASI PCFB                                                                                                                                                                                                                                    | Maintenance Period - Results and Analysis - EASI PCFB                                                                                                                                                                                                                                    |
| Analysis Description                                                                    | Maintenance major secondary endpoint: Percentage change in EASI from baseline at Week 52 in the subset of participants who were randomly reassigned at Week 16                                                                                                                           | Maintenance major secondary endpoint: Percentage change in EASI from baseline at Week 52 in the subset of participants who were randomly reassigned at Week 16                                                                                                                           | Maintenance major secondary endpoint: Percentage change in EASI from baseline at Week 52 in the subset of participants who were randomly reassigned at Week 16                                                                                                                           | Maintenance major secondary endpoint: Percentage change in EASI from baseline at Week 52 in the subset of participants who were randomly reassigned at Week 16                                                                                                                           | Maintenance major secondary endpoint: Percentage change in EASI from baseline at Week 52 in the subset of participants who were randomly reassigned at Week 16                                                                                                                           |
| Statistical Model                                                                       | Maintenance primary estimand (hybrid): ANCOVA with MCMC-MI e                                                                                                                                                                                                                             | Maintenance primary estimand (hybrid): ANCOVA with MCMC-MI e                                                                                                                                                                                                                             | Maintenance primary estimand (hybrid): ANCOVA with MCMC-MI e                                                                                                                                                                                                                             | Maintenance primary estimand (hybrid): ANCOVA with MCMC-MI e                                                                                                                                                                                                                             | Maintenance primary estimand (hybrid): ANCOVA with MCMC-MI e                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| Descriptive Statistics and Estimate Variability                                                           | Treatment group                                                                                                                                                                                              | PBO (LEB withdrawal)                                                                                                                                                                                         | LEB 250 mg Q4W                                                                                                                                                                                               | LEB 250 mg Q4W                                                                                                                                                                                               | LEB 250 mg Q2W                                                                                                                                                                                               |
|-----------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Descriptive Statistics and Estimate Variability                                                           | Number of participants (Nx)                                                                                                                                                                                  | 32                                                                                                                                                                                                           | 62                                                                                                                                                                                                           | 62                                                                                                                                                                                                           | 61                                                                                                                                                                                                           |
| Descriptive Statistics and Estimate Variability                                                           | LSM (SE)                                                                                                                                                                                                     | -60.67 (6.3)                                                                                                                                                                                                 | -79.44 (4.5)                                                                                                                                                                                                 | -79.44 (4.5)                                                                                                                                                                                                 | -77.93 (4.5)                                                                                                                                                                                                 |
| Effect Estimate per Comparison                                                                            | Comparison groups                                                                                                                                                                                            | LEB 250 mg Q4W vs PBO                                                                                                                                                                                        | LEB 250 mg Q4W vs PBO                                                                                                                                                                                        | LEB 250 mg Q2W vs PBO                                                                                                                                                                                        | LEB 250 mg Q2W vs PBO                                                                                                                                                                                        |
| Effect Estimate per Comparison                                                                            | LSM difference (95% CI)                                                                                                                                                                                      | -18.77 (7.5)                                                                                                                                                                                                 | -18.77 (7.5)                                                                                                                                                                                                 | -17.26 (7.7)                                                                                                                                                                                                 | -17.26 (7.7)                                                                                                                                                                                                 |
| Effect Estimate per Comparison                                                                            | p-value                                                                                                                                                                                                      | .012                                                                                                                                                                                                         | .012                                                                                                                                                                                                         | .025                                                                                                                                                                                                         | .025                                                                                                                                                                                                         |
| Maintenance Period - Results and Analysis - EASI 90 at Week 52                                            | Maintenance Period - Results and Analysis - EASI 90 at Week 52                                                                                                                                               | Maintenance Period - Results and Analysis - EASI 90 at Week 52                                                                                                                                               | Maintenance Period - Results and Analysis - EASI 90 at Week 52                                                                                                                                               | Maintenance Period - Results and Analysis - EASI 90 at Week 52                                                                                                                                               | Maintenance Period - Results and Analysis - EASI 90 at Week 52                                                                                                                                               |
| Analysis Description                                                                                      | Other endpoint: Percentage of participants with EASI 90 at Week 52 in the subset of participants who achieved EASI 75 and were randomly reassigned at Week 16 (EASI 90 calculated relative to baseline EASI) | Other endpoint: Percentage of participants with EASI 90 at Week 52 in the subset of participants who achieved EASI 75 and were randomly reassigned at Week 16 (EASI 90 calculated relative to baseline EASI) | Other endpoint: Percentage of participants with EASI 90 at Week 52 in the subset of participants who achieved EASI 75 and were randomly reassigned at Week 16 (EASI 90 calculated relative to baseline EASI) | Other endpoint: Percentage of participants with EASI 90 at Week 52 in the subset of participants who achieved EASI 75 and were randomly reassigned at Week 16 (EASI 90 calculated relative to baseline EASI) | Other endpoint: Percentage of participants with EASI 90 at Week 52 in the subset of participants who achieved EASI 75 and were randomly reassigned at Week 16 (EASI 90 calculated relative to baseline EASI) |
| Statistical model                                                                                         | Maintenance primary estimand (hybrid): CMH with MCMC-MI d                                                                                                                                                    | Maintenance primary estimand (hybrid): CMH with MCMC-MI d                                                                                                                                                    | Maintenance primary estimand (hybrid): CMH with MCMC-MI d                                                                                                                                                    | Maintenance primary estimand (hybrid): CMH with MCMC-MI d                                                                                                                                                    | Maintenance primary estimand (hybrid): CMH with MCMC-MI d                                                                                                                                                    |
| Descriptive statistics and estimate variability                                                           | Treatment group                                                                                                                                                                                              | PBO (LEB withdrawal)                                                                                                                                                                                         | LEB 250 mg Q4W                                                                                                                                                                                               | LEB 250 mg Q4W                                                                                                                                                                                               | LEB 250 mg Q2W                                                                                                                                                                                               |
| Descriptive statistics and estimate variability                                                           | Participants with EASI 75 at Week 16 (Nx)                                                                                                                                                                    | 30                                                                                                                                                                                                           | 62                                                                                                                                                                                                           | 62                                                                                                                                                                                                           | 61                                                                                                                                                                                                           |
| Descriptive statistics and estimate variability                                                           | Response, n (%)                                                                                                                                                                                              | 14 (45.2)                                                                                                                                                                                                    | 41 (66.6)                                                                                                                                                                                                    | 41 (66.6)                                                                                                                                                                                                    | 40 (66.1)                                                                                                                                                                                                    |
| Effect estimate per comparison                                                                            | Comparison groups                                                                                                                                                                                            | LEB 250 mg Q4W vs PBO                                                                                                                                                                                        | LEB 250 mg Q4W vs PBO                                                                                                                                                                                        | 250 mg Q2W vs PBO                                                                                                                                                                                            | 250 mg Q2W vs PBO                                                                                                                                                                                            |
| Effect estimate per comparison                                                                            | Common risk difference n, (95% CI)                                                                                                                                                                           | 21.4 (-1.2, 44.1)                                                                                                                                                                                            | 21.4 (-1.2, 44.1)                                                                                                                                                                                            | 20.2 (-2.9, 43.2)                                                                                                                                                                                            | 20.2 (-2.9, 43.2)                                                                                                                                                                                            |
| Effect estimate per comparison                                                                            | p-value                                                                                                                                                                                                      | .064                                                                                                                                                                                                         | .064                                                                                                                                                                                                         | .088                                                                                                                                                                                                         | .088                                                                                                                                                                                                         |
| Maintenance Week 16 Escape Population - Results and Analysis - IGA 0,1 and 2-Point Improvement at Week 52 | Maintenance Week 16 Escape Population - Results and Analysis - IGA 0,1 and 2-Point Improvement at Week 52                                                                                                    | Maintenance Week 16 Escape Population - Results and Analysis - IGA 0,1 and 2-Point Improvement at Week 52                                                                                                    | Maintenance Week 16 Escape Population - Results and Analysis - IGA 0,1 and 2-Point Improvement at Week 52                                                                                                    | Maintenance Week 16 Escape Population - Results and Analysis - IGA 0,1 and 2-Point Improvement at Week 52                                                                                                    | Maintenance Week 16 Escape Population - Results and Analysis - IGA 0,1 and 2-Point Improvement at Week 52                                                                                                    |
| Analysis Description                                                                                      | Other endpoint: Percentage of participants with IGA 0,1 and a ≥2 -point improvement at Week 52                                                                                                               | Other endpoint: Percentage of participants with IGA 0,1 and a ≥2 -point improvement at Week 52                                                                                                               | Other endpoint: Percentage of participants with IGA 0,1 and a ≥2 -point improvement at Week 52                                                                                                               | Other endpoint: Percentage of participants with IGA 0,1 and a ≥2 -point improvement at Week 52                                                                                                               | Other endpoint: Percentage of participants with IGA 0,1 and a ≥2 -point improvement at Week 52                                                                                                               |
| Statistical Model                                                                                         | Descriptive statistics with observed data                                                                                                                                                                    | Descriptive statistics with observed data                                                                                                                                                                    | Descriptive statistics with observed data                                                                                                                                                                    | Descriptive statistics with observed data                                                                                                                                                                    | Descriptive statistics with observed data                                                                                                                                                                    |
| Descriptive Statistics and Estimate Variability                                                           | Treatment group                                                                                                                                                                                              | PBO nonresponders to LEB 250 mg Q2W                                                                                                                                                                          | PBO nonresponders to LEB 250 mg Q2W                                                                                                                                                                          | LEB nonresponders to LEB 250 mg Q2W                                                                                                                                                                          | LEB nonresponders to LEB 250 mg Q2W                                                                                                                                                                          |
| Descriptive Statistics and Estimate Variability                                                           | Number of participants (Nx)                                                                                                                                                                                  | 76                                                                                                                                                                                                           | 76                                                                                                                                                                                                           | 77                                                                                                                                                                                                           | 77                                                                                                                                                                                                           |
| Descriptive Statistics and Estimate Variability                                                           | Response, n (%)                                                                                                                                                                                              | 42 (55.3)                                                                                                                                                                                                    | 42 (55.3)                                                                                                                                                                                                    | 30 (39.0)                                                                                                                                                                                                    | 30 (39.0)                                                                                                                                                                                                    |
| Maintenance Week 16 Escape Population - Results and Analysis - EASI 75 at Week 52                         | Maintenance Week 16 Escape Population - Results and Analysis - EASI 75 at Week 52                                                                                                                            | Maintenance Week 16 Escape Population - Results and Analysis - EASI 75 at Week 52                                                                                                                            | Maintenance Week 16 Escape Population - Results and Analysis - EASI 75 at Week 52                                                                                                                            | Maintenance Week 16 Escape Population - Results and Analysis - EASI 75 at Week 52                                                                                                                            | Maintenance Week 16 Escape Population - Results and Analysis - EASI 75 at Week 52                                                                                                                            |
| Analysis Description                                                                                      | Percentage of participants with EASI 75 at Week 52 (EASI 75 calculated relative to baseline EASI)                                                                                                            | Percentage of participants with EASI 75 at Week 52 (EASI 75 calculated relative to baseline EASI)                                                                                                            | Percentage of participants with EASI 75 at Week 52 (EASI 75 calculated relative to baseline EASI)                                                                                                            | Percentage of participants with EASI 75 at Week 52 (EASI 75 calculated relative to baseline EASI)                                                                                                            | Percentage of participants with EASI 75 at Week 52 (EASI 75 calculated relative to baseline EASI)                                                                                                            |
| Statistical Model                                                                                         | Descriptive statistics with observed data                                                                                                                                                                    | Descriptive statistics with observed data                                                                                                                                                                    | Descriptive statistics with observed data                                                                                                                                                                    | Descriptive statistics with observed data                                                                                                                                                                    | Descriptive statistics with observed data                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| Descriptive Statistics and Estimate Variability                                                            | Treatment group                                                                                                              | PBO nonresponders to LEB 250 mg Q2W                                                                                          | LEB nonresponders to LEB 250 mg Q2W                                                                                          |
|------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|
| Descriptive Statistics and Estimate Variability                                                            | Number of participants (Nx)                                                                                                  | 76                                                                                                                           | 77                                                                                                                           |
| Descriptive Statistics and Estimate Variability                                                            | Response, n (%)                                                                                                              | 66 (86.8)                                                                                                                    | 62 (80.5)                                                                                                                    |
| Maintenance Week 16 Escape Population - Results and Analysis - EASI 90 at Week 52                          | Maintenance Week 16 Escape Population - Results and Analysis - EASI 90 at Week 52                                            | Maintenance Week 16 Escape Population - Results and Analysis - EASI 90 at Week 52                                            | Maintenance Week 16 Escape Population - Results and Analysis - EASI 90 at Week 52                                            |
| Analysis Description                                                                                       | Other endpoint: Percentage of participants with EASI 90 at Week 52 (EASI 90 calculated relative to baseline EASI)            | Other endpoint: Percentage of participants with EASI 90 at Week 52 (EASI 90 calculated relative to baseline EASI)            | Other endpoint: Percentage of participants with EASI 90 at Week 52 (EASI 90 calculated relative to baseline EASI)            |
| Statistical Model                                                                                          | Descriptive statistics with observed data                                                                                    | Descriptive statistics with observed data                                                                                    | Descriptive statistics with observed data                                                                                    |
| Descriptive Statistics and Estimate Variability                                                            | Treatment group                                                                                                              | PBO nonresponders to LEB 250 mg Q2W                                                                                          | LEB nonresponders to LEB 250 mg Q2W                                                                                          |
| Descriptive Statistics and Estimate Variability                                                            | Number of participants (Nx)                                                                                                  | 76                                                                                                                           | 77                                                                                                                           |
| Descriptive Statistics and Estimate Variability                                                            | Response, n (%)                                                                                                              | 52 (68.4)                                                                                                                    | 38 (49.4)                                                                                                                    |
| Maintenance Week 16 Escape Population - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 52 | Maintenance Week 16 Escape Population - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 52                   | Maintenance Week 16 Escape Population - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 52                   | Maintenance Week 16 Escape Population - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 52                   |
| Analysis Description                                                                                       | Other endpoint: Percentage of participants with a pruritus NRS of ≥4 points at baseline with ≥4 - point reduction at Week 52 | Other endpoint: Percentage of participants with a pruritus NRS of ≥4 points at baseline with ≥4 - point reduction at Week 52 | Other endpoint: Percentage of participants with a pruritus NRS of ≥4 points at baseline with ≥4 - point reduction at Week 52 |
| Statistical Model                                                                                          | Descriptive statistics with observed data                                                                                    | Descriptive statistics with observed data                                                                                    | Descriptive statistics with observed data                                                                                    |
| Descriptive Statistics and Estimate Variability                                                            | Treatment group                                                                                                              | PBO nonresponders to LEB 250 mg Q2W                                                                                          | LEB nonresponders to LEB 250 mg Q2W                                                                                          |
| Descriptive Statistics and Estimate Variability                                                            | Number of participants (Nx)                                                                                                  | 73                                                                                                                           | 67                                                                                                                           |
| Descriptive Statistics and Estimate Variability                                                            | Response, n (%)                                                                                                              | 46 (63.0)                                                                                                                    | 52 (77.6)                                                                                                                    |

## Analyses

a  Primary estimand (hybrid), CMH-MCMC-MI: Participants who received any topical or systemic rescue medication, or discontinued treatment due to lack of efficacy had values set to their baseline value after this time through Week 16; MCMC-MI was used to handle the remaining missing data. CMH test stratified by geographic region, age group, and baseline IGA.

b   Primary  estimand (hybrid), ANCOVA with  MCMC-MI:  Participants  who  received any  topical  or  systemic  rescue medication, or discontinued  treatment due to lack of efficacy had values set to their baseline value after this time through Week 16; MCMC-MI was used to handle the remaining missing data. ANCOVA model adjusted for treatment group, baseline value, geographic region, age group, and baseline IGA.

c   Supportive  estimand  (hypothetical),  MMRM:  Data  after  topical  or  systemic  rescue  medication  or  treatment discontinuation  were  treated  as  missing  and  missing  data  were  handled  by  MMRM.  The  MMRM  model  includes treatment, baseline value, visit, the interaction of the baseline value-by-visit, the interaction of treatment-by-visit, and the stratification factors as fixed factors.

<div style=\"page-break-after: always\"></div>

- d   Maintenance  primary estimand (hybrid), CMH-MCMC-MI: Participants  who  received systemic rescue  medication, discontinued  treatment due to lack of efficacy, or transferred  to escape arm had values set to their baseline value after this time through Week 52; participants who received topical rescue medication or discontinued treatment due to other  reasons  had values set to missing; MCMC-MI  was  used to handle  the remaining missing  data. CMH test stratified by geographic region.
- e Maintenance  primary  estimand  (hybrid),  ANCOVA  with  MCMC-MI:  Participants  who  received  systemic  rescue medication, discontinued treatment due to lack of efficacy, or transferred to escape arm had values set to their baseline value after this time through Week 52; participants who received topical rescue medication or discontinued treatment due to other reasons had values set to missing; MCMC-MI was used to handle the remaining missing data. ANCOVA model adjusted for geographic region.

Abbreviations: ANCOVA  =  analysis  of  covariance;  CFB =  change from  baseline;  CI = confidence interval; CMH = Cochran-Mantel-Haenszel;  DLQI = Dermatology Life Quality Index; EASI  = Eczema  Area and  Severity Index; EASI 75 = at least 75% reduction in EASI; EASI 90 = at least 90% reduction in EASI; IGA = Investigator's Global Assessment;  LEB =  lebrikizumab; LSM =  least squares  mean; MCMC-MI = Markov  Chain  Monte  Carlo Multiple Imputation; MMRM = Mixed Model Repeated Measures; N = total number of participants; n = calculated number of participants experiencing endpoint; NRS = Numerical Rating Scale; Nx = number of participants in the analysis population; PBO = placebo; PCFB = percentage change from baseline; POEM = Patient Oriented Eczema Measure; Q2W = every 2 weeks; Q4W = every 4 weeks; SE = standard error; vs = versus; W= week.

## Table 52: Summary of Efficacy for Study KGAC

| Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS   | Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study Identifier                                                                                                                                                        | J2T-DM-KGAC; DRM06-AD05                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | J2T-DM-KGAC; DRM06-AD05                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Design                                                                                                                                                                  | Phase 3, randomised, double-blind, placebo-controlled, parallel-group study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Phase 3, randomised, double-blind, placebo-controlled, parallel-group study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|                                                                                                                                                                         | Duration of Induction Period Duration of Maintenance Period                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 16 weeks 36 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Treatment Groups                                                                                                                                                        | The study comprises 2 treatment periods: • Induction: Participants were randomly assigned 2:1 to LEB 500 mg loading dose at baseline and Week 2 then 250 mg Q2W or PBO. • Maintenance: Participants who were LEB responders were randomly assigned 2:2:1 to LEB 250 mg Q2W, LEB 250 mg Q4W, or PBO (LEB withdrawal). • Participants who achieved neither IGA 0,1 nor EASI 75 at Week 16 or who received rescue therapy from Baseline to Week 16 were assigned to an escape arm and received LEB 250 mg Q2W (following blinded 500 mg loading dose at Weeks 16 and 18 for participants who received PBO during Induction) as an open- label treatment through Week 52. | The study comprises 2 treatment periods: • Induction: Participants were randomly assigned 2:1 to LEB 500 mg loading dose at baseline and Week 2 then 250 mg Q2W or PBO. • Maintenance: Participants who were LEB responders were randomly assigned 2:2:1 to LEB 250 mg Q2W, LEB 250 mg Q4W, or PBO (LEB withdrawal). • Participants who achieved neither IGA 0,1 nor EASI 75 at Week 16 or who received rescue therapy from Baseline to Week 16 were assigned to an escape arm and received LEB 250 mg Q2W (following blinded 500 mg loading dose at Weeks 16 and 18 for participants who received PBO during Induction) as an open- label treatment through Week 52. |
| Hypothesis                                                                                                                                                              | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Induction Period                                                                                                                                                        | LEB Q2W subcutaneous injection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Randomised N = 295 LEB 500-mg at baseline and at Week 2 (loading dose), and LEB 250 mg Q2W from Week 4 through Week 14                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|                            | PBO Q2W subcutaneous injection                                             | PBO Q2W subcutaneous injection                  | Randomised N = 150 4-mL PBO at baseline and at Week 2, and 2-mL PBO Q2W from Week 4 through Week 14                                       |
|----------------------------|----------------------------------------------------------------------------|-------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| Maintenance Period         | Maintenance primary population (LEB responders)                            | Maintenance primary population (LEB responders) | Re-randomised N = 148 • LEB 250 mg Q2W (N = 30) • LEB 250 mg Q4W (N = 59) • PBO (LEB withdrawal) (N = 59)                                 |
| Maintenance Period         | Maintenance Week 16 Escape Population: Participants neither IGA at Week 16 | achieved nor EASI 75 used any                   | Assigned N = 233 Open-label LEB 250 mg Q2W through Week 52 • LEB 250 mg Q2W to LEB 250 mg Q2W (N = 125)                                   |
| Endpoints Induction Period | Coprimary endpoint                                                         | IGA 0,1                                         | Percentage of participants with an IGA score of 0 or 1 and a reduction ≥2 points from baseline to Week 16                                 |
| Endpoints Induction Period | Coprimary endpoint                                                         | EASI 75                                         | Percentage of participants achieving EASI 75 (at least 75% reduction from baseline in EASI) at Week 16                                    |
| Endpoints Induction Period | Major secondary endpoint                                                   | EASI 90, W16                                    | Percentage of participants achieving EASI 90 at least (≥90% reduction from baseline in EASI) at Week 16                                   |
| Endpoints Induction Period | Major secondary endpoint                                                   | EASI 90, W4                                     | Percentage of participants achieving EASI 90 at Week 4                                                                                    |
| Endpoints Induction Period | Major secondary endpoint                                                   | EASI PCFB                                       | Percentage change in EASI score from baseline to Week 16                                                                                  |
| Endpoints Induction Period | Major secondary endpoint                                                   | Pruritus NRS PCFB                               | Percentage change in pruritus NRS score from baseline to Week 16                                                                          |
| Endpoints Induction Period | Major secondary endpoint                                                   | Pruritus NRS 4 - point Improveme nt, W16        | Percentage of participants with a pruritus NRS score of ≥4 points at baseline who achieved a ≥4 -point reduction from baseline to Week 16 |
| Endpoints Induction Period | Major secondary endpoint                                                   | Pruritus NRS 4 - point Improveme nt, W4         | Percentage of participants with a pruritus NRS score of ≥4 points at baseline who achieved a ≥4 -point reduction from baseline to Week 4  |
| Endpoints Induction Period | Major secondary endpoint                                                   | Pruritus NRS 4 - point Improveme nt, W2         | Percentage of participants with a pruritus NRS of ≥4 points at baseline who achieve a ≥4 -point reduction from baseline to Week 2         |

<div style=\"page-break-after: always\"></div>

|                              | Major secondary endpoint   | DLQI CFB                           | CFB in DLQI total score at Week 16                                                                                                                                                                                                          |
|------------------------------|----------------------------|------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                              | Major secondary endpoint   | DLQI 4 - pt Improveme nt           | Percentage of participants with a DLQI total score of ≥4 points at baseline who achieve a ≥4 -point improvement from baseline to Week 16                                                                                                    |
|                              | Major secondary endpoint   | Sleep-Loss CFB                     | CFB in Sleep-Loss scale score at Week 16                                                                                                                                                                                                    |
|                              | Major secondary endpoint   | Sleep-Loss, 2 - point Improveme nt | Percentage of participants with a Sleep-Loss scale score ≥2 points at baseline who achieve a ≥2 -point reduction from baseline at Week 16                                                                                                   |
|                              | Other Endpoint             | POEM                               | CFB in POEM at Week 16                                                                                                                                                                                                                      |
| Endpoints Maintenance Period | Major secondary endpoint   | EASI 75                            | Percentage of participants having achieved EASI 75 at Week 16 who continued to experience EASI 75 at Week 52 (EASI 75 calculated relative to baseline EASI)                                                                                 |
| Endpoints Maintenance Period | Major secondary endpoint   | IGA 0,1                            | Percentage of participants from those randomly re- assigned, having achieved IGA 0,1 and a ≥2 -point improvement from baseline at Week 16 who continue to exhibit an IGA 0,1 and a ≥2 -point improvement from baseline at Week 52           |
| Endpoints Maintenance Period | Major secondary endpoint   | Pruritus 4-point Improveme nt      | Percentage of participants from those with a pruritus NRS of ≥4 -points at baseline randomly re-assigned, having achieved ≥4 -point reduction from baseline at Week 16 who continue to exhibit ≥4 -point reduction from baseline at Week 52 |
| Endpoints Maintenance Period | Major secondary endpoint   | EASI PCFB                          | Percentage change in EASI from baseline at Week 52 in the subset of participants who were randomly reassigned at Week 16                                                                                                                    |
| Endpoints Maintenance Period | Other endpoint             | EASI 90                            | Percentage of participants with EASI 90 at Week 52 in the subset of participants who achieved EASI 75 and randomly reassigned at Week 16 (EASI 90 calculated relative to baseline EASI)                                                     |
| Endpoints Maintenance        | Other endpoint             | IGA 0,1                            | Percentage of participants achieving an IGA score of 0 or 1 and a ≥2 -point improvement from baseline at Week 52                                                                                                                            |
| Escape Population            | Other endpoint             | EASI 75                            | Percentage of participants with EASI 75 at Week 52 (EASI 75 calculated relative to baseline EASI)                                                                                                                                           |
| Escape Population            | Other endpoint             | EASI 90                            | Percentage of participants with EASI 90 at Week 52 (EASI 90 calculated relative to baseline EASI)                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|                                                              | Other endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Pruritus NRS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Percentage of participants reporting a pruritus NRS score of ≥4 points at baseline with ≥4 -point reduction from baseline at Week 52                                                                                                                                                                                                                                                                                                                                                           | Percentage of participants reporting a pruritus NRS score of ≥4 points at baseline with ≥4 -point reduction from baseline at Week 52                                                                                                                                                                                                                                                                                                                                                           |
|--------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Multiplicity Adjustment                                      | Two families for alpha control were defined: 1 for induction and 1 for maintenance with each family-wise error rate at 0.05. For all primary and key secondary endpoints for Induction Period, a prespecified graphical multiple testing approach was implemented to control the overall Type I error rate at 2-sided alpha of 0.05. For all maintenance key secondary endpoints, a hierarchal testing scheme with a prespecified order was implemented with a family-wise error rate at 0.05. | Two families for alpha control were defined: 1 for induction and 1 for maintenance with each family-wise error rate at 0.05. For all primary and key secondary endpoints for Induction Period, a prespecified graphical multiple testing approach was implemented to control the overall Type I error rate at 2-sided alpha of 0.05. For all maintenance key secondary endpoints, a hierarchal testing scheme with a prespecified order was implemented with a family-wise error rate at 0.05. | Two families for alpha control were defined: 1 for induction and 1 for maintenance with each family-wise error rate at 0.05. For all primary and key secondary endpoints for Induction Period, a prespecified graphical multiple testing approach was implemented to control the overall Type I error rate at 2-sided alpha of 0.05. For all maintenance key secondary endpoints, a hierarchal testing scheme with a prespecified order was implemented with a family-wise error rate at 0.05. | Two families for alpha control were defined: 1 for induction and 1 for maintenance with each family-wise error rate at 0.05. For all primary and key secondary endpoints for Induction Period, a prespecified graphical multiple testing approach was implemented to control the overall Type I error rate at 2-sided alpha of 0.05. For all maintenance key secondary endpoints, a hierarchal testing scheme with a prespecified order was implemented with a family-wise error rate at 0.05. |
| Database Lock                                                | 03 May 2022                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 03 May 2022                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 03 May 2022                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 03 May 2022                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Induction Period - Results and Analysis - IGA 0,1 at Week 16 | Induction Period - Results and Analysis - IGA 0,1 at Week 16                                                                                                                                                                                                                                                                                                                                                                                                                                   | Induction Period - Results and Analysis - IGA 0,1 at Week 16                                                                                                                                                                                                                                                                                                                                                                                                                                   | Induction Period - Results and Analysis - IGA 0,1 at Week 16                                                                                                                                                                                                                                                                                                                                                                                                                                   | Induction Period - Results and Analysis - IGA 0,1 at Week 16                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Analysis Description                                         | Coprimary endpoint: Percentage of participants with an IGA score of 0 or 1 and a reduction of ≥2 points from baseline to Week 16                                                                                                                                                                                                                                                                                                                                                               | Coprimary endpoint: Percentage of participants with an IGA score of 0 or 1 and a reduction of ≥2 points from baseline to Week 16                                                                                                                                                                                                                                                                                                                                                               | Coprimary endpoint: Percentage of participants with an IGA score of 0 or 1 and a reduction of ≥2 points from baseline to Week 16                                                                                                                                                                                                                                                                                                                                                               | Coprimary endpoint: Percentage of participants with an IGA score of 0 or 1 and a reduction of ≥2 points from baseline to Week 16                                                                                                                                                                                                                                                                                                                                                               |
| Statistical Model                                            | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Descriptive Statistics and Estimate Variability              | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | PBO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | LEB 250 mg Q2W                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Descriptive Statistics and Estimate Variability              | Number of participants (Nx)                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Number of participants (Nx)                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 146                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 281                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Descriptive Statistics and Estimate Variability              | Response, n (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Response, n (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 16 (10.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 93 (33.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Effect Estimate per Comparison                               | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | LEB 250 mg Q2W versus PBO                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Effect Estimate per Comparison                               | Common risk difference (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Common risk difference (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Common risk difference (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 21.9 (14.2, 29.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Effect Estimate per Comparison                               | p-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | p-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | p-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | <.001                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Induction Period - Results and Analysis - EASI 75 at Week 16 | Induction Period - Results and Analysis - EASI 75 at Week 16                                                                                                                                                                                                                                                                                                                                                                                                                                   | Induction Period - Results and Analysis - EASI 75 at Week 16                                                                                                                                                                                                                                                                                                                                                                                                                                   | Induction Period - Results and Analysis - EASI 75 at Week 16                                                                                                                                                                                                                                                                                                                                                                                                                                   | Induction Period - Results and Analysis - EASI 75 at Week 16                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Analysis Description                                         | Coprimary endpoint: Percentage of participants achieving EASI 75 at least (≥75% reduction from baseline in EASI) at Week 16                                                                                                                                                                                                                                                                                                                                                                    | Coprimary endpoint: Percentage of participants achieving EASI 75 at least (≥75% reduction from baseline in EASI) at Week 16                                                                                                                                                                                                                                                                                                                                                                    | Coprimary endpoint: Percentage of participants achieving EASI 75 at least (≥75% reduction from baseline in EASI) at Week 16                                                                                                                                                                                                                                                                                                                                                                    | Coprimary endpoint: Percentage of participants achieving EASI 75 at least (≥75% reduction from baseline in EASI) at Week 16                                                                                                                                                                                                                                                                                                                                                                    |
| Statistical Model                                            | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Descriptive Statistics and Estimate Variability              | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | PBO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | LEB 250 mg Q2W                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Descriptive Statistics and Estimate Variability              | Number of participants (Nx)                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Number of participants (Nx)                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 146                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 281                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Descriptive Statistics and Estimate Variability              | Response, n (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Response, n (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 26 (18.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 146 (52.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Effect Estimates per Comparison                              | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | LEB 250 mg Q2W versus PBO                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Effect Estimates per Comparison                              | Common risk difference (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Common risk difference (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Common risk difference (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 33.3 (24.4, 42.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Effect Estimates per Comparison                              | p-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | p-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | p-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | <.001                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Induction Period - Results and Analysis - EASI 90 at Week 16 | Induction Period - Results and Analysis - EASI 90 at Week 16                                                                                                                                                                                                                                                                                                                                                                                                                                   | Induction Period - Results and Analysis - EASI 90 at Week 16                                                                                                                                                                                                                                                                                                                                                                                                                                   | Induction Period - Results and Analysis - EASI 90 at Week 16                                                                                                                                                                                                                                                                                                                                                                                                                                   | Induction Period - Results and Analysis - EASI 90 at Week 16                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Analysis Description                                         | Majorsecondary endpoint: Percentage of participants achieving EASI 90 at least (≥90% reduction from baseline in EASI) at Week 16                                                                                                                                                                                                                                                                                                                                                               | Majorsecondary endpoint: Percentage of participants achieving EASI 90 at least (≥90% reduction from baseline in EASI) at Week 16                                                                                                                                                                                                                                                                                                                                                               | Majorsecondary endpoint: Percentage of participants achieving EASI 90 at least (≥90% reduction from baseline in EASI) at Week 16                                                                                                                                                                                                                                                                                                                                                               | Majorsecondary endpoint: Percentage of participants achieving EASI 90 at least (≥90% reduction from baseline in EASI) at Week 16                                                                                                                                                                                                                                                                                                                                                               |
| Statistical Model                                            | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|                                                              | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | PBO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | LEB 250 mg Q2W                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| Descriptive Statistics and Estimate                         | Number of participants (Nx)                                                                | 146                                                                                        | 281                                                                                        |
|-------------------------------------------------------------|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|
| Variability                                                 | Response, n (%)                                                                            | 14 (9.5)                                                                                   | 86 (30.7)                                                                                  |
| Effect Estimate per Comparison                              | Comparison groups                                                                          | Comparison groups                                                                          | LEB 250 mg Q2W versus PBO                                                                  |
| Effect Estimate per Comparison                              | Common risk difference (95% CI)                                                            | Common risk difference (95% CI)                                                            | 20.7 (13.3, 28.1)                                                                          |
| Effect Estimate per Comparison                              | p-value                                                                                    | p-value                                                                                    | <.001                                                                                      |
| Induction Period - Results and Analysis - EASI 90 at Week 4 | Induction Period - Results and Analysis - EASI 90 at Week 4                                | Induction Period - Results and Analysis - EASI 90 at Week 4                                | Induction Period - Results and Analysis - EASI 90 at Week 4                                |
| Analysis Description                                        | Major secondary endpoint: Percentage of participants achieving EASI 90 at Week 4           | Major secondary endpoint: Percentage of participants achieving EASI 90 at Week 4           | Major secondary endpoint: Percentage of participants achieving EASI 90 at Week 4           |
| Statistical Model                                           | Primary estimand (hybrid): CMH with MCMC-MI a                                              | Primary estimand (hybrid): CMH with MCMC-MI a                                              | Primary estimand (hybrid): CMH with MCMC-MI a                                              |
| Descriptive Statistics and Estimate Variability             | Treatment group                                                                            | PBO                                                                                        | LEB 250 mg Q2W                                                                             |
| Descriptive Statistics and Estimate Variability             | Number of participants (Nx)                                                                | 146                                                                                        | 281                                                                                        |
| Descriptive Statistics and Estimate Variability             | Response, n (%)                                                                            | 2 (1.5)                                                                                    | 18 (6.3)                                                                                   |
| Effect Estimate per Comparison                              | Comparison groups                                                                          | Comparison groups                                                                          | LEB 250 mg Q2W versus PBO                                                                  |
| Effect Estimate per Comparison                              | Common risk difference (95% CI)                                                            | Common risk difference (95% CI)                                                            | 4.9 (1.4, 8.4)                                                                             |
| Effect Estimate per Comparison                              | p-value                                                                                    | p-value                                                                                    | .023                                                                                       |
| Induction Period - Results and Analysis - EASI PCFB         | Induction Period - Results and Analysis - EASI PCFB                                        | Induction Period - Results and Analysis - EASI PCFB                                        | Induction Period - Results and Analysis - EASI PCFB                                        |
| Analysis Description                                        | Major secondary endpoint: Percentage change in EASI score from baseline to Week 16         | Major secondary endpoint: Percentage change in EASI score from baseline to Week 16         | Major secondary endpoint: Percentage change in EASI score from baseline to Week 16         |
| Statistical Model                                           | Primary estimand (hybrid): ANCOVA with MCMC-MI b                                           | Primary estimand (hybrid): ANCOVA with MCMC-MI b                                           | Primary estimand (hybrid): ANCOVA with MCMC-MI b                                           |
| Descriptive Statistics and Estimate Variability             | Treatment group                                                                            | PBO                                                                                        | LEB 250 mg Q2W                                                                             |
| Descriptive Statistics and Estimate Variability             | Number of participants (Nx)                                                                | 146                                                                                        | 281                                                                                        |
| Descriptive Statistics and Estimate Variability             | LSM (SE)                                                                                   | -28.0 (3.9)                                                                                | -61.5 (3.3)                                                                                |
| Effect Estimate per Comparison                              | Comparison groups                                                                          | Comparison groups                                                                          | LEB 250 mg Q2W versus PBO                                                                  |
| Effect Estimate per Comparison                              | LSM difference (95% CI)                                                                    | LSM difference (95% CI)                                                                    | -33.6 (-41.2, -26.0)                                                                       |
| Effect Estimate per Comparison                              | p-value                                                                                    | p-value                                                                                    | <.001                                                                                      |
| Induction Period - Results and Analysis - Pruritus NRS PCFB | Induction Period - Results and Analysis - Pruritus NRS PCFB                                | Induction Period - Results and Analysis - Pruritus NRS PCFB                                | Induction Period - Results and Analysis - Pruritus NRS PCFB                                |
| Analysis Description                                        | Major secondary endpoint: Percentage change in pruritus NRS score from baseline to Week 16 | Major secondary endpoint: Percentage change in pruritus NRS score from baseline to Week 16 | Major secondary endpoint: Percentage change in pruritus NRS score from baseline to Week 16 |
| Statistical Model                                           | Primary estimand (hybrid): ANCOVA with MCMC-MI b                                           | Primary estimand (hybrid): ANCOVA with MCMC-MI b                                           | Primary estimand (hybrid): ANCOVA with MCMC-MI b                                           |
| Statistical Model                                           | Treatment group                                                                            | PBO                                                                                        | LEB 250 mg Q2W                                                                             |

<div style=\"page-break-after: always\"></div>

| Descriptive Statistics and Estimate Variability                                       | Number of participants in the mITT population with baseline Pruritis NRS score >0 (Nx)                                                                              | 143                                                                                                                                                                 | 268                                                                                                                                                                 |
|---------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Descriptive Statistics and Estimate Variability                                       | LSM (SE)                                                                                                                                                            | -9.0 (3.9)                                                                                                                                                          | -36.6 (3.3)                                                                                                                                                         |
| Effect Estimate per Comparison                                                        | Comparison groups                                                                                                                                                   | Comparison groups                                                                                                                                                   | LEB 250 mg Q2W versus PBO                                                                                                                                           |
| Effect Estimate per Comparison                                                        | LSM difference (95% CI)                                                                                                                                             | LSM difference (95% CI)                                                                                                                                             | -27.5 (-34.9, -20.2)                                                                                                                                                |
| Effect Estimate per Comparison                                                        | p-value                                                                                                                                                             | p-value                                                                                                                                                             | <.001                                                                                                                                                               |
| Induction Period - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 16 | Induction Period - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 16                                                                               | Induction Period - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 16                                                                               | Induction Period - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 16                                                                               |
| Analysis Description                                                                  | Major secondary endpoint: Percentage of participants with a pruritus NRS score of ≥4 points at baseline who achieved a ≥4 -point reduction from baseline to Week 16 | Major secondary endpoint: Percentage of participants with a pruritus NRS score of ≥4 points at baseline who achieved a ≥4 -point reduction from baseline to Week 16 | Major secondary endpoint: Percentage of participants with a pruritus NRS score of ≥4 points at baseline who achieved a ≥4 -point reduction from baseline to Week 16 |
| Statistical Model                                                                     | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                       | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                       | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                       |
| Descriptive Statistics and Estimate Variability                                       | Treatment group                                                                                                                                                     | PBO                                                                                                                                                                 | LEB 250 mg Q2W                                                                                                                                                      |
| Descriptive Statistics and Estimate Variability                                       | Number of participants in the mITT population with a baseline pruritus NRS score ≥4 (Nx)                                                                            | 134                                                                                                                                                                 | 253                                                                                                                                                                 |
| Descriptive Statistics and Estimate Variability                                       | Response, n (%)                                                                                                                                                     | 15 (11.5)                                                                                                                                                           | 101 (39.8)                                                                                                                                                          |
| Effect Estimate per Comparison                                                        | Comparison groups                                                                                                                                                   | LEB 250 mg Q2W versus PBO                                                                                                                                           | LEB 250 mg Q2W versus PBO                                                                                                                                           |
| Effect Estimate per Comparison                                                        | Common risk difference (95% CI)                                                                                                                                     | 28.3 (20.0, 36.5)                                                                                                                                                   | 28.3 (20.0, 36.5)                                                                                                                                                   |
| Effect Estimate per Comparison                                                        | p-value                                                                                                                                                             | <.001                                                                                                                                                               | <.001                                                                                                                                                               |
| Induction Period - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 4  | Induction Period - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 4                                                                                | Induction Period - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 4                                                                                | Induction Period - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 4                                                                                |
| Analysis Description                                                                  | Major secondary endpoint: Percentage of participants with a pruritus NRS score of ≥4 points at baseline who achieved a ≥4 -point reduction from baseline to Week 4  | Major secondary endpoint: Percentage of participants with a pruritus NRS score of ≥4 points at baseline who achieved a ≥4 -point reduction from baseline to Week 4  | Major secondary endpoint: Percentage of participants with a pruritus NRS score of ≥4 points at baseline who achieved a ≥4 -point reduction from baseline to Week 4  |
| Statistical Model                                                                     | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                       | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                       | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                       |
| Descriptive Statistics and Estimate Variability                                       | Treatment group                                                                                                                                                     | PBO                                                                                                                                                                 | LEB 250 mg Q2W                                                                                                                                                      |
| Descriptive Statistics and Estimate Variability                                       | Number of participants in the mITT population with a baseline pruritus NRS score ≥4 (Nx)                                                                            | 134                                                                                                                                                                 | 253                                                                                                                                                                 |
| Descriptive Statistics and Estimate Variability                                       | Response, n (%)                                                                                                                                                     | 4 (3.0)                                                                                                                                                             | 42 (16.8)                                                                                                                                                           |
| Effect Estimate per Comparison                                                        | Comparison groups                                                                                                                                                   | LEB 250 mg Q2W versus PBO                                                                                                                                           | LEB 250 mg Q2W versus PBO                                                                                                                                           |
| Effect Estimate per Comparison                                                        | Common risk difference (95% CI)                                                                                                                                     | 13.2 (7.7, 18.7)                                                                                                                                                    | 13.2 (7.7, 18.7)                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                                                                                      | p-value                                                                                                                                                            | <.001                                                                                                                                                              | <.001                                                                                                                                                              |
|--------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Induction Period - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 2 | Induction Period - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 2                                                                               | Induction Period - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 2                                                                               | Induction Period - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 2                                                                               |
| Analysis Description                                                                 | Major secondary endpoint: Percentage of participants with a Pruritus NRS of ≥4 points at baseline who achieve a ≥4 -point reduction from baseline to Week 2        | Major secondary endpoint: Percentage of participants with a Pruritus NRS of ≥4 points at baseline who achieve a ≥4 -point reduction from baseline to Week 2        | Major secondary endpoint: Percentage of participants with a Pruritus NRS of ≥4 points at baseline who achieve a ≥4 -point reduction from baseline to Week 2        |
| Statistical Model                                                                    | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                      | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                      | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                      |
| Descriptive Statistics and Estimate Variability                                      | Treatment group                                                                                                                                                    | PBO                                                                                                                                                                | LEB 250 mg Q2W                                                                                                                                                     |
| Descriptive Statistics and Estimate Variability                                      | Number of participants in the mITT population with a baseline pruritus NRS score ≥4 (Nx)                                                                           | 134                                                                                                                                                                | 253                                                                                                                                                                |
| Descriptive Statistics and Estimate Variability                                      | Response, n (%)                                                                                                                                                    | 1 (0.7)                                                                                                                                                            | 9 (3.6)                                                                                                                                                            |
| Effect Estimate per Comparison                                                       | Comparison groups                                                                                                                                                  | LEB 250 mg Q2W versus PBO                                                                                                                                          | LEB 250 mg Q2W versus PBO                                                                                                                                          |
| Effect Estimate per Comparison                                                       | Common risk difference (95% CI)                                                                                                                                    | 2.7 (-0.1, 5.4)                                                                                                                                                    | 2.7 (-0.1, 5.4)                                                                                                                                                    |
| Effect Estimate per Comparison                                                       | p-value                                                                                                                                                            | .113                                                                                                                                                               | .113                                                                                                                                                               |
| Induction Period - Results and Analysis - DLQI CFB                                   | Induction Period - Results and Analysis - DLQI CFB                                                                                                                 | Induction Period - Results and Analysis - DLQI CFB                                                                                                                 | Induction Period - Results and Analysis - DLQI CFB                                                                                                                 |
| Analysis Description                                                                 | Major secondary endpoint: CFB in DLQI total score at Week 16                                                                                                       | Major secondary endpoint: CFB in DLQI total score at Week 16                                                                                                       | Major secondary endpoint: CFB in DLQI total score at Week 16                                                                                                       |
| Statistical Model                                                                    | Primary estimand (hybrid): ANCOVA with MCMC-MI b                                                                                                                   | Primary estimand (hybrid): ANCOVA with MCMC-MI b                                                                                                                   | Primary estimand (hybrid): ANCOVA with MCMC-MI b                                                                                                                   |
| Descriptive Statistics and Estimate Variability                                      | Treatment group                                                                                                                                                    | PBO                                                                                                                                                                | LEB 250 mg Q2W                                                                                                                                                     |
| Descriptive Statistics and Estimate Variability                                      | Number of participants in the mITT population with non-missing baseline DLQI score (Nx)                                                                            | 118                                                                                                                                                                | 218                                                                                                                                                                |
| Descriptive Statistics and Estimate Variability                                      | LSM (SE)                                                                                                                                                           | -2.4 (1.2)                                                                                                                                                         | -7.3 (1.2)                                                                                                                                                         |
| Effect Estimate per Comparison                                                       | Comparison groups                                                                                                                                                  | LEB 250 mg Q2W versus PBO                                                                                                                                          | LEB 250 mg Q2W versus PBO                                                                                                                                          |
| Effect Estimate per Comparison                                                       | LSM difference (95% CI)                                                                                                                                            | -4.9 (-6.3, -3.5)                                                                                                                                                  | -4.9 (-6.3, -3.5)                                                                                                                                                  |
| Effect Estimate per Comparison                                                       | p-value                                                                                                                                                            | <.001                                                                                                                                                              | <.001                                                                                                                                                              |
| Induction Period - Results and Analysis - DLQI 4-Point Improvement at Week 16        | Induction Period - Results and Analysis - DLQI 4-Point Improvement at Week 16                                                                                      | Induction Period - Results and Analysis - DLQI 4-Point Improvement at Week 16                                                                                      | Induction Period - Results and Analysis - DLQI 4-Point Improvement at Week 16                                                                                      |
| Analysis Description                                                                 | Major secondary endpoint: Percentage of participants with a DLQI Total Score of ≥4 points at baseline who achieve a ≥4 -point improvement from baseline to Week 16 | Major secondary endpoint: Percentage of participants with a DLQI Total Score of ≥4 points at baseline who achieve a ≥4 -point improvement from baseline to Week 16 | Major secondary endpoint: Percentage of participants with a DLQI Total Score of ≥4 points at baseline who achieve a ≥4 -point improvement from baseline to Week 16 |
| Statistical Model                                                                    | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                      | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                      | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                      |
| Descriptive Statistics and Estimate Variability                                      | Treatment group                                                                                                                                                    | PBO                                                                                                                                                                | LEB 250 mg Q2W                                                                                                                                                     |
| Descriptive Statistics and Estimate Variability                                      | Number of participants in the mITT population with a baseline DLQI score of ≥4 points (Nx)                                                                         | 115                                                                                                                                                                | 215                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|                                                                                                 | Response, n (%)                                                                                                                                                       | 39 (33.6)                                                                                                                                                             | 143 (66.3)                                                                                                                                                            |
|-------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Effect Estimate per Comparison                                                                  | Comparison groups                                                                                                                                                     | Comparison groups                                                                                                                                                     | LEB 250 mg Q2W versus PBO                                                                                                                                             |
| Effect Estimate per Comparison                                                                  | Common risk difference (95% CI)                                                                                                                                       | Common risk difference (95% CI)                                                                                                                                       | 33.0 (22.2, 43.8)                                                                                                                                                     |
| Effect Estimate per Comparison                                                                  | p-value                                                                                                                                                               | p-value                                                                                                                                                               | <.001                                                                                                                                                                 |
| Induction Period - Results and Analysis - Sleep-Loss Scale Score 2-Point Improvement at Week 16 | Induction Period - Results and Analysis - Sleep-Loss Scale Score 2-Point Improvement at Week 16                                                                       | Induction Period - Results and Analysis - Sleep-Loss Scale Score 2-Point Improvement at Week 16                                                                       | Induction Period - Results and Analysis - Sleep-Loss Scale Score 2-Point Improvement at Week 16                                                                       |
| Analysis Description                                                                            | Major secondary endpoint: Percentage of participants with a Sleep- Loss scale score ≥2 points at baseline who achieved a ≥2 -point reduction from baseline at Week 16 | Major secondary endpoint: Percentage of participants with a Sleep- Loss scale score ≥2 points at baseline who achieved a ≥2 -point reduction from baseline at Week 16 | Major secondary endpoint: Percentage of participants with a Sleep- Loss scale score ≥2 points at baseline who achieved a ≥2 -point reduction from baseline at Week 16 |
| Statistical Model                                                                               | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                         | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                         | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                         |
| Descriptive Statistics and Estimate Variability                                                 | Treatment group                                                                                                                                                       | PBO                                                                                                                                                                   | LEB 250 mg Q2W                                                                                                                                                        |
| Descriptive Statistics and Estimate Variability                                                 | Number of participants in the mITT population with baseline Sleep-Loss scale score of ≥2 points (Nx)                                                                  | 97                                                                                                                                                                    | 161                                                                                                                                                                   |
| Descriptive Statistics and Estimate Variability                                                 | Response, n (%)                                                                                                                                                       | 8 (8.2)                                                                                                                                                               | 45 (28.0)                                                                                                                                                             |
| Effect Estimate per Comparison                                                                  | Comparison groups                                                                                                                                                     | Comparison groups                                                                                                                                                     | LEB 250 mg Q2W versus PBO                                                                                                                                             |
| Effect Estimate per Comparison                                                                  | Common risk difference (95% CI)                                                                                                                                       | Common risk difference (95% CI)                                                                                                                                       | 18.9 (9.6, 28.1)                                                                                                                                                      |
| Effect Estimate per Comparison                                                                  | p-value                                                                                                                                                               | p-value                                                                                                                                                               | <.001                                                                                                                                                                 |
| Induction Period - Results and Analysis - Sleep-Loss Scale Score CFB                            | Induction Period - Results and Analysis - Sleep-Loss Scale Score CFB                                                                                                  | Induction Period - Results and Analysis - Sleep-Loss Scale Score CFB                                                                                                  | Induction Period - Results and Analysis - Sleep-Loss Scale Score CFB                                                                                                  |
| Analysis Description                                                                            | Major secondary endpoint: CFB in Sleep-Loss Scale score at Week 16                                                                                                    | Major secondary endpoint: CFB in Sleep-Loss Scale score at Week 16                                                                                                    | Major secondary endpoint: CFB in Sleep-Loss Scale score at Week 16                                                                                                    |
| Statistical Model                                                                               | Primary estimand (hybrid): ANCOVA with MCMC-MI b                                                                                                                      | Primary estimand (hybrid): ANCOVA with MCMC-MI b                                                                                                                      | Primary estimand (hybrid): ANCOVA with MCMC-MI b                                                                                                                      |
| Descriptive Statistics and Estimate Variability                                                 | Treatment group                                                                                                                                                       | PBO                                                                                                                                                                   | LEB 250 mg Q2W                                                                                                                                                        |
| Descriptive Statistics and Estimate Variability                                                 | Number of participants in the mITT population with non-missing baseline Sleep-Loss scale score (Nx)                                                                   | 143                                                                                                                                                                   | 268                                                                                                                                                                   |
| Descriptive Statistics and Estimate Variability                                                 | LSM (SE)                                                                                                                                                              | -0.4 (0.1)                                                                                                                                                            | -1.1 (0.1)                                                                                                                                                            |
| Effect Estimate per Comparison                                                                  | Comparison groups                                                                                                                                                     | Comparison groups                                                                                                                                                     | LEB 250 mg Q2W versus PBO                                                                                                                                             |
| Effect Estimate per Comparison                                                                  | LSM difference (95% CI)                                                                                                                                               | LSM difference (95% CI)                                                                                                                                               | -0.7 (-0.9, -0.5)                                                                                                                                                     |
| Effect Estimate per Comparison                                                                  | p-value                                                                                                                                                               | p-value                                                                                                                                                               | <.001                                                                                                                                                                 |
| Induction Period - Results and Analysis - POEM CFB                                              | Induction Period - Results and Analysis - POEM CFB                                                                                                                    | Induction Period - Results and Analysis - POEM CFB                                                                                                                    | Induction Period - Results and Analysis - POEM CFB                                                                                                                    |
| Analysis Description                                                                            | Other endpoint: CFB in POEM at Week 16                                                                                                                                | Other endpoint: CFB in POEM at Week 16                                                                                                                                | Other endpoint: CFB in POEM at Week 16                                                                                                                                |
| Statistical Model                                                                               | Supportive estimand for continuous endpoints (hypothetical): MMRM c                                                                                                   | Supportive estimand for continuous endpoints (hypothetical): MMRM c                                                                                                   | Supportive estimand for continuous endpoints (hypothetical): MMRM c                                                                                                   |
| Statistical Model                                                                               | Treatment group                                                                                                                                                       | PBO                                                                                                                                                                   | LEB 250 mg Q2W                                                                                                                                                        |
| Statistical Model                                                                               | Number of participants (Nx)                                                                                                                                           | 141                                                                                                                                                                   | 266                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| Descriptive Statistics and Estimate Variability                | LSM (SE)                                                                                                                                                                                                                                                                                         | -3.5 (0.8)                                                                                                                                                                                                                                                                                       | -9.5 (0.5)                                                                                                                                                                                                                                                                                       | -9.5 (0.5)                                                                                                                                                                                                                                                                                       |
|----------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Effect Estimate per Comparison                                 | Comparison groups                                                                                                                                                                                                                                                                                | Comparison groups                                                                                                                                                                                                                                                                                | LEB 250 mg Q2W versus PBO                                                                                                                                                                                                                                                                        | LEB 250 mg Q2W versus PBO                                                                                                                                                                                                                                                                        |
| Effect Estimate per Comparison                                 | LSM difference (SE)                                                                                                                                                                                                                                                                              | LSM difference (SE)                                                                                                                                                                                                                                                                              | -6.0 (0.9)                                                                                                                                                                                                                                                                                       | -6.0 (0.9)                                                                                                                                                                                                                                                                                       |
| Effect Estimate per Comparison                                 | p-value                                                                                                                                                                                                                                                                                          | p-value                                                                                                                                                                                                                                                                                          | <.001                                                                                                                                                                                                                                                                                            | <.001                                                                                                                                                                                                                                                                                            |
| Maintenance Period - Results and Analysis - EASI 75 at Week 52 | Maintenance Period - Results and Analysis - EASI 75 at Week 52                                                                                                                                                                                                                                   | Maintenance Period - Results and Analysis - EASI 75 at Week 52                                                                                                                                                                                                                                   | Maintenance Period - Results and Analysis - EASI 75 at Week 52                                                                                                                                                                                                                                   | Maintenance Period - Results and Analysis - EASI 75 at Week 52                                                                                                                                                                                                                                   |
| Analysis Description                                           | Maintenance major secondary endpoint: Percentage of participants from those randomly reassigned, having achieved EASI 75 at Week 16 who continued to exhibit EASI 75 at Week 52 (EASI 75 calculated relative to baseline EASI)                                                                   | Maintenance major secondary endpoint: Percentage of participants from those randomly reassigned, having achieved EASI 75 at Week 16 who continued to exhibit EASI 75 at Week 52 (EASI 75 calculated relative to baseline EASI)                                                                   | Maintenance major secondary endpoint: Percentage of participants from those randomly reassigned, having achieved EASI 75 at Week 16 who continued to exhibit EASI 75 at Week 52 (EASI 75 calculated relative to baseline EASI)                                                                   | Maintenance major secondary endpoint: Percentage of participants from those randomly reassigned, having achieved EASI 75 at Week 16 who continued to exhibit EASI 75 at Week 52 (EASI 75 calculated relative to baseline EASI)                                                                   |
| Statistical Model                                              | Maintenance primary estimand (hybrid): CMH with MCMC-MI d                                                                                                                                                                                                                                        | Maintenance primary estimand (hybrid): CMH with MCMC-MI d                                                                                                                                                                                                                                        | Maintenance primary estimand (hybrid): CMH with MCMC-MI d                                                                                                                                                                                                                                        | Maintenance primary estimand (hybrid): CMH with MCMC-MI d                                                                                                                                                                                                                                        |
| Descriptive Statistics and Estimate Variability                | Treatment group                                                                                                                                                                                                                                                                                  | PBO                                                                                                                                                                                                                                                                                              | LEB 250 mg Q4W                                                                                                                                                                                                                                                                                   | LEB 250 mg Q2W                                                                                                                                                                                                                                                                                   |
| Descriptive Statistics and Estimate Variability                | Participants with EASI 75 at Week 16 (Nx)                                                                                                                                                                                                                                                        | 27                                                                                                                                                                                                                                                                                               | 53                                                                                                                                                                                                                                                                                               | 51                                                                                                                                                                                                                                                                                               |
| Descriptive Statistics and Estimate Variability                | Response, n (%)                                                                                                                                                                                                                                                                                  | 19 (72.0)                                                                                                                                                                                                                                                                                        | 45 (84.7)                                                                                                                                                                                                                                                                                        | 39 (77.4)                                                                                                                                                                                                                                                                                        |
| Effect Estimate per Comparison                                 | Comparison groups                                                                                                                                                                                                                                                                                | LEB 250 mg Q4W vs PBO                                                                                                                                                                                                                                                                            | LEB 250 mg Q2W vs PBO                                                                                                                                                                                                                                                                            | LEB 250 mg Q2W vs PBO                                                                                                                                                                                                                                                                            |
| Effect Estimate per Comparison                                 | Common risk difference n, (95% CI)                                                                                                                                                                                                                                                               | 12.8 (-9.5, 35.1)                                                                                                                                                                                                                                                                                | 4.8 (-17.8, 27.3)                                                                                                                                                                                                                                                                                | 4.8 (-17.8, 27.3)                                                                                                                                                                                                                                                                                |
| Effect Estimate per Comparison                                 | p-value                                                                                                                                                                                                                                                                                          | .238                                                                                                                                                                                                                                                                                             | .612                                                                                                                                                                                                                                                                                             | .612                                                                                                                                                                                                                                                                                             |
| Maintenance Period - Results and Analysis - IGA 0,1 at Week 52 | Maintenance Period - Results and Analysis - IGA 0,1 at Week 52                                                                                                                                                                                                                                   | Maintenance Period - Results and Analysis - IGA 0,1 at Week 52                                                                                                                                                                                                                                   | Maintenance Period - Results and Analysis - IGA 0,1 at Week 52                                                                                                                                                                                                                                   | Maintenance Period - Results and Analysis - IGA 0,1 at Week 52                                                                                                                                                                                                                                   |
| Analysis Description                                           | Maintenance major secondary endpoint: Percentage of participants from those randomly reassigned having achieved an IGA score of 0 or 1 and a ≥2 -point improvement from baseline at Week 16 who continued to exhibit an IGA score of 0 or 1 and a ≥2 -point improvement from baseline at Week 52 | Maintenance major secondary endpoint: Percentage of participants from those randomly reassigned having achieved an IGA score of 0 or 1 and a ≥2 -point improvement from baseline at Week 16 who continued to exhibit an IGA score of 0 or 1 and a ≥2 -point improvement from baseline at Week 52 | Maintenance major secondary endpoint: Percentage of participants from those randomly reassigned having achieved an IGA score of 0 or 1 and a ≥2 -point improvement from baseline at Week 16 who continued to exhibit an IGA score of 0 or 1 and a ≥2 -point improvement from baseline at Week 52 | Maintenance major secondary endpoint: Percentage of participants from those randomly reassigned having achieved an IGA score of 0 or 1 and a ≥2 -point improvement from baseline at Week 16 who continued to exhibit an IGA score of 0 or 1 and a ≥2 -point improvement from baseline at Week 52 |
| Statistical Model                                              | Maintenance primary estimand (hybrid): CMH with MCMC-MI d                                                                                                                                                                                                                                        | Maintenance primary estimand (hybrid): CMH with MCMC-MI d                                                                                                                                                                                                                                        | Maintenance primary estimand (hybrid): CMH with MCMC-MI d                                                                                                                                                                                                                                        | Maintenance primary estimand (hybrid): CMH with MCMC-MI d                                                                                                                                                                                                                                        |
| Descriptive Statistics and Estimate Variability                | Treatment group                                                                                                                                                                                                                                                                                  | PBO (LEB withdrawal)                                                                                                                                                                                                                                                                             | LEB 250 mg Q4W                                                                                                                                                                                                                                                                                   | LEB 250 mg Q2W                                                                                                                                                                                                                                                                                   |
| Descriptive Statistics and Estimate Variability                | Participants with IGA 0,1 at W16 (Nx)                                                                                                                                                                                                                                                            | 16                                                                                                                                                                                                                                                                                               | 32                                                                                                                                                                                                                                                                                               | 32                                                                                                                                                                                                                                                                                               |
| Descriptive Statistics and Estimate Variability                | Response, n (%)                                                                                                                                                                                                                                                                                  | 8 (49.8)                                                                                                                                                                                                                                                                                         | 26 (80.6)                                                                                                                                                                                                                                                                                        | 21 (64.6)                                                                                                                                                                                                                                                                                        |
| Effect Estimate per Comparison                                 | Comparison groups                                                                                                                                                                                                                                                                                | LEB 250 mg Q4W vs PBO                                                                                                                                                                                                                                                                            | LEB 250 mg Q2W vs PBO                                                                                                                                                                                                                                                                            | LEB 250 mg Q2W vs PBO                                                                                                                                                                                                                                                                            |
| Effect Estimate per Comparison                                 | Common risk difference n, (95% CI)                                                                                                                                                                                                                                                               | 32.6 (2.6, 62.5)                                                                                                                                                                                                                                                                                 | 13.4 (-17.5, 44.3)                                                                                                                                                                                                                                                                               | 13.4 (-17.5, 44.3)                                                                                                                                                                                                                                                                               |
| Effect Estimate per Comparison                                 | p-value                                                                                                                                                                                                                                                                                          | .034                                                                                                                                                                                                                                                                                             | .407                                                                                                                                                                                                                                                                                             | .407                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| Maintenance Period - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 52   | Maintenance Period - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 52                                                                                                                                                                                        | Maintenance Period - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 52                                                                                                                                                                                        | Maintenance Period - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 52                                                                                                                                                                                        | Maintenance Period - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 52                                                                                                                                                                                        |
|-------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Analysis Description                                                                      | Maintenance major secondary endpoint: Percentage of participants with a pruritus NRS score of ≥4 - points at baseline randomly reassigned, having achieved ≥4 -point reduction from baseline at Week 16, who continued to exhibit ≥4 -point reduction from baseline at Week 52 | Maintenance major secondary endpoint: Percentage of participants with a pruritus NRS score of ≥4 - points at baseline randomly reassigned, having achieved ≥4 -point reduction from baseline at Week 16, who continued to exhibit ≥4 -point reduction from baseline at Week 52 | Maintenance major secondary endpoint: Percentage of participants with a pruritus NRS score of ≥4 - points at baseline randomly reassigned, having achieved ≥4 -point reduction from baseline at Week 16, who continued to exhibit ≥4 -point reduction from baseline at Week 52 | Maintenance major secondary endpoint: Percentage of participants with a pruritus NRS score of ≥4 - points at baseline randomly reassigned, having achieved ≥4 -point reduction from baseline at Week 16, who continued to exhibit ≥4 -point reduction from baseline at Week 52 |
| Statistical Model                                                                         | Maintenance primary estimand (hybrid): CMH with MCMC-MI d                                                                                                                                                                                                                      | Maintenance primary estimand (hybrid): CMH with MCMC-MI d                                                                                                                                                                                                                      | Maintenance primary estimand (hybrid): CMH with MCMC-MI d                                                                                                                                                                                                                      | Maintenance primary estimand (hybrid): CMH with MCMC-MI d                                                                                                                                                                                                                      |
| Descriptive Statistics and Estimate Variability                                           | Treatment group                                                                                                                                                                                                                                                                | PBO (LEB withdrawal)                                                                                                                                                                                                                                                           | LEB 250 mg Q4W                                                                                                                                                                                                                                                                 | LEB 250 mg Q2W                                                                                                                                                                                                                                                                 |
| Descriptive Statistics and Estimate Variability                                           | Participants with pruritus NRS 4-point improvement at W16 (Nx)                                                                                                                                                                                                                 | 11                                                                                                                                                                                                                                                                             | 36                                                                                                                                                                                                                                                                             | 23                                                                                                                                                                                                                                                                             |
| Descriptive Statistics and Estimate Variability                                           | Response, n (%)                                                                                                                                                                                                                                                                | 7 (67.6)                                                                                                                                                                                                                                                                       | 32 (88.1)                                                                                                                                                                                                                                                                      | 21 (90.3)                                                                                                                                                                                                                                                                      |
| Effect Estimate per Comparison                                                            | Comparison groups                                                                                                                                                                                                                                                              | LEB 250 mg Q4W vs PBO                                                                                                                                                                                                                                                          | LEB 250 mg Q2W vs PBO                                                                                                                                                                                                                                                          | LEB 250 mg Q2W vs PBO                                                                                                                                                                                                                                                          |
| Effect Estimate per Comparison                                                            | Common risk difference n, (95% CI)                                                                                                                                                                                                                                             | 20.3 (-11.4, 52.0)                                                                                                                                                                                                                                                             | 20.4 (-10.6, 51.4)                                                                                                                                                                                                                                                             | 20.4 (-10.6, 51.4)                                                                                                                                                                                                                                                             |
| Effect Estimate per Comparison                                                            | p-value                                                                                                                                                                                                                                                                        | .159                                                                                                                                                                                                                                                                           | .165                                                                                                                                                                                                                                                                           | .165                                                                                                                                                                                                                                                                           |
| Maintenance Period - Results and Analysis - EASI PCFB                                     | Maintenance Period - Results and Analysis - EASI PCFB                                                                                                                                                                                                                          | Maintenance Period - Results and Analysis - EASI PCFB                                                                                                                                                                                                                          | Maintenance Period - Results and Analysis - EASI PCFB                                                                                                                                                                                                                          | Maintenance Period - Results and Analysis - EASI PCFB                                                                                                                                                                                                                          |
| Analysis Description                                                                      | Maintenance major secondary endpoint: Percentage change in EASI from baseline at Week 52 in the subset of participants who were those randomly reassigned at Week 16                                                                                                           | Maintenance major secondary endpoint: Percentage change in EASI from baseline at Week 52 in the subset of participants who were those randomly reassigned at Week 16                                                                                                           | Maintenance major secondary endpoint: Percentage change in EASI from baseline at Week 52 in the subset of participants who were those randomly reassigned at Week 16                                                                                                           | Maintenance major secondary endpoint: Percentage change in EASI from baseline at Week 52 in the subset of participants who were those randomly reassigned at Week 16                                                                                                           |
| Statistical Model                                                                         | Maintenance primary estimand (hybrid): ANCOVA with MCMC-MI e                                                                                                                                                                                                                   | Maintenance primary estimand (hybrid): ANCOVA with MCMC-MI e                                                                                                                                                                                                                   | Maintenance primary estimand (hybrid): ANCOVA with MCMC-MI e                                                                                                                                                                                                                   | Maintenance primary estimand (hybrid): ANCOVA with MCMC-MI e                                                                                                                                                                                                                   |
| Descriptive Statistics and Estimate Variability                                           | Treatment group                                                                                                                                                                                                                                                                | PBO (LEB withdrawal)                                                                                                                                                                                                                                                           | LEB 250 mg Q4W                                                                                                                                                                                                                                                                 | LEB 250 mg Q2W                                                                                                                                                                                                                                                                 |
| Descriptive Statistics and Estimate Variability                                           | Number of participants (Nx)                                                                                                                                                                                                                                                    | 28                                                                                                                                                                                                                                                                             | 55                                                                                                                                                                                                                                                                             | 51                                                                                                                                                                                                                                                                             |
| Descriptive Statistics and Estimate Variability                                           | LSM (SE)                                                                                                                                                                                                                                                                       | -72.9 (6.3)                                                                                                                                                                                                                                                                    | -87.6 (4.4)                                                                                                                                                                                                                                                                    | -77.2 (4.4)                                                                                                                                                                                                                                                                    |
| Effect Estimate per Comparison                                                            | Comparison groups                                                                                                                                                                                                                                                              | LEB 250 mg Q4W vs PBO                                                                                                                                                                                                                                                          | LEB 250 mg Q2W vs PBO                                                                                                                                                                                                                                                          | LEB 250 mg Q2W vs PBO                                                                                                                                                                                                                                                          |
| Effect Estimate per Comparison                                                            | LSM difference (95% CI)                                                                                                                                                                                                                                                        | -14.7 (-29.8, 0.4)                                                                                                                                                                                                                                                             | -4.3 (-19.4, 10.8)                                                                                                                                                                                                                                                             | -4.3 (-19.4, 10.8)                                                                                                                                                                                                                                                             |
| Effect Estimate per Comparison                                                            | p-value                                                                                                                                                                                                                                                                        | .057                                                                                                                                                                                                                                                                           | .575                                                                                                                                                                                                                                                                           | .575                                                                                                                                                                                                                                                                           |
| Maintenance Period - Results and Analysis - EASI 90 at Week 52                            | Maintenance Period - Results and Analysis - EASI 90 at Week 52                                                                                                                                                                                                                 | Maintenance Period - Results and Analysis - EASI 90 at Week 52                                                                                                                                                                                                                 | Maintenance Period - Results and Analysis - EASI 90 at Week 52                                                                                                                                                                                                                 | Maintenance Period - Results and Analysis - EASI 90 at Week 52                                                                                                                                                                                                                 |
| Analysis Description                                                                      | Other endpoint: Percentage of participants with EASI 90 at Week 52 in the subset of participants who achieved EASI 75 and were randomly reassigned at Week 16 (EASI 90 calculated relative to baseline EASI                                                                    | Other endpoint: Percentage of participants with EASI 90 at Week 52 in the subset of participants who achieved EASI 75 and were randomly reassigned at Week 16 (EASI 90 calculated relative to baseline EASI                                                                    | Other endpoint: Percentage of participants with EASI 90 at Week 52 in the subset of participants who achieved EASI 75 and were randomly reassigned at Week 16 (EASI 90 calculated relative to baseline EASI                                                                    | Other endpoint: Percentage of participants with EASI 90 at Week 52 in the subset of participants who achieved EASI 75 and were randomly reassigned at Week 16 (EASI 90 calculated relative to baseline EASI                                                                    |
| Statistical Model                                                                         | Maintenance primary estimand (hybrid): CMH with MCMC-MI d                                                                                                                                                                                                                      | Maintenance primary estimand (hybrid): CMH with MCMC-MI d                                                                                                                                                                                                                      | Maintenance primary estimand (hybrid): CMH with MCMC-MI d                                                                                                                                                                                                                      | Maintenance primary estimand (hybrid): CMH with MCMC-MI d                                                                                                                                                                                                                      |
|                                                                                           | Treatment group                                                                                                                                                                                                                                                                | PBO (LEB withdrawal)                                                                                                                                                                                                                                                           | LEB 250 mg Q4W                                                                                                                                                                                                                                                                 | LEB 250 mg Q2W                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| Descriptive Statistics and Estimate Variability                                                            | Participants with EASI 75 at Week 16 (Nx)                                                                                        | 27                                                                                                                               | 53                                                                                                                               | 51                                                                                                                               |
|------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|
| Descriptive Statistics and Estimate Variability                                                            | Response, n (%)                                                                                                                  | 10 (38.2)                                                                                                                        | 35 (66.2)                                                                                                                        | 31 (61.5)                                                                                                                        |
| Effect Estimate per Comparison                                                                             | Comparison groups                                                                                                                | LEB 250 mg Q4W vs PBO                                                                                                            | LEB 250 mg Q2W vs PBO                                                                                                            | LEB 250 mg Q2W vs PBO                                                                                                            |
| Effect Estimate per Comparison                                                                             | Common risk difference n, (95% CI)                                                                                               | 28.5 (4.4, 52.7)                                                                                                                 | 23.3 (-1.0, 47.6)                                                                                                                | 23.3 (-1.0, 47.6)                                                                                                                |
| Effect Estimate per Comparison                                                                             | p-value                                                                                                                          | .024                                                                                                                             | .064                                                                                                                             | .064                                                                                                                             |
| Maintenance Week 16 Escape Population - Results and Analysis - IGA 0,1 and 2-Point Improvement at Week 52  | Maintenance Week 16 Escape Population - Results and Analysis - IGA 0,1 and 2-Point Improvement at Week 52                        | Maintenance Week 16 Escape Population - Results and Analysis - IGA 0,1 and 2-Point Improvement at Week 52                        | Maintenance Week 16 Escape Population - Results and Analysis - IGA 0,1 and 2-Point Improvement at Week 52                        | Maintenance Week 16 Escape Population - Results and Analysis - IGA 0,1 and 2-Point Improvement at Week 52                        |
| Analysis Description                                                                                       | Other endpoint: Percentage of participants achieving an IGA score of 0 or 1 and a ≥2 -point improvement from baseline at Week 52 | Other endpoint: Percentage of participants achieving an IGA score of 0 or 1 and a ≥2 -point improvement from baseline at Week 52 | Other endpoint: Percentage of participants achieving an IGA score of 0 or 1 and a ≥2 -point improvement from baseline at Week 52 | Other endpoint: Percentage of participants achieving an IGA score of 0 or 1 and a ≥2 -point improvement from baseline at Week 52 |
| Statistical Model                                                                                          | Descriptive statistic with observed data                                                                                         | Descriptive statistic with observed data                                                                                         | Descriptive statistic with observed data                                                                                         | Descriptive statistic with observed data                                                                                         |
| Descriptive Statistics and Estimate Variability                                                            | Treatment group                                                                                                                  | PBO nonresponders to LEB 250 mg Q2W                                                                                              | LEB nonresponders to LEB 250 mg Q2W                                                                                              | LEB nonresponders to LEB 250 mg Q2W                                                                                              |
| Descriptive Statistics and Estimate Variability                                                            | Number of participants (Nx)                                                                                                      | 84                                                                                                                               | 83                                                                                                                               | 83                                                                                                                               |
| Descriptive Statistics and Estimate Variability                                                            | Response, n (%)                                                                                                                  | 42 (50.0)                                                                                                                        | 34 (41.0)                                                                                                                        | 34 (41.0)                                                                                                                        |
| Maintenance Week 16 Escape Population - Results and Analysis - EASI 75 at Week 52                          | Maintenance Week 16 Escape Population - Results and Analysis - EASI 75 at Week 52                                                | Maintenance Week 16 Escape Population - Results and Analysis - EASI 75 at Week 52                                                | Maintenance Week 16 Escape Population - Results and Analysis - EASI 75 at Week 52                                                | Maintenance Week 16 Escape Population - Results and Analysis - EASI 75 at Week 52                                                |
| Analysis Description                                                                                       | Other endpoint: Percentage of participants with EASI 75 at Week 52 (EASI 75 calculated relative to baseline EASI)                | Other endpoint: Percentage of participants with EASI 75 at Week 52 (EASI 75 calculated relative to baseline EASI)                | Other endpoint: Percentage of participants with EASI 75 at Week 52 (EASI 75 calculated relative to baseline EASI)                | Other endpoint: Percentage of participants with EASI 75 at Week 52 (EASI 75 calculated relative to baseline EASI)                |
| Statistical Model                                                                                          | Descriptive statistics with observed data                                                                                        | Descriptive statistics with observed data                                                                                        | Descriptive statistics with observed data                                                                                        | Descriptive statistics with observed data                                                                                        |
| Descriptive Statistics and Estimate Variability                                                            | Treatment group                                                                                                                  | PBO nonresponders to LEB 250 mg Q2W                                                                                              | LEB nonresponders to LEB 250 mg Q2W                                                                                              | LEB nonresponders to LEB 250 mg Q2W                                                                                              |
| Descriptive Statistics and Estimate Variability                                                            | Number of participants (Nx)                                                                                                      | 85                                                                                                                               | 83                                                                                                                               | 83                                                                                                                               |
| Descriptive Statistics and Estimate Variability                                                            | Response, n (%)                                                                                                                  | 69 (81.2)                                                                                                                        | 61 (73.5)                                                                                                                        | 61 (73.5)                                                                                                                        |
| Maintenance Week 16 Escape Population - Results and Analysis- EASI 90 at Week 52                           | Maintenance Week 16 Escape Population - Results and Analysis- EASI 90 at Week 52                                                 | Maintenance Week 16 Escape Population - Results and Analysis- EASI 90 at Week 52                                                 | Maintenance Week 16 Escape Population - Results and Analysis- EASI 90 at Week 52                                                 | Maintenance Week 16 Escape Population - Results and Analysis- EASI 90 at Week 52                                                 |
| Analysis Description                                                                                       | Other endpoint: Percentage of participants with EASI 90 at Week 52 (EASI 90 calculated relative to baseline EASI)                | Other endpoint: Percentage of participants with EASI 90 at Week 52 (EASI 90 calculated relative to baseline EASI)                | Other endpoint: Percentage of participants with EASI 90 at Week 52 (EASI 90 calculated relative to baseline EASI)                | Other endpoint: Percentage of participants with EASI 90 at Week 52 (EASI 90 calculated relative to baseline EASI)                |
| Statistical Model                                                                                          | Descriptive statistics with observed data                                                                                        | Descriptive statistics with observed data                                                                                        | Descriptive statistics with observed data                                                                                        | Descriptive statistics with observed data                                                                                        |
| Descriptive Statistics and Estimate Variability                                                            | Treatment group                                                                                                                  | PBO nonresponders to LEB 250 mg Q2W                                                                                              | LEB nonresponders to LEB 250 mg Q2W                                                                                              | LEB nonresponders to LEB 250 mg Q2W                                                                                              |
| Descriptive Statistics and Estimate Variability                                                            | Number of participants (Nx)                                                                                                      | 85                                                                                                                               | 83                                                                                                                               | 83                                                                                                                               |
| Descriptive Statistics and Estimate Variability                                                            | Response, n (%)                                                                                                                  | 46 (54.1)                                                                                                                        | 38 (45.8)                                                                                                                        | 38 (45.8)                                                                                                                        |
| Maintenance Week 16 Escape Population - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 52 | Maintenance Week 16 Escape Population - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 52                       | Maintenance Week 16 Escape Population - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 52                       | Maintenance Week 16 Escape Population - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 52                       | Maintenance Week 16 Escape Population - Results and Analysis - Pruritus NRS 4-Point Improvement at Week 52                       |

<div style=\"page-break-after: always\"></div>

| Analysis Description                            | Other endpoint: Percentage of participants with a pruritus NRS of ≥4 points at baseline with ≥4 - point reduction at Week 52   | Other endpoint: Percentage of participants with a pruritus NRS of ≥4 points at baseline with ≥4 - point reduction at Week 52   | Other endpoint: Percentage of participants with a pruritus NRS of ≥4 points at baseline with ≥4 - point reduction at Week 52   |
|-------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|
| Statistical Model                               | Descriptive statistics with observed data                                                                                      | Descriptive statistics with observed data                                                                                      | Descriptive statistics with observed data                                                                                      |
| Descriptive Statistics and Estimate Variability | Treatment group                                                                                                                | PBO nonresponders to LEB 250 mg Q2W                                                                                            | LEB nonresponders to LEB 250 mg Q2W                                                                                            |
| Descriptive Statistics and Estimate Variability | Number of participants (Nx)                                                                                                    | 71                                                                                                                             | 67                                                                                                                             |
| Descriptive Statistics and Estimate Variability | Response, n (%)                                                                                                                | 49 (69.0)                                                                                                                      | 40 (59.7)                                                                                                                      |

## Analyses

a  Primary estimand (hybrid), CMH-MCMC-MI: Participants who received any topical or systemic rescue medication, or discontinued treatment due to lack of efficacy had values set to their baseline value after this time through Week 16; MCMC-MI was used to handle the remaining missing data. CMH test stratified by geographic region, age group, and baseline IGA.

b   Primary  estimand  (hybrid), ANCOVA with  MCMC-MI:  Participants  who  received  any  topical  or  systemic  rescue medication, or  discontinued  treatment due to lack of efficacy had values set to their baseline value after this time through  Week 16; MCMC-MI was used to handle the remaining missing data. ANCOVA model adjusted for treatment group, baseline value, geographic region, age group, and baseline IGA.

c   Supportive  estimand  (hypothetical),  MMRM:  Data  after  topical  or  systemic  rescue medication  or  treatment discontinuation were treated as missing and missing data were handled by MMRM. The MMRM model includes treatment, baseline  value,  visit, the  interaction  of  the  baseline  value-by-visit, the  interaction  of treatment-by-visit, and  the stratification factors as fixed factors.

d   Maintenance  primary estimand  (hybrid), CMH-MCMC-MI: Participants  who  received  systemic rescue  medication, discontinued treatment due to lack of efficacy, or transferred to escape arm had values set to their baseline value after this time through Week 52; participants who received topical rescue medication or discontinued treatment due to other reasons had values set to missing; MCMC-MI was used to handle the remaining missing data. CMH test stratified by geographic region.

e   Maintenance  primary  estimand  (hybrid),  ANCOVA with  MCMC-MI:  Participants  who  received  systemic  rescue medication, discontinued treatment due to lack of efficacy, or transferred to escape arm had values set to their baseline value after this time through Week 52; participants who received topical rescue medication or discontinued treatment due to other reasons had values set to missing; MCMC-MI was used to handle the remaining missing data. ANCOVA model adjusted for geographic region.

Abbreviations: ANCOVA  =  analysis  of  covariance;  CFB =  change from  baseline;  CI = confidence interval; CMH = Cochran-Mantel-Haenszel;  DLQI = Dermatology Life Quality Index; EASI  = Eczema  Area and  Severity Index; EASI 75 = at least 75% reduction in EASI; EASI 90 = at least 90% reduction in EASI; IGA = Investigator's Global Assessment;  LEB =  lebrikizumab; LSM =  least squares  mean; MCMC-MI = Markov  Chain  Monte  Carlo Multiple Imputation; mITT= modified intent-to-treat population; MMRM = Mixed Model Repeated Measures; N = total  number  of participants;  n = calculated  number  of  participants  experiencing  endpoint;  NRS =  Numerical Rating Scale; Nx = number of participants in the analysis population; PBO = placebo; PCFB = percentage change from baseline; POEM = Patient Oriented Eczema Measure; Q2W = every 2 weeks; Q4W = every 4 weeks; SE = standard error; vs = versus; W = week.

<div style=\"page-break-after: always\"></div>

Table 53: Summary of Efficacy for Pivotal Study KGAD

| Title: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB WHEN USED IN COMBINATION WITH TOPICAL CORTICOSTEROID TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS   | Title: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB WHEN USED IN COMBINATION WITH TOPICAL CORTICOSTEROID TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS                                                                            | Title: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB WHEN USED IN COMBINATION WITH TOPICAL CORTICOSTEROID TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS                                                                            | Title: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB WHEN USED IN COMBINATION WITH TOPICAL CORTICOSTEROID TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS                                                                            |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study Identifier                                                                                                                                                                                                                     | J2T-DM-KGAD; DRM06-AD06                                                                                                                                                                                                                                                                                       | J2T-DM-KGAD; DRM06-AD06                                                                                                                                                                                                                                                                                       | J2T-DM-KGAD; DRM06-AD06                                                                                                                                                                                                                                                                                       |
| Design                                                                                                                                                                                                                               | Phase 3, randomised, double-blind, placebo-controlled, parallel-group study.                                                                                                                                                                                                                                  | Phase 3, randomised, double-blind, placebo-controlled, parallel-group study.                                                                                                                                                                                                                                  | Phase 3, randomised, double-blind, placebo-controlled, parallel-group study.                                                                                                                                                                                                                                  |
| Design                                                                                                                                                                                                                               | This study had a single treatment period of 16 weeks. Participants were randomly assigned at a ratio of 2:1 to LEB 500 mg loading dose at baseline and Week 2 then 250 mg Q2W or PBO. Participants were required to use TCS at baseline and then were allowed to use as needed for the duration of the study. | This study had a single treatment period of 16 weeks. Participants were randomly assigned at a ratio of 2:1 to LEB 500 mg loading dose at baseline and Week 2 then 250 mg Q2W or PBO. Participants were required to use TCS at baseline and then were allowed to use as needed for the duration of the study. | This study had a single treatment period of 16 weeks. Participants were randomly assigned at a ratio of 2:1 to LEB 500 mg loading dose at baseline and Week 2 then 250 mg Q2W or PBO. Participants were required to use TCS at baseline and then were allowed to use as needed for the duration of the study. |
| Treatment Groups                                                                                                                                                                                                                     | PBO + TCS                                                                                                                                                                                                                                                                                                     | PBO + TCS                                                                                                                                                                                                                                                                                                     | Randomised N = 75 4 mL was administered via 2 preassembled needle safety devices (PFS-NSD) at baseline and Week 2 and 2 mL Q2W was administered through Week 14 via 1 PFS-NSD. TCS treatment was initiated at baseline and applied as needed.                                                                 |
| Treatment Groups                                                                                                                                                                                                                     | LEB 250 mg Q2W + TCS                                                                                                                                                                                                                                                                                          | LEB 250 mg Q2W + TCS                                                                                                                                                                                                                                                                                          | Randomised N = 153 LEB 500 mg at baseline and Week 2 (loading dose) and 250 mg given Q2W through Week 14 with TCS treatment initiated at baseline and applied as needed.                                                                                                                                      |
| Hypothesis                                                                                                                                                                                                                           | Superiority                                                                                                                                                                                                                                                                                                   | Superiority                                                                                                                                                                                                                                                                                                   | Superiority                                                                                                                                                                                                                                                                                                   |
| Endpoints and Definitions                                                                                                                                                                                                            | Coprimary endpoint                                                                                                                                                                                                                                                                                            | IGA 0,1, W16                                                                                                                                                                                                                                                                                                  | Percentage of participants with an IGA 0,1 and a ≥2 -point reduction from baseline to Week 16                                                                                                                                                                                                                 |
| Endpoints and Definitions                                                                                                                                                                                                            | Coprimary endpoint                                                                                                                                                                                                                                                                                            | EASI 75, W16                                                                                                                                                                                                                                                                                                  | Percentage of participants achieving EASI 75 (≥75% reduction from baseline in EASI) at Week 16                                                                                                                                                                                                                |
| Endpoints and Definitions                                                                                                                                                                                                            | Major secondary endpoint                                                                                                                                                                                                                                                                                      | EASI 90, W16                                                                                                                                                                                                                                                                                                  | Percentage of participants achieving EASI 90 (≥90% reduction from baseline in EASI) at Week 16                                                                                                                                                                                                                |
| Endpoints and Definitions                                                                                                                                                                                                            | Major secondary endpoint                                                                                                                                                                                                                                                                                      | EASI PCFB, W16                                                                                                                                                                                                                                                                                                | Percentage change in EASI score from baseline to Week 16                                                                                                                                                                                                                                                      |
| Endpoints and Definitions                                                                                                                                                                                                            | Major secondary endpoint                                                                                                                                                                                                                                                                                      | Pruritus NRS 4-point improvement, W16                                                                                                                                                                                                                                                                         | Percentage of participants with a pruritus NRS of ≥4 -points at baseline who achieve a ≥4 -point reduction from baseline to Week 16                                                                                                                                                                           |
| Endpoints and Definitions                                                                                                                                                                                                            | Major secondary endpoint                                                                                                                                                                                                                                                                                      | Pruritus NRS PCFB, W16                                                                                                                                                                                                                                                                                        | Percentage change in pruritus NRS score from baseline to Week 16                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|                                                 |                                                                                                                   | Major secondary endpoint                                                                                                                                              | Pruritus NRS 4-point improvement and                                                                                                                                  | Pruritus NRS 4-point improvement and                                                                                                                                  | Percentage of participants with a pruritus NRS score of ≥4 points at baseline who achieve both EASI 75 and a ≥4 - point reduction in pruritus NRS score from baseline at Week 16   | Percentage of participants with a pruritus NRS score of ≥4 points at baseline who achieve both EASI 75 and a ≥4 - point reduction in pruritus NRS score from baseline at Week 16   |
|-------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                 |                                                                                                                   | Major secondary endpoint                                                                                                                                              | DLQI CFB, W16                                                                                                                                                         | DLQI CFB, W16                                                                                                                                                         | CFB in DLQI at Week 16                                                                                                                                                             | CFB in DLQI at Week 16                                                                                                                                                             |
|                                                 |                                                                                                                   | Major secondary endpoint                                                                                                                                              | DLQI 4-point improvement, W16                                                                                                                                         | DLQI 4-point improvement, W16                                                                                                                                         | Percentage of participants with a DLQI total score of ≥4 - points at baseline who achieve ≥4 -point improvement in DLQI from baseline to Week 16                                   | Percentage of participants with a DLQI total score of ≥4 - points at baseline who achieve ≥4 -point improvement in DLQI from baseline to Week 16                                   |
|                                                 |                                                                                                                   | Major secondary endpoint                                                                                                                                              | Sleep-Loss CFB, W16                                                                                                                                                   | Sleep-Loss CFB, W16                                                                                                                                                   | CFB in Sleep-Loss scale score at Week 16                                                                                                                                           | CFB in Sleep-Loss scale score at Week 16                                                                                                                                           |
|                                                 |                                                                                                                   | Other secondary endpoint                                                                                                                                              | POEM CFB, W16                                                                                                                                                         | POEM CFB, W16                                                                                                                                                         | CFB in POEM at Week 16                                                                                                                                                             | CFB in POEM at Week 16                                                                                                                                                             |
| Database Lock                                   | Database Lock                                                                                                     | 16 December 2021                                                                                                                                                      | 16 December 2021                                                                                                                                                      | 16 December 2021                                                                                                                                                      | 16 December 2021                                                                                                                                                                   | 16 December 2021                                                                                                                                                                   |
| Multiplicity Adjustment                         | Multiplicity Adjustment                                                                                           | For all primary and key secondary endpoints, a prespecified gatekeeping approach was implemented to control the overall Type I error rate at a 2-sided alpha of 0.05. | For all primary and key secondary endpoints, a prespecified gatekeeping approach was implemented to control the overall Type I error rate at a 2-sided alpha of 0.05. | For all primary and key secondary endpoints, a prespecified gatekeeping approach was implemented to control the overall Type I error rate at a 2-sided alpha of 0.05. | For all primary and key secondary endpoints, a prespecified gatekeeping approach was implemented to control the overall Type I error rate at a 2-sided alpha of 0.05.              | For all primary and key secondary endpoints, a prespecified gatekeeping approach was implemented to control the overall Type I error rate at a 2-sided alpha of 0.05.              |
| Results and Analysis                            | Results and Analysis                                                                                              | Results and Analysis                                                                                                                                                  | Results and Analysis                                                                                                                                                  | Results and Analysis                                                                                                                                                  | Results and Analysis                                                                                                                                                               | Results and Analysis                                                                                                                                                               |
| Analysis Description                            | Coprimary endpoint: Percentage of participants with an IGA 0,1 and a ≥2 -point reduction from baseline to Week 16 | Coprimary endpoint: Percentage of participants with an IGA 0,1 and a ≥2 -point reduction from baseline to Week 16                                                     | Coprimary endpoint: Percentage of participants with an IGA 0,1 and a ≥2 -point reduction from baseline to Week 16                                                     | Coprimary endpoint: Percentage of participants with an IGA 0,1 and a ≥2 -point reduction from baseline to Week 16                                                     | Coprimary endpoint: Percentage of participants with an IGA 0,1 and a ≥2 -point reduction from baseline to Week 16                                                                  | Coprimary endpoint: Percentage of participants with an IGA 0,1 and a ≥2 -point reduction from baseline to Week 16                                                                  |
| Statistical Model                               | Primary estimand (hybrid): CMH with MCMC-MI a                                                                     | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                         | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                         | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                         | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                                      | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                                      |
| Descriptive Statistics and Estimate Variability | Treatment group                                                                                                   | Treatment group                                                                                                                                                       | Treatment group                                                                                                                                                       | PBO + TCS                                                                                                                                                             | PBO + TCS                                                                                                                                                                          | LEB 250 mg Q2W + TCS                                                                                                                                                               |
| Descriptive Statistics and Estimate Variability | Number of participants (Nx)                                                                                       | Number of participants (Nx)                                                                                                                                           | Number of participants (Nx)                                                                                                                                           | 66                                                                                                                                                                    | 66                                                                                                                                                                                 | 145                                                                                                                                                                                |
| Descriptive Statistics and Estimate Variability | Response, n (%)                                                                                                   | Response, n (%)                                                                                                                                                       | Response, n (%)                                                                                                                                                       | 15 (22.1)                                                                                                                                                             | 15 (22.1)                                                                                                                                                                          | 60 (41.2)                                                                                                                                                                          |
| Effect Estimate per Comparison                  | Comparison groups                                                                                                 | Comparison groups                                                                                                                                                     | Comparison groups                                                                                                                                                     | Comparison groups                                                                                                                                                     | LEB 250 mg Q2W vs PBO                                                                                                                                                              | LEB 250 mg Q2W vs PBO                                                                                                                                                              |
| Effect Estimate per Comparison                  | Common risk difference (95% CI)                                                                                   | Common risk difference (95% CI)                                                                                                                                       | Common risk difference (95% CI)                                                                                                                                       | Common risk difference (95% CI)                                                                                                                                       | 18.3 (5.1, 31.5)                                                                                                                                                                   | 18.3 (5.1, 31.5)                                                                                                                                                                   |
| Effect Estimate per Comparison                  | p-value                                                                                                           | p-value                                                                                                                                                               | p-value                                                                                                                                                               | p-value                                                                                                                                                               | .011                                                                                                                                                                               | .011                                                                                                                                                                               |
| Results and Analysis                            | Results and Analysis                                                                                              | Results and Analysis                                                                                                                                                  | Results and Analysis                                                                                                                                                  | Results and Analysis                                                                                                                                                  | Results and Analysis                                                                                                                                                               | Results and Analysis                                                                                                                                                               |
| Analysis Description                            | Analysis Description                                                                                              | Coprimary endpoint: Percentage of participants achieving EASI 75 (≥75% reduction from baseline in EASI) at Week 16                                                    | Coprimary endpoint: Percentage of participants achieving EASI 75 (≥75% reduction from baseline in EASI) at Week 16                                                    | Coprimary endpoint: Percentage of participants achieving EASI 75 (≥75% reduction from baseline in EASI) at Week 16                                                    | Coprimary endpoint: Percentage of participants achieving EASI 75 (≥75% reduction from baseline in EASI) at Week 16                                                                 | Coprimary endpoint: Percentage of participants achieving EASI 75 (≥75% reduction from baseline in EASI) at Week 16                                                                 |
| Statistical Model                               | Statistical Model                                                                                                 | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                         | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                         | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                         | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                                      | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                                      |
|                                                 |                                                                                                                   | Treatment group                                                                                                                                                       | Treatment group                                                                                                                                                       | PBO + TCS                                                                                                                                                             | PBO + TCS                                                                                                                                                                          | LEB 250 mg Q2W + TCS                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| Descriptive Statistics and Estimate             | Number of participants (Nx)                                                                                                                                  | 66                                                                                                                                                           | 66                                                                                                                                                           | 145                                                                                                                                                          |
|-------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variability                                     | Response, n (%)                                                                                                                                              | 28 (42.2)                                                                                                                                                    | 28 (42.2)                                                                                                                                                    | 101 (69.5)                                                                                                                                                   |
| Effect Estimate per Comparison                  | Comparison groups                                                                                                                                            | Comparison groups                                                                                                                                            | LEB 250 mg Q2W vs PBO                                                                                                                                        | LEB 250 mg Q2W vs PBO                                                                                                                                        |
| Effect Estimate per Comparison                  | Common risk difference, n (95% CI)                                                                                                                           | Common risk difference, n (95% CI)                                                                                                                           | 26.4 (12.1, 40.8)                                                                                                                                            | 26.4 (12.1, 40.8)                                                                                                                                            |
| Effect Estimate per Comparison                  | p-value                                                                                                                                                      | p-value                                                                                                                                                      | <.001                                                                                                                                                        | <.001                                                                                                                                                        |
| Results and Analysis                            | Results and Analysis                                                                                                                                         | Results and Analysis                                                                                                                                         | Results and Analysis                                                                                                                                         | Results and Analysis                                                                                                                                         |
| Analysis Description                            | Major secondary endpoint: Percentage of participants experiencing EASI 90 (≥90% reduction from baseline in EASI) at Week 16                                  | Major secondary endpoint: Percentage of participants experiencing EASI 90 (≥90% reduction from baseline in EASI) at Week 16                                  | Major secondary endpoint: Percentage of participants experiencing EASI 90 (≥90% reduction from baseline in EASI) at Week 16                                  | Major secondary endpoint: Percentage of participants experiencing EASI 90 (≥90% reduction from baseline in EASI) at Week 16                                  |
| Statistical Model                               | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                |
| Descriptive Statistics and Estimate Variability | Treatment group                                                                                                                                              | PBO + TCS                                                                                                                                                    | PBO + TCS                                                                                                                                                    | LEB 250 mg Q2W + TCS                                                                                                                                         |
| Descriptive Statistics and Estimate Variability | Number of participants (Nx)                                                                                                                                  | 66                                                                                                                                                           | 66                                                                                                                                                           | 145                                                                                                                                                          |
| Descriptive Statistics and Estimate Variability | Response, n (%)                                                                                                                                              | 14 (21.7)                                                                                                                                                    | 14 (21.7)                                                                                                                                                    | 60 (41.2)                                                                                                                                                    |
| Effect Estimate per Comparison                  | Comparison groups                                                                                                                                            | Comparison groups                                                                                                                                            | LEB 250 mg Q2W vs                                                                                                                                            | LEB 250 mg Q2W vs                                                                                                                                            |
| Effect Estimate per Comparison                  | Common risk difference (95% CI)                                                                                                                              | Common risk difference (95% CI)                                                                                                                              | 18.9 (6.1, 31.7)                                                                                                                                             | 18.9 (6.1, 31.7)                                                                                                                                             |
| Effect Estimate per Comparison                  | p-value                                                                                                                                                      | p-value                                                                                                                                                      | .008                                                                                                                                                         | .008                                                                                                                                                         |
| Results and analysis                            | Results and analysis                                                                                                                                         | Results and analysis                                                                                                                                         | Results and analysis                                                                                                                                         | Results and analysis                                                                                                                                         |
| Analysis Description                            | Major secondary endpoint: Percentage change in EASI from baseline to Week 16                                                                                 | Major secondary endpoint: Percentage change in EASI from baseline to Week 16                                                                                 | Major secondary endpoint: Percentage change in EASI from baseline to Week 16                                                                                 | Major secondary endpoint: Percentage change in EASI from baseline to Week 16                                                                                 |
| Statistical Model                               | Primary estimand (hybrid): ANCOVA with MCMC-MI b                                                                                                             | Primary estimand (hybrid): ANCOVA with MCMC-MI b                                                                                                             | Primary estimand (hybrid): ANCOVA with MCMC-MI b                                                                                                             | Primary estimand (hybrid): ANCOVA with MCMC-MI b                                                                                                             |
| Descriptive Statistics and Estimate Variability | Treatment group                                                                                                                                              | PBO + TCS                                                                                                                                                    | PBO + TCS                                                                                                                                                    | LEB 250 mg Q2W + TCS                                                                                                                                         |
| Descriptive Statistics and Estimate Variability | Number of participants (Nx)                                                                                                                                  | 66                                                                                                                                                           | 66                                                                                                                                                           | 145                                                                                                                                                          |
| Descriptive Statistics and Estimate Variability | LSM (SE)                                                                                                                                                     | -53.1 (5.1)                                                                                                                                                  | -53.1 (5.1)                                                                                                                                                  | -76.8 (4.1)                                                                                                                                                  |
| Effect Estimate per Comparison                  | Comparison groups                                                                                                                                            | Comparison groups                                                                                                                                            | LEB 250 mg Q2W vs PBO                                                                                                                                        | LEB 250 mg Q2W vs PBO                                                                                                                                        |
|                                                 | LSM difference (95% CI)                                                                                                                                      | LSM difference (95% CI)                                                                                                                                      | -23.6 ( -33.6, -13.7)                                                                                                                                        | -23.6 ( -33.6, -13.7)                                                                                                                                        |
|                                                 | p-value                                                                                                                                                      | p-value                                                                                                                                                      | <.001                                                                                                                                                        | <.001                                                                                                                                                        |
| Results and analysis                            | Results and analysis                                                                                                                                         | Results and analysis                                                                                                                                         | Results and analysis                                                                                                                                         | Results and analysis                                                                                                                                         |
| Analysis Description                            | Major secondary endpoint: Percentage of participants with a pruritus NRS of ≥4 points at baseline who achieve a ≥4 -point reduction from baseline to Week 16 | Major secondary endpoint: Percentage of participants with a pruritus NRS of ≥4 points at baseline who achieve a ≥4 -point reduction from baseline to Week 16 | Major secondary endpoint: Percentage of participants with a pruritus NRS of ≥4 points at baseline who achieve a ≥4 -point reduction from baseline to Week 16 | Major secondary endpoint: Percentage of participants with a pruritus NRS of ≥4 points at baseline who achieve a ≥4 -point reduction from baseline to Week 16 |
| Statistical Model                               | Primary Estimand (hybrid): CMH with MCMC-MI a                                                                                                                | Primary Estimand (hybrid): CMH with MCMC-MI a                                                                                                                | Primary Estimand (hybrid): CMH with MCMC-MI a                                                                                                                | Primary Estimand (hybrid): CMH with MCMC-MI a                                                                                                                |

<div style=\"page-break-after: always\"></div>

| Descriptive Statistics and Estimate Variability   | Treatment group                                                                                                                                                                                           | PBO + TCS                                                                                                                                                                                                 | PBO + TCS                                                                                                                                                                                                 | LEB 250 mg Q2W + TCS                                                                                                                                                                                      |
|---------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Descriptive Statistics and Estimate Variability   | Number of participants with baseline pruritus NRS score ≥4 (Nx)                                                                                                                                           | 57                                                                                                                                                                                                        | 57                                                                                                                                                                                                        | 130                                                                                                                                                                                                       |
| Descriptive Statistics and Estimate Variability   | Response, n (%)                                                                                                                                                                                           | 18 (31.9)                                                                                                                                                                                                 | 18 (31.9)                                                                                                                                                                                                 | 66 (50.6)                                                                                                                                                                                                 |
| Effect Estimate per Comparison                    | Comparison groups                                                                                                                                                                                         | Comparison groups                                                                                                                                                                                         | LEB 250 mg Q2W vs PBO                                                                                                                                                                                     | LEB 250 mg Q2W vs PBO                                                                                                                                                                                     |
| Effect Estimate per Comparison                    | Common risk difference (95% CI)                                                                                                                                                                           | Common risk difference (95% CI)                                                                                                                                                                           | 19.2 (4.3, 34.1)                                                                                                                                                                                          | 19.2 (4.3, 34.1)                                                                                                                                                                                          |
| Effect Estimate per Comparison                    | p-value                                                                                                                                                                                                   | p-value                                                                                                                                                                                                   | .017                                                                                                                                                                                                      | .017                                                                                                                                                                                                      |
| Results and Analysis                              | Results and Analysis                                                                                                                                                                                      | Results and Analysis                                                                                                                                                                                      | Results and Analysis                                                                                                                                                                                      | Results and Analysis                                                                                                                                                                                      |
| Analysis Description                              | Major secondary endpoint: Percentage change in pruritus NRS score from baseline to Week 16                                                                                                                | Major secondary endpoint: Percentage change in pruritus NRS score from baseline to Week 16                                                                                                                | Major secondary endpoint: Percentage change in pruritus NRS score from baseline to Week 16                                                                                                                | Major secondary endpoint: Percentage change in pruritus NRS score from baseline to Week 16                                                                                                                |
| Statistical Model                                 | Primary estimand (hybrid): ANCOVA with MCMC-MI b                                                                                                                                                          | Primary estimand (hybrid): ANCOVA with MCMC-MI b                                                                                                                                                          | Primary estimand (hybrid): ANCOVA with MCMC-MI b                                                                                                                                                          | Primary estimand (hybrid): ANCOVA with MCMC-MI b                                                                                                                                                          |
| Descriptive Statistics and Estimate Variability   | Treatment group                                                                                                                                                                                           | PBO + TCS                                                                                                                                                                                                 | PBO + TCS                                                                                                                                                                                                 | LEB 250 mg Q2W + TCS                                                                                                                                                                                      |
| Descriptive Statistics and Estimate Variability   | Number of participants (Nx)                                                                                                                                                                               | 63                                                                                                                                                                                                        | 63                                                                                                                                                                                                        | 139                                                                                                                                                                                                       |
| Descriptive Statistics and Estimate Variability   | LSM (SE)                                                                                                                                                                                                  | -35.5 (6.4)                                                                                                                                                                                               | -35.5 (6.4)                                                                                                                                                                                               | -50.7 (4.5)                                                                                                                                                                                               |
| Effect Estimate per Comparison                    | Comparison groups                                                                                                                                                                                         | Comparison groups                                                                                                                                                                                         | LEB 250 mg Q2W vs PBO                                                                                                                                                                                     | LEB 250 mg Q2W vs PBO                                                                                                                                                                                     |
| Effect Estimate per Comparison                    | LSM difference (95% CI)                                                                                                                                                                                   | LSM difference (95% CI)                                                                                                                                                                                   | -15.2 (-27.7, -2.7)                                                                                                                                                                                       | -15.2 (-27.7, -2.7)                                                                                                                                                                                       |
| Effect Estimate per Comparison                    | p-value                                                                                                                                                                                                   | p-value                                                                                                                                                                                                   | .017                                                                                                                                                                                                      | .017                                                                                                                                                                                                      |
| Results and Analysis                              | Results and Analysis                                                                                                                                                                                      | Results and Analysis                                                                                                                                                                                      | Results and Analysis                                                                                                                                                                                      | Results and Analysis                                                                                                                                                                                      |
| Analysis Description                              | Major secondary endpoint: Percentage of participants with a pruritus NRS score of ≥4 points at baseline who achieve both EASI 75 and a ≥4 -point reduction in pruritus NRS score from baseline at Week 16 | Major secondary endpoint: Percentage of participants with a pruritus NRS score of ≥4 points at baseline who achieve both EASI 75 and a ≥4 -point reduction in pruritus NRS score from baseline at Week 16 | Major secondary endpoint: Percentage of participants with a pruritus NRS score of ≥4 points at baseline who achieve both EASI 75 and a ≥4 -point reduction in pruritus NRS score from baseline at Week 16 | Major secondary endpoint: Percentage of participants with a pruritus NRS score of ≥4 points at baseline who achieve both EASI 75 and a ≥4 -point reduction in pruritus NRS score from baseline at Week 16 |
| Statistical Model                                 | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                                                             | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                                                             | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                                                             | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                                                             |
| Descriptive Statistics and Estimate Variability   | Treatment group                                                                                                                                                                                           | PBO + TCS                                                                                                                                                                                                 | PBO + TCS                                                                                                                                                                                                 | LEB 250 mg Q2W + TCS                                                                                                                                                                                      |
| Descriptive Statistics and Estimate Variability   | Number of participants with baseline pruritus NRS score ≥4 (Nx)                                                                                                                                           | 57                                                                                                                                                                                                        | 57                                                                                                                                                                                                        | 130                                                                                                                                                                                                       |
| Descriptive Statistics and Estimate Variability   | Response, n (%)                                                                                                                                                                                           | 10 (16.8)                                                                                                                                                                                                 | 10 (16.8)                                                                                                                                                                                                 | 50 (38.3)                                                                                                                                                                                                 |
| Effect Estimate per Comparison                    | Comparison groups                                                                                                                                                                                         | Comparison groups                                                                                                                                                                                         | LEB 250 mg Q2W vs PBO                                                                                                                                                                                     | LEB 250 mg Q2W vs PBO                                                                                                                                                                                     |
| Effect Estimate per Comparison                    | Common risk difference, n (95% CI)                                                                                                                                                                        | Common risk difference, n (95% CI)                                                                                                                                                                        | 21.6 (8.3, 35.0)                                                                                                                                                                                          | 21.6 (8.3, 35.0)                                                                                                                                                                                          |
| Effect Estimate per Comparison                    | p-value                                                                                                                                                                                                   | p-value                                                                                                                                                                                                   | 0.005                                                                                                                                                                                                     | 0.005                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| Results and Analysis                            | Results and Analysis                                                                                                                                                     | Results and Analysis                                                                                                                                                     | Results and Analysis                                                                                                                                                     |
|-------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Analysis Description                            | Major secondary endpoint: CFB in DLQI at Week 16                                                                                                                         | Major secondary endpoint: CFB in DLQI at Week 16                                                                                                                         | Major secondary endpoint: CFB in DLQI at Week 16                                                                                                                         |
| Statistical Model                               | Primary Estimand (hybrid): ANCOVA with MCMC-MI b                                                                                                                         | Primary Estimand (hybrid): ANCOVA with MCMC-MI b                                                                                                                         | Primary Estimand (hybrid): ANCOVA with MCMC-MI b                                                                                                                         |
| Descriptive Statistics and Estimate Variability | Treatment group                                                                                                                                                          | PBO + TCS                                                                                                                                                                | LEB 250 mg Q2W + TCS                                                                                                                                                     |
| Descriptive Statistics and Estimate Variability | Number of participants (Nx)                                                                                                                                              | 51                                                                                                                                                                       | 109                                                                                                                                                                      |
| Descriptive Statistics and Estimate Variability | LSM (SE)                                                                                                                                                                 | -6.5 (1.9)                                                                                                                                                               | -9.8 (1.8)                                                                                                                                                               |
| Effect Estimate per Comparison                  | Comparison groups                                                                                                                                                        | Comparison groups                                                                                                                                                        | LEB 250 mg Q2W vs PBO                                                                                                                                                    |
| Effect Estimate per Comparison                  | LSM difference (95% CI)                                                                                                                                                  | LSM difference (95% CI)                                                                                                                                                  | -3.3 (-5.3, -1.3)                                                                                                                                                        |
| Effect Estimate per Comparison                  | p-value                                                                                                                                                                  | p-value                                                                                                                                                                  | .001                                                                                                                                                                     |
| Results and Analysis                            | Results and Analysis                                                                                                                                                     | Results and Analysis                                                                                                                                                     | Results and Analysis                                                                                                                                                     |
| Analysis Description                            | Majorsecondary endpoint: Percentage of participants with a DLQI total score of ≥4 -points at baseline who achieve ≥4 -point improvement in DLQI from baseline to Week 16 | Majorsecondary endpoint: Percentage of participants with a DLQI total score of ≥4 -points at baseline who achieve ≥4 -point improvement in DLQI from baseline to Week 16 | Majorsecondary endpoint: Percentage of participants with a DLQI total score of ≥4 -points at baseline who achieve ≥4 -point improvement in DLQI from baseline to Week 16 |
| Statistical Model                               | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                            | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                            | Primary estimand (hybrid): CMH with MCMC-MI a                                                                                                                            |
| Descriptive Statistics and Estimate Variability | Treatment group                                                                                                                                                          | PBO + TCS                                                                                                                                                                | LEB 250 mg Q2W + TCS                                                                                                                                                     |
| Descriptive Statistics and Estimate Variability | Number of participants with baseline DLQI score ≥4 (Nx)                                                                                                                  | 48                                                                                                                                                                       | 105                                                                                                                                                                      |
| Descriptive Statistics and Estimate Variability | Response, n (%)                                                                                                                                                          | 28 (58.7)                                                                                                                                                                | 81 (77.4)                                                                                                                                                                |
| Effect Estimate per Comparison                  | Comparison groups                                                                                                                                                        | Comparison groups                                                                                                                                                        | LEB 250 mg Q2W vs PBO                                                                                                                                                    |
| Effect Estimate per Comparison                  | Common risk difference (95% CI)                                                                                                                                          | Common risk difference (95% CI)                                                                                                                                          | 17.2 (0.1, 34.3)                                                                                                                                                         |
| Effect Estimate per Comparison                  | p-value                                                                                                                                                                  | p-value                                                                                                                                                                  | .036                                                                                                                                                                     |
| Results and Analysis                            | Results and Analysis                                                                                                                                                     | Results and Analysis                                                                                                                                                     | Results and Analysis                                                                                                                                                     |
| Analysis Description                            | Major secondary endpoint: CFB in Sleep-Loss Scale score at Week 16                                                                                                       | Major secondary endpoint: CFB in Sleep-Loss Scale score at Week 16                                                                                                       | Major secondary endpoint: CFB in Sleep-Loss Scale score at Week 16                                                                                                       |
| Statistical Model                               | Primary estimand (hybrid): ANCOVA with MCMC-MI b                                                                                                                         | Primary estimand (hybrid): ANCOVA with MCMC-MI b                                                                                                                         | Primary estimand (hybrid): ANCOVA with MCMC-MI b                                                                                                                         |
| Descriptive Statistics and Estimate Variability | Treatment group                                                                                                                                                          | PBO + TCS                                                                                                                                                                | LEB 250 mg Q2W + TCS                                                                                                                                                     |
| Descriptive Statistics and Estimate Variability | Number of participants (Nx)                                                                                                                                              | 63                                                                                                                                                                       | 139                                                                                                                                                                      |
| Descriptive Statistics and Estimate Variability | LSM (SE)                                                                                                                                                                 | -0.8 (0.1)                                                                                                                                                               | -1.1 (0.1)                                                                                                                                                               |
| Descriptive Statistics and Estimate Variability | Comparison groups                                                                                                                                                        |                                                                                                                                                                          | LEB 250 mg Q2W vs PBO                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| Effect Estimate per Comparison                  | LSM difference (95% CI)                                             | LSM difference (95% CI)                                             | -0.3 (-0.6, -0.0)                                                   |
|-------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|
| Effect Estimate per Comparison                  | p-value                                                             | p-value                                                             | .025                                                                |
| Results and Analysis                            | Results and Analysis                                                | Results and Analysis                                                | Results and Analysis                                                |
| Analysis Description                            | Other secondary endpoint: CFB in POEM at Week 16                    | Other secondary endpoint: CFB in POEM at Week 16                    | Other secondary endpoint: CFB in POEM at Week 16                    |
| Statistical Model                               | Supportive estimand for continuous endpoints (hypothetical): MMRM c | Supportive estimand for continuous endpoints (hypothetical): MMRM c | Supportive estimand for continuous endpoints (hypothetical): MMRM c |
| Descriptive Statistics and Estimate Variability | Treatment group                                                     | PBO + TCS                                                           | LEB 250 mg Q2W + TCS                                                |
| Descriptive Statistics and Estimate Variability | Number of participants (Nx)                                         | 64                                                                  | 135                                                                 |
| Descriptive Statistics and Estimate Variability | LSM (SE)                                                            | -6.2 (1.0)                                                          | -10.2 (07)                                                          |
| Effect Estimate per Comparison                  | Comparison groups                                                   | Comparison groups                                                   | LEB 250 mg Q2W vs PBO                                               |
| Effect Estimate per Comparison                  | LSM difference (SE)                                                 | LSM difference (SE)                                                 | -4.0 (1.1)                                                          |
| Effect Estimate per Comparison                  | p-value                                                             | p-value                                                             | <.001                                                               |
| Analyses                                        | Analyses                                                            | Analyses                                                            | Analyses                                                            |

a  Primary estimand (hybrid), CMH-MCMC-MI: Participants who received high potency topical or systemic rescue medication, or discontinued treatment due to lack of efficacy had values set to their baseline value after this time through  Week 16; MCMC-MI was used to handle the remaining missing data. CMH test stratified by geographic region, age group, and baseline IGA.

b  Primary estimand (hybrid), ANCOVA with MCMC-MI: Participants who received high potency topical or systemic rescue medication, or discontinued treatment due to lack of efficacy had values set to their baseline value after this time through  Week 16; MCMC-MI was used to handle the remaining missing data. ANCOVA model adjusted for treatment group, baseline value, geographic region, age group, and baseline IGA.

c   Supportive estimand (hypothetical), MMRM:  Data after high potency  topical or systemic rescue medication or treatment discontinuation  were treated as missing and missing data were handled by MMRM. The MMRM model includes treatment, baseline value, visit, the interaction of the baseline value-by-visit, the interaction of treatmentby-visit, and the stratification factors as fixed factors.

Abbreviations: ANCOVA  = analysis of covariance; CFB =change from baseline; CI = confidence interval; CMH = Cochran-Mantel-Haenszel;  DLQI = Dermatology Life Quality Index; EASI  = Eczema  Area and  Severity Index; EASI 75 = at least 75% reduction in EASI; EASI 90 = at least 90% reduction in EASI; IGA = Investigator's Global Assessment;  LEB =  lebrikizumab; LSM =  least squares  mean; MCMC-MI = Markov  Chain  Monte  Carlo Multiple Imputation; MMRM = Mixed Model Repeated Measures; N = total number of participants; n = calculated number  of participants  experiencing  endpoint;  NRS =  Numerical Rating  Scale;  NSD =  needle  safety  device; Nx = number of participants in the analysis population; PBO = placebo; PCFB = percentage change from baseline; PFS= pre-filled syringe; POEM = Patient Oriented Eczema Measure; Q2W = every 2 weeks; SE = standard error; TCS = topical corticosteroid; vs = versus; W = week.

<div style=\"page-break-after: always\"></div>

## 2.6.5.4. Clinical studies in special populations

|                       | Age 65-74 (Older subjects number /total number)   | Age 75-84 (Older subjects number /total number)   | Age 85+ (Older subjects number /total number)   |
|-----------------------|---------------------------------------------------|---------------------------------------------------|-------------------------------------------------|
| Controlled Trials     | 102/1600                                          | 22/1600                                           | 4/1600                                          |
| Non Controlled trials | 5/294                                             | 4/294                                             | 1/294                                           |

## Study KGAE (J2T-DM-KGAE  or ADore)

KGAE was a 52 week, open-label, single-arm study to assess the safety and efficacy of lebrikizumab in adolescent patients ( ≥12 years to less than 18 years, weighing ≥40 kg) with moderate-to-severe AD. The patients were to have a chronic AD for at least 1 year and key inclusion criteria included EASI ≥16, IGA score ≥3, BSA ≥10% and been a candidate for systemic therapy.

At  baseline  and  Week  2,  all  patients  were administered  subcutaneously  a  loading  dose of  500  mg lebrikizumab. From Week 4 onwards, all patients were administered 250 mg lebrikizumab Q2W through Week 52 subcutaneously.

The use of  any potency TCS, TCIs and PDE4  inhibitors  were permitted  to be  used as add-on rescue treatment  when a patient  experienced clinical  worsening of symptoms that  were intolerable. Patients who required short-term systemic treatment for symptoms of AD were assessed on a case-by-case basis by the investigator. Patients who required long-term systemic treatment for symptoms of AD (e.g., nonresponders) were discontinued from the study as per the protocol requirements.

A posttreatment  follow-up visit was conducted approximately 12  weeks after the last  injection of the study  drug for patients  who  had discontinued  early from the  study or  completed participation in  the Open-Label Treatment Period and did not wish to enter the long-term extension study (KGAA).

## Efficacy results

Altogether 206 received study treatment. All efficacy measures were included as secondary endpoints in the Study KGAE study design. The results are summarised below (Table 54).

<div style=\"page-break-after: always\"></div>

Table 54: Secondary Endpoints and Summary of Efficacy Results (Safety Population)

| Endpoints                                                                                                                                                             | LEB 250 mg Q2W N = 206   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| Percentage of participants with an IGA score of 0 or 1 and a reduction ≥2 points from baseline at Week 52; % (MCMC-MI analysis)                                       | 62.6                     |
| Percentage of participants achieving EASI 75 at Week 52; % (MCMC-MI analysis)                                                                                         | 81.9                     |
| Percentage of participants achieving EASI 50 at Week 52; % (MCMC-MI analysis)                                                                                         | 94.4                     |
| Percentage of participants achieving EASI 90 at Week 52; % (MCMC-MI analysis)                                                                                         | 61.4                     |
| Percentage change from baseline in EASI at Week 52; Mean (SE) (MCMC-MI analysis)                                                                                      | -86.0 (1.6)              |
| Change from baseline in BSA at Week 52; Mean (SD) (as-observed analysis)                                                                                              | -37.6 (21.1)             |
| Change from baseline in PROMIS Anxiety and Depression scores at Week 52; mean (SD) (as-observed analysis)                                                             |                          |
| Changefrom baseline in PROMIS Anxiety scores                                                                                                                          | -6.3 (10.0)              |
| Change frombaselineinPROMISDepressionscores                                                                                                                           | -3.4 (9.1)               |
| Change from baseline in DLQI total score at Week 52; mean (SE) (MCMC-MI analysis)                                                                                     | -8.9 (0.9)               |
| Percentage of participants with a DLQI Total Score of ≥4 points at baseline who reported ≥4-point improvement in DLQI from baseline to Week 52; % (MCMC- MI analysis) | 91.4                     |
| Percentage of participants with baseline DLQI Score >1 reporting a score of 0 or 1 at Week 52; % (MCMC-MI analysis)                                                   | 36.9                     |
| Change from baseline in CDLQI total score at Week 52; mean (SE) (MCMC-MI analysis)                                                                                    | -6.5 (0.5)               |
| Percentage of participants reporting a CDLQI score of 0 or 1 at Week 52; % (MCMC-MI analysis)                                                                         | 37.2                     |

Abbreviations: BSA = body surface area; CDLQI = Children's Dermatology Life Quality Index;

DLQI = Dermatology Life Quality Index; EASI = Eezema Area and Severity Index; EASI 50 = 50% reduction in EASI; EASI 75 = 75% reduction in EASI; EASI 90 = 90% reduction in EASI; IGA = Investigator's Global Assessment; LEB = lebrikizumab; MCMC-MI = Markov Chain Monte Carlo Multiple Imputation; N = number of participants in the analysis population; PROMIS = Patient-Reported Outcomes Measurement Information System; Q2W = every 2 weeks; SD = standard deviation; SE = standard error.

## 2.6.5.5. Analysis performed across trials (pooled analyses and meta-analysis)

According to the Applicant, data from study KGAB and KGAC was pooled when applicable. The key pooled efficacy data from Studies KGAB and KGAC Maintenance Period is summarised in Table 55 and discussed in section 2.6.6.

<div style=\"page-break-after: always\"></div>

Table 55: Summary of Efficacy for Maintenance Period: Pooled Data for Studies KGAB and KGAC

| Maintenance Period - Pooled Studies KGAB and KGAC   | Maintenance Period - Pooled Studies KGAB and KGAC                                                                                      | Maintenance Period - Pooled Studies KGAB and KGAC                                                                                      | Maintenance Period - Pooled Studies KGAB and KGAC                                                                                      | Maintenance Period - Pooled Studies KGAB and KGAC                                                                                      | Maintenance Period - Pooled Studies KGAB and KGAC                                                                                      | Maintenance Period - Pooled Studies KGAB and KGAC                                                                                      |
|-----------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|
| Analysis Description                                | Maintenance majorsecondary endpoint: Percentage of participants maintaining IGA 0, 1 at Week 52 LEB responders with IGA 0,1 at Week 16 | Maintenance majorsecondary endpoint: Percentage of participants maintaining IGA 0, 1 at Week 52 LEB responders with IGA 0,1 at Week 16 | Maintenance majorsecondary endpoint: Percentage of participants maintaining IGA 0, 1 at Week 52 LEB responders with IGA 0,1 at Week 16 | Maintenance majorsecondary endpoint: Percentage of participants maintaining IGA 0, 1 at Week 52 LEB responders with IGA 0,1 at Week 16 | Maintenance majorsecondary endpoint: Percentage of participants maintaining IGA 0, 1 at Week 52 LEB responders with IGA 0,1 at Week 16 | Maintenance majorsecondary endpoint: Percentage of participants maintaining IGA 0, 1 at Week 52 LEB responders with IGA 0,1 at Week 16 |
| Statistical Model                                   | Maintenance Primary Estimand (hybrid): CMH with MCMC-MI a                                                                              | Maintenance Primary Estimand (hybrid): CMH with MCMC-MI a                                                                              | Maintenance Primary Estimand (hybrid): CMH with MCMC-MI a                                                                              | Maintenance Primary Estimand (hybrid): CMH with MCMC-MI a                                                                              | Maintenance Primary Estimand (hybrid): CMH with MCMC-MI a                                                                              | Maintenance Primary Estimand (hybrid): CMH with MCMC-MI a                                                                              |
| Descriptive Statistics and Estimate Variability     | Treatment group                                                                                                                        | PBO (LEB withdrawal)                                                                                                                   | PBO (LEB withdrawal)                                                                                                                   | LEB 250 mg Q4W                                                                                                                         | LEB 250 mg Q4W                                                                                                                         | LEB 250 mg Q2W                                                                                                                         |
| Descriptive Statistics and Estimate Variability     | W16 LEB-responders with IGA 0,1 (Nx)                                                                                                   | 38                                                                                                                                     | 38                                                                                                                                     | 77                                                                                                                                     | 77                                                                                                                                     | 77                                                                                                                                     |
| Descriptive Statistics and Estimate Variability     | Maintained response at W52, n (%)                                                                                                      | 18 (47.9)                                                                                                                              | 18 (47.9)                                                                                                                              | 59 (76.9)                                                                                                                              | 59 (76.9)                                                                                                                              | 55 (71.2)                                                                                                                              |
| Effect Estimate per Comparison                      | Comparison groups                                                                                                                      | Comparison groups                                                                                                                      | LEB 250 mg Q4W vs PBO                                                                                                                  | LEB 250 mg Q4W vs PBO                                                                                                                  | LEB 250 mg Q2W vs PBO                                                                                                                  | LEB 250 mg Q2W vs PBO                                                                                                                  |
| Effect Estimate per Comparison                      | Common risk difference n, (95% CI)                                                                                                     | Common risk difference n, (95% CI)                                                                                                     | 29.9 (10.5, 49.3)                                                                                                                      | 29.9 (10.5, 49.3)                                                                                                                      | 22.6 (3.2, 42.0)                                                                                                                       | 22.6 (3.2, 42.0)                                                                                                                       |
| Effect Estimate per Comparison                      | p-value                                                                                                                                | p-value                                                                                                                                | .003                                                                                                                                   | .003                                                                                                                                   | .022                                                                                                                                   | .022                                                                                                                                   |
| Maintenance Period - Pooled Studies KGAB and KGAC   | Maintenance Period - Pooled Studies KGAB and KGAC                                                                                      | Maintenance Period - Pooled Studies KGAB and KGAC                                                                                      | Maintenance Period - Pooled Studies KGAB and KGAC                                                                                      | Maintenance Period - Pooled Studies KGAB and KGAC                                                                                      | Maintenance Period - Pooled Studies KGAB and KGAC                                                                                      | Maintenance Period - Pooled Studies KGAB and KGAC                                                                                      |
| Analysis Description                                | Maintenance major secondary endpoint: Percentage of participants maintaining EASI 75 at Week 52 LEB-Responders                         | Maintenance major secondary endpoint: Percentage of participants maintaining EASI 75 at Week 52 LEB-Responders                         | Maintenance major secondary endpoint: Percentage of participants maintaining EASI 75 at Week 52 LEB-Responders                         | Maintenance major secondary endpoint: Percentage of participants maintaining EASI 75 at Week 52 LEB-Responders                         | Maintenance major secondary endpoint: Percentage of participants maintaining EASI 75 at Week 52 LEB-Responders                         | Maintenance major secondary endpoint: Percentage of participants maintaining EASI 75 at Week 52 LEB-Responders                         |
| Statistical Model                                   | Maintenance primary estimand (hybrid): CMH with MCMC-MI a                                                                              | Maintenance primary estimand (hybrid): CMH with MCMC-MI a                                                                              | Maintenance primary estimand (hybrid): CMH with MCMC-MI a                                                                              | Maintenance primary estimand (hybrid): CMH with MCMC-MI a                                                                              | Maintenance primary estimand (hybrid): CMH with MCMC-MI a                                                                              | Maintenance primary estimand (hybrid): CMH with MCMC-MI a                                                                              |
| Descriptive Statistics and Estimate Variability     | Treatment group                                                                                                                        | PBO (LEB withdrawal)                                                                                                                   | PBO (LEB withdrawal)                                                                                                                   | LEB 250 mg Q4W                                                                                                                         | LEB 250 mg Q4W                                                                                                                         | LEB 250 mg Q2W                                                                                                                         |
| Descriptive Statistics and Estimate Variability     | EASI 75 Responders at W16, (Nx)                                                                                                        | 57                                                                                                                                     | 57                                                                                                                                     | 115                                                                                                                                    | 115                                                                                                                                    | 112                                                                                                                                    |
| Descriptive Statistics and Estimate Variability     | Maintained response at W52, n (%)                                                                                                      | 38 (66.4)                                                                                                                              | 38 (66.4)                                                                                                                              | 94 (81.7)                                                                                                                              | 94 (81.7)                                                                                                                              | 88 (78.4)                                                                                                                              |
| Effect Estimate per Comparison                      | Comparison groups                                                                                                                      | Comparison groups                                                                                                                      | LEB 250 mg Q4W vs PBO                                                                                                                  | LEB 250 mg Q4W vs PBO                                                                                                                  | LEB 250 mg Q2W vs PBO                                                                                                                  | LEB 250 mg Q2W vs PBO                                                                                                                  |
| Effect Estimate per Comparison                      | Common risk difference n, (95% CI)                                                                                                     | Common risk difference n, (95% CI)                                                                                                     | 15.5 (0.3, 30.8)                                                                                                                       | 15.5 (0.3, 30.8)                                                                                                                       | 11.6 (-4.5, 27.6)                                                                                                                      | 11.6 (-4.5, 27.6)                                                                                                                      |
| Effect Estimate per Comparison                      | p-value                                                                                                                                | p-value                                                                                                                                | .038                                                                                                                                   | .038                                                                                                                                   | .147                                                                                                                                   | .147                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| Maintenance Period - Pooled Studies KGAB and KGAC   | Maintenance Period - Pooled Studies KGAB and KGAC                                                                                                        | Maintenance Period - Pooled Studies KGAB and KGAC                                                                                                        | Maintenance Period - Pooled Studies KGAB and KGAC                                                                                                        | Maintenance Period - Pooled Studies KGAB and KGAC                                                                                                        | Maintenance Period - Pooled Studies KGAB and KGAC                                                                                                        |
|-----------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|
| Analysis Description                                | Other endpoint: Percentage of participants with EASI 90 at Week 16 and Week 52 Week 16 LEB responders                                                    | Other endpoint: Percentage of participants with EASI 90 at Week 16 and Week 52 Week 16 LEB responders                                                    | Other endpoint: Percentage of participants with EASI 90 at Week 16 and Week 52 Week 16 LEB responders                                                    | Other endpoint: Percentage of participants with EASI 90 at Week 16 and Week 52 Week 16 LEB responders                                                    | Other endpoint: Percentage of participants with EASI 90 at Week 16 and Week 52 Week 16 LEB responders                                                    |
| Statistical Model                                   | Maintenance primary estimand (hybrid): CMH with MCMC-MI a                                                                                                | Maintenance primary estimand (hybrid): CMH with MCMC-MI a                                                                                                | Maintenance primary estimand (hybrid): CMH with MCMC-MI a                                                                                                | Maintenance primary estimand (hybrid): CMH with MCMC-MI a                                                                                                | Maintenance primary estimand (hybrid): CMH with MCMC-MI a                                                                                                |
| Descriptive Statistics and Estimate Variability     | Treatment group                                                                                                                                          | PBO (LEB withdrawal)                                                                                                                                     | PBO (LEB withdrawal)                                                                                                                                     | LEB 250 mg Q4W LEB 250 mg Q2W                                                                                                                            | LEB 250 mg Q4W LEB 250 mg Q2W                                                                                                                            |
| Descriptive Statistics and Estimate Variability     | EASI-75 responders at W16, (Nx)                                                                                                                          | 57                                                                                                                                                       | 57                                                                                                                                                       | 115 112                                                                                                                                                  | 115 112                                                                                                                                                  |
| Descriptive Statistics and Estimate Variability     | EASI-75 responders with EASI 90 at W16, n (%)                                                                                                            | 36 (63.2)                                                                                                                                                | 36 (63.2)                                                                                                                                                | 69 (60.0) 69 (61.6)                                                                                                                                      | 69 (60.0) 69 (61.6)                                                                                                                                      |
| Descriptive Statistics and Estimate Variability     | EASI-75 responders with EASI 90 at W52, n (%)                                                                                                            | 24 (41.9) 76                                                                                                                                             | 24 (41.9) 76                                                                                                                                             | 72 (64.0)                                                                                                                                                | 72 (64.0)                                                                                                                                                |
| Effect Estimate per Comparison                      | Comparison groups LEB                                                                                                                                    | Comparison groups LEB                                                                                                                                    | 250 mg Q4W vs PBO                                                                                                                                        | 250 mg Q4W vs PBO                                                                                                                                        | LEB 250 mg Q2W vs PBO                                                                                                                                    |
| Effect Estimate per Comparison                      | Common risk difference n, (95% CI)                                                                                                                       | Common risk difference n, (95% CI)                                                                                                                       | 24.8 (8.4, 41.1)                                                                                                                                         | 24.8 (8.4, 41.1)                                                                                                                                         | 21.6 (4.9, 38.4)                                                                                                                                         |
| Effect Estimate per Comparison                      | p-value                                                                                                                                                  | p-value                                                                                                                                                  | .004                                                                                                                                                     | .004                                                                                                                                                     | .012                                                                                                                                                     |
| Maintenance Period - Pooled Studies KGAB and KGAC   | Maintenance Period - Pooled Studies KGAB and KGAC                                                                                                        | Maintenance Period - Pooled Studies KGAB and KGAC                                                                                                        | Maintenance Period - Pooled Studies KGAB and KGAC                                                                                                        | Maintenance Period - Pooled Studies KGAB and KGAC                                                                                                        | Maintenance Period - Pooled Studies KGAB and KGAC                                                                                                        |
| Analysis Description                                | Maintenance major secondary endpoint: Percentage of participants maintaining pruritus NRS 4 - point improvement at Week 52 and Week 16 in LEB responders | Maintenance major secondary endpoint: Percentage of participants maintaining pruritus NRS 4 - point improvement at Week 52 and Week 16 in LEB responders | Maintenance major secondary endpoint: Percentage of participants maintaining pruritus NRS 4 - point improvement at Week 52 and Week 16 in LEB responders | Maintenance major secondary endpoint: Percentage of participants maintaining pruritus NRS 4 - point improvement at Week 52 and Week 16 in LEB responders | Maintenance major secondary endpoint: Percentage of participants maintaining pruritus NRS 4 - point improvement at Week 52 and Week 16 in LEB responders |
| Statistical Model                                   | Maintenance primary estimand (hybrid): CMH with MCMC-MI a                                                                                                | Maintenance primary estimand (hybrid): CMH with MCMC-MI a                                                                                                | Maintenance primary estimand (hybrid): CMH with MCMC-MI a                                                                                                | Maintenance primary estimand (hybrid): CMH with MCMC-MI a                                                                                                | Maintenance primary estimand (hybrid): CMH with MCMC-MI a                                                                                                |
| Descriptive Statistics and Estimate Variability     | Treatment group                                                                                                                                          | PBO (LEB withdrawal)                                                                                                                                     | PBO (LEB withdrawal)                                                                                                                                     | LEB 250 mg Q4W LEB 250 mg Q2W                                                                                                                            | LEB 250 mg Q4W LEB 250 mg Q2W                                                                                                                            |
| Descriptive Statistics and Estimate Variability     | Participants with pruritus NRS 4-point improvement at W16, (Nx)                                                                                          | 28                                                                                                                                                       | 28                                                                                                                                                       | 61                                                                                                                                                       | 61                                                                                                                                                       |
| Descriptive Statistics and Estimate Variability     | Maintained response at W52, n (%)                                                                                                                        | 19 (66.3)                                                                                                                                                | 19 (66.3)                                                                                                                                                | 52 (84.6)                                                                                                                                                | 52 (84.6)                                                                                                                                                |
| Effect Estimate per Comparison                      | Comparison groups LEB                                                                                                                                    | Comparison groups LEB                                                                                                                                    | 250 mg Q4W vs PBO LEB                                                                                                                                    | 250 mg Q4W vs PBO LEB                                                                                                                                    | 250 mg Q2W vs PBO                                                                                                                                        |
| Effect Estimate per Comparison                      | Common risk difference n, (95% CI)                                                                                                                       | Common risk difference n, (95% CI)                                                                                                                       | 17.7 (-3.1, 38.6)                                                                                                                                        | 17.7 (-3.1, 38.6)                                                                                                                                        | 18.1 (-1.7, 37.9)                                                                                                                                        |
| Effect Estimate per Comparison                      | p-value                                                                                                                                                  | p-value                                                                                                                                                  | .077                                                                                                                                                     | .077                                                                                                                                                     | .058                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| Maintenance Week 16 Escape Population Pooled Studies KGAB and KGAC - IGA 0,1 and 2-Point Improvement   | Maintenance Week 16 Escape Population Pooled Studies KGAB and KGAC - IGA 0,1 and 2-Point Improvement                                                 | Maintenance Week 16 Escape Population Pooled Studies KGAB and KGAC - IGA 0,1 and 2-Point Improvement                                                 | Maintenance Week 16 Escape Population Pooled Studies KGAB and KGAC - IGA 0,1 and 2-Point Improvement                                                 |
|--------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|
| Analysis Description                                                                                   | Other endpoint: Proportion of participants achieving IGA 0,1 at Week 52 among Maintenance Week 16 Escape Population who are nonresponders at Week 16 | Other endpoint: Proportion of participants achieving IGA 0,1 at Week 52 among Maintenance Week 16 Escape Population who are nonresponders at Week 16 | Other endpoint: Proportion of participants achieving IGA 0,1 at Week 52 among Maintenance Week 16 Escape Population who are nonresponders at Week 16 |
| Statistical Model                                                                                      | Escape supportive estimand (hybrid): MCMC-MI b                                                                                                       | Escape supportive estimand (hybrid): MCMC-MI b                                                                                                       | Escape supportive estimand (hybrid): MCMC-MI b                                                                                                       |
| Descriptive Statistics and Estimate Variability                                                        | Treatment group                                                                                                                                      | PBO nonresponders to LEB 250 mg Q2W                                                                                                                  | LEB nonresponders to LEB 250 mg Q2W                                                                                                                  |
| Descriptive Statistics and Estimate Variability                                                        | Number of participants (Nx)                                                                                                                          | 158                                                                                                                                                  | 147                                                                                                                                                  |
| Descriptive Statistics and Estimate Variability                                                        | Response, n (%)                                                                                                                                      | 86 (43.2)                                                                                                                                            | 61 (28.4)                                                                                                                                            |
| Descriptive Statistics and Estimate Variability                                                        | 95% CI                                                                                                                                               | (36.2, 50.2)                                                                                                                                         | (22.0, 34.9)                                                                                                                                         |
| Maintenance Week 16 Escape Population Pooled Studies KGAB and KGAC - EASI 75                           | Maintenance Week 16 Escape Population Pooled Studies KGAB and KGAC - EASI 75                                                                         | Maintenance Week 16 Escape Population Pooled Studies KGAB and KGAC - EASI 75                                                                         | Maintenance Week 16 Escape Population Pooled Studies KGAB and KGAC - EASI 75                                                                         |
| Analysis Description                                                                                   | Other endpoint: Proportion of participants achieving EASI 75 at Week 52 among Maintenance Week 16 Escape Population who are nonresponders at Week 16 | Other endpoint: Proportion of participants achieving EASI 75 at Week 52 among Maintenance Week 16 Escape Population who are nonresponders at Week 16 | Other endpoint: Proportion of participants achieving EASI 75 at Week 52 among Maintenance Week 16 Escape Population who are nonresponders at Week 16 |
| Statistical Model                                                                                      | Escape supportive estimand (hybrid): MCMC-MI b                                                                                                       | Escape supportive estimand (hybrid): MCMC-MI b                                                                                                       | Escape supportive estimand (hybrid): MCMC-MI b                                                                                                       |
| Descriptive Statistics and Estimate Variability                                                        | Treatment group                                                                                                                                      | PBO nonresponders to LEB 250 mg Q2W                                                                                                                  | LEB nonresponders to LEB 250 mg Q2W                                                                                                                  |
| Descriptive Statistics and Estimate Variability                                                        | Number of participants (Nx)                                                                                                                          | 159                                                                                                                                                  | 147                                                                                                                                                  |
| Descriptive Statistics and Estimate Variability                                                        | Response, n (%)                                                                                                                                      | 139 (69.4)                                                                                                                                           | 124 (57.7)                                                                                                                                           |
| Descriptive Statistics and Estimate Variability                                                        | 95% CI                                                                                                                                               | (62.8, 76.0)                                                                                                                                         | (50.9, 64.6)                                                                                                                                         |
| Analyses                                                                                               | Analyses                                                                                                                                             | Analyses                                                                                                                                             | Analyses                                                                                                                                             |

a   Maintenance  primary  estimand  (hybrid), CMH-MCMC-MI:  Participants  who  received  systemic rescue  medication, discontinued treatment due to lack of efficacy, or transferred to escape arm had values set to their baseline value after this time through Week 52; participants who received topical rescue medication or discontinued treatment due to other reasons had values set to missing; MCMC-MI was used to handle the remaining missing data. CMH test stratified by geographic region. Pooled analysis is additionally stratified for study factor.

b  Escape supportive estimand (hybrid), MCMC-MI: Participants who discontinued treatment due to lack of efficacy had values set  to their baseline  value after this time through  Week 52.  Data were treated  as missing after treatment discontinuation due to any other reasons. MCMC-MI was used to handle the remaining missing data.

Abbreviations: CI = confidence interval; CMH = Cochran-Mantel-Haenszel; EASI = Eczema Area and Severity Index; EASI 75 = at least 75% reduction  in EASI; EASI 90 = at least 90% reduction  in EASI; IGA = Investigator's Global Assessment; LEB = lebrikizumab; MCMC-MI = Markov Chain Monte Carlo Multiple Imputation; n = calculated number of participants experiencing endpoint; Nx = number of participants in the analysis population; PBO = placebo; Q2W = every 2 weeks; Q4W = every 4 weeks; vs = versus; W = week.

## 2.6.5.6. Supportive study(ies)

An overview of the supportive studies is provided in Table 56.

<div style=\"page-break-after: always\"></div>

Table 56: Supportive Clinical Studies in AD

<!-- image -->

|                            | StudyKGAA (LTE Study) (KGADParticipants in Study KGAAa) Phase 3   | Study KGAE Phase 3          | StudyKGAG Phase 2                                                                                                             | StudyKGAH Phase 2   | Study KGAF Phase 2b                                  |
|----------------------------|-------------------------------------------------------------------|-----------------------------|-------------------------------------------------------------------------------------------------------------------------------|---------------------|------------------------------------------------------|
| N                          | 86                                                                | 206                         | 209                                                                                                                           | 55                  | 280                                                  |
| Participants               | Adultsandadolescentsb                                             | Adolescentsb                | Adults                                                                                                                        | Adults              | Adults                                               |
| Monotherapy or combination | Combination w/TCS                                                 | Monotherapyc                | Combination w/TCS                                                                                                             | Monotherapy         | Monotherapy                                          |
| Treatmentduration          | 100weeks                                                          | 52weeks                     | 12 weeks                                                                                                                      | 12 weeks            | 16 weeks                                             |
| Treatment                  | LEB 250mgQ2W+ TCS LEB 250mg Q4W + TCS                             | ·LEB250mgQ2W                | PBOQ4W+TCS LEB 250mg. single dose +TCS LEB125mg.single dose +TCS LEB125mgQ4W+ TCS                                             | TCS LEB 125mg Q4W   | PBOQ2W LEB 125mg Q4Wd LEB 250mg Q4Wd LEB 250mg Q2W d |
| Randomization ratio        | 2:1                                                               | Single-arm open-label       | 1:1:1:1                                                                                                                       | 1:1                 | 2:3:3:3                                              |
| Location of study          | Canada, Germany, Poland, US                                       | Australia,Canada Poland, US | Australia,Canada Czech Republic. Finland,France, Germany,Netherlands, Poland, South Korea, Spain, Switzerland, Taiwan. UK, US | Canada, US          | sn                                                   |
| Study status               | Ongoing (data cutoff date: 06June2022)                            | Complete                    | Complete                                                                                                                      | Complete            | Complete                                             |

- StudyKGAE results reported in this CSE are only for those participants originating from StudyKGADwho achieved an IGA 0 or 1 or EASI 75 at Week 16 without receivingrescue therapy,while treatedwithLEB250mg inStudyKGAD
- Adults (≥18 years);Adolescents (12 to &lt;18years Weighing≥40 kg)
- Participants were permitted to use TCS throughout StudyKGAE but were not required touse them at any time during the study
- Participants randomly assigned to LEB 125 mg Q4W received 250-mg loading dose at Week 0. Those assigned to LEB 250 mg Q4W received a 500-mg loading dose atWeek 0.Participants assigned toLEB250 mg Q2Wreceived 500-mg loading doses atWeek 0 andWeek 2.

## Study KGAA (J2T-DM-KGAA  or ADjoin)

KGAA is an ongoing long-term extension study which will provide data over 100 weeks when complete and will include patients from KGAB, KGAC, KGAD, KGAE and KGAK studies. The CRS is anticipated to become available by February 2025.

## Key interim results for patients enrolling from Study KGAD

Results in the initial MAA are reported from the 86 lebrikizumab responders from KGAD study who were re-randomised to treatment with lebrikizumab 250 mg Q2W or Q4W.

## IGA

Among lebrikizumab-treated  patients  who  were  responders at  week  16,  67.6%  and  71.7%  in  the lebrikizumab 250 mg Q4W and QW2 groups, respectively, maintained IGA 0 or 1 in Study KGAA after 56 weeks  of  continued  treatment.  Table  57  shows  the  proportions  of  lebrikizumab-responders  who maintained IGA 0,1, with  a 2-point or greater improvement from Baseline (Study KGAD Week 0) after 56 weeks of continued treatment.

<div style=\"page-break-after: always\"></div>

Table 57: Proportion of Patients Maintaining IGA 0,1 Induction Period Response at 56 Weeks of Treatment (MCMC-MI)

|                                   | LEB 250mgQ4W +TCS N= 29   | LEB 250mg Q2W + TCS N=57   |
|-----------------------------------|---------------------------|----------------------------|
| LEB-Responder's with IGA 0,1 (Nx) | 16                        | 37                         |
| Maintained response, n (%)        | 14 (86.8)                 | 28 (75.4)                  |
| 95% CI                            | 69.7, 103.8               | 60.8, 89.9                 |

Abbreviations: CI = confidence interval; CSE = clinical summary of efficacy; IGA =Investigator's Global Assessment; IGA 0,1 = IGA score of 0 or 1, with a 2-point or greater reduction from Baseline; LEB = lebrikizumab; MCMC-MI = Markov Chain Monte Carlo multiple imputation; PBO = placebo; N = total number of participants in the treatment arm; n = number of participants in the specified category; Nx = number of participants in analysis population; Q2W = every 2 weeks; Q4W = every 4 weeks; TCS = topical corticosteroids. Note: 56 weeks of treatment corresponds to Week 40 of Study KGAA.

## EASI 75

Among lebrikizumab-treated  patients  who  were  responders at  week  16,  81.2%  and  85.9%  in  the lebrikizumab 250  mg  Q4W  and  QW2 groups,  respectively, maintained  EASI 75  in  Study  KGAA after 56 weeks  of  continued  treatment.  Table  58  shows  the  proportions  of  Study  KGAD  lebrikizumabresponders who maintained EASI 75 after 56 weeks of continued treatment.

Table 58: Proportion of Patients Maintaining EASI 75 at 56 Weeks of Treatment (MCMC-MI)

|                                   | LEB 250mg Q4W + TCS N=29   | LEB 250mg Q2W + TCS N=57   |
|-----------------------------------|----------------------------|----------------------------|
| LEB-responder's with EASI 75 (Nx) | 29                         | 56                         |
| Maintained response, n (%)        | 24 (81.2)                  | 48 (85.6)                  |
| I0 %S6                            | 66.5, 96.0                 | 75.6, 95.7                 |

Abbreviations: CI= confidence interval; CSE =clinical summary of efficacy; EASI =Eczema Area and Severity Index; EASI 75 = 75% improvement from Baseline in EASI; LEB = lebrikizumab; MCMC-MI = Markov Chain Monte Carlo multiple imputation; N = total number of participants; n = number of participants in the specified category; Nx = number of participants in analysis population; Q2W = every 2 weeks; Q4W = every 4 weeks; TCS =topical corticosteroids.

Note: 56 weeks of treatment corresponds to Week 40 of Study KGAA.

## Study  KGAG  (GS29250  or  J2T-DM-KGAG or  TREBLE)  and  Study  KGAH  (J2T-DM-KGAH or ARBAN)

Study KGAG and KGAH were phase 2 studies that  provided initial effectiveness of lebrikizumab in AD. These studies are summarised in Table 59.

## Study KGAE (J2T-DM-KGAE  or ADore)

See section 2.6.5.4

## Study KGAF (J2T-DM-KGAF)

See section 2.6.5.1

## Study KGAK (J2T-MC-KGAK)

The study was a 16-week, randomised, double-blind, placebo-controlled, parallel-group study designed to  assess the impact  of lebrikizumab on vaccine immune  responses in adult  patients  (aged 18 to  55 years) with moderate-to-severe atopic dermatitis.

<div style=\"page-break-after: always\"></div>

Participants  were randomly assigned in  a 1:1  ratio  to  receive either lebrikizumab (a loading  dose of 500 mg administered at baseline and Week 2, and 250 mg Q2W thereafter through Week 14) or placebo. At Week 12, after  the predose  blood  sample vaccine  titres were  withdrawn, 1 dose of each  of the following 2 commercially available vaccines were administered to all participants still on study drug: Diphtheria and  Tetanus  Toxoids  and  Acellular  Pertussis  Vaccine Adsorbed  (Sanofi)  (Tdap),  and  Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (GlaxoSmithKline) (MCV). The antibody titres were determined 4 weeks later (Figure 18).

Figure 18: Study design for study KGAK

<!-- image -->

Abbreviations: MCV = Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (GlaxoSmithKline); Q2W = once every 2 weeks; Tdap = Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (Sanofi).

- Lebrikizumab 1oading dose of 500 mg was administered at Baseline and Week 2
- b The safety follow-up occurred at Week 26 (or approximately 12 weeks after last study drug injection).
- If eligible, participants continued to the long-term extension study (DRM06AD07/J2T-DM-KGAA).

The results of the primary endpoints are shown in Table 59.

<div style=\"page-break-after: always\"></div>

Table 59: Results of Primary Endpoints (Per Protocol Set Population)

| Primary Endpoints                                                                                                                                                          | PBO N=81   | LEB 250mg Q2W N=107   | Difference (90%) CI vs. PBO b   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----------------------|---------------------------------|
| The percentage of participants who develop a booster response a to tetanus toxoid 4 weeks after the administration of the Tdap vaccine at Week 16, n (%)                   | 58 (73.4)  | 78 (73.6)             | 0.3 (-10.2, 11.2)               |
| The percentage of participants who have positive antibody response a to Meningococcus C antigen of the MCV 4weeks after the administration of thevaccine at Week 16, n (%) | 60 (75.0)  | 86 (86.9)             | 12.2 (2.5, 22.0)                |

- Abbreviations: CI = confidence interval; IGA = Investigator's Global Assessment; LEB = lebrikizumab; MCV = Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (GlaxoSmithKline); N = number of participants in the analysis population; n = number of participants in the specified category; PBO = placebo; Q2W= every 2 weeks; Tdap = Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (Sanofi).
- The definitions of booster response to tetanus toxoid and positive antibody response to MCV are specified in Section 3 of Protocol J2T-MC-KGAK/DRM06-AD18.
- D Two-sided 90% confidence interval for the difference between treatment arms using the stratified (by baseline IGA severity) Newcombe approach.

## Usability of the autoinjector  and PFS-NSD  - Human factor  studies

For  the  autoinjector  a  use-related  risk  assessment, usability  studies  and  HF  validation  testing  was performed. The HFE  of PFS-NSD  presentation of lebrikizumab included an exploratory human  factors study and a threshold analysis.

The Applicant  also conducted  a  known problems analysis to  identify  use-related problems that  have occurred with  products  that  are comparable to  the  lebrikizumab autoinjector  and  PFS-NSD.  Findings were identified  and compiled from multiple sources, including  device constituent  manufacturer known use problems, clinical evaluation reports, complaint data from clinical trials, engineering evaluation of returned products, risk analyses, and predicate device human factors studies.

The lebrikizumab autoinjector was found to fulfil the usability needs of the intended users and the study results supported the safe  and effective  use of the PFP. All use problems observed  were  already  identified in  the use-related risk analysis and are known use problems. No  new or unanticipated  use problems were observed.

Based on the results of the Final Formative Human Factors Study #2 (RTP-814408) and the validation protocol advice  from  FDA the Applicant decided  to exclude  adolescent  patients from  the group of intended users for self-injection in the human factors study and stated that the adolescent patients must receive injections from a caregiver  or  HCP. This was because  untrained adolescent  user (without assistance from a guardian) represented a high-risk scenario  and also overdosing  errors  were made by three adolescents in  the  formative  studies.  However,  the  PI  texts  in  and  PL  differ  from  this  stating  that  it  is  only recommended that lebrikizumab is administered by or under supervision of an adult and the healthcare professional determines if self-injection is appropriate. The Applicant has adequately justified that the commercial  settings  differ  from  the  human  factor  study  settings  and  adolescent  patients  or  their caregivers will  receive instructions  on  the  dose  regimen and  training  in  the  use  of  the  device by a healthcare provider prior to use. Therefore it  is reasonable to assume that  adolescents will be able to appropriately administer the drug under adult supervision.

The Applicant has adequately assessed the  use-related risk of the lebrikizumab PFS-NSD through the HFE process and was found to fulfil the usability needs of the intended users.

<div style=\"page-break-after: always\"></div>

The  IFU  contains  step  by step  instructions  on  how  to  inject  with  the  lebrikizumab autoinjector  and lebrikizumab PSF-NSD along with graphic representations of what each step looks like.

## 2.6.6. Discussion on clinical efficacy

The clinical program of lebrikizumab in moderate-to-severe AD consists of 3 pivotal studies, evaluating efficacy  of  lebrikizumab  as  monotherapy  (studies  KGAB  and  KGAC)  or  in  combination  with  TCS (study KGAD).

The  finally  agreed  indication  for  lebrikizumab  is  as  follows: 'Lebrikizumab  is  indicated  for  the treatment  of moderate-to-severe  atopic  dermatitis  in adults and  adolescents  12 years  and older with a body weight of at  least 40 kg who are  candidates  for systemic  therapy' .  SmPC further states that lebrikizumab can be used with or without TCS or TCI: 'Lebrikizumab can be used with or without topical corticosteroids. Topical calcineurin inhibitors may be used, but should be reserved for problem areas only, such  as the  face,  neck, intertriginous  and  genital  areas'. The initially  proposed indication did not include body weight restriction, but was later modified upon CHMP's request, as there was no clinical data in patients with a body weight &lt; 40 kg.

The Applicant sought SA from EMA initially in 2013 (EMA/CHMP/15140/2013)  and follow-up SA in 2016 (EMA/CHMP/24061/2017). At the time of the initial advice in 2013, no studies in AD had been conducted and e.g. protocol(s) for Phase 3 studies were not available. After the initial EMA SA, the Applicant's plans evolved substantially. Further,  at the time of the follow-up SA (EMA/CHMP/24061/2017),  only results from the initial Phase 2 studies KGAG (TREBLE) and KGAH (URBAN) were available, and the plans of the Phase 3 pivotal studies were further modified after completion of the Phase 2b dose-range finding study (KGAF). In general, however, it can be concluded that  no discrepancies between the EMA SA and the conducted Phase 3 studies are identified that would be critical for  an adequate  assessment of the efficacy of lebrikizumab in moderate-to-severe AD.

Overall, the extent of the clinical program seems adequate for evaluation of efficacy of lebrikizumab in moderate-to-severe AD in adults and adolescents.

## Design and conduct of clinical studies

## Pivotal studies KGAB KGAC and KGAD

## Study design and treatments

KGAB and KGAC studies were similar in design and consisted of 16-week induction period where subjects were randomly assigned 2:1 to lebrikizumab 250  mg Q2W (with a loading dose of 500 mg at baseline and week 2) or placebo, and 36-week maintenance treatment  period where the responders from the 16-week induction period (i.e. patients achieving IGA score of 0 or 1, or EASI 75, and not receiving any rescue treatment) were re-randomised 2:2:1 to  lebrikizumab 250  mg Q2W,  250  mg Q4W or placebo (maintenance blinded period). Non-responders or subjects who required rescue medication during the induction  period, were enrolled into escape arm receiving open-label lebrikizumab 250 mg Q2W until week 52 (maintenance escape period). Rescue medication during induction period included any topical or  systemic medication.  TCSs were prohibited  during  the  induction  period  (unless used  as  a rescue therapy) but  permitted intermittently  during  the maintenance period. Patients using  TCS as a rescue therapy  during  the  induction  period  could  continue  using  study  drug  until  Week 16  but  were  then assigned to Escape arm. On the other hand, patients using systemic rescue therapy during the Induction period, discontinued the study drug, but could enter the Escape arm after appropriate washout.

In KGAD study, patients were randomised 2:1 to receive lebrikizumab 250 mg (with  a loading dose of 500 mg at baseline and week 2) + TCS or placebo + TCS for 16 weeks. Low- and mid-potency TCS was

<div style=\"page-break-after: always\"></div>

provided to be used as needed. The use of low potency TCI also permitted in sensitive areas, but not supplied by the study site.

Overall, the study designs for the 3 pivotal studies were appropriate. In terms of lebrikizumab doses in the  pivotal  studies,  the  data  from  the  16-week  Phase  2b  study  KGAF  supported  selection  of  the lebrikizumab 250 mg Q2W (with the 500 mg loading doses at weeks 0 and week 2) as the induction dose (weeks 0-16)  for  the  Phase 3  studies.  The  results  of  the  primary efficacy analysis showed  a  dosedependent, statistically significant reduction in EASI scores from baseline to Week 16. The reductions, i.e. LS mean percentage change (SD) in EASI, were observed in the 250 mg Q2W -72.09% (37.229%), 250 mg Q4W -69.21% (38.282%) and in 125 mg Q4W -62.34% (37.266%). Given the fact that the 250 mg Q4W dose (with baseline loading dose of 500 mg) demonstrated statistically significant efficacy in terms of the primary and several secondary endpoints, the Applicant selected both 250 mg Q2W and Q4W as maintenance doses in Phase 3 to determine whether a lower dosing frequency was adequate once response was  achieved, or  whether the  induction  dosing  frequency should  be continued,  which seems well justified. Despite the lack of active comparator, the design of the pivotal study is considered acceptable by CHMP to characterise the efficacy profile of lebrikizumab in AD.

In  terms  of  concomitant  medications,  e.g.  use  of  anti-histamines,  the  complete  list  of  permitted concomitant  treatments  was  initially  not  found  in  the  submitted  dossier. Upon  CHMP's  request,  the Applicant  provided  the  full  list.  It  seemed  that  many  participants  used  the  prohibited,  rescue  or intermittent  corticosteroid treatments  during induction  and  maintenance periods of the  studies KGAB and KGAC. Upon request, the Applicant further confirmed that  the protocols were strictly followed, i.e. that  concomitant  treatments  were  recorded  as  protocol  deviations  or  that  the  study  drug  was discontinued per protocol where applicable.

## Study population

The eligibility criteria for the KGAB and KGAC studies were identical. The enrolled patients were adults or adolescents ≥12 to &lt;18 years of age and weighing ≥40 kg with chronic AD that had been present for ≥1 year (according to American Academy of Dermatol ogy Consensus Criteria), and been a candidate for systemic therapy. The AD was defined as moderate-tosevere at baseline by EASI score ≥16, IGA score ≥3 and ≥10% BSA of AD involvement, which can be supported. The patients were to apply a stable dose of  non-medicated topical  moisturiser  daily throughout  the  study.  Overall, the  inclusion  criteria  were appropriate for an AD  study. The enrolled patients were to  have a history of inadequate response to treatment  with  topical medications;  or determination that  topical  treatments are otherwise medically inadvisable. In terms of the  key exclusion criteria, patients  using topical  medication, including  TCSs, TCIs, PDE4 inhibitors or prescription moisturisers, as well as systemic medication, e.g. immunosuppressive/immunomodulating  agents,  phototherapy/photochemotherapy  or  biologics  were excluded from the study. Otherwise, the exclusion criteria were mostly related to safety of the patients.

Overall, the eligibility criteria in the KGAB and KGAC studies are acceptable. Some of the inclusion and exclusion  criteria  were  amended  during  the  study. However,  the  changes  were  mostly minor clarifications, and it seems unlikely that the changes had relevant impact on the study conduct.

The eligibility criteria for the KGAD study were  identical to the KGAB  and KGAC  studies in terms of patient population (adults  and adolescents) and criteria of moderate-to-severe AD  (chronic AD  present for at least 1 year (according to American Academy of Dermatology Consensus Criteria), EASI score ≥16, IGA score ≥3 and ≥10% BSA), as well as most of the other criteria. In the KGAD study, however, patients with prior exposure to dupilumab could enter the study after 8 weeks washout. Further, some eligibility criteria due to the concomitant use of TCS in the KGAD study differed from the monotherapy studies, e.g. patients with important side effects to TCS were excluded from the study.

<div style=\"page-break-after: always\"></div>

## Endpoints

The co-primary endpoints of all three pivotal phase 3 studies KGAB, KGAC and KGAD were percentage of patients with  an IGA score of 0 or 1 and a reduction ≥2 points from baseline to Week 16, and patients achieving EASI 75 at Week 16. These endpoints measure the same domain (improvement in extent of AD on skin), are  widely used, aligned with the CHMP SA  and acceptable. Both measures are dichotomised derivatives of the actual scales used, IGA and EASI.

Several key secondary, as well as other (secondary) efficacy endpoints were included in the studies. These  endpoints  can  be  considered  relevant efficacy  endpoints  for  AD,  including  the  used  patientreported outcome measures, i.e., DLQI, POEM and PROMIS.

Two new PROs to provide additional daily data on symptoms of AD were incorporated into the studies, i.e., Pruritus NRS and Sleep-Loss Scale. The former asks about worst itching during the last 24 hours on a scale from 0 to 10, while Sleep-Loss Scale concerns the level of interference of itching  on sleep last night on a likert scale: 0= not at all, 1= a little, 2= moderately, 3= quite a bit, and 4= unable to sleep. The psychometric validation of these assessments has been completed and is described in separate PRO dossiers. Both measures are single-item and included in the daily electronic diary. The validation work based on the Phase 2b trial as well as the data analysis in Phase 3 studies is based on weekly average scores that are calculated if data from at least 1 of the 7 prior days was provided by the subject.

## Sample size

The  sample  size assumptions  were  informed  by  the  results  of  the  Phase 2b  dose-ranging  and  well applicable to  the  then  planned  phase 3  studies.  For  KGAD,  reasonable adjustments  were  made the expected  response rates  due  to  the  concomitant  use  of  TCS.  Each  of  the  studies  were  more  than sufficiently powered for detecting a clinically relevant difference in efficacy of the induction treatment. The chosen sample size was driven by the need to collect sufficient safety data and to ensure sufficient responders for the Maintenance Period which is acceptable.

## Randomisation

Randomisation  by  strata  defined  by  three  factors  representing  geography,  a  demographic  factor (adolescent patients 12 to &lt;18 years versus adults ≥18 years) and disease severity (IGA 3 versus 4) is conventional  and  acceptable.  The  three  factors  generate 3  x  2  x  2  =  12  randomisation  lists  and, inevitably, few subjects will enter a study from some of the strata. As such the procedure is acceptable if  the  stratification  information  is  adequately  taken  into  account  in  the  data  analysis.  The  primary analyses  for  the  dichotomised  co-primary  endpoints  are  fully  stratified  such  that  comparisons  are performed within each of the 12 strata and then combined with a specified weighing method. According to the protocol, the quantitative variables were to be analysed somewhat analogously by including each stratification strata in an ANCOVA model, however, this was turned into a conventional data modelling approach including a main effect for each stratification level in the model. While model used appears to deviate somewhat from the  model that  was pre-stated, it  is conventional and in accordance with  the EMA Guideline on adjustment for baseline covariates in clinical trials (EMA/CHMP/295050/2013).

## Blinding

The  standard  double-blind,  placebo-controlled experimental  setting  applied  in  all  of  the  three  main studies is considered  adequate for  isolating the pharmacological effect  of the IMP on signs and symptoms of AD. The active and placebo PFS's were identical in appearance. Furthermore, lebrikizumab was not associated with immediate side-effects that would risk the blinding.

In studies KGAB and KGAC, during the maintenance period, patients that reached EASI 75 or IGA 0,1 response at Week 16,  were re-randomised to  placebo (withdrawal)  or lebrikizumab at  Q2W  or Q4W dosing frequency. Blinding to the treatment assignments during the initial 16 weeks and that during the

<div style=\"page-break-after: always\"></div>

maintenance period was ensured by using placebo dummies as needed: to mimic loading doses and to mask the difference between withdrawal, reduced dosing frequency (Q4W) and continued Q2W during the maintenance period. Also, for those that entered the Escape arm at Week 16 or later, blinding of the previous treatment assignment was ensured by using, as applicable, dummy loading doses. However, the escape treatment of lebrikizumab Q2W was known.

The blinding was opened following database locks for induction and maintenance periods separately.

Overall,  the  blinding  procedures  are  considered  appropriate  to  avoid  bias  in  individual  patient assessments and  in  the  statistical  analysis  and  reporting.  Specifically, blinding  was  ensured for  the assessments relevant  to  the  two  main  types  of  questions:  efficacy during  induction  treatment  and efficacy during maintenance among lebrikizumab responders at Week 16.

## Statistical methods

In the three pivotal studies, the comparability of the treatment arms with respect to the pharmacological effect is distorted  by intercurrent  events: treatment discontinuation  and  the allowance/use of rescue medications. The Applicant describes the primary estimand of each of the Phase 3 trials as ' the difference between  treatment  conditions,  i.e.,  Lebrikizumab  vs  Placebo,  in  the  target  patient  population,  in successful responses or means after  16  weeks  achieved without  use  of rescue medication  and  if all patients continued with treatment except those who discontinued due to lack of efficacy '. Indeed, ideally the  treatment  effect  would  have been  assessed without  use  of  rescue medication among  treatment compliant patients, and the fact these intercurrent events did happen should not be allowed to lead to anticonservative analyses.

Applicant's primary estimand and supportive estimand both consider any use of such rescue medication as a treatment failure. The supportive estimand for dichotomous variables also consider any treatment discontinuation  as  a  treatment  failure.  This  approach  may  not  be  conservative  and  may  lead  to overestimation of treatment effect especially for endpoints that are not closely related with the decision to initiate rescue  medication or discontinue study treatment due to lack of efficacy.  Upon CHMP's request, the Applicant provided descriptive analyses of disease activity and HRQoL (IGA, EASI, Pruritus NRS and DLQI) before and after initiation  of rescue medication to allow comparison of the outcome trajectories that tended to precede rescue medication as compared with those that did not. Based on these analyses, although participants who used rescue medication generally had higher disease activity than those who did not, extensive overlap was noted in outcome profiles within the same treatment group. It was also noted  that  few  patients  continued  efficacy  assessment  after  premature  discontinuation  of  study medication. These analyses further questioned the necessity of declaring 'nonresponse' solely based on rescue medication and highlighted the need to evaluate treatment effect as  per treatment policy strategy.

The Applicant was requested to analyse the primary and key secondary endpoints in accordance with ITT principle,  i.e.,  treatment  policy estimand  for which  data  are used regardless of any intercurrent events. Furthermore, should rescue medication or treatment discontinuation also lead to missing data, any imputation models was to account for what is known about the subjects status with respect to these intercurrent events. Still, the analyses provided by the Applicant imputed any missing data with MCMCMI which,  in  practice, implies a hypothetical  scenario where the patients  with  missing data had  used randomised treatment and rescue medication in a similar manner with those that provided data. Despite this  caveat,  these  analyses  supported  the  existence  of  robust  treatment  effects  even  if  rescue medications were allowed, whether measured in terms of difference in proportion of responders or mean change from baseline. As compared with  the prespecified primary estimand, these analyses that  used data regardless of rescue medication, however, attenuated treatment effect considerably for DLQI which could have been expected. This endpoint may be less driven by the factors that  drive the  decision to initiate rescue treatment.

<div style=\"page-break-after: always\"></div>

Upon CHMP's request, the Applicant clarified that for estimation of treatment-arm specific LSmeans, the default covariate weights of the respective SAS procedure were used. These imply a target population where a third  of patients are from each region, half  are adolescents and half have IGA of 3.  As was expected based on theoretical grounds, use of covariate weights that correspond to study population improved the precision of estimation of LS means: The difference in SE was the greatest for DLQI: the SEs of the  LSmeans reported in  CSR were 2-3  -fold greater in comparison with  SEs estimated using covariate weights that correspond to the study population. The LS mean point estimates happened to differ only little depending on whether the default covariate weights or covariates weights proportional to  the study  population  were used.  Also noting  that  no choice of covariate weights  could  impact the estimate of treatment effect, the issue was not pursued further.

## Protocol amendments

Substantial  changes in  the  pivotal  trials  were described in  the  initial  MAA  and further  clarified upon CHMP's  request. It  can  be concluded that  these changes did  not  have relevant impact  on the  study outcomes.

## Protocol deviations and other GCP issues

Following primary outcome database lock in study KGAD (Week 16), a site audit triggered by statistically implausible data at one study site resulted in a critical finding. Due to this GCP  non-compliance at 1 study site,  35  patients  were excluded from the  mITT population,  18  from Study KGAC and 17  from Study KGAD. According to the Applicant, any efficacy analyses performed on the data of these patients would have led to inconclusive and unreliable results due to the unreliable baseline AD values. For this reason, efficacy analyses in this population were not performed. Based on further details upon CHMP's request, the  use of  using  the  mITT population  as the  primary analysis population  appeared justified and  the findings do not change the overall conclusion on the B/R.

16.3% and 15.5% of the patients during the Induction Period and 8.6 % and 7.9% of the patients during the Maintenance Period were identified to have at least 1 important protocol deviation in the KGAB and KGAC studies,  respectively. Upon  CHMP's  request,  the  Applicant  provided  further  discussion  on  the impact of important protocol deviations on participants' safety and overall assessment of study results. It can be concluded that  participants' safety was ensured and that  no major impact on assessment of results is expected.

In  KGAD  study,  altogether 52.6%  of  the  patients  were  identified  with  at  least  1  important  protocol deviation. Although  this is  can be considered a high number, a majority were in the  category 'study procedure/missing safety assessments', which  are unlikely  to  affect assessment  of efficacy. The  18 patients  in  KGAC study  and  17  patients  in  the  KGAD  study were  included in  the  important  protocol deviations in the category 'inclusion/exclusion'.

All pivotal studies were conducted during the COVID-19 pandemic and altogether 10.8%,  10.3% and 7.9% of the patients in the KGAB, KGAC and KGAD studies reported at least 1 protocol deviation related to the COVID-19 pandemic. According to the  Applicant, however, the primary, coprimary, and all key secondary endpoints were not impacted.

## Efficacy data and additional analyses

## Participant  flow

Altogether 424 patients were randomised in the KGAB study, 283 to the lebrikizumab 250 Q2W group and  141  to  placebo  group.  157  (55.5%)  of  the  patients  lebrikizumab  group  were  considered  as responders (vs. 17%  in the placebo group), were re-randomised into the maintenance blinded period and received either placebo, lebrikizumab (n=32),  lebrikizumab 250  mg Q4W (n=63)  or lebrikizumab 250 mg Q2W (n=48), out of which 68.8%, 85.7% and 77.4% of patients completed the 52-week study,

<div style=\"page-break-after: always\"></div>

respectively. Altogether 106 patients (37.5%) receiving lebrikizumab during the induction period were classified  as non-responders and were enrolled into the escape arm, and 20 patients (7.1%) discontinued the study prior to week 16.

A total of 445 patients  were randomised into  the KGAC study. Following  findings of a site audit, data from all 18 participants at a specific site were excluded, creating an mITT Population of 427 participants, 281  in the  lebrikizumab 250  Q2W  group and 146  in the  placebo group. 134  (47.7%)  of the  patients lebrikizumab  group  were  considered  as  responders  (vs.  15.1%  in  the  placebo  group),  were  rerandomised into  the  maintenance  blinded  period  and  received either  placebo, lebrikizumab  (n=28), lebrikizumab 250 mg Q4W (n=55) or lebrikizumab 250 mg Q2W (n=51), out of which 78.6%,  92.7% and 80.4% of the patients completed the 52-week study, respectively. Altogether 125 patients (44.5%) receiving lebrikizumab during the induction period were classified as non-responders and were enrolled into the escape arm, and 22 patients (7.8%) discontinued the study prior to week 16.

Percentages of screen failures were approximately 21% in KGAB and 27% in KGAC study, being in the range presented for the pivotal studies for mAbs approved in moderate to severe AD indication. Upon CHMP's request, the Applicant provided further details on the reasons for screen failures and no external validity issues arose.

In the  KGAD  study,  228  participants  were randomly assigned to  treatment groups.  mITT population comprised of 211 participants (145  in the lebrikizumab 250 Q2W + TCS group and 66  in the placebo +TCS group). Altogether  134  patients  (92.4%)  in  the  lebrikizumab 250  Q2W  +  TCS  group  and  58 patients (87.9%)  in the placebo +TCS group completed the 16-week treatment. Percentage of screen failures  was approximately  27%, being roughly similar as  for add-on study for  mAb approved  in moderate to severe AD indication. The Applicant provided reasons for screen failures. No external validity issues arose.

## Demographic and other baseline characteristics

Overall, the demographic and baseline characteristics were well balanced between the study groups in the  KGAB,  KGAC  and  KGAD  studies  in  terms  of  age,  percentage  of  adolescent  patients,  gender, weight/BMI and duration since the AD onset. Across the 3 pivotal studies, 49.7% were females, so both genders  were  equally  represented.  Overall,  patients  from  the  EU  represented  27.3%  of  the  total population; more specifically 32.5% in study KGAB, 26.7% in study KGAC and 18.0% in study 18.0%.

Overall, 61.5% of patients had a baseline IGA of 3 (moderate atopic dermatitis), 38.5% of patients had a baseline IGA of 4 (severe atopic dermatitis), and 54.8% of patients had received prior systemic treatment. The mean baseline EASI was 29.6, the mean baseline Pruritus NRS was 7.2 and the mean baseline DLQI was 15.5.

In terms of prior AD therapies, the  study groups were well  balanced in  all pivotal studies. Almost all reported prior use of TCS and depending on the  study prior TCI use was  reported by 33.6-43.4%  of patients. Approximately half of patients reported use  of prior  systemic treatment in pivotal studies. Unlike in KGAB and KGAC studies,  prior use of dupilumab  was allowed in KGAD study  and was reported by 13.7% of the patients (13.8% in the lebrikizumab 250 mg Q2W + TCS group and 13.6% in the placebo + TCS group). In KGAD study, previous tralokinumab use was reported by 1 patient in each group.

## Primary  endpoints results (Weeks 0 to 16)

Lebrikizumab demonstrated a statistically significant and clinically relevant improvements over placebo when used as monotherapy (KGAB and KGAC) or in combination with  TCS (KGAD) and the co-primary endpoints,  i.e.  proportion of  patients  achieving  EASI 75  a nd IGA 0,1  (with  ≥2  point  reduction  from baseline) at Week 16 were met in all 3 pivotal studies.

<div style=\"page-break-after: always\"></div>

## IGA 0,1

Based on the primary analysis using the 'hybrid' estimand, 43.1% and 33.2% of patients treated with lebrikizumab and 12.7% and 10.8% of patients treated with placebo achieved IGA 0,1 with ≥2 -point reduction in the KGAB and KGAC studies at Week 16. This translated into a 29.7% (95% CI 21.6, 37.8, p&lt;0.001)  and 21.9%  (95%  CI 14.2,  29.6,  p&lt;0.001)  difference from placebo in the  KGAB and KGAC studies, respectively.

In KGAD, 41.2% of patients treated with lebrikizumab + TCS and 22.1% of patients treated with placebo + TCS achieved IGA 0,1 with ≥2 -point reduction at Week 16. This translated into a 18.3% (95% CI 5.1, 31.5, p=0.011) difference from placebo.

## EASI 75

In KGAB and KGAC, 58.8% and 52.1% of patients treated with lebrikizumab and 16.2% and 18.1%  of patients treated with placebo achieved EASI 75 at Week 16. This translated into a 42% (95% CI 33.3, 50.6,  p&lt;0.001)  and 33.3%  (95%  CI 24.4,  42.2,  p&lt;0.001)  differe nce from placebo in the  KGAB and KGAC studies, respectively.

In KGAD, 69.5% of patients treated with lebrikizumab + TCS and 42.2% of patients treated with placebo + TCS achieved EASI 75 at Week 16. This translated  into  a 26.4%  (95%  CI 12.1,  40.8,  p&lt;0.001) difference from placebo.

The supportive 'composite' estimand yielded similar results to the primary analysis of the co-primary endpoints, with statistically significant differences  and clinically relevant  improvements  with lebrikizumab over placebo when used either as monotherapy (KGAB and KGAC) or in combination with TCS (KGAD).

Unlike in KGAB and KGAC studies, prior use of dupilumab was allowed in KGAD study and was reported by 13.7%  of the  patients  (13.8%  in  the  lebrikizumab 250  mg Q2W  +  TCS group and  13.6%  in  the placebo + TCS group). Subgroup analyses of the  primary and  key secondary endpoints suggest that lebrikizumab shows benefit also in patients previously exposed to dupilumab. However, the number of these patients is too small to make any firm conclusions.

## Key secondary  endpoints (Weeks 0 to 16)

For the Induction Period, the key secondary endpoints in studies KGAB and KGAC supported the effects seen  in  the  co-primary endpoints.  In  KGAB and  KGAC, 38.3%  and  30.7%  of  patients  treated  with lebrikizumab achieved EASI 90 at  Week 16 compared to  9.0% and  9.5% of participants treated with placebo. The treatment difference between lebrikizumab and placebo was higher in KGAB compared to KGAC: 28.8 (95% CI 21.3, 36.3) vs 20.7 (95% CI 13.3, 28.1).

In KGAB and KGAC, 45.9% and 39.8% of patients treated with lebrikizumab achieved pruritus NRS score ≥4 point improvement at Week 16 compared to 13.0% and 11.5% of participants treated with placebo. The treatment difference between lebrikizumab and placebo was slightly  higher in KGAB compared to KGAC: 32.9 (95% CI 24.6, 41.3) vs 28.3 (95% CI 20.0, 36.5).

Overall,  for the secondary  endpoints under multiplicity adjustment, statistically significant improvements (i.e. p&lt;0.05) in lebrikizumab group vs. placebo group were seen in all endpoints, except for 'Percentage of patients with a Pruritus NRS of ≥4 points at Baseline who achieve a ≥4 -point reduction from Baseline to Week 2' in KGAC study.

Similarly to the KGAB and KGAC studies, the key secondary endpoints in the KGAD study supported the effects seen in the co-primary endpoints. 41.2% of patients treated with lebrikizumab + TSC achieved EASI 90 at  Week 16  compared to  21.7%  of participants  treated with  placebo +  TSC. The treatment difference between  lebrikizumab +  TSC and placebo +  TSC was 18.9  (95%  CI 6.1,  31.7).  50.6%  of patients treated with lebrikizumab + TSC achieved pruritus NRS score ≥4 point improvement at Week

<div style=\"page-break-after: always\"></div>

16 compared to 31.9% of participants treated with placebo + TSC. The treatment difference between lebrikizumab and placebo was 19.2 (95% CI 4.3, 34.1). Overall, for all key secondary endpoints under multiplicity  adjustment,  a statistically  significant  improvements were seen in  lebrikizumab group  vs. placebo group.

## Other  secondary endpoints (Weeks  0 to 16)

In addition to the co-primary  and several  major  secondary  efficacy endpoints, the pivotal Phase 3 studies included an extensive list of  other secondary  endpoints. Only selected secondary  endpoints are  presented by the Applicant. Overall, lebrikizumab demonstrated an improvement over placebo in several of these secondary endpoints, whether used as monotherapy or in combination with TCS.

## Maintenance  Treatment  period (KGAB and KGAC)

Regarding the key secondary endpoints specific for maintenance period, in lebrikizumab-responders rerandomised to the Maintenance Blinded Period, the maintenance of EASI 75 response, IGA 0,1 (with a ≥2 point improvement from Baseline), Pruritus NRS 4 -Point Improvement and percentage improvement in EASI was higher in patients re-randomised to lebrikizumab vs. placebo. In general, the maintenance of responses from week 16 to week 52 was similar in patients re-randomised to lebrikizumab Q2W and Q4W, or even somewhat better in the lebrikizumab Q4W group, supporting the proposed Q4W dosing after  the  Induction  Period.  It  is  noted  that  a  relatively large  proportion  of  patients  that  were  rerandomised  to placebo  after  receiving  lebrikizumab  during the Induction Period  (lebrikizumab withdrawal), maintained the treatment responses i.e. in the pooled analysis of KGAB and KGAC studies 66.4% maintained EASI 75 response, 47.9% maintained IGA 0,1  (with a ≥2 point  improvement from Baseline) and 66.3% maintained Pruritus NRS 4-Point Improvement at Week 52.

Simulation  data  suggested  that  patients  with  adequate  initial  response  may  continue  to  maintain response  with  250  mg  QXW  dosing  but  there  is  no  clinical  data  to  confirm  this.  It  is  therefore recommended that the Applicant conducts a clinical study that compares Q4W vs. QXW dosing during the maintenance period in subjects who are initial responders at week 16.

## Maintenance  Week  16 Escape Population Results (KGAB and KGAC)

Among the patients who were treated with placebo and lebrikizumab during the Induction Period and received open-label lebrikizumab 250 mg Q2W (Maintenance Week 16 Escape Population), 52.5% and 40% achieved IGA 0,1 and 83.9% and 76.9% achieved EASI 75 at Week 52. The responses were slightly higher in patients that  received placebo during the Induction Period, but  this group also received two loading doses of lebrikizumab when entering the Escape Arm and used somewhat more rescue therapy, i.e.  42.2%  of  patients  that  received placebo  vs. 28.6%  vs. those  that  received lebrikizumab during Induction Period, respectively, received any rescue therapy during Weeks 16 to 52.

The proposed Posology Section of the SmPC states that 'Consideration should be given to discontinuing treatment in patients who have shown no response after 16 weeks of treatment'. Given that part of the lebrikizumab non-responders during  the  Induction  Period achieved clinically relevant responses (e.g. EASI 75, IGA 0,1) during continued treatment, the optimal time point for lebrikizumab discontinuation in non-responders was inconclusive. Upon  CHMP's request, the Applicant provided further analysis on patients  that  were  partial  responders at  week  16,  showing  that  some  patients  could  benefit  if  the induction dosing is continued until week 24. Consequently, the SmPC was revised to include the option to continue Q2W up to week 24 in patients with initial partial response.

## Rescue therapy

During the Induction Period in KGAB and KGAC studies, the use of rescue medications was clearly more frequent in  the placebo group vs. lebrikizumab group. TCS was the most  common rescue treatment, used by 29.8% vs. 8.5% of the patients  (KGAB), and 37%  vs. 16.7%  (KGAC) of the  patients  in the

<div style=\"page-break-after: always\"></div>

placebo and lebrikizumab groups, respectively. Systemic rescue treatment was used by 7.8% vs. 2.5% of the  patients  (KGAB), and 6.2%  vs. 2.8%  (KGAC) of the  patients  in the  placebo and lebrikizumab groups, respectively. During the  Induction period, patients in the  lebrikizumab group demonstrated a 73% and 65% reduction in the risk of initiating rescue therapy vs. placebo in the KGAB study (HR: 0.27, 95% CI: 0.17 to 0.42) and KGAC study (HR: 0.35, 95% CI: 0.24 to 0.52), respectively. In pooled analysis for  the  KGAB  and  KGAC  study,  altogether  105  (36.6%)  placebo-treated  patients  vs.  83  (14.7%) lebrikizumab-treated patients required at least 1 rescue therapy before Week 16.

During the Maintenance Period of the KGAB and KGAC studies, there were less differences in the use of rescue medications between groups. In the pooled analysis, 18.3%, 16.1% and 12.4% of patients in the placebo group (lebrikizumab withdrawal), lebrikizumab 250 mg Q4W and Q2W, respectively, used any rescue medication. High-potency topical rescue therapy was used somewhat more in the placebo group (lebrikizumab  withdrawal),  i.e.  by  10%  of  the  patients  vs.  5.1%  and  4.4%  of  the  patients  in  the lebrikizumab 250 mg Q4W and Q2W groups, respectively.

Overall,  rescue therapy use was comparable for all treatment groups during the Maintenance Period. Use of high-potency topical rescue therapy was highest for patients re-randomised to placebo (lebrikizumab withdrawal). Use of systemic rescue therapy was low for all treatment groups.

In study KGAD, use of low-to-mid-potency  TCS and TCI was allowed to be used and not regarded as rescue therapy and therefore the overall use of rescue therapy was lower compared to the KGAB and KGAC monotherapy studies. Nevertheless, the use of rescue therapy was higher in the placebo + TCS group vs. lebrikizumab + TCS group. 10.6%  of patients  in  the placebo + TCS group used at  least 1 rescue therapy during the study compared to 4.1% in the lebrikizumab + TCS group, mostly high potency TCS (4.5% vs. 1.4%), and systemic treatment (7.6% vs. 3.4%).

In the  pooled analysis for the Week 16  Escape Arm of the  KGAB and KGAC study  where all patients received open label lebrikizumab 250 mg Q2W (Week 16 to 52), any rescue therapy was used slightly more in  patients  that  received placebo  (42.2%)  vs.  patients  that  received lebrikizumab  during  the induction period (28.6%).

## Subgroup analysis

Based on the subgroup analysis of pooled data from the Induction Periods of Studies KGAB and KGAC, and data from Study KGAD at Week 16, the treatment effect in subgroups were generally consistent with the overall study population, although in the pooled data from KGAB and KGAC studies, the proportion of patients achieving IGA 0,1, EASI 75 and EASI 90 was somewhat lower in patients in the weight group ≥100 kg vs. weight group ≤60 kg. For the Maintenance Period, the responses in the weight group ≥100 kg were somewhat higher with  Q2W dosing vs. Q4W dosing. However, the  number of patients  in the ≥100 kg subgroup was too low to make further conclusions based on these results. In summary, the proposed Q4W dosing in subjects ≥100 kg is acceptable, as the overall benefit -risk balance of Q4W dosing is considered positive also in these subjects.

## Adolescents

A subgroup analysis was performed for the adolescent population from the pivotal Phase 3 studies KGAB, KGAC and KGAD.  In the pooled  analysis  of  the  KGAB and  KGAC  studies,  46.6%  vs.  14.3%  of  the adolescent patients achieved IGA 0,1 and 62.0% vs. 17.3% achieved EASI 75 at Week 16 in lebrikizumab vs. placebo groups, respectively. In KGAD study,  57.3%  vs. 28.6%  of the  of the adolescent patients achieved IGA 0,1 and 88.0% vs. 57.1% achieved EASI 75 at Week 16 in lebrikizumab vs. placebo groups, respectively.  Furthermore,  16-week  results  were  presented  separately  for  the  KGAE  study,  which enrolled only adolescent patients. Altogether, these analyses provided evidence that  lebrikizumab has similar or somewhat better efficacy in adolescent population compared to adult population.

<div style=\"page-break-after: always\"></div>

KGAE study was an open label  52-week study,  with  the  aim  to  evaluate the  safety  and  efficacy of lebrikizumab in adolescent patients (from 12 years to &lt;18 years weighing ≥40 kg). The eligibility criteria were similar as in the Ph3 studies KGAB and KGAC in terms of moderate to severe AD, i.e. all patients had EASI≥16, IGA score≥ and BSA≥10%, and were candidate for systemic therapy. Altogether 206 patients were evaluated for efficacy (MCMC-MI analysis). At week 52, 62.6% had an IGA score of 0 or 1 and  a  reduct ion  of  ≥2  points  from  baseline,  and  81.9%  achieved  EASI  75.  It  is  noted  that  the lebrikizumab dose used in the study (after the 500 mg loading doses at week 0 and 2) was 250 mg Q2W from Week 4 through Week 52, which differs from the proposed maintenance dose of 250 mg Q4W after Week 16 in the SmPC. Nevertheless, the study provided supportive long-term efficacy data in adolescents and provided additional safety exposure data in this population.

## Supportive studies

In addition to the pivotal studies, the clinical program in AD includes a long-term extension study (LTE) up to 100 weeks (KGAA), a separate 52-week study in adolescents (KGAE) (see above) and supportive Phase 2 studies (KGAG, KGAH and KGAF). At the time of the initial MAA, the LTE study and a study to evaluate the effect of lebrikizumab on vaccine responses (KGAK) were ongoing. The CSR of the KGAK study was submitted  as part of the second round of assessment. Whereas immune responses to Tdap were not affected by lebrikizumab, significantly higher immune responses to MCV vaccine were seen in lebrikizumab-treated subjects vs. placebo-treated subjects. Upon request, the Applicant provided further discussion on the higher responses to the MCV vaccination in the lebrikizumab-treated group vs. placebo group. Although no clear root cause was identified, it is reassuring that the response rates to MCV in the lebrikizumab  group  was  within the range  reported  in  other  studies,  e.g.  with  dupilumab  and tralokinumab. Therefore, it can be concluded that the antibody responses to both non-live vaccines were not  negatively  impacted  by  the  concomitant  lebrikizumab  treatment.  The  results  of  the  effect  of lebrikizumab on vaccine responses is reflected in section 4.5 of the SmPC.

## KGAA study

In terms of the LTE study KGAA, the initial MAA included data for 86 lebrikizumab-responders from KGAD study,  who  were  re-randomised  2:1  to  receive  lebrikizumab  250  mg  Q2W  or  Q4W.  Out  of  the lebrikizumab-responders at week 16 of the KGAD study, 71.7% and 67.6% of the patients had IGA 0,1 response, and 85.9% and 81.2% had EASI 75 response after 56 weeks of continuous treatment in the lebrikizumab 250 mg Q2W and Q4W groups, respectively. Out of the lebrikizumab-responders who had IGA 0,1 or EASI 75 response at week 16, 75.4% and 86.8% maintained IGA 0,1 and 85.9% and 81.2% maintained EASI 75 in lebrikizumab 250 mg Q2W and Q4W groups, respectively after 56 weeks in KGAA study. The patients were allowed to use low to moderate potency TCS as needed, and over 70% of the patients used TCS. Rescue therapy, including high potency TCS and systemic rescue therapy, was used by 7.0% and 13.8% of the patients  in the  lebrikizumab 250 mg Q2W  and Q4W groups, respectively. Overall, the  efficacy results  were similar  in  the  lebrikizumab  250  mg  Q2W  and  Q4W  groups,  which support the Q4W dosing in the long-term treatment.

## 2.6.7. Conclusions on the clinical efficacy

Lebrikizumab demonstrated a statistically significant and clinically relevant improvements over placebo when used as monotherapy or in combination with TCS in adolescent and adult patients with moderate to severe AD who are candidate for systemic therapy. The co-primary endpoints were met in all 3 pivotal studies, supported by several key secondary efficacy endpoints. The proposed posology for the induction period is 500 mg at week 0 and week 2 followed by 250  mg every other week until  week 16. For the maintenance period, the proposed posology is 250 mg every four weeks. The posology is endorsed by CHMP. The CHMP concluded that the efficacy data supports the following indication: 'Ebglyss is indicated

<div style=\"page-break-after: always\"></div>

for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy'.

## 2.6.8. Clinical safety

The safety of lebrikizumab in the treatment of adults and adolescents with AD is supported by data from 13 studies included in the clinical development program for AD (6 phase 1, 3 phase 2 and 4 phase 3 studies). Placebo-controlled safety data in AD patients treated with the intended dose for 16 weeks was available from studies KGAB, KGAC, KGAD and KGAF. Long term safety data up to 52/56 weeks was available from studies KGAB, KGAC and KGAA (an extension study). Adolescents were included in studies KGAB, KGAC and KGAD. In addition, an open-label single arm study KGAE provided safety data in only adolescents.

Safety  data  are  presented  separately for  4  periods:  the  induction  period,  the  maintenance  period, combined induction  and maintenance period and any exposure to lebrikizumab. To evaluate safety for the  mentioned  periods, 6  different analysis sets  were defined. In  the induction period, 3  different analysis sets were defined: AD ALL PC Weeks 0 to 16 (also referred to as LEB with or without TCS), AD Mono PC Weeks 0 to 16 (also referred to as LEB monotherapy) and AD TCS PC Weeks 0 to 16 (from a single study - KGAD, also referred to as LEB+TCS). The maintenance period is evaluated in the AD Mono PC Weeks 16 to 52 set (Maintenance Period Placebo-Controlled Analysis Set; includes lebrikizumab responders during the induction period who were re-randomised to LEB Q2W, LEB Q4W or placebo during the  maintenance  period;  of  note:  patients  treated  with  placebo  during  induction  could  also  be  rerandomised to one of the 3 arms in maintenance). The combined induction and maintenance  period are evaluated in the AD Mono/TCS Weeks 0 to 52/56 set (Combined Induction and Maintenance Periods Analysis Set), while any exposure to lebrikizumab is evaluated in the AD All LEB set.

The safety population used in this application is the modified safety population , which includes all participants receiving at least 1 dose of study drug minus 38 participants (from studies KGAD, KGAC and KGAA; 36 lebrikizumab-treated and 2 placebo-treated patients) who were excluded due to unreliable data from one centre discovered during a site audit. Data for the concerned 38 participants are however available in the Dossier.

The most important analysis set is that which allows for assessment of causality between the treatment and safety outcome. This analysis set (AD ALL PC Weeks 0-16) includes the 16-week safety profile of lebrikizumab 250 mg Q2W in three placebo-controlled monotherapy studies (KGAF, KGAB, KGAC) and one placebo-controlled combo study  (KGAD). Data  from this  pooled analysis set were used to  report ADRs and frequencies in the product information.

Safety data for indications other than AD were provided as supportive safety data but these data were not integrated into the AD safety database due to differences in disease states and comorbid conditions, dose level and regimen, and drug product and process change.

Supportive safety data was also provided from a study to evaluate the effect of lebrikizumab on vaccine responses in patients  with  AD (KGAK). The study was ongoing at  the time of data cut-off  and safety results were not pooled in the integrated analysis set but are presented separately.

## 2.6.8.1. Patient exposure

As  of  the  data  cutoff  date  of  06  June  2022,  the  AD  safety  database  included  1720  participants (372 adolescents) exposed to lebrikizumab at any dose. Overall exposure was 1637.02 patient-years.

<div style=\"page-break-after: always\"></div>

Of the 1720 participants with moderate-to-severe AD, 891 participants (270 adolescents) were exposed to lebrikizumab for at least 1 year, 744 participants (246 adolescents) were treated with Q2W only, and 132 participants (23 adolescents) were treated Q2W followed by Q4W for at least 1 year.

Table 60: Total Exposure to Lebrikizumab in the AD All LEB Integrated Analysis Set

|                                     | AD All LEB              | AD All LEB                     | AD All LEB                   | AD All LEB                   | AD All LEB                                       |
|-------------------------------------|-------------------------|--------------------------------|------------------------------|------------------------------|--------------------------------------------------|
|                                     | Any LEB N = 1720        | Any LEB Q2W Exposure a N =1367 | Any LEB Q4W Exposure N = 245 | LEB 250mg Q2WOnly b N = 1218 | LEB 250mg Q2W Induction, Q4W Maintenance N = 147 |
| Patient days of exposure, mean (SD) | 347.6 (194.12)          | 347.8 (189.66)                 | 341.5 (188.98)               | 375.7 (181.54)               | 537.0 (170.75)                                   |
| Weeks of exposure n (%)             | Weeks of exposure n (%) | Weeks of exposure n (%)        | Weeks of exposure n (%)      | Weeks of exposure n (%)      | Weeks of exposure n (%)                          |
| ≥1 day                              | 1720 (100)              | 1367 (100)                     | 245 (100)                    | 1218 (100)                   | 147 (100)                                        |
| ≥16 weeks                           | 1567 (91.1)             | 1228 (89.8)                    | 217 (88.6)                   | 1108 (91.0)                  | 147 (100)                                        |
| ≥24 weeks                           | 1301 (75.6)             | 1040 (76.1)                    | 204 (83.3)                   | 1034 (84.9)                  | 146 (99.3)                                       |
| ≥40 weeks                           | 998 (58.0)              | 850 (62.2)                     | 138 (56.3)                   | 848 (69.6)                   | 134 (91.2)                                       |
| ≥52 c weeks                         | 891 (51.8)              | 745 (54.5)                     | 115 (46.9)                   | 744 (61.1)                   | 132 (89.8)                                       |
| ≥78 weeks                           | 269 (15.6)              | 197 (14.4)                     | 31 (12.7)                    | 196 (16.1)                   | 68 (46.3)                                        |
| ≥104 weeks                          | 59 (3.4)                | 34 (2.5)                       | 9 (3.7)                      | 34 (2.8)                     | 23 (15.6)                                        |
| Total patient-years d               | 1637.02                 | 1301.67                        | 229.08                       | 1252.97                      | 216.11                                           |

Abbreviations: AD = atopic dermatitis; LEB = lebrikizumab; N = number of patients in the safety analysis set; n = number of patients in specified category; Q2W = every 2 weeks; Q4W = every 4 weeks; SD = standard deviation.

a Includes all patients who received lebrikizumab 250 mg Q2W treatment at any time. Only the time on lebrikizumab 250 mg Q2W was included, time on other lebrikizumab dose/frequency or placebo was not included.

b Includes  patients  who  received  LEB  250  mg  Q2W  as  their  only  lebrikizumab  treatment.  Only  the  time  on lebrikizumab 250 mg Q2W was included, time on placebo was not included.

c Includes participants treated for at least 360 days (consistent with the minimum protocol window of 5 days). Oneyear exposures are bolded for emphasis.

d Total patient-years is calculated as sum of duration of exposure in days for all patients in dosing regimen/365.25.

<div style=\"page-break-after: always\"></div>

Table 61: Summary of Lebrikizumab Exposure from the Placebo-Controlled Induction Period Analysis Sets

|                               | AD ALL PC Weeks 0-16     | AD ALL PC Weeks 0-16     | AD Mono PC Weeks 0-16    | AD Mono PC Weeks 0-16    | AD TCS Weeks 0-16 (ADhere)   | AD TCS Weeks 0-16 (ADhere)   |
|-------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|------------------------------|------------------------------|
|                               | PBO                      | LEB 250mg Q2W            | PBO                      | LEB 250mg Q2W            | PBO+TCS                      | LEB 250mg Q2W+TCS            |
|                               | N = 404                  | N = 783                  | N = 338                  | N = 638                  | N = 66                       | N = 145                      |
| Patient days of exposure (SD) | 102.8 (26.59)            | 108.8 (17.77)            | 102.2 (26.84)            | 108.4 (18.15)            | 106.3 (25.14)                | 110.4 (15.96)                |
| Weeks of exposure, n (%)      | Weeks of exposure, n (%) | Weeks of exposure, n (%) | Weeks of exposure, n (%) | Weeks of exposure, n (%) | Weeks of exposure, n (%)     | Weeks of exposure, n (%)     |
| ≥1 day                        | 404 (100)                | 783 (100)                | 338 (100)                | 638 (100)                | 66 (100.0)                   | 145 (100.0)                  |
| ≥16 weeks                     | 266 (65.8)               | 571 (72.9)               | 218 (64.5)               | 452 (70.8)               | 48 (72.7)                    | 119 (82.1)                   |
| Total patient- years a        | 113.76                   | 233.26                   | 94.55                    | 189.43                   | 19.21                        | 43.82                        |

Abbreviations: AD =  atopic dermatitis; LEB =  lebrikizumab; N  = number  of patients  in  the safety analysis  set; n = number of patients in the specified category; PBO = placebo; PC = placebo-controlled; Q2W = every 2 weeks; Q4W = every 4 weeks; SD = standard deviation; TCS = topical corticosteroids.

a Total patient-years is calculated as sum of duration of exposure in days for all patients in dosing regimen/365.25.

Of the 1720 participants with moderate-to-severe AD exposed to any dose of lebrikizumab,

- 372 (21.6%) were 12 to less than 18 years of age
- 1225 (71.2%) were 18 to less than 65 years of age
- 94 (5.5%) were 65 to less than 75 years of age
- 123 (7.2%) were 65 or more years of age, and
- 29 (1.7%) were 75 or more years of age.

## 2.6.8.2. Adverse events

## 2.6.8.2.1. Overview  of Adverse Events

Table 62  and  Table 63  provide an  overview of  adverse events  for the  different  analysis sets during induction and maintenance treatment.

## Induction period (placebo-controlled  Weeks 0 to 16)

During the induction phase, the frequencies of SAEs  were similar in the lebrikizumab  and placebo groups. Most TEAEs were mild or moderate in severity. A higher proportion of participants discontinued treatment due to  an AE in  the  lebrikizumab group (2.3%)  compared to placebo (1.4%),  with  the  most notable difference coming from the AD TCS analysis set. TEAE related to study treatment were more common in the lebrikizumab group (42 (10.4%) vs. 131 (16.8%) for PBO vs LEB respectively).

The frequencies of SAEs, TEAEs, and AEs leading to discontinuation were similar between lebrikizumabtreated subjects regardless of TCS.

<div style=\"page-break-after: always\"></div>

Table 62: Overview of Adverse Events in the Placebo-Controlled Induction Period

|                                   | AD ALL PC Weeks 0-16                          | AD ALL PC Weeks 0-16                                    | AD Mono PC Weeks 0-16                        | AD Mono PC Weeks 0-16                                   | AD TCS Weeks 0-16 (ADhere)              | AD TCS Weeks 0-16 (ADhere)                         |
|-----------------------------------|-----------------------------------------------|---------------------------------------------------------|----------------------------------------------|---------------------------------------------------------|-----------------------------------------|----------------------------------------------------|
|                                   | PBO N = 404 PYE = 113.8 n (adj %) [adj IR a ] | LEB 250mg Q2W N = 783 PYE = 233.3 n (adj %) [adj IR a ] | PBO N = 338 PYE = 94.6 n (adj %) [adj IR a ] | LEB 250mg Q2W N = 638 PYE = 189.4 n (adj %) [adj IR a ] | PBO+TCS N = 66 PYE = 19.2 n (%) [IR a ] | LEB 250mg Q2W+TCS N = 145 PYE = 43.8 n (%) [IR a ] |
| Deaths                            | 1 (0.2)                                       | 0                                                       | 1 (0.3)                                      | 0                                                       | 0                                       | 0                                                  |
| SAE                               | 8 (1.9) [7.0]                                 | 10 (1.3) [4.3]                                          | 7 (2.0) [7.4]                                | 8 (1.2) [4.2]                                           | 1 (1.5) [5.2]                           | 2 (1.4) [4.6]                                      |
| TEAE                              | 215 (53.1) [307.0]                            | 384 (49.2) [247.3]                                      | 192 (57.1) [342.5]                           | 321 (50.4) [257.8]                                      | 23 (34.8) [147.0]                       | 63 (43.4) [199.8]                                  |
| Mild                              | 98 (24.2)                                     | 201 (25.7)                                              | 86 (25.5)                                    | 169 (26.4)                                              | 12 (18.2)                               | 32 (22.1)                                          |
| Moderate                          | 99 (24.6)                                     | 165 (21.2)                                              | 89 (26.6)                                    | 137 (21.6)                                              | 10 (15.2)                               | 28 (19.3)                                          |
| Severe                            | 18 (4.4)                                      | 18 (2.3)                                                | 17 (5.0)                                     | 15 (2.4)                                                | 1 (1.5)                                 | 3 (2.1)                                            |
| TEAE related to study treatment b | 42 (10.4)                                     | 131 (16.8)                                              | 39 (11.7)                                    | 114 (17.9)                                              | 3 (4.5)                                 | 17 (11.7)                                          |
| DC from study drug due to AE      | 6 (1.4) [5.1]                                 | 18 (2.3) [7.9]                                          | 6 (1.8) [6.3]                                | 15 (2.4) [8.1]                                          | 0                                       | 3 (2.1) [6.9]                                      |

Abbreviations: AD = atopic dermatitis; AE = adverse event; adj % = adjusted percentage; DC = discontinuation; IR

= incidence rate; LEB = lebrikizumab; Mono = monotherapy; n = number of patients in the specified category; N

= number of patients in the analysis population; PBO = placebo; PC = placebo-controlled; PY = patient-year; PYE

= patient-years of exposure; Q2W = every 2 weeks; SAE = serious adverse event; TCS = topical corticosteroids; TEAE = treatment-emergent adverse event.

a Events per 100 PY.

b Relationship to study treatment is assessed by the investigator.

## Combined induction and maintenance period (AD Mono/TCS Weeks 0 to 52/56)

The  exposure  adjusted  incidence  rates  (events  per  100  PY)  of  SAEs  in  the  lebrikizumab-treated participants through Weeks 52/56  (3.9 for LEB 250  mg Q2W only and 3.6  for LEB 250 mg Q2W/Q4W only) were similar compared to  the  LEB 250  mg  Q2W group of  the induction  period (4.3)  and  lower compared to placebo (6.6).

The IRs per 100 PY for TEAEs in the lebrikizumab-treated participants through Weeks 52/56 (159.4 for LEB 250  mg Q2W only and 119.7  for LEB 250  mg Q2W/Q4W only) were lower compared to  the LEB 250 mg Q2W group of the placebo-controlled induction period (247.3).

<div style=\"page-break-after: always\"></div>

Table 63: Overview of Adverse Events in the Maintenance  Period, Combined Induction and Maintenance Period, and AD All LEB Analyses Sets

|                                   | AD Mono PC Weeks 16-52                            | AD Mono PC Weeks 16-52                          | AD Mono PC Weeks 16-52                          | AD Mono/TCS Weeks 0-52/56             | AD Mono/TCS Weeks 0-52/56                            | AD Mono/TCS Weeks 0-52/56                                | AD All LEB                                            | AD All LEB                                          | AD All LEB                                  |
|-----------------------------------|---------------------------------------------------|-------------------------------------------------|-------------------------------------------------|---------------------------------------|------------------------------------------------------|----------------------------------------------------------|-------------------------------------------------------|-----------------------------------------------------|---------------------------------------------|
|                                   | PBO (LEB Withdra wal) N = 60 PYE = 37.0 n (adj %) | LEB 250mg Q2W N = 113 PYE = 71.1 n (adj %) [adj | LEB 250mg Q4W N = 118 PYE = 77.4 n (adj %) [adj | PBO N = 352 PYE = 106.8 n (%) [IR a ] | LEB 250mg Q2W only N = 844 PYE = 622.3 n (%) [IR a ] | LEB 250mg Q2W/Q4 Wonly N = 147 PYE = 143.8 n (%) [IR a ] | Any LEB 250mg Q2W N = 1367 PYE = 1301.7 n (%) [IR a ] | Any LEB 250mg Q4W N = 245 PYE = 229.1 n (%) [IR a ] | Any LEB N = 1720 PYE = 1637.0 n (%) [IR a ] |
| Deaths                            | 0                                                 | 0                                               | 0                                               | 1 (0.3)                               | 1 (0.1)                                              | 0                                                        | 3 (0.2)                                               | 0                                                   | 3 (0.2)                                     |
| SAE                               | 1 (1.6) [2.7]                                     | 2 (1.8) [3.0]                                   | 2 (1.7) [2.7]                                   | 7 (2.0) [6.6]                         | 24 (2.8) [3.9]                                       | 5 (3.4) [3.6]                                            | 45 (3.3) [3.5]                                        | 5 (2.0) [2.2]                                       | 56 (3.3) [3.5]                              |
| TEAE                              | 30 (50.0) [117.5]                                 | 56 (49.7) [121.1]                               | 61 (51.7) [124.4]                               | 194 (55.1) [286.9]                    | 524 (62.1) [159.4]                                   | 93 (63.3) [119.7]                                        | 866 (63.4) [135.6]                                    | 129 (52.7) [94.1]                                   | 1106 (64.3) [137.9]                         |
| Mild                              | 15 (25.0)                                         | 35 (31.0)                                       | 24 (20.4)                                       | 86 (24.4)                             | 250 (29.6)                                           | 43 (29.3)                                                | 396 (29.0)                                            | 54 (22.0)                                           | 505 (29.4)                                  |
| Mod erat                          | 15 (25.0)                                         | 17 (15.2)                                       | 31 (26.2)                                       | 93 (26.4)                             | 242 (28.7)                                           | 42 (28.6)                                                | 407 (29.8)                                            | 66 (26.9)                                           | 510 (29.7)                                  |
| Sev                               | 0                                                 | 4 (3.5)                                         | 6 (5.1)                                         | 15 (4.3)                              | 32 (3.8)                                             | 8 (5.4)                                                  | 63 (4.6)                                              | 9 (3.7)                                             | 91 (5.3)                                    |
| TEAE related to study treatment b | 7 (11.6)                                          | 12 (10.7)                                       | 22 (18.6)                                       | 39 (11.1)                             | 187 (22.2)                                           | 42 (28.6)                                                | 301 (22.0)                                            | 44 (18.0)                                           | 372 (21.6)                                  |
| DC from study drug                | 0                                                 | 1 (0.9) [1.4]                                   | 2 (1.7) [2.6]                                   | 5 (1.4) [4.7]                         | 32 (3.8) [5.2]                                       | 3 (2.0) [2.1]                                            | 62 (4.5) [4.8]                                        | 6 (2.4) [2.6]                                       | 73 (4.2) [4.5]                              |

Abbreviations: AD = atopic dermatitis; adj % = adjusted percentage; AE = adverse event; DC = discontinuation; IR

= incidence rate; LEB = lebrikizumab; Mono = monotherapy; n = number of patients in the specified category; N = number of patients in the analysis population; PBO = placebo; PC = placebo-controlled; PY = patient-years; PYE = patient years of exposure; Q2W = every 2 weeks; Q4W = every 4 weeks; SAE = serious adverse event; TCS = topical corticosteroids; TEAE = treatment-emergent adverse event.

a Events per 100 PY.

b Relationship to study treatment is judged by the investigator.

## 2.6.8.2.2. Common Treatment-Emergent  Adverse Events

Common TEAEs are those reported at a frequency of greater than or equal to 1% before rounding in the lebrikizumab-treated group.

## Induction period (Placebo-controlled  Weeks  0 to 16)

Across all analysis sets in the  placebo-controlled induction period, the following  preferred terms were reported more frequently in the lebrikizumab group compared to placebo:

- conjunctivitis (6.5% in the LEB 250 mg Q2W group versus 1.8% in the placebo group)

<div style=\"page-break-after: always\"></div>

- nasopharyngitis (4.4% in the LEB 250 mg Q2W group versus 3.2% in the placebo group)
- headache (4.4% in the LEB 250 mg Q2W group versus 2.9% in the placebo group)
- conjunctivitis allergic (1.8% in the LEB 250 mg Q2W group versus 0.7% in the placebo group)
- dry eye (1.4% in the LEB 250 mg Q2W group versus 0.9% in the placebo group), and
- rhinitis allergic (1.0% in the LEB 250 mg Q2W group versus 0.2% in the placebo group).

## Table 64: Treatment-Emergent Adverse Events Occurring in at Least 1% of LebrikizumabTreated Participants from the Induction Period Placebo-Controlled Analysis Sets

|                                       | AD ALL PC Weeks 0-16                         | AD ALL PC Weeks 0-16                                   | AD Mono PC Weeks 0-16                       | AD Mono PC Weeks 0-16                                  | AD TCS Weeks 0-16 (ADhere)               | AD TCS Weeks 0-16 (ADhere)                         |
|---------------------------------------|----------------------------------------------|--------------------------------------------------------|---------------------------------------------|--------------------------------------------------------|------------------------------------------|----------------------------------------------------|
| Preferred Term                        | PBO N = 404 PYE = 113.8 n (adj%) [adj IR a ] | LEB 250mg Q2W N = 783 PYE = 233.3 n (adj%) [adj IR a ] | PBO N = 338 PYE = 94.6 n (adj%) [adj IR a ] | LEB 250mg Q2W N = 638 PYE = 189.4 n (adj%) [adj IR a ] | PBO +TCS N = 66 PYE = 19.2 n (%) [IR a ] | LEB 250mg Q2W+TCS N = 145 PYE = 43.8 n (%) [IR a ] |
| Patients with at least 1 TEAE         | 215 (53.1) [307.0]                           | 384 (49.2) [247.3]                                     | 192 (57.1) [342.5]                          | 321 (50.4) [257.8]                                     | 23 (34.8) [147.0]                        | 63 (43.4) [199.8]                                  |
| Conjunctivitis                        | 7 (1.8) [6.2]                                | 51 (6.5) [22.8]                                        | 7 (2.1) [7.6]                               | 44 (6.8) [24.2]                                        | 0                                        | 7 (4.8) [16.5]                                     |
| Dermatitis atopic                     | 74 (18.4) [76.9]                             | 47 (6.0) [21.2]                                        | 71 (21.4) [90.3]                            | 44 (6.8) [24.3]                                        | 3 (4.5) [16.1]                           | 3 (2.1) [6.9]                                      |
| Nasopharyngitis                       | 13 (3.2) [11.8]                              | 34 (4.4) [15.2]                                        | 9 (2.6) [9.6]                               | 31 (4.9) [17.0]                                        | 4 (6.1) [21.7]                           | 3 (2.1) [7.0]                                      |
| Headache                              | 12 (2.9) [10.5]                              | 34 (4.4) [15.0]                                        | 11 (3.2) [11.7]                             | 27 (4.3) [14.7]                                        | 1 (1.5) [5.2]                            | 7 (4.8) [16.4]                                     |
| Oral herpes                           | 9 (2.3) [8.1]                                | 15 (1.9) [6.5]                                         | 8 (2.4) [8.8]                               | 13 (2.0) [6.9]                                         | 1 (1.5) [5.2]                            | 2 (1.4) [4.6]                                      |
| Conjunctivitis allergic               | 3 (0.7) [2.6]                                | 14 (1.8) [6.1]                                         | 3 (0.9) [3.2]                               | 14 (2.2) [7.5] 8 (1.2)                                 | 0 0                                      | 0                                                  |
| Dry eye                               | 4 (0.9) [3.4]                                | 11 (1.4) [4.8]                                         | 4 (1.1) [4.2]                               | [4.3]                                                  |                                          | 3 (2.1) [7.0]                                      |
| Pruritis                              | 7 (1.8) [6.4]                                | 9 (1.2) [3.9]                                          | 7 (2.1) [7.8]                               | 9 (1.4) [4.8]                                          | 0                                        | 0                                                  |
| COVID-19                              | 5 (1.3) [4.4]                                | 9 (1.1) [3.8]                                          | 5 (1.5) [5.4]                               | 7 (1.1) [3.7]                                          | 0                                        | 2 (1.4) [4.6]                                      |
| Hypertension                          | 4 (1.0) [3.6]                                | 9 (1.1) [3.8]                                          | 3 (0.9) [3.2]                               | 5 (0.8) [2.6]                                          | 1 (1.5) [5.2]                            | 4 (2.8) [9.3]                                      |
| Rhinitis allergic Injection site pain | 1 (0.2) [0.9] 4 (1.0)                        | 8 (1.0) [3.5] 7 (1.0)                                  | 1 (0.3) [1.1] 4 (1.2)                       | 7 (1.1) [3.7] 7 (1.2)                                  | 0 0                                      | 1 (0.7) [2.3] 0                                    |
| Herpes zoster                         | 0                                            | 5 (0.6) [2.1]                                          | 0                                           | 3 (0.5) [1.6]                                          | 0                                        | 2 (1.4)                                            |
|                                       |                                              |                                                        |                                             |                                                        |                                          | [4.6]                                              |
| Impetigo                              | 6 (1.5) [5.4]                                | 6 (0.8) [2.6]                                          | 5 (1.5) [5.4]                               | 4 (0.6) [2.1]                                          | 1 (1.5) [5.3]                            | 2 (1.4) [4.6]                                      |
| Urinary tract infection               | 2 (0.5) [1.7] 1 (0.2)                        | 5 (0.6) [2.1]                                          | 2 (0.6) [2.1]                               | 3 (0.5) [1.6] 1 (0.2)                                  | 0 0                                      | 2 (1.4) [4.6]                                      |
| Fall                                  |                                              | 3 (0.4)                                                | 1 (0.3)                                     |                                                        |                                          | 2 (1.4)                                            |

<div style=\"page-break-after: always\"></div>

|                     | AD ALL PC Weeks 0-16                         | AD ALL PC Weeks 0-16                                   | AD Mono PC Weeks 0-16                       | AD Mono PC Weeks 0-16                                  | AD TCS Weeks 0-16 (ADhere)               | AD TCS Weeks 0-16 (ADhere)                         |
|---------------------|----------------------------------------------|--------------------------------------------------------|---------------------------------------------|--------------------------------------------------------|------------------------------------------|----------------------------------------------------|
|                     | PBO N = 404 PYE = 113.8 n (adj%) [adj IR a ] | LEB 250mg Q2W N = 783 PYE = 233.3 n (adj%) [adj IR a ] | PBO N = 338 PYE = 94.6 n (adj%) [adj IR a ] | LEB 250mg Q2W N = 638 PYE = 189.4 n (adj%) [adj IR a ] | PBO +TCS N = 66 PYE = 19.2 n (%) [IR a ] | LEB 250mg Q2W+TCS N = 145 PYE = 43.8 n (%) [IR a ] |
|                     | [0.8]                                        | [1.3]                                                  | [1.0]                                       | [0.5]                                                  |                                          | [4.6]                                              |
| Preferred Term      |                                              |                                                        |                                             |                                                        |                                          |                                                    |
| Type 2 diabetes     | 0                                            | 2 (0.2)                                                | 0                                           | 0                                                      | 0                                        | 2 (1.4) [4.6]                                      |
| mellitus            |                                              | [0.8]                                                  |                                             |                                                        |                                          |                                                    |
| Nausea              | 2 (0.5)                                      | 6 (0.8)                                                | 2 (0.6)                                     | 4 (0.6)                                                | 0                                        | 2 (1.4)                                            |
|                     | [1.8]                                        | [2.6]                                                  | [2.0]                                       | [2.2]                                                  |                                          | [4.6]                                              |
| Vomiting            | 1 (0.3)                                      | 4 (0.5)                                                | 1 (0.3)                                     | 2 (0.3)                                                | 0                                        | 2 (1.4)                                            |
|                     | [0.9]                                        | [1.7]                                                  | [1.1]                                       | [1.1]                                                  |                                          | [4.6]                                              |
| Thrombocytopenia    | 0                                            | 4 (0.5)                                                | 0                                           | 2 (0.3)                                                | 0                                        | 2 (1.4)                                            |
|                     |                                              | [1.7]                                                  |                                             | [1.0]                                                  |                                          | [4.6]                                              |
| Injection site rash | 0                                            | 3 (0.4)                                                | 0                                           | 1 (0.2)                                                | 0                                        | 2 (1.4)                                            |
|                     |                                              | [1.3]                                                  |                                             | [0.6]                                                  |                                          | [4.6]                                              |
| Injection site      | 1 (0.3)                                      | 5 (0.6)                                                | 0                                           | 3 (0.5)                                                | 1 (1.5)                                  | 2 (1.4)                                            |
| reaction            | [1.0]                                        | [2.1]                                                  |                                             | [1.6]                                                  | [5.3]                                    | [4.6]                                              |

Abbreviations: AD = atopic dermatitis; adj % = adjusted percentage; COVID-19 = coronavirus  disease 2019; IR = incidence rate; LEB = lebrikizumab; n = number of patients in the specified category; N = number of patients in the safety analysis set; PC = placebo-controlled; PY = patient-years; PYE = patient-years of exposure; Q2W = every 2 weeks; TCS = topical corticosteroids; TEAE = treatment-emergent adverse event.

- a Events per 100 PY.

## Maintenance  period (AD Mono PC Weeks 16 to 52)

In the maintenance period, the frequencies of common TEAEs were similar between the LEB 250 mg Q2W and placebo groups, except for folliculitis which was reported more frequently in the LEB 250 Q2W group (3 subjects, 2.7%) compared to placebo (0 subjects).

The following TEAEs were more frequently reported in the LEB 250 mg Q4W group compared to placebo

- COVID-19
- nasopharyngitis
- headache
- folliculitis
- conjunctivitis allergic, and
- oral herpes.

The following TEAEs were more frequently reported in the LEB 250 mg Q4W group compared to the LEB 250 mg Q2W group

- COVID-19
- nasopharyngitis
- conjunctivitis allergic

<div style=\"page-break-after: always\"></div>

- headache
- conjunctivitis, and
- oral herpes.

## Combined induction and maintenance period (AD Mono/TCS Weeks 0 to 52/56)

In  addition  to  common  TEAEs  reported in  the  placebo-controlled  period,  the  following  TEAEs  were reported  by  at  least  1%  of  lebrikizumab-treated participant  through  Weeks  52/56  and  with  higher frequency with lebrikizumab compared to placebo.

- vaccination complication
- folliculitis
- URTI
- back pain
- vaccination site pain
- herpes dermatitis
- acne
- asthma
- arthralgia
- dizziness
- eye pruritus
- fatigue, and
- blepharitis.

The IRs of common TEAEs were similar in the lebrikizumab groups compared to the LEB 250 mg Q2W group from the placebo-controlled induction period, except for COVID-19.

## Any AD lebrikizumab exposure (AD All LEB)

In addition to the previously reported common TEAEs, the following TEAEs were reported by at least 1% of participants in the Any LEB group: alanine aminotransferase increased, anxiety, cough, diarrhea, and eosinophilia.

<div style=\"page-break-after: always\"></div>

Table 65: Treatment-Emergent Adverse Events Occurring in at Least 1% of Lebrikizumab-Treated Participants from the Maintenance Period, Combined Induction and Maintenance Period, or AD All LEB Analysis Sets

|                               | AD Mono PC Weeks 16-52                     | AD Mono PC Weeks 16-52                                | AD Mono PC Weeks 16-52                                | AD Mono/TCS Weeks 0-52/56             | AD Mono/TCS Weeks 0-52/56                           | AD Mono/TCS Weeks 0-52/56                                | AD All LEB                                            | AD All LEB                                          | AD All LEB                                  |
|-------------------------------|--------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|---------------------------------------|-----------------------------------------------------|----------------------------------------------------------|-------------------------------------------------------|-----------------------------------------------------|---------------------------------------------|
| Preferred Term                | PBO N = 60 PYE = 37.0 n (adj%) [adj IR a ] | LEB 250mg Q2W N = 113 PYE = 71.1 n (adj%) [adj IR a ] | LEB 250mg Q4W N = 118 PYE = 77.4 n (adj%) [adj IR a ] | PBO N = 352 PYE = 106.8 n (%) [IR a ] | LEB 250mg Q2WOnly N = 844 PYE = 622.3 n (%) [IR a ] | LEB 250mg Q2W/Q4W Only N = 147 PYE = 143.8 n (%) [IR a ] | Any LEB 250mg Q2W N = 1367 PYE = 1301.7 n (%) [IR a ] | Any LEB 250mg Q4W N = 245 PYE = 229.1 n (%) [IR a ] | Any LEB N = 1720 PYE = 1637.0 n (%) [IR a ] |
| Patients with at least 1 TEAE | 30 (50.0) [117.5]                          | 56 (49.7) [121.1]                                     | 61 (51.7) [124.4]                                     | 194 (55.1) [286.9]                    | 524 (62.1) [159.4]                                  | 93 (63.3) [119.7]                                        | 866 (63.4) [135.6]                                    | 129 (52.7) [94.1]                                   | 1106 (64.3) [137.9]                         |
| COVID-19                      | 2 (3.3) [5.5]                              | 3 (2.6) [4.2]                                         | 11 (9.4) [14.9]                                       | 5 (1.4) [4.7]                         | 39 (4.6) [6.4]                                      | 13 (8.8) [9.3]                                           | 111 (8.1) [8.8]                                       | 22 (9.0) [10.1]                                     | 133 (7.7) [8.4]                             |
| Nasopharyngit is              | 3 (5.0) [8.3]                              | 4 (3.5) [5.8]                                         | 9 (7.6) [12.2]                                        | 11 (3.1) [10.5]                       | 55 (6.5) [9.2]                                      | 19 (12.9) [14.2]                                         | 116 (8.5) [9.4]                                       | 19 (7.8) [8.6]                                      | 157 (9.1) [10.2]                            |
| Dermatitis atopic             | 7 (11.7) [19.8]                            | 5 (4.4) [7.2]                                         | 7 (5.9) [9.3]                                         | 73 (20.7) [79.4]                      | 68 (8.1) [11.6]                                     | 10 (6.8) [7.2]                                           | 110 (8.0) [9.0]                                       | 14 (5.7) [6.3]                                      | 128 (7.4) [8.3]                             |
| Conjunctivitis allergic       | 2 (3.3) [5.5]                              | 2 (1.8) [2.9]                                         | 7 (5.9) [9.4]                                         | 3 (0.9) [2.8]                         | 42 (5.0) [7.0]                                      | 9 (6.1) [6.5]                                            | 54 (4.0) [4.3]                                        | 9 (3.7) [4.0]                                       | 70 (4.1) [4.4]                              |
| Vaccination complication      | 2 (3.3) [5.4]                              | 3 (2.7) [4.5]                                         | 3 (2.5) [3.9]                                         | 0                                     | 17 (2.0) [2.8]                                      | 3 (2.0) [2.1]                                            | 22 (1.6) [1.7]                                        | 3 (1.2) [1.3]                                       | 25 (1.5) [1.5]                              |
| Folliculitis Headache         | 0 (1.6)                                    | 3 (2.7) [4.4] 1 (0.9)                                 | 3 (2.5) [3.9] 5 (4.2)                                 | 4 (1.1) [3.8] 10 (2.8)                | 13 (1.5) [2.1] 35 (4.1)                             | 4 (2.7) [2.8] 10 (6.8)                                   | [1.2] 62 (4.5)                                        | [1.8] 8 (3.3)                                       | [1.3] 81 (4.7)                              |
|                               | 1 [2.7]                                    | [1.5]                                                 | [6.5]                                                 | [9.5]                                 | [5.8]                                               | [7.3]                                                    | [4.9]                                                 | [3.6]                                               | [5.1]                                       |
| Conjunctivitis                | 3 (5.0) [8.4]                              | 0                                                     | 6 (5.0) [8.1]                                         | 7 (2.0) [6.6]                         | 60 (7.1) [10.2]                                     | 18 (12.2) [13.6]                                         | 98 (7.2) [8.0]                                        | 9 (3.7) [4.0]                                       | 112 (6.5) [7.2]                             |

<div style=\"page-break-after: always\"></div>

|                                       | AD Mono PC Weeks 16-52                     | AD Mono PC Weeks 16-52                                | AD Mono PC Weeks 16-52                                | AD Mono/TCS Weeks 0-52/56             | AD Mono/TCS Weeks 0-52/56                           | AD Mono/TCS Weeks 0-52/56                                | AD All LEB                                            | AD All LEB                                          | AD All LEB                                  |
|---------------------------------------|--------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|---------------------------------------|-----------------------------------------------------|----------------------------------------------------------|-------------------------------------------------------|-----------------------------------------------------|---------------------------------------------|
| Preferred Term                        | PBO N = 60 PYE = 37.0 n (adj%) [adj IR a ] | LEB 250mg Q2W N = 113 PYE = 71.1 n (adj%) [adj IR a ] | LEB 250mg Q4W N = 118 PYE = 77.4 n (adj%) [adj IR a ] | PBO N = 352 PYE = 106.8 n (%) [IR a ] | LEB 250mg Q2WOnly N = 844 PYE = 622.3 n (%) [IR a ] | LEB 250mg Q2W/Q4W Only N = 147 PYE = 143.8 n (%) [IR a ] | Any LEB 250mg Q2W N = 1367 PYE = 1301.7 n (%) [IR a ] | Any LEB 250mg Q4W N = 245 PYE = 229.1 n (%) [IR a ] | Any LEB N = 1720 PYE = 1637.0 n (%) [IR a ] |
| Upper respiratory tract infection     | 3 (5.1) [8.8]                              | 2 (1.8) [2.9]                                         | 2 (1.7) [2.6]                                         | 6 (1.7) [5.7]                         | 13 (1.5) [2.1]                                      | 3 (2.0) [2.1]                                            | 39 (2.9) [3.0]                                        | 9 (3.7) [4.0]                                       | 66 (3.8) [4.1]                              |
| Back pain                             | 1 (1.7) [2.8]                              | 2 (1.8) [3.0]                                         | 2 (1.7) [2.6]                                         | 2 (0.6) [1.9]                         | 7 (0.8) [1.1]                                       | 3 (2.0) [2.1]                                            | 12 (0.9) [0.9]                                        | 2 (0.8) [0.9]                                       | 17 (1.0) [1.0]                              |
| Vaccination site pain                 | 0                                          | 2 (1.8) [3.0]                                         | 2 (1.7) [2.6]                                         | 1 (0.3) [0.9]                         | 9 (1.1) [1.5]                                       | 2 (1.4) [1.4]                                            | 14 (1.0) [1.1]                                        | 2 (0.8) [0.9]                                       | 16 (0.9) [1.0]                              |
| Food allergy                          | 0                                          | 1 (0.9) [1.5]                                         | 3 (2.5) [3.9]                                         | 1 (0.3) [0.9]                         | 1 (0.1) [0.2]                                       | 3 (2.0) [2.1]                                            | 3 (0.2) [0.2]                                         | 3 (1.2) [1.3]                                       | 7 (0.4) [0.4]                               |
| Herpes dermatitis                     | 0                                          | 1 (0.9) [1.4]                                         | 3 (2.5) [3.9]                                         | 2 (0.6) [1.9]                         | 8 (0.9) [1.3]                                       | 3 (2.0) [2.1]                                            | 14 (1.0) [1.1]                                        | 4 (1.6) [1.8]                                       | 18 (1.0) [1.1]                              |
| Acne                                  | 1 (1.6) [2.7]                              | 1 (0.9) [1.5]                                         | 2 (1.7) [2.6]                                         | 3 (0.9) [2.8]                         | 12 (1.4) [1.9]                                      | 2 (1.4) [1.4]                                            | 22 (1.6) [1.7]                                        | 2 (0.8) [0.9]                                       | 26 (1.5) [1.6]                              |
| Aspartate aminotransfer ase increased | 0                                          | 1 (0.9) [1.4]                                         | 2 (1.7) [2.6]                                         | 0                                     | 5 (0.6) [0.8]                                       | 2 (1.4) [1.4]                                            | 10 (0.7) [0.8]                                        | 3 (1.2) [1.3]                                       | 13 (0.8) [0.8]                              |
| Contusion                             | 0                                          | 1 (0.9) [1.5]                                         | 2 (1.7) [2.7]                                         | 2 (0.6) [1.9]                         | 4 (0.5) [0.6]                                       | 2 (1.4) [1.4]                                            | 5 (0.4) [0.4]                                         | 2 (0.8) [0.9]                                       | 8 (0.5) [0.5]                               |
| Erythema                              | 0                                          | 1 (0.9) [1.4]                                         | 2 (1.7) [2.6]                                         | 0                                     | 4 (0.5) [0.6]                                       | 2 (1.4) [1.4]                                            | 6 (0.4) [0.5]                                         | 2 (0.8) [0.9]                                       | 9 (0.5) [0.6]                               |
| Ligament sprain                       | 0                                          | 1 (0.9) [1.5]                                         | 2 (1.7) [2.6]                                         | 1 (0.3) [0.9]                         | 6 (0.7) [1.0]                                       | 2 (1.4) [1.4]                                            | 10 (0.7) [0.8]                                        | 3 (1.2) [1.3]                                       | 14 (0.8) [0.9]                              |
| Weight increased                      | 0                                          | 1 (0.9) [1.4]                                         | 2 (1.7) [2.6]                                         | 0                                     | 3 (0.4) [0.5]                                       | 2 (1.4) [1.4]                                            | 3 (0.2) [0.2]                                         | 2 (0.8) [0.9]                                       | 5 (0.3) [0.3]                               |

<div style=\"page-break-after: always\"></div>

|                         | AD Mono PC Weeks 16-52                     | AD Mono PC Weeks 16-52                                | AD Mono PC Weeks 16-52                                | AD Mono/TCS Weeks 0-52/56             | AD Mono/TCS Weeks 0-52/56                           | AD Mono/TCS Weeks 0-52/56                                | AD All LEB                                            | AD All LEB                                          | AD All LEB                                  |
|-------------------------|--------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|---------------------------------------|-----------------------------------------------------|----------------------------------------------------------|-------------------------------------------------------|-----------------------------------------------------|---------------------------------------------|
| Preferred Term          | PBO N = 60 PYE = 37.0 n (adj%) [adj IR a ] | LEB 250mg Q2W N = 113 PYE = 71.1 n (adj%) [adj IR a ] | LEB 250mg Q4W N = 118 PYE = 77.4 n (adj%) [adj IR a ] | PBO N = 352 PYE = 106.8 n (%) [IR a ] | LEB 250mg Q2WOnly N = 844 PYE = 622.3 n (%) [IR a ] | LEB 250mg Q2W/Q4W Only N = 147 PYE = 143.8 n (%) [IR a ] | Any LEB 250mg Q2W N = 1367 PYE = 1301.7 n (%) [IR a ] | Any LEB 250mg Q4W N = 245 PYE = 229.1 n (%) [IR a ] | Any LEB N = 1720 PYE = 1637.0 n (%) [IR a ] |
| Dry eye                 | 0                                          | 1 (0.9) [1.4]                                         | 1 (0.8) [1.3]                                         | 2 (0.6) [1.9]                         | 17 (2.0) [2.8]                                      | 2 (1.4) [1.4]                                            | 19 (1.4) [1.5]                                        | 1 (0.4) [0.4]                                       | 25 (1.5) [1.5]                              |
| Rhinitis allergic       | 0                                          | 0                                                     | 0                                                     | 1 (0.3) [0.9]                         | 15 (1.8) [2.4]                                      | 0                                                        | 17 (1.2) [1.3]                                        | 0                                                   | 18 (1.0) [1.1]                              |
| Hypertension            | 1 (1.6) [2.7]                              | 2 (1.7) [2.8]                                         | 0                                                     | 4 (1.1) [3.8]                         | 13 (1.5) [2.1]                                      | 2 (1.4) [1.4]                                            | 26 (1.9) [2.0]                                        | 1 (0.4) [0.4]                                       | 31 (1.8) [1.9]                              |
| Urinary tract infection | 2 (3.4) [5.7]                              | 0                                                     | 1 (0.9) [1.3]                                         | 1 (0.3) [0.9]                         | 13 (1.5) [2.1]                                      | 1 (0.7) [0.7]                                            | 27 (2.0) [2.1]                                        | 3 (1.2) [1.3]                                       | 32 (1.9) [2.0]                              |
| Asthma                  | 0                                          | 0                                                     | 1 (0.8) [1.3]                                         | 1 (0.3) [0.9]                         | 12 (1.4) [1.9]                                      | 2 (1.4) [1.4]                                            | 15 (1.1) [1.2]                                        | 1 (0.4) [0.4]                                       | 21 (1.2) [1.3]                              |
| Arthralgia              | 0                                          | 1 (0.9) [1.5]                                         | 0                                                     | 1 (0.3) [0.9]                         | 11 (1.3) [1.8]                                      | 1 (0.7) [0.7]                                            | 19 (1.4) [1.5]                                        | 4 (1.6) [1.8]                                       | 27 (1.6) [1.7]                              |
| Pruritus                | 0                                          | 1 (0.9) [1.5]                                         | 1 (0.9) [1.3]                                         | 7 (2.0) [6.6]                         | 10 (1.2) [1.6]                                      | 3 (2.0) [2.1]                                            | 20 (1.5) [1.6]                                        | 3 (1.2) [1.3]                                       | 33 (1.9) [2.0]                              |
| Injection site reaction | 0                                          | 0                                                     | 0                                                     | 1 (0.3) [0.9]                         | 12 (1.4) [1.9]                                      | 1 (0.7) [0.7]                                            | 18 (1.3) [1.4]                                        | 1 (0.4) [0.4]                                       | 20 (1.2) [1.2]                              |
| Dizziness               | 0                                          | 0                                                     | 0                                                     | 1 (0.3) [0.9]                         | 10 (1.2) [1.6]                                      | 0                                                        | 11 (0.8) [0.9]                                        | 0                                                   | 14 (0.8) [0.9]                              |
| Eye pruritus            | 0                                          | 0                                                     | 1 (0.8) [1.3]                                         | 0                                     | 9 (1.1) [1.5]                                       | 1 (0.7) [0.7]                                            | 11 (0.8) [0.8]                                        | 3 (1.2) [1.3]                                       | 16 (0.9) [1.0]                              |
| Fatigue                 | 1 (1.7) [2.8]                              | 0                                                     | 0                                                     | 3 (0.9) [2.8]                         | 8 (0.9) [1.3]                                       | 2 (1.4) [1.4]                                            | 18 (1.3) [1.4]                                        | 5 (2.0) [2.2]                                       | 25 (1.5) [1.5]                              |
| Blepharitis             | 0                                          | 1 (0.9) [1.4]                                         | 0                                                     | 1 (0.3) [0.9]                         | 7 (0.8) [1.1]                                       | 3 (2.0) [2.1]                                            | 10 (0.7) [0.8]                                        | 0                                                   | 11 (0.6) [0.7]                              |

<div style=\"page-break-after: always\"></div>

|                                     | AD Mono PC Weeks 16-52                     | AD Mono PC Weeks 16-52                                | AD Mono PC Weeks 16-52                                | AD Mono/TCS Weeks 0-52/56       | AD Mono/TCS Weeks 0-52/56                     | AD Mono/TCS Weeks 0-52/56                          | AD All LEB                                            | AD All LEB                                          | AD All LEB                                  |
|-------------------------------------|--------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|---------------------------------|-----------------------------------------------|----------------------------------------------------|-------------------------------------------------------|-----------------------------------------------------|---------------------------------------------|
| Preferred Term                      | PBO N = 60 PYE = 37.0 n (adj%) [adj IR a ] | LEB 250mg Q2W N = 113 PYE = 71.1 n (adj%) [adj IR a ] | LEB 250mg Q4W N = 118 PYE = 77.4 n (adj%) [adj IR a ] | PBO N = 352 PYE = 106.8 n (%) a | LEB 250mg Q2WOnly N = 844 PYE = 622.3 n (%) a | LEB 250mg Q2W/Q4W Only N = 147 PYE = 143.8 n (%) a | Any LEB 250mg Q2W N = 1367 PYE = 1301.7 n (%) [IR a ] | Any LEB 250mg Q4W N = 245 PYE = 229.1 n (%) [IR a ] | Any LEB N = 1720 PYE = 1637.0 n (%) [IR a ] |
| Abdominal pain                      | 0                                          | 1 (0.9) [1.4]                                         | 1 (0.8) [1.3]                                         | [IR ] 0                         | [IR ] 4 (0.5) [0.6]                           | [IR ] 3 (2.0) [2.1]                                | 14 (1.0) [1.1]                                        | 1 (0.4) [0.4]                                       | 17 (1.0) [1.0]                              |
| Anxiety                             | 2 (3.3) [5.6]                              | 1 (0.9) [1.4]                                         | 1 (0.8) [1.3]                                         | 3 (0.9) [2.8]                   | 4 (0.5) [0.6]                                 | 3 (2.0) [2.1]                                      | 14 (1.0) [1.1]                                        | 2 (0.8) [0.9]                                       | 23 (1.3) [1.4]                              |
| Cough                               | 0                                          | 0                                                     | 2 (1.7) [2.6]                                         | 1 (0.3) [0.9]                   | 4 (0.5) [0.6]                                 | 3 (2.0) [2.1]                                      | 19 (1.4) [1.5]                                        | 2 (0.8) [0.9]                                       | 27 (1.6) [1.7]                              |
| Diarrhea                            | 2 (3.3) [5.5]                              | 0                                                     | 0                                                     | 1 (0.3) [0.9]                   | 7 (0.8) [1.1]                                 | 0                                                  | 18 (1.3) [1.4]                                        | 4 (1.6) [1.8]                                       | 29 (1.7) [1.8]                              |
| Nausea                              | 1 (1.6) [2.7]                              | 0                                                     | 0                                                     | 2 (0.6) [1.9]                   | 7 (0.8) [1.1]                                 | 1 (0.7) [0.7]                                      | 18 (1.3) [1.4]                                        | 1 (0.4) [0.4]                                       | 21 (1.2) 1.3]                               |
| Alanine aminotransfer ase increased | 1 (1.6) [2.6]                              | 0                                                     | 1 (0.9) [1.3]                                         | 0                               | 4 (0.5) [0.6]                                 | 1 (0.7) [0.7]                                      | 16 (1.2) [1.2]                                        | 3 (1.2) [1.3]                                       | 21 (1.2) [1.3]                              |
| Eosinophilia                        | 0                                          | 0                                                     | 0                                                     | 2 (0.6) [1.9]                   | 8 (0.9) [1.3]                                 | 0                                                  | 17 (1.2) [1.3]                                        | 0                                                   | 20 (1.2) [1.2]                              |

Abbreviations: AD = atopic dermatitis; adj % = adjusted percentage; COVID-19 = coronavirus disease 2019; IR = incidence rate; LEB = lebrikizumab; n = number of patients in the specified category; N = number of patients in the safety analysis set; PY = patient-years; PYE = patient-years of exposure; Q2W = every 2 weeks; Q4W = every 4 weeks; TCS = topical corticosteroids; TEAE = treatment-emergent adverse event.

a Events per 100 PY.

<div style=\"page-break-after: always\"></div>

## 2.6.8.2.3. Other  Treatment-Emergent  Adverse Events by SOC

TEAEs were analysed by SOC to assist in identification of AEs that may be apparent only when all effects on a given organ system are evaluated in aggregate.

## Induction period (Placebo-controlled  Weeks  0 to 16)

## LEB with or without TCS (AD ALL PC)

The most frequently reported SOCs for lebrikizumab-treated participants compared to placebo-treated participants were

- Infections and infestations
- o 21.2% in the LEB 250 mg Q2W group versus 18.9% in the placebo group (primarily driven by the PTs conjunctivitis and nasopharyngitis)
- Eye disorders
- o 6.6% in  the LEB 250 mg Q2W group versus 4.4% in the  placebo group (primarily driven by the PTs conjunctivitis allergic and dry eye)
- Nervous system disorders
- o 6.3% in the LEB 250 mg Q2W group versus 4.6% in the placebo group, and
- General disorders and administration site conditions
- o 5.1% in the LEB 250 mg Q2W group versus 3.9% in the placebo group.

Odds ratios for the  frequencies of TEAEs within  SOCs were presented in appended tables (not shown here for brevity). In addition to the common TEAEs presented above, the following less common TEAEs were more than twice as frequent with LEB than with PBO (o dds ratio ≥2) in the induction phase:

Within the SOC Infections and infestations: gastroenteritis.

Within the SOC Eye disorders: blepharitis.

Within the SOC Nervous system disorders: dizziness.

Within  the  SOC  General  disorders  and  administration  site  conditions:  injection  site  erythema  and injection site reaction.

Within the SOC Respiratory, thoracic and mediastinal disorders: asthma, cough, oropharyngeal pain and sinus congestion.

Within the SOC Gastrointestinal disorders: diarrhoea.

Within the SOC Musculoskeletal and connective tissue disorders: Pain in extremity

## Maintenance  period (AD Mono PC Weeks 16 to 52)

The frequencies of TEAEs within the following SOCs were higher in the LEB 250 mg Q4W group compared to the placebo (LEB withdrawal) group.

- Infections and infestations
- o 30.5% in the  LEB 250  mg Q4W group versus 21.0%  in the  placebo (LEB  withdrawal) group
- Eye disorders

<div style=\"page-break-after: always\"></div>

- o 9.3% in the LEB 250 mg Q4W group versus 5.0% in the placebo (LEB withdrawal) group (primarily driven by the PT Conjunctivitis allergic)
- Nervous system disorders
- o 7.6% in the LEB 250 mg Q4W group versus 3.3% in the placebo (LEB withdrawal) group (primarily driven by the PT Headache), and
- Musculoskeletal and connective tissue disorders
- o 3.4% in the LEB 250 mg Q4W group versus 1.7% in the placebo (LEB withdrawal) group (primarily driven by 2 events of Back pain).

## Combined induction and maintenance period (AD Mono/TCS Weeks 0 to 52/56)

The frequencies of TEAEs in the following SOCs were higher in the lebrikizumab-treated groups through Weeks 0 to 52/56 compared to the LEB 250 mg Q2W group of the placebo-controlled induction period. This was not unexpected based on longer exposure to lebrikizumab.

The frequencies of these SOCs were

- Infections and infestations
- o 30.1% in the LEB 250 mg Q2W only group
- o 44.9% in the LEB 250 mg Q2W/Q4W only group, and
- o 19.0% in the placebo group.
- Eye disorders
- o 11.5% in the LEB 250 mg Q2W only group
- o 12.9% in the LEB 250 mg Q2W/Q4W only group, and
- o 4.5% in the placebo group.
- Respiratory, thoracic and mediastinal disorders
- o 6.6% in the LEB 250 mg Q2W only group
- o 6.1% in the LEB 250 mg Q2W/Q4W only group, and
- o 2.6% in the placebo group.
- Musculoskeletal and connective tissue disorders
- o 6.0% in the LEB 250 mg Q2W only group
- o 5.4% in the LEB 250 mg Q2W/Q4W only group, and
- o 3.4% in the placebo group.

## 2.6.8.2.4. Adverse events of special interest

## Conjunctivitis

In the SmPC, the term Conjunctivitis includes the PTs of Conjunctivitis and Conjunctivitis bacterial. The PT of Conjunctivitis allergic is listed as a separate ADR.

<div style=\"page-break-after: always\"></div>

In the induction phase the frequency of conjunctivitis events was 6.9%% in the LEB 250 mg Q2W group versus 1.8% in  the placebo group. During  maintenance, the  frequency of conjunctivitis  was 5.0% in the  LEB  250  mg  Q4W  group  and  5.9%  in  the  placebo (LEB  withdrawal)  group.  14.2%  of  patients experienced Conjunctivitis  or Conjunctivitis bacterial during one year of treatment with the intended dose. Overall, events within the conjunctivitis, keratitis, ocular symptoms, and dry eye clusters and PT of blepharitis were reported in 17.7% of patients treated with the intended dose for one year.

All  events  reported  within  conjunctivitis,  keratitis,  ocular  symptom,  and  dry  eye  clusters  were nonserious and mild or moderate in severity. One lebrikizumab-treated participant reported a severe event of blepharitis.

Table 66: Summary of Conjunctivitis from the Induction Period Placebo-Controlled Analysis Sets

|                                                        | AD ALL PC Weeks 0-16                          | AD ALL PC Weeks 0-16                                    | AD Mono PC Weeks 0-16                        | AD Mono PC Weeks 0-16                                   | AD TCS Weeks 0-16                       | AD TCS Weeks 0-16                                  |
|--------------------------------------------------------|-----------------------------------------------|---------------------------------------------------------|----------------------------------------------|---------------------------------------------------------|-----------------------------------------|----------------------------------------------------|
| Participants with ≥1 TEAE Event cluster Preferred Term | PBO N = 404 PYE = 113.8 n (adj %) [adj IR a ] | LEB 250mg Q2W N = 783 PYE = 233.3 n (adj %) [adj IR a ] | PBO N = 338 PYE = 94.6 n (adj %) [adj IR a ] | LEB 250mg Q2W N = 638 PYE = 189.4 n (adj %) [adj IR a ] | PBO+TCS N = 66 PYE = 19.2 n (%) [IR a ] | LEB 250mg Q2W+TCS N = 145 PYE = 43.8 n (%) [IR a ] |
| Conjunctivitis cluster                                 | 10 (2.5) [8.9]                                | 67 (8.5) [30.6]                                         | 10 (3.0) [10.9]                              | 60 (9.3) [33.7]                                         | 0                                       | 7 (4.8) [16.5]                                     |
| Conjunctivitis                                         | 7 (1.8) [6.2]                                 | 51 (6.5) [22.8]                                         | 7 (2.1) [7.6]                                | 44 (6.8) [24.2]                                         | 0                                       | 7 (4.8) [16.5]                                     |
| Conjunctivitis allergic                                | 3 (0.7) [2.6]                                 | 14 (1.8) [6.1]                                          | 3 (0.9) [3.2]                                | 14 (2.2) [7.5]                                          | 0                                       | 0                                                  |
| Conjunctivitis bacterial                               | 0                                             | 3 (0.4) [1.3]                                           | 0                                            | 3 (0.5) [1.6]                                           | 0                                       | 0                                                  |
| Keratitis cluster                                      | 1 (0.3) [0.9]                                 | 5 (0.6) [2.2]                                           | 1 (0.3) [1.1]                                | 4 (0.6) [2.1]                                           | 0                                       | 1 (0.7) [2.3]                                      |
| Keratitis                                              | 1 (0.3) [0.9]                                 | 1 (0.1) [0.4]                                           | 1 (0.3) [1.1]                                | 1 (0.2) [0.5]                                           | 0                                       | 0                                                  |
| Vernal keratoconjunctiviti s                           | 0                                             | 2 (0.2) [0.8]                                           | 0                                            | 1 (0.2) [0.5]                                           | 0                                       | 1 (0.7) [2.3]                                      |
| Atopic keratoconjunctiviti s                           | 0                                             | 2 (0.3) [0.9]                                           | 0                                            | 2 (0.3) [1.1]                                           | 0                                       | 0                                                  |
| Ocular symptoms cluster                                | 1 (0.2) [0.9]                                 | 9 (1.1) [3.9]                                           | 1 (0.3) [1.1]                                | 7 (1.1) [3.7]                                           | 0                                       | 2 (1.4) [4.6]                                      |
| Dry Eye cluster                                        | 4 (0.9) [3.4]                                 | 12 (1.5) [5.2]                                          | 4 (1.1) [4.2]                                | 8 (1.2) [4.3]                                           | 0                                       | 4 (2.8) [9.3]                                      |
| Blepharitis                                            | 1 (0.2) [0.9]                                 | 6 (0.8) [2.6]                                           | 1 (0.3) [1.1]                                | 5 (0.8) [2.6]                                           | 0                                       | 1 (0.7) [2.3]                                      |

<div style=\"page-break-after: always\"></div>

- Abbreviations: AD = atopic dermatitis; adj % = study size adjusted percentage; adj IR = study size adjusted incidence rate; LEB = lebrikizumab; Mono  = monotherapy; N = number  of patients in the analysis set; n = number  of patients in the specified category; PBO = placebo; PC = placebo-controlled; PY = patient-years; PYE = patientyears of exposure; Q2W = every 2 weeks; TCS = topical corticosteroids; TEAE = treatment-emergent adverse event.
- a Events per 100 PY.

Note: Conjunctivitis  as  identified in this  table refers broadly  to several ocular  symptoms  and  disorders  including blepharitis, conjunctivitis of various etiologies (that is, bacterial, viral, allergic), and dry eye.

## Infections, including herpes infections, relevant  parasitic  infections, and opportunistic infections

The  incidence  of  the  Infections  and  infestations  SOC  was  higher  in  lebrikizumab-treated participants versus placebo-treated participants.

The  most  frequently  reported  events  within  this  SOC  and  reported  with  higher  frequency  in  the lebrikizumab group compared to placebo were nasopharyngitis (4.4% in the  lebrikizumab group and 3.2% in the placebo group) and Herpes zoster (0.6% in the lebrikizumab group and 0 events in the placebo  group).  No  confirmed  opportunistic  infections  were  reported.  A  lower  frequency  of  skin infections was reported in the lebrikizumab-treated participants (2.2%) during the placebo-controlled period compared to placebo (5.9%). One helminth-parasitic infection was reported by a participant who received LEB  250  mg  Q2W  during  induction  and LEB  250  mg  Q4W  during  maintenance in  the  AD Mono/TCS Weeks 0 to 52/56 analysis set.

In the induction phase, all herpes infections combined were balanced across treatment groups (2.9% in  the  lebrikizumab  group  and  3.7%  in  the  placebo  group).  However,  Herpes  zoster  events  were reported only in the lebrikizumab group (0.6%) during induction, therefore, Herpes zoster is included as an ADR in proposed labeling.

The incidence of serious infections was low; 1 case of severe infectious colitis, two cases of COVID-19, one case of acarodermatitis and erysipelas and one case of pneumonia in the combined induction and maintenance phases in patients treated with lebrikizumab. All events were recovered/resolved and did not lead to treatment discontinuation.

These findings were consistent when participants were treated with lebrikizumab with or without  TCS. No clinically meaningful differences were observed between different dosing regimens of LEB 250 mg Q2W and LEB 250 mg Q4W.

## Eosinophilia and eosinophil-related disorders

From baseline to Week 16  the frequency of participants  with increased blood eosinophils at any time point  post-baseline  was  higher  in  lebrikizumab-treated  participants  (20.3%)  compared  to  placebotreated participants (11.7%).  Mean increases in eosinophil from baseline to Week 16 for the LEB 250 mg Q2W group was 0.11 x 109 cells/L while the mean increases from baseline for the placebo group was 0.  Overall, mean increases were small  and  did not  lead to  eosinophil-related disorders. Eosinophilia (greater than 5000 cells/mm3) is included as an ADR in proposed labeling.

## Hypersensitivity  reactions

During  the  placebo-controlled induction  period, no clinically significant  imbalance in the  frequency of hypersensitivity events was reported with lebrikizumab compared to placebo. No specific pattern of PTs

<div style=\"page-break-after: always\"></div>

was observed besides Dermatitis  atopic (as most events were related to  the  underlying disease). No serious events of immediate hypersensitivity or anaphylaxis were reported.

## Injection site reactions

ISRs were reported in a numerically higher frequency in the lebrikizumab-treated group (n=20,  2.6%) compared to placebo  (n=6,  1.5%)  during  the  induction  period  with  or  without  TCS.  A  total  of  53 participants reported an ISR TEAE during the one-year follow-up. The majority of participants reported ISR TEAEs within Week 0 to 16 (n = 38) and Weeks 16 to 32 (n = 15).

No dose related differences  were reported. Most events were mild or moderate in severity and none were serious. ISR is included as an ADR in proposed labeling.

## Atopic dermatitis exacerbation

Events representing AD exacerbation, specifically  dermatitis atopic, were reported  with a lower  frequency in the lebrikizumab-treated group (6.4%) compared to the  placebo-treated group (18.9%) during the induction  period with  or  without  TCS. The  majority of  events were nonserious,  mild  or moderate in severity, and  did not  lead to  treatment discontinuation.  The  IR of AD exacerbations in  lebrikizumabtreated participants  was  lower in  the  AD All  LEB  group (8.8  per 100  PY)  compared to  lebrikizumabtreated participants during the placebo-controlled period (22.3 per 100 PY).

## Hepatic  safety

Based on the hepatic disorders SMQ (narrow terms), the percentage of participants that reported at least 1 TE hepatic disorder during the induction period was 1.1% (n = 8) in the lebrikizumab group, and 0 in the placebo group.

Shifts to high serum AST and ALT were more common in participants receiving lebrikizumab during the induction period. During induction, a shift to high serum alanine aminotransferase  is noted in LEB 250mg Q2w  (54  events,  7.8%)  compared  to  placebo  (12  events,  3.6%).  A  shift  to  high  serum  aspartate aminotransferase is  noted  in  LEB  250mg  Q2W  (31  events,  4.2%)  compared to  placebo (11  events, 3.1%).  Of note, the frequencies were calculated among patients with  normal baseline values and ata least one  post-baseline  measure. During maintenance,  a TE shift to high in serum  alanine aminotransferase has been observed in LEB 250mg Q4W arm (7 events, 6.8%) and LEB 250mg Q2w (8 events, 8.4%)  compared to placebo (2 events, 4.3%).  A shift  to high aspartate aminotransferase has been recorded in 4 participants (7.5%) in placebo, 3 (2.8%) in LEB Q4W and 5 (5%) in LEB Q2W.

The frequency of hepatic TEAEs through Weeks 52/56 (in the combined induction and maintenance set, ie. AD Mono/TCS Weeks 0 to 52/56) were: 17 (2.0%) in the LEB 250 mg Q2W only group; 4 (2.7%) in the LEB 250 mg Q2W/Q4W only group, and 0 in the placebo group. The most frequently PTs reported across all treatment groups were AST increased, ALT increased, and GGT increased.

The frequency of participants reporting at least 1 hepatic TEAE any AD lebrikizumab exposure set (ie. AD All LEB) were: 48 (2.8%) in the Any LEB group; 34 (2.5%) in the Any LEB Q2W group, and 10 (4.1%) in the Any LEB Q4W group.

In any lebrikizumab exposure set, participants with elevated transaminase (and normal bilirubin) were recorded. ALT values ≥5x ULN (and normal bilirubin) were recorded in 3 (0.2%) additional participants. Narratives of those patients are provided, however follow-up laboratory data could not be obtained for any of the 3 patients after peak ALT values were recorded. AST values ≥5x ULN  (and normal bilirubin)

<div style=\"page-break-after: always\"></div>

were recorded in 1 (0.1%)  additional participant (in any lebrikizumab exposure set). The participant's narrative  provides  a plausible alternative  explanation for  the observed  lab values  and myopathy  (extreme weightlifting). One participant with AST value at least 10x ULN and normal TBL was identified. According to the participant's narrative, the study drug was not  interrupted despite a significant rise in enzymes on Day 525 (AST 11,2xULN, GGT 12.5xULN, ALT 4.3xULN, ALP 1.7xULN) but no more data is available.

## Suicide/self-injury

Two (0.1%) events of suicidal ideation within  the suicide/self-injury standardised MedDRA query were reported across the entire AD program. One event was reported during the induction period and 1 SAE was reported during the long-term extension study associated with an acute stressor. No events led to treatment discontinuation.

An adult female participant with history of anxiety and depression and treated with lebrikizumab during induction  period reported a nonserious moderate event of suicidal ideation on  Study Day 66.  Patient recovered on the same day.

An adult female participant with  no medical history of depression reported a SAE of major depression with  suicidal ideation following  a major traumatic life event on Study Day 449.  She was treated with escitalopram and  therapy  visits.  The  event  recovered on  Study  Day  503  and  did  not  lead  to  study discontinuation.Given that the prevalence of clinical depression in adults with  AD is around 15% (Patel et al.  2019)  and that  suicidal ideation  is common in  severe depression, and that  there is  no specific signal of increased  risk of suicide by blocking  IL-13, it is agreed  that the data do not suggest an increased risk of suicide/self-injury among those treated with lebrikizumab.

## Malignancies

Overall, 13 lebrikizumab-treated participants (0.8%) reported 20 malignancy events after any exposure to lebrikizumab during 0-52/56 weeks of follow-up. During the placebo-controlled period, nonmelanoma skin cancer (NMSC) events were reported in 2 patients (0.3%) in the lebrikizumab group and 2 patients (0.5%)  in  the  placebo group.  No  malignancies  other than  NMSC  were reported  during  the  placebocontrolled  induction  period.  NMSC  events  were  generally  unremarkable,  localised,  and  a  similar frequency was reported across treatment groups. All NMSC events were nonserious, mild or moderate in severity, and did not lead to treatment discontinuation.

Seven participants  reported  malignancies  other  than  NMSC  in  the  Any  AD  Lebrikizumab  Exposure analysis set. One participant died from pancreatic carcinoma with metastases to liver and bone during the  Study KGAC maintenance escape period. For  brevity, only narratives of  malignancies in  younger participants will be presented here.

An adult female with no pertinent medical history reported a neuroendocrine tumor of the appendix on Study Day 245 in the open-label arm of Study KGAA and received lebrikizumab 250 mg Q2W. The SAE was not resolved during the study period and led to study discontinuation on Study Day 282.

An adolescent male with a history of AD and lower lip epidermoid cysts treated with LEB 250 mg Q2W on Study Day 1 reported a mild nonserious event of cutaneous T-cell lymphoma (mycosis fungoides). Investigator  could  not  confirm  the  diagnosis  of  mycosis  fungoides due  to  the  participant's  age and

<div style=\"page-break-after: always\"></div>

immunohistochemical stains  required for a definitive  diagnosis was  pending. Participant  discontinued from the study.

An adult male participant reported a moderate nonserious event of cutaneous T-cell lymphoma during the maintenance period on Study Day 149. The event was not recovered. Participant discontinued from the study due to physician decision.

An adult  female participant reported a moderate and nonserious event of left  ovarian teratoma.  The event recovered and did not lead to treatment discontinuation.

## 2.6.8.3. Serious adverse  event/deaths/other  significant events

## Deaths in the AD Program

There were 4 deaths in the lebrikizumab AD clinical programme.

- 1 death due to myocardial infarction was reported in the placebo group during the 16-week induction period of Study KGAC, and
- 3 deaths were reported in participants treated with lebrikizumab 250 mg Q2W
- o 1 death due to pancreatic cancer was reported in the maintenance escape period of Study KGAC
- o 1 death due to natural  causes was reported in the  long-term extension Study KGAA after rolling over from Study KGA
- o 1 death due to cardiac arrest was reported in the open-label period of Study KGAE.

The available information indicate no apparent relation to  study drug. However, two events with very limited data available are described in more detail below.

An adult male participant was enrolledin Study KGAD and laterentered the long-term extension Study KGAA. During the long-term extension Study KGAA, the participant died of natural causes, as reported by the investigator. The  participant had a  medical history of  hypertension, cardiac  ablation, AD, insomnia, and  gastroesophageal reflux disease.  The investigator  assessed  the  event  to  be  unrelated  to  study treatment.

During the open-label Study KGAE, an adolescentmale participant died of cardiac arrest , as reported by the investigator. The participant tested positive for COVID-19 in the hospital emergency room as part of screening. The investigator reported the cardiac arrest was likely due to  COVID-19. The  investigator assessed the event to be unrelated to study treatment.

## Deaths in the Asthma Program

To support safety evaluations for the AD submission, an integrated database with all studies (Phases 1 to 3) conducted in participants with asthma was created to form an Asthma ALL Lebrikizumab Exposure Analysis Set  (Asthma  ALL  Lebrikizumab).  This  is  an  uncontrolled  dataset  and  included  studies  with various treatment regimens and doses. Only descriptive statistics are provided for this analysis set.

Treatment doses for asthma studies were lower than for AD studies. In Phase 2, doses studied varied and  included  37.5  mg,  125  mg,  or  250  mg  Q4W,  and  in  some  studies  participants  were dosed  at 0.3 mg/kg to 5 mg/kg. In Phase 3, doses studied included 37.5 mg or 125 mg administered Q4W.

There were 5 deaths in the Asthma ALL LEB analysis set reported for lebrikizumab-treated participants, 3 of which occurred in lebrikizumab-treated participants during the treatment period.

<div style=\"page-break-after: always\"></div>

The provided narratives indicate no relation to study drug.

## Other  Serious Adverse Events

All SAEs in the placebo-controlled  induction period  were single cases. No clinically meaningful differences between treatment  groups  were  noted  for  SAEs  in  either  the  induction  or  the  maintenance  phase. Frequencies of SAEs during the maintenance phase and IRs of SAEs in the AD All LEB analysis set did not suggest an increase with longer exposure.

## Induction period (Placebo-controlled  Weeks  0 to 16)

The frequency of participants reporting at least 1 SAE was similar in the lebrikizumab  and placebo groups (Table 67). No single PT within a SOC was reported by more than 1 participant in each treatment group during induction.

<div style=\"page-break-after: always\"></div>

Table 67: Summary of Serious Adverse Events by Preferred Term from the Induction Period Placebo-Controlled Analysis Sets

|                              | AD ALL PC Weeks 0-16                         | AD ALL PC Weeks 0-16                                   | AD Mono PC Weeks 0-16             | AD Mono PC Weeks 0-16                                  | AD TCS Weeks 0-16 (Adhere)                  | AD TCS Weeks 0-16 (Adhere)                             |
|------------------------------|----------------------------------------------|--------------------------------------------------------|-----------------------------------|--------------------------------------------------------|---------------------------------------------|--------------------------------------------------------|
| Preferred                    | PBO N = 404 PYE = 113.8 n (adj%) [adj IR a ] | LEB 250mg Q2W N = 783 PYE = 233.3 n (adj%) [adj IR a ] | PBO N = 338 PYE = 94.6 n (adj%) a | LEB 250mg Q2W N = 638 PYE = 189.4 n (adj%) [adj IR a ] | PBO+TCS N = 66 PYE = 19.2 n (%) [adj IR a ] | LEB 250mg Q2W+TCS N = 145 PYE = 43.8 n (%) [adj IR a ] |
| Term                         |                                              | 10 (1.3)                                               | [adj IR ]                         |                                                        |                                             |                                                        |
| Patients with at least 1 SAE | 8 (1.9) [7.0]                                | [4.3]                                                  | 7 (2.0) [7.4]                     | 8 (1.2) [4.2]                                          | 1 (1.5) [5.2]                               | 2 (1.4) [4.6]                                          |
| Dermatitis atopic            | 1 (0.2) [0.9]                                | 1 (0.1) [0.4]                                          | 1 (0.3) [1.1]                     | 1 (0.2) [0.5]                                          | 0                                           | 0                                                      |
| Myocardial infarction        | 1 (0.2) [0.9]                                | 1 (0.1) [0.4]                                          | 1 (0.3) [1.1]                     | 1 (0.2) [0.5]                                          | 0                                           | 0                                                      |
| Edema peripheral             | 1 (0.2) [0.8]                                | 1 (0.1) [0.4]                                          | 1 (0.3) [1.0]                     | 1 (0.2) [0.5]                                          | 0                                           | 0                                                      |
| Accidental overdose          | 0                                            | 1 (0.1) b [0.4]                                        | 0                                 | 1 (0.2) b [0.5]                                        | 0                                           | 0                                                      |
| Arthralgia                   | 0                                            | 1 (0.1) [0.4]                                          | 0                                 | 1 (0.2) [0.5]                                          | 0                                           | 0                                                      |
| Cardiac failure              | 0                                            | 1 (0.1) [0.4]                                          | 0                                 | 1 (0.2) [0.5]                                          | 0                                           | 0                                                      |
| Carpel tunnel syndrome       | 0                                            | 1 (0.1) [0.4]                                          | 0                                 | 1 (0.2) [0.5]                                          | 0                                           | 0                                                      |
| Cerebellar syndrome          | 0                                            | 1 (0.1) [0.4]                                          | 0                                 | 1 (0.2) [0.5]                                          | 0                                           | 0                                                      |
| Fall                         | 0                                            | 1 (0.1) [0.4]                                          | 0                                 | 0                                                      | 0                                           | 1 (0.7) [2.3]                                          |
| Large intestine infection    | 0                                            | 1 (0.1) [0.4]                                          | 0                                 | 1 (0.2) [0.5]                                          | 0                                           | 0                                                      |
| Multiple injuries            | 0                                            | 1 (0.1) [0.4]                                          | 0                                 | 1 (0.2) [0.5]                                          | 0                                           | 0                                                      |
| Sinus node dysfunction       | 0                                            | 1 (0.1) [0.4]                                          | 0                                 | 0                                                      | 0                                           | 1 (0.7) [2.3]                                          |
| Synovitis                    | 0                                            | 1 (0.1) [0.4]                                          | 0                                 | 1 (0.2) [0.5]                                          | 0                                           | 0                                                      |
| Uterine leiomyoma            | 1 (0.5) [1.7]                                | 0                                                      | 1 (0.6) [2.0]                     | 0                                                      | 0                                           | 0                                                      |
| Acute kidney injury          | 1 (0.3) [0.9]                                | 0                                                      | 0                                 | 0                                                      | 1 (1.5) [5.2]                               | 0                                                      |
| Cellulitis                   | 1 (0.3) [0.9]                                | 0                                                      | 1 (0.3) [1.1]                     | 0                                                      | 0                                           | 0                                                      |
| Dehydration                  | 1 (0.3) [0.9]                                | 0                                                      | 0                                 | 0                                                      | 1 (1.5) [5.2]                               | 0                                                      |
| Fibula fracture c            | 1 (0.2) [0.9]                                | 0                                                      | 1 (0.3) [1.1]                     | 0                                                      | 0                                           | 0                                                      |
| Tibia fracture c             | 1 (0.2) [0.9]                                | 0                                                      | 1 (0.3) [1.1]                     | 0                                                      | 0                                           | 0                                                      |

<div style=\"page-break-after: always\"></div>

|                    | AD ALL PC Weeks 0-16                         | AD ALL PC Weeks 0-16                                   | AD Mono PC Weeks 0-16                       | AD Mono PC Weeks 0-16                                  | AD TCS Weeks 0-16 (Adhere)                  | AD TCS Weeks 0-16 (Adhere)                             |
|--------------------|----------------------------------------------|--------------------------------------------------------|---------------------------------------------|--------------------------------------------------------|---------------------------------------------|--------------------------------------------------------|
| Preferred Term     | PBO N = 404 PYE = 113.8 n (adj%) [adj IR a ] | LEB 250mg Q2W N = 783 PYE = 233.3 n (adj%) [adj IR a ] | PBO N = 338 PYE = 94.6 n (adj%) [adj IR a ] | LEB 250mg Q2W N = 638 PYE = 189.4 n (adj%) [adj IR a ] | PBO+TCS N = 66 PYE = 19.2 n (%) [adj IR a ] | LEB 250mg Q2W+TCS N = 145 PYE = 43.8 n (%) [adj IR a ] |
| Pulmonary embolism | 1 (0.2) [0.8]                                | 0                                                      | 1 (0.3) [1.0]                               | 0                                                      | 0                                           | 0                                                      |
| Sepsis             | 1 (0.3) [0.9]                                | 0                                                      | 1 (0.3) [1.1]                               | 0                                                      | 0                                           | 0                                                      |

Abbreviations: AD = atopic dermatitis; adj % = adjusted percentage; IR = incidence rate; LEB = lebrikizumab; Mono =  monotherapy;  n  =  number  of patients  in the  specified  category; N  = number  of patients  in  the  analysis population; PY = patient-years; PC = placebo-controlled; PYE = patient-years of exposure; Q2W = every 2 weeks; SAE = serious adverse event; TCS = topical corticosteroids.

a Events per 100 PY.

b Accidental overdose was with Xanax.

c Fibula and tibia fracture occurred in the same patient.

## Maintenance  period (AD Mono PC Weeks 16 to 52)

The frequencies of participants with at least 1 SAE were similar for both lebrikizumab groups and placebo (LEB withdrawal).

The frequencies of participants reporting SAEs were

- 1.8% in the LEB 250 mg Q2W group
- 1.7% in the LEB 250 mg Q4W group, and
- 1.6% in the placebo (LEB withdrawal) group.

No SAE was reported by more than 1 participant.

## Combined induction and maintenance period (AD Mono/TCS Weeks 0 to 52/56)

The IRs per 100 PY of SAEs were

- 3.9 in the LEB 250 mg Q2W only group
- 3.6 in the LEB 250 mg Q2W/Q4W only group, and
- 6.6 in the placebo group.

These IRs for lebrikizumab-treated participants were similar to those reported in the LEB 250 mg Q2W group in the placebo-controlled induction period.

## Any AD lebrikizumab exposure (AD All LEB)

The IRs per 100 PY of SAEs were

- 3.5 in the Any LEB group
- 3.5 in the Any LEB 250 mg Q2W group, and
- 2.2 in the Any LEB 250 mg Q4W group.

<div style=\"page-break-after: always\"></div>

These IRs for any lebrikizumab-treated participant  were similar to  those reported in the  LEB 250 mg Q2W group in the placebo-controlled induction period.

## 2.6.8.4. Laboratory  findings

Chemistry  analytes  where  numerical  differences  were  observed  between  lebrikizumab  and  placebo groups and which were not yet addressed in safety topics of special interest include:

- Blood urea nitrogen (BUN)
- potassium
- sodium
- chloride
- phosphate
- urate

Based on  assessment  of  the  provided  data,  the  observed differences were  not  considered  clinically meaningful.

There were no  clinically meaningful  differences observed for changes in  haematology and  chemistry analytes for lebrikizumab-treated participants compared to those treated with placebo. In some of the analytes, differences in prevalence of 'high', 'low', or 'abnormal' haematology findings were observed; however, mean changes from baseline were small and not clinically meaningful.

## Weight

This section describes weight changes in adult participants. Weight in adolescents is discussed separately.

## Induction period (Placebo-controlled  Weeks  0 to 16)

## LEB with or without TCS (AD ALL PC)

The  frequency of  adult  participants  with  weight  gain  defined as  at  least a  7%  increase at  any time postbaseline was higher in the LEB 250 mg Q2W group (5.1%) compared with placebo (1.8%). Box plots with changes up to Week 16 illustrate that these frequencies were influenced by a few participants with higher values.

The frequency of  adult  participants  with  weight  loss defined as  at  least a  7%  decrease at  any time postbaseline was 3.3% in the LEB 250 mg Q2W group compared to 5.2% in the placebo group.

Overall, in  the  induction  period the  mean and  median  changes in  weight  from  last  baseline  to  last postbaseline in adults were

- LEB 250 mg Q2W (n = 657)
- o Mean (SD): 0.57 (3.22) kg
- o Median: 0.40 kg
- o minimum: -17.6 kg
- o maximum: 20.0 kg
- Placebo (n = 336)
- o Mean (SD): -0.18 (3.86) kg

- o Median: 0.25 kg

- o minimum: -24.3kg

<div style=\"page-break-after: always\"></div>

- o maximum: 26.9 kg

## Combined induction and maintenance period (AD Mono/TCS Weeks 0 to 52/56)

The frequencies of participants with weight gain at any time were

- 9.7% in the LEB 250 mg Q2W only group
- 18.3% in the LEB 250 mg Q2W/Q4W only group, and
- 2.1% in the placebo group.

These frequencies of participants with weight gain (at least 7%) in any lebrikizumab-treated participant through  Weeks 0  to  52/56  were  higher than  the  LEB  250  mg  Q2W  group  in  the  placebo-controlled induction period (5.2%).

The frequencies of participants with weight loss at any time were

- 5.7% in the LEB 250 mg Q2W only group
- 11.7% in the LEB 250 mg Q2W/Q4W only group, and
- 5.5% in the placebo group.

The frequencies of participants with  weight loss (at least 7%) at any time in any lebrikizumab-treated participant  through Weeks 0 to  52/56  were higher than the  LEB 250  mg Q2W  group in the  placebocontrolled induction period (3.3%).

## 2.6.8.5. Safety in special populations

## 2.6.8.5.1. Safety Analyses in the Adolescent Population

The AD safety database included 372 adolescents (12-18 years of age) exposed to lebrikizumab at any dose. 270 adolescents were exposed to lebrikizumab for at least 1 year. 246 adolescents were treated with Q2W only, and 23 adolescents were treated Q2W followed by Q4W for at least 1 year.

## Induction period (Placebo-controlled  Weeks  0 to 16)

## LEB with or without TCS (AD ALL PC)

A total of 1187 participants (1040 adults and 147 adolescents) were included in the AD ALL PC analysis set.

In the adolescent population, TEAEs were reported at a lower frequency in the lebrikizumab (35.6%) group compared to the placebo (55.3%) group. All events were mild or moderate in severity. No deaths occurred  in  the  placebo-controlled  analysis  set.  One  (1%)  SAE  of  synovitis  was  reported  in  the lebrikizumab group compared to no events in the placebo group.

The most common TEAEs in adolescents (ages 12 to less than 18 years old) occurring more frequently in the lebrikizumab-treated adolescents compared to placebo were

- conjunctivitis
- nasopharyngitis
- dry eye, and
- rhinitis allergic

<div style=\"page-break-after: always\"></div>

Although the sample size is small and frequencies are low, the reported numbers of the following PTs were  numerically higher in the lebrikizumab-treated adolescent population compared  to the lebrikizumab-treated adult population (at least 18 years of age)

- Dry eye (2.9% versus 1.2%)
- Pruritus (2.2% versus 1.0%), and
- Rhinitis allergic (2.2% versus 0.9%)

All other common PTs were reported with similar or numerically higher frequency in the adult population compared to adolescents.

Table 68: Overview of Adverse Events in Adolescent and Adult Participants in the PlaceboControlled Induction Period from the AD ALL PC Analysis Set

|                                                            | AD ALL PC           | AD ALL PC                     | AD ALL PC            | AD ALL PC                      |
|------------------------------------------------------------|---------------------|-------------------------------|----------------------|--------------------------------|
|                                                            | Adolescents         | Adolescents                   | Adults               | Adults                         |
|                                                            | PBO N = 48 n (adj%) | LEB 250mg Q2W N = 99 n (adj%) | PBO N = 356 n (adj%) | LEB 250mg Q2W N = 684 n (adj%) |
| Deaths                                                     | 0                   | 0                             | 1 (0.3)              | 0                              |
| SAE                                                        | 0                   | 1 (1.0)                       | 8 (2.2)              | 9 (1.3)                        |
| TEAE                                                       | 27 (55.3)           | 35 (35.6)                     | 188 (52.8)           | 349 (51.1)                     |
| Mild                                                       | 15 (30.8)           | 19 (19.4)                     | 83 (23.3)            | 182 (26.6)                     |
| Moderate                                                   | 11 (22.4)           | 16 (16.2)                     | 88 (24.8)            | 149 (21.9)                     |
| Severe                                                     | 1 (2.1)             | 0                             | 17 (4.7)             | 18 (2.6)                       |
| Discontinuation from study treatment due to adverse events | 0                   | 0                             | 6 (1.7)              | 18 (2.7)                       |
| TEAE within special safety topics                          |                     |                               |                      |                                |
| Conjunctivitis cluster                                     | 2 (3.9)             | 6 (6.1)                       | 8 (2.3)              | 61 (8.9)                       |
| Keratitis cluster                                          | 0                   | 0                             | 1 (0.3)              | 5 (0.7)                        |
| Infections                                                 | 12 (24.5)           | 16 (16.3)                     | 65 (18.1)            | 150 (21.9)                     |
| Potential opportunistic infections (broad)                 | 0                   | 0                             | 3 (0.8)              | 8 (1.2)                        |
| Herpes infections                                          | 2 (3.9)             | 1 (1.0)                       | 13 (3.7)             | 22 (3.2)                       |
| Parasitic infections                                       | 0                   | 0                             | 0                    | 0                              |
| Skin infections                                            | 6 (12.3)            | 1 (1.0)                       | 18 (5.0)             | 16 (2.4)                       |
| Eosinophilia and eosinophil-related disorders              | 0                   | 1 (1.0)                       | 3 (0.9)              | 4 (0.6)                        |
| Hypersensitivity                                           |                     |                               |                      |                                |
| Potential immediate events                                 | 6 (12.1)            | 3 (3.1)                       | 19 (5.4)             | 19 (2.8)                       |
| Potential non-immediate events                             | 6 (12.4)            | 7 (7.2)                       | 63 (17.8)            | 70 (10.3)                      |
| Injection site reactions                                   | 1 (2.1)             | 0                             | 5 (1.4)              | 20 (3.0)                       |
| Atopic dermatitis exacerbation                             | 11 (22.6)           | 5 (5.2)                       | 65 (18.4)            | 45 (6.5)                       |
| Hepatic events (broad)                                     | 0                   | 0                             | 0                    | 8 (1.2)                        |
| Suicide/self-injury                                        | 0                   | 0                             | 0                    | 1 (0.2)                        |
| Malignancies                                               | 0                   | 0                             | 2 (0.6)              | 2 (0.3)                        |
| NMSC                                                       | 0                   | 0                             | 2 (0.6)              | 2 (0.3)                        |
| Malignancies excluding NMSC                                | 0                   | 0                             | 0                    | 0                              |

<div style=\"page-break-after: always\"></div>

Abbreviations: AD = atopic dermatitis; adj % = adjusted percentage; LEB = lebrikizumab; n = number of patients in the specified category; N = number of patients in the analysis population; NMSC = nonmelanoma skin cancer; PBO = placebo; PC = placebo-controlled; TEAE = treatment-emergent adverse event; Q2W = every 2 weeks.

No  clinically meaningful differences between  the lebrikizumab and placebo groups were observed for adolescent growth parameters (weight, height, and BMI).

## Any lebrikizumab exposure (AD All LEB)

The long-term safety profile in all adolescents exposed to any dose of lebrikizumab was consistent with the safety profile in adults.

Table 69: Overview of Adverse Events in Adolescent and Adult Participants in the AD All LEB Analysis Set

|                                                            | AD All LEB                | AD All LEB               | AD All LEB            | AD All LEB                | AD All LEB                | AD All LEB             |
|------------------------------------------------------------|---------------------------|--------------------------|-----------------------|---------------------------|---------------------------|------------------------|
|                                                            | Adolescents               | Adolescents              | Adolescents           | Adults                    | Adults                    | Adults                 |
|                                                            | Any LEB Q2W N = 371 n (%) | Any LEB Q4W N = 29 n (%) | Any LEB N = 372 n (%) | Any LEB Q2W N = 996 n (%) | Any LEB Q4W N = 216 n (%) | Any LEB N = 1348 n (%) |
| Deaths                                                     | 1 (0.3)                   | 0                        | 1 (0.3)               | 2 (0.2)                   | 0                         | 2 (0.1)                |
| SAE                                                        | 7 (1.9)                   | 1 (3.4)                  | 8 (2.2)               | 38 (3.8)                  | 4 (1.9)                   | 48 (3.6)               |
| TEAE                                                       | 219 (59.0)                | 11 (37.9)                | 227 (61.0)            | 647 (65.0)                | 118 (54.6)                | 879 (65.2)             |
| Mild                                                       | 103 (27.8)                | 8 (27.6)                 | 108 (29.0)            | 293 (29.4)                | 46 (21.3)                 | 397 (29.5)             |
| Moderate                                                   | 108 (29.1)                | 3 (10.3)                 | 111 (29.8)            | 299 (30.0)                | 63 (29.2)                 | 399 (29.6)             |
| Severe                                                     | 8 (2.2)                   | 0                        | 8 (2.2)               | 55 (5.5)                  | 9 (4.2)                   | 83 (6.2)               |
| Discontinuation from study treatment due to adverse events | 10 (2.7)                  | 1 (3.4)                  | 11 (3.0)              | 52 (5.2)                  | 5 (2.3)                   | 62 (4.6)               |
| TEAE within special safety topics                          |                           |                          |                       |                           |                           |                        |
| Conjunctivitis cluster                                     | 28 (7.5)                  | 3 (10.3)                 | 31 (8.3)              | 125 (12.6)                | 15 (6.9)                  | 152 (11.3)             |
| Keratitis cluster                                          | 1 (0.3)                   | 0                        | 1 (0.3)               | 8 (0.8)                   | 1 (0.5)                   | 8 (0.6)                |
| Infections                                                 | 126 (34.0)                | 6 (20.7)                 | 131 (35.2)            | 350 (35.1)                | 73 (33.8)                 | 484 (35.9)             |
| Potential opportunistic infections (broad)                 | 7 (1.9)                   | 0                        | 7 (1.9)               | 18 (1.8)                  | 2 (0.9)                   | 24 (1.8)               |
| Herpes infections                                          | 22 (5.9)                  | 0                        | 22 (5.9)              | 53 (5.3)                  | 11 (5.1)                  | 65 (4.8)               |
| Parasitic infections                                       | 0                         | 0                        | 0                     | 0                         | 1 (0.5)                   | 1 (0.1)                |
| Skin infections                                            | 13 (3.5)                  | 1 (3.4)                  | 14 (3.8)              | 34 (3.4)                  | 6 (2.8)                   | 49 (3.6)               |
| Eosinophilia and eosinophil-related                        | 12 (3.2)                  | 0                        | 12 (3.2)              | 9 (0.9)                   | 1 (0.5)                   | 15 (1.1)               |
| disorders Hypersensitivity                                 |                           |                          |                       |                           |                           |                        |
| Potential immediate events                                 | 12 (3.2)                  | 0                        | 12 (3.2)              | 38 (3.8)                  | 4 (1.9)                   | 43 (3.2)               |
| Potential non- immediate events                            | 53 (14.3)                 | 6 (20.7)                 | 59 (15.9)             | 141 (14.2)                | 22 (10.2)                 | 178 (13.2)             |
| Injection site reactions                                   | 7 (1.9)                   | 0                        | 7 (1.9)               | 37 (3.7)                  | 6 (2.8)                   | 46 (3.4)               |
| Atopic dermatitis exacerbation                             | 38 (10.2)                 | 3 (10.3)                 | 41 (11.0)             | 79 (7.9)                  | 11 (5.1)                  | 95 (7.0)               |
| Hepatic events (broad)                                     | 9 (2.4)                   | 0                        | 9 (2.4)               | 26 (2.6)                  | 10 (4.6)                  | 40 (3.0)               |
| Suicide/self-injury                                        | 0                         | 0                        | 0                     | 2 (0.2)                   | 0                         | 2 (0.1)                |
| Malignancies                                               | 1 (0.3)                   | 0                        | 1 (0.3)               | 12 (1.2)                  | 0                         | 12 (0.9)               |
| NMSC                                                       | 0                         | 0                        | 0                     | 5 (0.5)                   | 0                         | 5 (0.4)                |

<div style=\"page-break-after: always\"></div>

|                | AD All LEB          | AD All LEB   | AD All LEB   | AD All LEB      | AD All LEB   | AD All LEB   |
|----------------|---------------------|--------------|--------------|-----------------|--------------|--------------|
|                | Adolescents         | Adolescents  | Adolescents  | Adults          | Adults       | Adults       |
|                | Any LEB Q2W N = 371 | Any LEB Q4W  | Any LEB      | Any LEB Q2W N = | Any LEB Q4W  | Any LEB      |
|                |                     | N = 29       | N = 372      | 996             | N = 216      | N = 1348     |
|                | n (%)               | n (%)        | n (%)        | n (%)           | n (%)        | n (%)        |
| Malignancies   | 1 (0.3)             | 0            | 1 (0.3)      | 7 (0.7)         | 0            | 7 (0.5)      |
| excluding NMSC |                     |              |              |                 |              |              |

Abbreviations: AD = atopic dermatitis; LEB = lebrikizumab; n = number of patients in the specified category; N = number  of patients in the analysis population; Q2W = every 2 weeks; Q4W = every 4 weeks; SAE = serious adverse event; TEAE = treatment-emergent adverse event.

Table 70: Number of events and frequencies of non-immediate hypersensitivity reactions

|             | AD All LEB   | AD All LEB   | AD All LEB   | Induction   | Induction   | Maintenance   | Maintenance   | Maintenance   |
|-------------|--------------|--------------|--------------|-------------|-------------|---------------|---------------|---------------|
|             | Q2W          | Q4W          | Any LEB      | Q2W         | PLAC        | Q2W           | Q4W           | PLAC          |
| Adolescents | 53 (14.3%)   | 6 (20.7%)    | 59 (15.9%)   | 7 (7.2%)    | 6 (12.4%)   | 0             | 3 (17.6%)     | 1 (12.5%)     |
| Adults      | 38 (14.2%)   | 3 (10.2%)    | 41 (13.2%)   | 70 (10.3%)  | 63 (17.8%)  | 8 (8%)        | 14 (13.9%)    | 7 (13.5%)     |

## 2.6.8.5.2. Elderly

The  frequency  of  participants  with  at  least  1  TEAE  in  the  adult  population  was  similar  across  age subgroups (adolescent, adult, elderly) The sample size for those older than 75 years of age was limited. Although  numerical differences for  individual  PTs may  show  some variability  across age  groups, no treatment by age group interaction was identified.

Table 71: Treatment-Emergent Adverse Events Occurring in at Least 1% of Participants from the Placebo-Controlled Induction Period Stratified by Age Group

| Preferred Term                    | Subgroup                                                  | PBO N = 404 n (% a )           | LEB 250mg Q2W N = 783 n (% a )   |
|-----------------------------------|-----------------------------------------------------------|--------------------------------|----------------------------------|
| Ns                                | Adolescents (12<18) Adults (≥18 - <65) (≥65 - <75) (>=75) | 48 322 28 6                    | 99 616 53 15                     |
| Participants with at least 1 TEAE | Adolescents (12<18) Adults (≥18 - <65) (≥65 - <75)        | 27 (56.3) 172 (53.4) 11 (39.3) | 35 (35.4) 321 (52.1) 19 (35.8)   |
| Conjunctivitis                    | Adolescents (12<18) Adults (≥18 - <65) (≥65 - <75)        | 1 (2.1) 5 (1.6) 0              | 4 (4.0) 47 (7.6) 0               |
| Dermatitis atopic                 | Adolescents (12<18) Adults (≥18 - <65)                    | 11 (22.9) 58 (18.0)            | 5 (5.1) 36 (5.8)                 |

<div style=\"page-break-after: always\"></div>

| Preferred Term          | Subgroup            | PBO N = 404 n (% a )   | LEB 250mg Q2W N = 783 n (% a )   |
|-------------------------|---------------------|------------------------|----------------------------------|
|                         | (≥65 - <75)         | 2 (7.1)                | 3 (5.7)                          |
|                         | (≥75)               | 3 (50.0)               | 3 (20.0)                         |
| Nasopharyngitis         | Adolescents (12<18) | 2 (4.2)                | 4 (4.0)                          |
|                         | Adults (≥18 - <65)  | 11 (3.4)               | 29 (4.7)                         |
|                         | (≥65 - <75)         | 0                      | 1 (1.9)                          |
|                         | (≥75)               | 0                      | 0                                |
| Headache                | Adolescents (12<18) | 3 (6.3)                | 3 (3.0)                          |
|                         | Adults (≥18 - <65)  | 8 (2.5)                | 29 (4.7)                         |
|                         | (≥65 - <75)         | 0                      | 2 (3.8)                          |
|                         | (≥75)               | 1 (16.7)               | 0                                |
| Oral herpes             | Adolescents (12<18) | 1 (2.1)                | 1 (1.0)                          |
|                         | Adults (≥18 - <65)  | 6 (1.9)                | 14 (2.3)                         |
|                         | (≥65 - <75)         | 1 (3.6)                | 0                                |
|                         | (≥75)               | 1 (16.7)               | 0                                |
| Conjunctivitis allergic | Adolescents (12<18) | 1 (2.1)                | 2 (2.0)                          |
|                         | Adults (≥18 - <65)  | 2 (0.6)                | 12 (1.9)                         |
|                         | (≥65 - <75)         | 0                      | 0                                |
|                         | (≥75)               | 0                      | 0                                |
| Dry eye                 | Adolescents (12<18) | 0                      | 3 (3.0)                          |
|                         | Adults (≥18 - <65)  | 4 (1.2)                | 8 (1.3)                          |
|                         | (≥65 - <75)         | 0                      | 0                                |
|                         | (≥75)               | 0                      | 0                                |
| Pruritis                | Adolescents (12<18) | 2 (4.2)                | 2 (2.0)                          |
|                         | Adults (≥18 - <65)  | 5 (1.6)                | 6 (1.0)                          |
|                         | (≥65 - <75)         | 0                      | 1 (1.9)                          |
|                         | (≥75)               | 0                      | 0                                |
| COVID-19                | Adolescents (12<18) | 1 (2.1)                | 0                                |
|                         | Adults (≥18 - <65)  | 4 (1.2)                | 8 (1.3)                          |
|                         | (≥65 - <75)         | 0                      | 1 (1.9)                          |
|                         | (≥75)               | 0                      | 0                                |
| Hypertension            | Adolescents (12<18) | 0                      | 0                                |
|                         | Adults (≥18 - <65)  | 3 (0.9)                | 7 (1.1)                          |
|                         | (≥65 - <75)         | 1 (3.6)                | 2 (3.8)                          |
|                         | (≥75)               | 0                      | 0                                |
| Rhinitis allergic       | Adolescents (12<18) | 0                      | 2 (2.0)                          |
|                         | Adults (≥18 - <65)  | 1 (0.3)                | 6 (1.0)                          |
|                         | (≥65 - <75)         | 0                      | 0                                |
|                         | (≥75)               | 0                      | 0                                |

Abbreviations: COVID-19 = coronavirus  disease 2019; LEB = lebrikizumab; N = number of patients in the analysis population; n = number of patients in the specified category; Ns = number of patients for each subgroup; PBO = placebo; Q2W = every 2 weeks; TEAE = treatment-emergent adverse event.

A Crude percentages  are presented  as some subgroups  are very small and  not represented in all studies and  all treatment groups, therefore, adjusted percentage could be misleading.

<div style=\"page-break-after: always\"></div>

Table 72: Adverse Events by Age Group in Lebrikizumab-Treated Participants MedDRA Terms

|                                                                                      | Age <65 Years N = 1597 n (%)   | Age 65-74 Years N = 94 n (%)   | Age 75-84 Years N = 24 n (%)   | Age ≥85 Years N = 5 n (%)   |
|--------------------------------------------------------------------------------------|--------------------------------|--------------------------------|--------------------------------|-----------------------------|
| Total TEAEs                                                                          | 1036 (64.9)                    | 53 (56.4)                      | 14 (58.3)                      | 3 (60.0)                    |
| Serious AEs - Total                                                                  | 47 (2.9)                       | 6 (6.4)                        | 2 (8.3)                        | 1 (20.2)                    |
| Fatal                                                                                | 2 (0.1)                        | 1 (1.1)                        | 0                              | 0                           |
| Hospitalisation/prolong existing hospitalisation                                     | 34 (2.1)                       | 5 (5.3)                        | 2 (8.3)                        | 0                           |
| Life-threatening                                                                     | 3 (0.2)                        | 0                              | 0                              | 1 (20.0)                    |
| Disability/incapacity                                                                | 1 (0.1)                        | 0                              | 0                              | 0                           |
| Other (medically significant)                                                        | 11 (0.7)                       | 1 (1.1)                        | 0                              | 0                           |
| AEs leading to treatment discontinuation                                             | 59 (3.7)                       | 8 (8.5)                        | 5 (20.8)                       | 1 (20.0)                    |
| Psychiatric disorders                                                                | 57 (3.6)                       | 1 (1.1)                        | 0                              | 0                           |
| Nervous system disorders                                                             | 132 (8.3)                      | 5 (5.3)                        | 1 (4.2)                        | 1 (20.0)                    |
| Accidents and injuries                                                               | 94 (5.9)                       | 8 (8.5)                        | 1 (4.2)                        | 0                           |
| Cardiac disorders                                                                    | 14 (0.9)                       | 2 (2.1)                        | 1 (4.2)                        | 0                           |
| Vascular disorders                                                                   | 33 (2.1)                       | 4 (4.3)                        | 1 (4.2)                        | 0                           |
| Cerebrovascular disorders                                                            | 2 (0.1)                        | 0                              | 0                              | 0                           |
| Infections and infestations                                                          | 587 (36.8)                     | 24 (25.5)                      | 3 (12.5)                       | 1 (20.0)                    |
| Anticholinergic syndrome                                                             | 0                              | 0                              | 0                              | 0                           |
| Quality of life decrease                                                             | 0                              | 0                              | 0                              | 0                           |
| Sum of postural hypotension, falls, blackouts, syncope, dizziness, ataxia, fractures | 41 (2.6)                       | 3 (3.2)                        | 1 (4.2)                        | 0                           |

Abbreviations: AE = adverse event; MedDRA = Medical Dictionary for Regulatory Activities; N = number of participants in the analysis population; n = number of participants in the specified category; TEAE = treatmentemergent adverse event.

## Supportive safety results from study KGAK

The most common AEs were COVID-19 (5.6%), nasopharyngitis (3.2%), headache (3.2%), dermatitis atopic  (4.8%),  and conjunctivitis  (2.4%).  No  subjects  in  the  placebo arm  experienced conjunctivitis compared to 2.4% in the LEB arm. The frequency of hypersensitivity and injection site reactions was balanced across treatment arms an in line with previous studies. Other events of special interest (herpes infections, malignancies, self-injury, severe eosinophilia) did  not occur in LEB  treated patients during

<div style=\"page-break-after: always\"></div>

this 16  week study. No new safety topics in terms of nature, frequency or severity of adverse events arose from the results of study KGAK.

The safety and immunogenicity profile in study KGAK is consistent with what has been observed in prior studies.

## 2.6.8.6. Immunological events

## ADA frequencies in Phase 1 and phase 2 Trials

In the phase 1 trials, ADA were present in 0-10% of the healthy subjects post baseline.

In the phase 2 trials, 18-25% of AD patients were at some point post baseline positive for ADA after any dose of lebrikizumab. Persistent positive ADA results (i.e., positive for more than 2 post-baseline time points or positive at the last time point) were less frequent. Although most of the positive post-baseline ADA results were deemed to be treatment-emergent, most ADAs were transient (positive ADA detected in only one post baseline sampling timepoint).

## ADA frequencies in Phase 3 Trials

In the  phase 3 trials,  immunogenicity was assessed using  a newly developed immunogenicity assay, which  was more sensitive, specific, and drug tolerant than  the  assays used for phase 1 and phase 2 trials.

A total of 822 participants randomly assigned to lebrikizumab 250 mg Q2W were evaluable for TE ADA. At baseline, the incidence of ADA was 72 (8.8%), (10.6% in KGAB, 8.5% in KGAC and 7.7% in KGAD).

Of the 822 evaluable participants in the lebrikizumab 250 mg Q2W only group through 1 year,

- 28 (3.4%) participants became TE ADA positive,
- 21 (2.6%) participants were treatment-induced,
- 7 (0.9%) participants were treatment boosted, and
- 24 (2.9%) participants were NAb positive.

Of the 145 evaluable participants who responded to lebrikizumab 250 mg Q2W and were re- randomised to lebrikizumab 250 mg Q4W through 1 year,

- 4 (2.8%) participants became TE ADA positive,
- 2 (1.4%) participants were treatment-induced,
- 2 (1.4%) participants were treatment boosted, and
- 4 (2.8%) participants were NAb positive.

Of the 330 evaluable participants treated with continuous placebo,

- 3 (0.9%) participants became TE ADA positive,
- 3 (0.9%) participants were treatment-induced, and
- 3 (0.9%) participants were NAb positive.

A vast majority of TE ADA positive participants (26 of 28, 92.9%) in the lebrikizumab 250 mg Q2W only treatment group had a maximum titre through the dosing period of 1:160 or less. The highest reported TE ADA titre in this treatment group was 1:640, and it was reported in only 1 patient.

<div style=\"page-break-after: always\"></div>

A similar titre distribution was seen for TE ADA positive responder participants treated with lebrikizumab 250  mg  Q2W  followed  by  lebrikizumab  250  mg  Q4W.  Both  treatment-induced  participants  had  a maximum postbaseline titre of 1:20, and the 2 treatment-boosted participants had maximum titres of 1:40 and 1:160, respectively.

For  TE ADA  positive participants  treated with  only placebo, the  highest  maximum reported titre was 1:40.

Among participants treated at any time with any dose of lebrikizumab (Atopic Dermatitis All Lebrikizumab Exposure Integrated Immunogenicity Analysis Set, Studies KGAB, KGAC, KGAD, KGAE, and/or KGAA), 117 (9.2%) participants had ADA present at baseline. For all participants exposed  to lebrikizumab  across the 5 clinical studies, 1272 were evaluable for TE ADA.

- 49 (3.9%) participants became TE ADA positive,
- 36 (2.8%) participants were treatment-induced,
- 13 (1.0%) participants were treatment boosted,
- 43 (3.4%) participants were NAb positive, and
- 9 (0.7%) participants were TE ADA inconclusive.

A  subset  analysis of  adolescent participants  (ages  12  to  less  than  18  years)  demonstrated  similar immunogenicity incidence to the overall population.

## Effect of Immunogenicity on Pharmacokinetics,  Efficacy and safety

## Phase 1 trials

In most  of the phase 1  trials no  or only few subjects were ADA positive at  baseline or had  TE ADA. Pharmacokinetics was comparable in TE ADA positive and TE ADA negative subjects in phase 1 trials.

## Phase 2 trials

According to the clinical study reports (CSRs), concentrations of lebrikizumab were slightly reduced in ADA positive patients relative to ADA negative patients in studies KGAG and KGAH. One patient in study KGAG (100701)  experienced a  substantial  drop  in  lebrikizumab serum  concentrations  from  Week 4 onwards that was likely ADA-induced.

The Applicant confirmed that the presence of ADA was not found to impact PK in study KGAF. Persistent positive neutralizing ADA (NAb) was observed for a total of 3 patients, PK results for these 3 patients were generally consistent with overall findings for corresponding dose groups.

## Phase 3 trials

The impact of baseline and TE ADA on the PK of lebrikizumab was evaluated using pooled phase 3 data from Week 0 to  52.  Two datasets were used, one  with  Q2W maintenance dosing  (data from studies KGAB, KGAC, KGAD, and KGAE) and the other for Q4W maintenance dosing (data from studies KGAB and  KGAC).  Graphical  exploration  indicated  that  patients  who  were  ADA  positive  had  lebrikizumab exposure that was consistent with patients who were ADA negative.

A summary of the effects of immunogenicity on the clinical outcomes of EASI75 and IGA (0,1), at Week 52 was provided. The percentage of responders at week 52 was equal or higher among patients who were TE ADA positive compared to patients who were TE ADA negative.

No summary on the association between TE ADA  and treatment effect was provided for the  week 16 timepoint, which was the time point for evaluation of primary efficacy.

<div style=\"page-break-after: always\"></div>

The frequency of hypersensitivity reactions  and ISRs was evaluated in patients who were  TE ADA positive versus TE  ADA negative  using the  AD  combined induction  and  maintenance periods immunogenicity analysis set.

Using all narrow and broad search terms, the frequency of hypersensitivity reactions in the continuous lebrikizumab 250 mg Q2W treatment group was similar between TE ADA negative and TE ADA positive participants (208  of 792,  26.3%  and 7 of 28, 25.0%,  respectively). Using  narrow search terms only, hypersensitivity  reactions  were  reported  with  a  higher  numerical  frequency  in  TE  ADA  negative participants  compared  to  TE  ADA  positive  participants  (138  of  792,  17.4%  and  4  of  28,  14.3% respectively). In the lebrikizumab 250 mg Q2W/Q4W treatment group, no TE ADA positive participants reported hypersensitivity reactions (broad and narrow terms) compared to 35 of 140, 25.0% of TE ADA negative participants. Similar results were seen for the continuous placebo treatment group.

The frequency of participants  with  at  least 1  Injection  site reaction  high-level term (HLT)  TEAE was higher in the  LEB 250  mg Q2W only participants who were TE ADA positive (N  = 28,  n = 3,  10.7%) compared to  those  who  were  TE  ADA  negative  (N  =  792,  n  =  23,  2.9%).  There  was  no  temporal association with ISRs and development of TE ADA.

In both the LEB 250 mg Q2W/Q4W only treatment group and continuous placebo treatment group, no TE ADA positive participants had ISRs, compared to 3 of 140 (2.1%)  and 5 of 327 (1.5%)  of TE ADA negative participants in each treatment group, respectively.

No clinically meaningful association was found between TE ADA status  and hypersensitivity events or ISRs.

## 2.6.8.7. Safety related  to drug-drug interactions  and other interactions

No formal studies have been conducted to examine the effect of lebrikizumab on the PK of other drugs. As a mAb, lebrikizumab is not anticipated to directly impact the PK of other drugs.

## 2.6.8.8. Discontinuation due to adverse  events

In the induction phase 18 (2.3%) subjects in the LEB 250 mg Q2W group had at least 1 AE leading to discontinuation of study treatment, compared to 6 (1.4%) subjects in the PBO group.

In  the  maintenance  phase,  the  frequencies  of  AEs  leading  to  permanent  discontinuation  of  study treatment were:

- 1 (0.9%) event of vernal keratoconjunctivitis in the LEB 250 mg Q2W group, and
- 2  (1.7%)  events (1  event  of  conjunctivitis  allergic and  1  event  of  conjunctivitis)  in  the  LEB 250 mg Q4W group.

Events  leading  to  discontinuation  in  the  lebrikizumab  treated  patients  were  mostly  related  to  the conjunctivitis cluster and to atopic dermatitis and other skin infestations which could be related to lack of efficacy. The number of subjects experiencing AEs leading to  withdrawal  was low, suggesting  that lebrikizumab is well tolerated.

## 2.6.8.9. Post marketing experience

Not applicable.

<div style=\"page-break-after: always\"></div>

## 2.6.9. Discussion on clinical safety

The clinical program designed to assess the safety of lebrikizumab is focused on adult and adolescent patients at least 12 years of age and &gt; 40kg with moderate-to-severe AD. To date, 1720 patients with moderate-to-severe AD have been exposed to lebrikizumab, 1228 patients have been treated with the intended induction dose for ≥16 weeks and 132 patients have been treated with the intended induction and maintenance posology for at least 1 year.  The ICH E1 requirements on the size  of the safety  database and the degree of patient exposure are well exceeded.

Safety data for this application have been obtained from adult and adolescent participants with AD from 8 studies: 1 Phase 2, randomised open-label Study KGAH (ARBAN), 5 multi-centre, randomised, double-blind, placebo-controlled studies (including 2 Phase 2 Studies KGAG (TREBLE) and KGAF, and 3 phase 3 Studies KGAB (Advocate 1), KGAC (Advocate 2), and KGAD (Adhere)), 1 Phase 3, open-label, adolescent single arm Study KGAE (Adore), and 1 Phase 3 long-term safety Study KGAA (Adjoin). Phase 3 clinical study programme consists of studies KGAB and KGAC (replicative design: randomised, double-blind, placebo controlled), KGAD (randomised, double-blind, placebo controlled, lebrikizumab in combination with TCS), KGAE (open-label single arm study in adolescents) and KGAA (long-term extension study). The cut-off date was 06 June 2022.

There is one ongoing extension study (KGAA) listed as a Category 3 study of the RMP that will address the safety concern on long term safety. The final study report is anticipated for February 2025.

## Proposed safety profile

No monitoring guidance is proposed in the SmPC. No dose adjustments are proposed for elderly, renal and hepatic impairment and body weight. No contraindications except for hypersensitivity is proposed. The  warnings listed  in  section 4.3  of  the  SmPC include  hypersensitivity, conjunctivitis,  vaccinations, helminth  infection  and  traceability.  Lebrikizumab  is  to  be  avoided  concurrently  with  live  and  live attenuated vaccines. These SmPC proposals are agreed by the CHMP.

Regarding the  safety concerns in  the  Risk Management  Plan  (section 2.7.1),  the  Applicant  does not propose any important  identified risks, nor important potential risks. Proposed as missing information are long term safety and safety in pregnant and breastfeeding women.

## Adverse events

The  Applicant  initially  proposed  to  include  conjunctivitis,  herpes  zoster,  eosinophilia,  keratitis  and injection site reaction as ADRs in section 4.8 of the SmPC. Based on differences between lebrikizumab and placebo arms, and upon CHMP's request, dry eye and blepharitis were also included in SmPC section 4.8 .

Despite  the  presence of long-term safety data  and the  intended continuous  use of lebrikizumab, the Applicant  chose  to  tabulate  only  TEAEs  from  the  16-week  induction  phase  as  ADRs  in  the  product information. The safety profile of lebrikizumab during the induction period can be well characterised by comparison to placebo (lebrikizumab 250mg Q2W vs placebo). However, causality assessment of TEAEs in the  maintenance period is difficult.  Responders in trials KGAB and KGAC were re-randomised after week 16 (with no washout period), and a new posology arm (lebrikizumab 250mg Q4w) was introduced. Placebo arms used for comparison of TEAE incidences during maintenance were not true placebo but represented patients re-randomised to placebo after initial response to lebrikizumab (LEB). Moreover, the majority of data for the placebo arm in the combined induction and maintenance analysis set comes from the induction  period which  makes the treatment  arms incomparable in terms of exposure time. Ultimately,  only 6 patients completed 52  weeks of treatment receiving placebo throughout  the whole period, limiting the soundness of comparison to placebo in the long-term setting. There is no comparator

<div style=\"page-break-after: always\"></div>

in the Any exposure to lebrikizumab set. Taken together, true and 'clean' comparator data exists for only the first 16 weeks.

Despite these difficulties, the ADR list in section 4.8 should include all AEs from various sources  for which a causal  relationship is  at  least a reasonable possibility,  as per the  SmPC Guideline. Upon  thorough reassessment of the data, no new ADRs were found during maintenance but all ADRs to be included were already seen during the placebo controlled 16-week induction.

Although the Applicant applied for the dosing regimen of lebrikizumab 250mg Q4W in the maintenance period, the  dosing  regimen of  Q2W  was also evaluated during  the  maintenance period. Many  TEAEs occurred with a higher frequency in LEB Q4W compared to Q2W. However, as previously commented, these data are difficult to interpret in a meaningful way.

## Common TEAEs

The most frequently reported SOCs for lebrikizumab-treated participants, occurring  more  often compared to placebo,  were Infections and  infestations (primarily driven by  the PTs conjunctivitis  and nasopharyngitis), Eye disorders (primarily driven by the PTs conjunctivitis allergic and dry eye), Nervous system disorders (primarily driven by the PT Headache) and General disorders and administration site conditions (injection site reactions).

Common TEAEs are those reported at a frequency of greater than or equal to 1% in the lebrikizumabtreated group. Common TAES reported more frequently in the lebrikizumab group compared to placebo in the  induction phase  were  conjunctivitis (6.9%), nasopharyngitis  (4.4%),  headache  (4.4%), conjunctivitis allergic (1.8%), dry eye (1.4%) and rhinitis allergic (1.0%).

Some TEAEs were reported more often with lebrikizumab than with  placebo during induction  but were not included as ADRs in the SmPC. The Applicant was requested to justify and clarify these decisions. Upon further  scrutiny of  the  data  it  was  concluded that  headache, nasopharyngitis, herpes simplex, rhinitis allergic, high serum cholesterol, hepatic enzymes elevated and weight gain are not ADRs.

In  the  maintenance period,  the  most  common  TEAEs in  lebrikizumab 250  mg  Q4W  were COVID-19 (9.4%),  nasopharyngitis (7.6),  conjunctivitis  allergic (5.9%),  conjunctivitis  (5.0%),  dermatitis atopic 5.9%),  headache (4.2%),  oral herpes (3.4%)  and  folliculitis  (2.5%).  All  of  these  TEAEs, except  for dermatitis atopic and conjunctivitis, were more frequent with  LEB 250 mg Q4W compared to those in the LEB withdrawal placebo arm.

Despite higher frequencies in patients treated with LEB, based on the totality of data it was concluded that  a plausible  causal relationship  was only  present for  the  following  TEAEs: Conjunctivitis,  Herpes zoster, Eosinophilia, Conjunctivitis allergic, Keratitis, Dry eye, Blepharitis, and Injection site reaction.

## Serious adverse events and deaths

The frequency of participants reporting  at least  1 SAE  was low and similar in the lebrikizumab  and placebo groups during both the induction and maintenance period. During  induction, frequencies of SAEs were similar for both treatment arms regardless of concomitant TCS.

All SAEs in the placebo-controlled  induction period  were single cases. No clinically meaningful differences between treatment groups were apparent for SAEs in either the induction  or the maintenance phase. Frequencies and incidence rates of SAEs did not suggest an increase with longer exposure.

In total 4 deaths were recorded during the AD lebrikizumab clinical programme. One death occurred in placebo arm while  3  deaths  occurred in  patients  receiving lebrikizumab 250  mg  Q2W.  Investigators assessed all deaths as unrelated to study drug treatments.

<div style=\"page-break-after: always\"></div>

## Adverse events of special interest

Conjunctivitis was an expected adverse event, as it has been commonly observed in AD patients treated with other drugs in the same drug class. The observed incidence rates (6.9% in the induction phase and 5.0% in  the maintenance phase) were similar to  those seen in AD  patients  treated with  other mAbs acting on IL-13. Over the whole 52-week treatment, the overall incidence of conjunctivitis was 14.2% in the target population treated with the intended dose (LEB 250mg Q2W/Q4W). The frequencies of TEAEs from keratitis cluster, ocular symptoms cluster and blepharitis cluster are all increased in LEB compared to placebo arms, albeit with rather small numerical differences between treatment arms. The observed keratitis events were regarded as extensions of more severe forms of allergic conjunctivitis and were included as ADRs.

The  majority  of  events  in  the  conjunctivitis  and  keratitis  clusters  were nonserious,  the  majority  of participants had 1 event, the majority of events resolved and almost all events required treatment with medications.

It appears that  conjunctivitis is an ADR specific to AD patients as it was not seen in the asthma study program nor in monkeys. A higher proportion of lebrikizumab-treated participants who reported an AE of conjunctivitis, keratitis, ocular symptom, dry eye clusters, and blepharitis PTs had a medical history of conjunctivitis or facial dermatitis compared to participants who  did not report conjunctivitis  related AEs.

In both the induction and maintenance period, the frequency of participants who reported eosinophilia TEAEs was higher among participants receiving lebrikizumab compared to placebo. There were no events of  eosinophil-related  disorders.  In  total  8  patients  treated  with  lebrikizumab  across  analyses sets experienced  severe  eosinophilia  (3  in  induction  period,  3  additional  in  combined  induction  and maintenance  period  and  2  additional  in  any  lebrikizumab  exposure). In  at  least  2  participants  the eosinophil  level  did  not  return  to  baseline  and  in  3  participants  a  lack  of  efficacy  was  observed. Eosinophilia is listed as an ADR which is endorsed. The eosinophilia frequency 'uncommon' in the ADR table refers only to severe eosinophilia (&gt;5000 cells/mm3). Given the clearly higher overall frequency of increased  blood eosinophils in lebrikizumab-treated  participants (20.3%) compared  to placebo-treated participants (11.7%), the Applicant was requested to add this information to the SmPC section 4.8 under the description of selected adverse reactions sub-section.

Of note, in the supportive study KGAK,  the frequency  of mild eosinophil elevation was in line with findings in other studies which indicates that the event is causally related to the drug and the frequency of around 20% is not a chance finding.

In the induction period, the frequency of TEAE Infections and infestations is somewhat higher in LEB 250 mg Q2W arm compared to placebo (21.2% vs 18.6%).

Based  on the  presented  data  and  the requested  additional discussion  it  can  be  agreed  that nasopharyngitis,  gastroenteritis,  diarrhoea,  and  herpes  simplex  are  not  ADRs  with  a  reasonable possibility for causality although slightly higher frequencies were seen.  Lack of biological mechanism  and no  dose-response  pattern  are  the  main  reasons  for  this  conclusion.  For  example,  in  the  case  of nasopharyngitis, the exposure adjusted incidence rate with  LEB 250mg Q2W was lower than that with placebo, which makes it implausible that the lower dose of LEB 250mg Q4W would be causally linked to nasopharyngitis.

Although the  incidence of herpes simplex was slightly higher with LEB during induction,  there was no difference  during  maintenance  and  the  number  of  subjects  is  very  small.  In  addition,  another manifestation of a herpes simplex infection, the eczema herpeticum was lower with  LEB than placebo during maintenance. Therefore, causality between LEB and herpes simplex is not considered plausible.

<div style=\"page-break-after: always\"></div>

No confirmed opportunistic infections were reported. A lower frequency of skin infections was reported in  the  lebrikizumab-treated  participants  (2.2%)  during  the  placebo-controlled  period  compared  to placebo (5.9%),  reflecting the  efficacy of lebrikizumab. The  incidence of  serious infections was  low; 1 case of severe infectious colitis, two cases of COVID-19, one case of acarodermatitis and erysipelas and one case of pneumonia in the combined induction and maintenance phases in patients treated with lebrikizumab. All events were recovered/resolved and did not lead to treatment discontinuation.

No  events of  parasitic  infections  were reported  in  any  treatment  group  in  the  induction  nor  in  the maintenance period. One (0.7%) parasitic infection in the LEB 250  mg Q2W/Q4W only group (KGAD6016-002)  was  reported  in  the  combined induction  and  maintenance  period.  It  was  a  case of  mild enterobiasis and ascariasis that resolved after treatment.

In the induction period, frequency of immediate hypersensitivity reactions was lower in LEB 250mg Q2W (n=22,  2.8%)  compared to  placebo (n=25,  6.2%).  All  the events were nonserious, and  only a small number  of  participants discontinued  treatment (in those who  did,  the events  were  not true hypersensitivity  reactions). In  the  maintenance  period,  the  frequency of  immediate  hypersensitivity reactions was slightly higher in both lebrikizumab arms although the number of events is very small.

The  frequencies of  nonimmediate  hypersensitivity events  in  the  induction  period  were  lower  in  the lebrikizumab group (n =  77, 9.9%)  compared to placebo (n =  69, 17.1%),  while in the  maintenance period  the  frequencies  were similar  in  LEB  Q4W  and  placebo  (n  =  17,  14.4%  and  n  =  8,  13.3%, respectively). The frequency of non-immediate hypersensitivity reactions in adolescents receiving LEB Q4W (17.6% in the maintenance period and 20.7% in any LEB exposure set) was higher compared to adults receiving the same dosing regimen (13.9% in maintenance and 10.2% in any LEB exposure) and higher compared to adolescents receiving placebo (12.5% in maintenance) or adolescents receiving LEB Q2W  (0  in  maintenance  and  14.3%  in  any  LEB  exposure  set).  Upon  request,  the  non-immediate hypersensitivity reactions were examined more closely, and the Applicant claims the reported PTs were not considered true nonimmediate hypersensitivity reactions (ie. dermatitis atopic, conjunctivitis allergic, dermatitis contact and rhinitis allergic). It is agreed that those reactions could be a manifestation of the underlying condition. The number of included adolescents is notably smaller compared to adults, which is a possible explanation for the difference in proportions among the two populations rather than a true difference in occurrence of these reactions. The observation of a higher frequency of these reactions in adolescents receiving LEB Q4W compared to LEB Q2W is likely due to a very small sample size in the LEB Q4W arm (29 adolescents in total).

In the induction period, the frequency of injection site reactions was higher in the lebrikizumab group (n = 20,  2.6%) compared to  placebo (n = 6,  1.5%). The most frequently reported PTs in lebrikizumabtreated participants were injection site pain, injection site erythema and injection site reaction. Injection site reactions are listed as ADRs.

Regarding hepatic safety, the frequency of participants reporting at least 1 TE hepatic disorder in the induction period was higher in lebrikizumab compared to placebo group (8 participants (1.1%) compared to 0). In the maintenance period, the situation  is similar, albeit with few events (3 participants (2.5%) in  LEB  Q4W;  1  participant  (0.9%)  in  LEB  Q2W  and  1  participant  (1.7%)  in  placebo).  Also,  in  any lebrikizumab exposure set, an imbalance in the frequency of hepatic TEAEs is observed in participants receiving  LEB  250  mg  Q4W  compared  to  Q2W  (10  participants  (4.1%)  vs  34  participants  (2.5%), respectively).

No participants with  laboratory criteria for Hy's law were identified, neither in the induction  nor in the maintenance period. In the Any AD lebrikizumab exposure set (AD All LEB), one participant meeting the criteria for potential Hy's law was identified. A narrative for this subject is provided which reveals selfreported drinking alcohol before drawing blood, thrombocytopenic at baseline, baseline GGT 4.7xULN, AST 2.3x ULN, AST:ALT ratio of 4:1. On Day 213 he developed jaundice and lab results showed GGT 5x

<div style=\"page-break-after: always\"></div>

ULN,  AST 153 (3.7x ULN), and TBL 92.3 umol/L (4.5x ULN). According to the narrative, the patient is most likely to have alcoholic liver disease. Moreover, since abnormal liver biochemistry was present at baseline,  it  would  be  more  appropriate  to  replace  the  ULN  with  the  pre-treatment  baseline  level (according  to  CIOMS  on  DILI:  consensus  report  from  2020).  According  to  this  modification  of  the definition,  the raise in  AST was 1.6 times from the baseline level, which  does not  reach the Hy's law threshold of transaminase elevation.

In any lebrikizumab set, additional 3 participants were identified with ALT values ≥5x ULN (and normal bilirubin) and 1 additional patient with AST values ≥5x ULN (and normal bilirubin).

The Applicant argues that  due to the lack of mechanistic plausibility,  the low frequency of TEAEs and SAEs, low  treatment  discontinuations,  the  absence of  DILI,  and  infrequent laboratory shifts,  hepatic events were not deemed to be associated with lebrikizumab. Based on further scrutiny of the data and a detailed individual case review for participants with  AST/ALT elevations above 3xULN,  a reasonable possibility of a causal relationship cannot be unequivocally established at this time.

There seemed to be a difference in weight gain between treatment arms. However, weight fluctuations were not sustained over time and only seen among some BMI categories. Based upon the totality of the data, it was concluded that a causal relationship between lebrikizumab and weight gain is not likely.

Two events of suicidal ideation were reported in the AD program (both treated with LEB) and one event of completed suicide was reported in the asthma program with lower dose lebrikizumab. Given that the prevalence of clinical depression in adults with  AD is around 15% (Patel et al. 2019) and that suicidal ideation is common in severe depression, and that there is also no specific signal of increased risk of suicide by blocking IL-13, it is agreed  that the data do not suggest an increased  risk of suicide/self-injury among those treated with lebrikizumab. This topic will continue to be routinely monitored and presented for discussion in PSURs as a topic of interest.

Regarding malignancies, there were no malignancy events other than NMSC reported during the placebocontrolled induction period. No malignancy was reported in the Weeks 16 to 52 maintenance period.

One death was reported during the combined induction and maintenance period in a 73-year-old male participant due to metastatic pancreatic carcinoma.

However,  in  any  lebrikizumab exposure set  7  additional  lebrikizumab-treated  participants  reporting malignancy (other than NMSC) were found. It is noted that out of these 7 additional cases, 4 occurred in  younger  patients  (aged  17-30)  and  included  2  participants  with  cutaneous  T-cell  lymphoma,  1 participant with neuroendocrine tumour of the appendix and 1 participant with ovarian teratoma. There is limited information about these events; 3 participants (out of these 4) discontinued study participation and the outcome of the malignancy is unknown. This is potentially concerning. The Applicant has agreed to  continue  monitoring  the  occurrence of  malignancies in  patients  receiving lebrikizumab as  part  of routine  surveillance  activities.  Based  on  a  comprehensive  discussion  provided,  this  approach  is reasonable for the time being.

## Immunogenicity

Characterisations of immunogenicity were conducted with data from seven clinical pharmacology studies, three Phase 2 AD studies and five Phase 3 AD studies. The focus of this assessment is on the Phase 3 AD studies as they are considered most relevant to the AD indication and the most adequate and up to date analytical method was used for ADA detection in these studies.

In the phase 1 trials, ADA were present in 0-10% of the healthy subjects post baseline. In the phase 2 trials,  18-25%  of  AD  patients  were at  some  point  post  baseline  positive for  ADA  after  any dose  of lebrikizumab. However, most of the positive post-baseline ADA results were transient.

<div style=\"page-break-after: always\"></div>

In the combined phase 3 Studies KGAB, KGAC and KGAD, 3.4% of participants treated with lebrikizumab 250  mg  Q2W,  2.8%  of  participants  treated  with  lebrikizumab  250  mg  Q2W/Q4W,  and  0.9%  of participants treated with placebo developed treatment-emergent ADA over 12 months. Nearly all TE ADA positive  participants  were  also  positive  for  NAb  to  lebrikizumab  but  most  ADAs  were low  titre.  No association between TE ADA (including titre magnitude) and treatment effect at week 16 or 52 could be established. ADA/Nab  frequencies and  titres  were similar in  the  adolescents compared to  the overall population. Upon request, the Applicant provided supplementary information and confirmed that ADAs are not expected to have clinically relevant impact on exposure to lebrikizumab.

No clinically meaningful association was found between TE ADA status  and hypersensitivity events or ISRs.

## Safety in special populations

There were 53 participants  older than  65 years of age exposed to  lebrikizumab during  the  induction period.  Only  15 participants  older than  75  were exposed in  the  same  period.  The  safety of  elderly subjects is addressed in the SmPC according to QRD template. Based on the subgroup analyses provided, no special concern in the elderly is evident.

The AD safety database included 372 adolescents (12-18 years of age) exposed to lebrikizumab at any dose. 270 adolescents were exposed to lebrikizumab for at least 1 year. 246 adolescents were treated with Q2W only, and 23 adolescents were treated Q2W followed by Q4W for at least 1 year.

The overall safety profile in all adolescents exposed to any dose of lebrikizumab was consistent with the safety profile  in adults in terms of frequency  and nature of adverse  events.  In the induction period  overall SAEs, TEAEs, discontinuations and TEAEs within special safety topics all occurred with lower frequency in adolescents compared to adults in both lebrikizumab and placebo groups.

The  most  common  TEAEs  in  adolescents  occurring  more  frequently  in  the  lebrikizumab-treated adolescents compared to placebo were conjunctivitis, nasopharyngitis, dry eye, and rhinitis allergic.

In the induction phase,  dry eye,  pruritus and rhinitis allergic  were PTs  with numerically higher  frequencies in the lebrikizumab-treated  adolescent  population compared  to the lebrikizumab-treated adult population (at least 18 years of age). After any exposure to LEB the frequency of eosinophilia was higher in the LEB treated  adolescents 12  (3.2%)  compared to  LEB  treated  adults  15  (1.1%).  These  small  differences between frequencies of AEs in adolescents compared to adults are of no clinical importance and do not affect how ADRs are reported in the SmPC section 4.8.

Regarding  weight,  height  and  BMI  in  adolescents,  no  meaningful  differences in  growth  parameters between placebo and lebrikizumab were observed based on the mean changes in any LEB group for Zscore close  to  0  for  all  growth  parameters. No  particular  patterns  arise from  the  numerically  small differences in common TEAEs in the induction period across age groups, for sex, weight, race, ethnicity and across geographical regions.

Additional  safety data  was  obtained  from  a study  to  evaluate the  effect of  lebrikizumab on  vaccine responses in patients  with  AD (KGAK). The study was ongoing at  the time of data cut-off  and safety results were not pooled in the integrated analysis set. The safety and immunogenicity profile in study KGAK was consistent with that in the pooled analysis set.

From the safety database all the adverse reactions reported in clinical trials have been included in the Summary of Product Characteristics.

<div style=\"page-break-after: always\"></div>

## 2.6.10. Conclusions on the clinical safety

No major safety issues are identified for patients with  atopic dermatitis treated with lebrikizumab and the overall  safety profile is manageable. The data suggest that most AEs occur within the first few months of drug treatment and that the AE pattern does not change over time. No clinically meaningful differences were  observed between  different  lebrikizumab  dosing  regimens  (Q2W  vs.  Q4W  in  the  maintenance phase).  No  differences  in  AE  pattern  were  seen  between  monotherapy  and  lebrikizumab +  topical treatment.  The  overall  safety  profile  in  all  adolescents  exposed  to  any  dose  of  lebrikizumab  was consistent with the safety profile in adults in terms of frequency and nature of adverse events.

The frequency of treatment  emergent anti-drug  antibody formation was  low, up  to  2.8%  of patients treated  with  250  mg  lebrikizumab  developed ADAs.  No  clinically  meaningful  association  was  found between TE ADA status and PK, efficacy or safety.

The ongoing open-label long-term safety extension study KGAA listed as a Category 3 study of the RMP will  provide further information  to  characterise long-term  safety. In addition,  an  observational study listed as a Category  3 study will provide  further information on the use of lebrikizumab  during pregnancy.

## 2.7. Risk Management Plan

## 2.7.1. Safety concerns

| Summary of safety concerns   | Summary of safety concerns                                               |
|------------------------------|--------------------------------------------------------------------------|
| Important identified risks   | None                                                                     |
| Important potential risks    | None                                                                     |
| Missing information          | Use in pregnant and breastfeeding women Long-Term safety of lebrikizumab |

<div style=\"page-break-after: always\"></div>

## 2.7.2. Pharmacovigilance plan

| Study Status                                                                                                                                                             | Summary of objectives                                                                                                                                                                                                                                                                                                                                               | Safety concerns addressed                                     | Mileston es                                                   | Estimate d Due Dates                                                       |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|----------------------------------------------------------------------------|
| Category 3 - Required additional pharmacovigilance activities                                                                                                            | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                                                                                                                                                       | Category 3 - Required additional pharmacovigilance activities | Category 3 - Required additional pharmacovigilance activities | Category 3 - Required additional pharmacovigilance activities              |
| Post-marketing observational study of pregnancy and infant outcomes among women exposed to lebrikizumab during pregnancy in US- based Administrative Claims Data Planned | Objectives include: • to estimate occurrence of pregnancy and infant outcomes among women exposed to lebrikizumab in pregnancy. • If the sample size permits, to evaluate the relative risk of the adverse pregnancy and infant outcomes among women with AD exposed to lebrikizumab in pregnancy compared to women with AD unexposed to lebrikizumab in pregnancy. | Missing information: Use in pregnant women                    | Protocol Final Study Report                                   | Within 6 months of EC decision, anticipate d 31 May 2024 31 September 2031 |
| A long-term study to assess the safety and efficacy of lebrikizumab in patients with moderate-to- severe atopic dermatitis (J2T-DM-KGAA) Ongoing                         | To evaluate the long-term safety and efficacy of lebrikizumab in patients with moderate-to-severe AD.                                                                                                                                                                                                                                                               | Missing information: Long-term safety of lebrikizumab         | Final Study Report                                            | February 2025                                                              |

<div style=\"page-break-after: always\"></div>

| Study Status                                                                                                                           | Summary of objectives                                                                                 | Safety concerns addressed                                     | Mileston es                                                   | Estimate d Due Dates                                                          |
|----------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|-------------------------------------------------------------------------------|
| Category 3 - Required additional pharmacovigilance activities                                                                          | Category 3 - Required additional pharmacovigilance activities                                         | Category 3 - Required additional pharmacovigilance activities | Category 3 - Required additional pharmacovigilance activities | Category 3 - Required additional pharmacovigilance activities                 |
| Long-term safety and efficacy of lebrikizumab in adult and adolescent patients with moderate-to- severe atopic dermatitis (M-17923-32) | To evaluate the long-term safety and efficacy of lebrikizumab in patients with moderate-to-severe AD. | Missing information: Long-term safety of lebrikizumab         | Protocol Final study report                                   | 05 April 2023 (first version approved by the Competent Authority) August 2026 |

Abbreviation: AD = atopic dermatitis; AE=adverse event; FPFV=first patient, first visit; LPLV=last patient, last visit; Q4W=every 4 weeks.

## 2.7.3. Risk minimisation measures

<div style=\"page-break-after: always\"></div>

| Safety Concern                          | Risk Minimisation Measures                                                                                             | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                                                                                                           |
|-----------------------------------------|------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Use in pregnant and breastfeeding women | Routine risk minimisation measures: SmPC Section 4.6 PL Section 2 Additional risk minimisation measures: None proposed | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None proposed. Additional pharmacovigilance activities (Pregnant woman): • Observational database study of pregnancy and infant outcomes among women exposed to lebrikizumab during pregnancy                                                                                                                                            |
| Long-term safety of lebrikizumab        | Routine risk minimisation: None Additional risk minimisation measures: None proposed                                   | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None proposed Additional pharmacovigilance activities: • A long-term study to assess the safety and efficacy of lebrikizumab in patients with moderate-to-severe atopic dermatitis (J2T-DM-KGAA) • Long-term safety and efficacy of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis (M-17923-32) |

## 2.7.4. Conclusion

The CHMP considers that the risk management plan version 1.0 is acceptable.

## 2.8. Pharmacovigilance

## 2.8.1. Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the applicant fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

## 2.8.2. Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the Annex II, Section C of the CHMP Opinion. The applicant did request alignment of the PSUR cycle with the international birth date (IBD). The IBD is 28.09.2023. The new EURD list entry will therefore use the IBD to determine the forthcoming Data Lock Points.

<div style=\"page-break-after: always\"></div>

## 2.9. Product information

## 2.9.1. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

## 2.9.2. Additional monitoring

Pursuant to Article 23(1) of Regulation No (EU) 726/2004, Ebglyss (lebrikizumab) is included in the additional monitoring list as a new active substance.

Therefore, the summary of product characteristics and the package leaflet includes a statement that this medicinal product is subject to additional monitoring and that this will allow quick identification of new safety information. The statement is preceded by an inverted equilateral black triangle.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The proposed indication for lebrikizumab is: 'treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.'

Atopic dermatitis (AD) is a chronic and relapsing inflammatory disorder characterised by erythematous, pruritic, dry, scaly and often lichenified skin. Pruritus is a hallmark of AD and is responsible for much of the disease burden for patients and their families. Moderate to severe AD is associated with significant burden, impacting sleep, quality of life, and treatment needs.

The goals of therapy are to reduce pruritus and establish persistent disease control that is sufficient to enable patients to be fully functional at home, work and school. These goals typically require a multistep approach with  interventions that  are aimed at  avoiding relevant triggers, improving the  skin barrier, normalizing the skin dysbiosis and reducing inflammation.

## 3.1.2. Available therapies and unmet medical need

Topical  therapies, e.g.  moisturisers  are  the  mainstay  of  therapy  for  patients  with  mild-to-moderate disease. TCS are used as the first-line anti-inflammatory treatment and reduce disease recurrence when used intermittently.  Use of low-potency TCS bears low risk, but inappropriate use of high-potency TCS can cause local side effect such as skin thinning, purpura, striae and dyspigmentation.

Topical calcineurin inhibitors (TCIs) tacrolimus and pimecrolimus are alternative topical immunomodulators for the  treatment  of  AD.  Currently  per  EMA  recommendations,  these  medicines should be only used in patients over the age of 2 years with  mild or moderate disease (in the case of pimecrolimus) and moderate to severe disease (in the case of tacrolimus), when treatment with topical corticosteroids should not or cannot be used.

<div style=\"page-break-after: always\"></div>

Other treatment  options  include short-term phototherapy if  disease cannot  be controlled with  topical therapies and oral glucocorticoids. Systemic non-biologic immunomodulatory therapies, e.g. ciclosporin, azathioprine, methotrexate and mycophenolate mofetil are also used, often off-label. Other treatments options  for  moderate-to-severe  AD  include  oral  JAK  inhibitors  abrocitinib,  baricitinib,  upadacitinib. However, the  use of JAK inhibitors has been associated with  some serious side effects and should be used with caution.

Recently, two biological therapies have been approved by EMA for moderate-to-severe AD. Dupilumab is a mAb against IL-4R α that inhibits  IL-4 signalling via the Type I receptor (IL-4R α/γ c), and both IL-4 and IL-13 signalling through the Type II receptor (IL-4R α/ IL-13R α). Tralokinumab is a mAb against IL13 that neutralises the biological activity of IL-13 by blocking its interaction with the IL-13R α1/ IL-4R α receptor complex.

Although several therapies have recently become available for the treatment of moderate-to-severe AD, new therapies that are effective and safe particularly in the long-term treatment of this chronic disease are needed.

## 3.1.3. Main clinical studies

The clinical development program supporting lebrikizumab for the treatment of moderate-to-severe AD in adults and adolescents 12 years of age and older with  a body weight of at least 40 kg and who are candidates for systemic therapy, is primarily based on 3 pivotal trials:

- KGAB and  KGAC studies were randomised, double-blind,  placebo-controlled,  parallel-group studies designed to confirm the safety and efficacy of lebrikizumab in adults and adolescents (12 to  less than  18 years of age that  weighted at least 40  kg) with  moderate-to-severe AD. Both studies included Induction period (0-16 weeks) and Maintenance period (16-52 weeks).
- KGAD study was a 16-week randomised, double blind, placebo-controlled, parallel-group study designed to evaluate the safety and efficacy of lebrikizumab + TCS compared with  placebo + TCS in adults and adolescents (12 to less than 18 years of age that  weighted at least 40 kg) with moderate-to-severe AD.

The co-primary endpoints in all 3 pivotal studies were:

- Percentage of patients with an IGA score  of 0 or 1 and a reduction ≥2 points from baseline to Week 16.
- Percentage of patients achieving EASI 75 (≥75% reduction from Baseline in EASI score) at Week 16

## 3.2. Favourable effects

Lebrikizumab demonstrated a statistically significant and clinically relevant improvements over placebo when used as monotherapy or in  combination with  TCS. The co-primary endpoints, i.e.  proportion of patients achieving EASI 75 and IGA 0,1 (with ≥2 point reduction from baseline) at Week 16 were met in all 3 pivotal studies.

Based on the primary analysis using the 'hybrid' estimand, 43.1% and 33.2% of patients treated with lebrikizumab and 12.7% and 10.8% of patients treated with placebo achieved IGA 0,1 in the KGAB and KGAC studies at Week 16. This translated into a 29.7% (95 % CI 21.6, 37.8, p&lt;0.001) and 21.9% (95% CI 14.2, 29.6,  p&lt;0.001)  difference from placebo in the KGAB and KGAC studies, respectively. 58.8% and 52.1% of patients treated with lebrikizumab and 16.2% and 18.1% of patients treated with placebo

<div style=\"page-break-after: always\"></div>

achieved EASI 75  in KGAB and KGAC studies at Week 16.  This translated into  a 42% (95%  CI 33.3, 50.6,  p&lt;0.001)  and 33.3%  (95%  CI 24.4,  42.2,  p&lt;0.001)  difference from placebo in the  KGAB and KGAC studies, respectively.

In KGAD, 41.2% of patients treated with lebrikizumab + TCS and 22.1% of patients treated with placebo + TCS achieved IGA 0,1 at Week 16. This translated into a  18.3% (95% CI 5.1, 31.5, p=0.011) difference from placebo. 69.5% of patients treated with lebrikizumab + TCS and 42.2% of patients treated with placebo + TCS achieved EASI 75 at Week 16. This translated into a 26.4% (95% CI 12.1, 40.8, p&lt;0.001) difference from placebo.

The supportive 'composite' estimand yielded similar results to the primary analysis of the co-primary endpoints.

For the Induction Period, the key secondary endpoints in studies KGAB and KGAC supported the effects seen in the co-primary endpoints with statistically significant differences over placebo e.g. in EASI 90, pruritus NRS ≥4 point improvement, sleep loss scale ≥2 improvement and DLQI ≥4 point improvement.

The pivotal studies included adults  and adolescents 12 to  less than  18 years of age that  weighted at least 40 kg. The subgroup analysis  in adolescent  patients provided  evidence  that lebrikizumab  has similar or somewhat better efficacy in adolescents compared to adult population. In the pooled analysis of the KGAB and KGAC studies, 46.6% vs. 14.3% of the adolescent patients achieved IGA 0,1 and 62.0% vs. 17.3% achieved EASI 75 at Week 16 in lebrikizumab vs. placebo groups, respectively. In KGAD study, 57.3% vs. 28.6% of the of the adolescent patients achieved IGA 0,1  and 88.0%  vs. 57.1% achieved EASI 75 at Week 16 in lebrikizumab vs. placebo groups, respectively.

Among IGA 0,1 responders at Week 16 in KGAB and KGAC studies, high proportions in 250 mg Q4W and Q2W lebrikizumab groups maintained the response at Week 52 (74.2% and 75.8% in KGAB, 80.6% and 64.6% in KGAC). Of note, high proportions were observed in placebo (lebrikizumab withdrawal)  group as well (46.5% in KGAB and 49.8% in KGAC).

Among EASI 75 responders at Week 16 in KGAB and KGAC studies, high proportions in 250 mg Q4W and  Q2W  lebrikizumab groups  maintained  the  response at  Week 52,  i.e.  in  the  Maintenance  period (79.2% and 79.2% in KGAB, 84.7% and 77.4% in KGAC). Of note, high proportions were observed in placebo (lebrikizumab withdrawal) group as well (61.3% in KGAB and 72.0% in KGAC).

## 3.3. Uncertainties and limitations about favourable effects

Simulation data suggest that patients with adequate initial response may continue to maintain response with 250 mg QXW dosing but there is no clinical data to confirm this. It is therefore recommended that the  Applicant  conducts a  clinical study  that  compares Q4W  vs. QXW dosing  during  the  maintenance period in subjects who are initial responders at week 16.

The efficacy and safety of lebrikizumab in adolescents weighing &lt;40 kg has not been demonstrated but is being addressed in a clinical study according to the agreed PIP.

Long-term efficacy data are very limited. A LTE study with planned duration of 100 Weeks is ongoing.

## 3.4. Unfavourable effects

A total of 1720 participants (including 372 adolescents) with AD were exposed to any dose of lebrikizumab for 1637.02 PY. The dosing regimen proposed for marketing (lebrikizumab 250 mg Q2W during the first 16 weeks followed by lebrikizumab 250 mg Q4W) was administered to 147 participants (216.11 PY).

<div style=\"page-break-after: always\"></div>

## Induction period (weeks 0-16)

During induction, higher incidences of TEAEs were reported in the lebrikizumab treated subjects than in those on placebo in the following SOCs: Infections and infestations, Eye disorders, and Nervous system disorders. Common TAES reported more frequently in the lebrikizumab group compared to placebo in the induction period were conjunctivitis (6.9%), nasopharyngitis (4.4%), headache  (4.4%), conjunctivitis allergic (1.8%), dry eye (1.4%) and rhinitis allergic (1.0%).

## Maintenance period (weeks 16-52)

In the  maintenance period (weeks 16-52),  the  same TEAEs  were common and  the  frequencies were roughly similar to those seen in the induction period.

## Events of special interest

The observed incidence rates of infectious conjunctivitis were 6.9% in the induction phase and 5.0% in the maintenance phase. Conjunctivitis allergic occurred in 1.8% of LEB treated subjects during induction and  5.9%  during  maintenance.  All  events of  conjunctivitis  were  nonserious according  to  (ICH)  E2A guidelines.  Two  (0.1%)  events of  conjunctivitis,  and  4  (0.2%)  events of  conjunctivitis  allergic were classified as severe (a severe event is defined as an event that prevents normal everyday activities). Most events of conjunctivitis (72.1%) were reported as recovered or resolved by the data cutoff date. Four events of conjunctivitis led to treatment discontinuation.

Of  the  183  participants  reporting  events  within  the  conjunctivitis  cluster  (conjunctivitis  of  various etiologies, that  is, bacterial, viral, allergic), the majority occurred earlier in treatment but throughout the whole 52 weeks of treatment with the proposed posology (LEB 250 Q2W/Q4W) the total frequency of conjunctivitis was 14.2% and of conjunctivitis allergic was 6.1%.

Of  the 1720  AD  patients  with  any exposure to  lebrikizumab 250  mg  total  of  9  (0.5%)  participants reported 14  events within  the  keratitis  cluster during  the  whole  study  period. Five  of these  events occurred during the induction period. One (0.9%) event of severe vernal keratoconjunctivitis in a LEB 250 mg Q2W participant led to treatment discontinuation.  Eleven (0.6%) participants reported a total of 13 events of blepharitis. Seven of these events occurred during the induction  period. One severe event of blepharitis was noted. None led to treatment discontinuation.

In the induction  period, the frequency of TEAE Infections and infestations was higher in LEB  250 mg Q2W arm compared to  placebo (21.2%  vs  18.6%).  This  was  primarily driven  by  conjunctivitis  and nasopharyngitis. The exposure adjusted incidence rate with LEB 250mg Q2W was lower than that with placebo.

Although the combined incidence of all herpes  infections was balanced  between treatment groups, herpes zoster and herpes simplex infections were more common with lebrikizumab compared to placebo. Herpes zoster occurred in 5 (0.6%) patients treated with LEB compared to 0 patients in the placebo arm during induction. Herpes simplex occurred in 2 (0.3%) patients treated with LEB compared to 0 patients in the placebo arm during induction.  No eczema herpeticum events were reported in the lebrikizumab group compared to  3 (0.7%)  events in  the placebo group. All herpes infection events were nonserious and none led to treatment discontinuation.

From baseline to Week 16,  the frequency of participants with  increased blood eosinophils at any time point  post-baseline  was  higher  in  lebrikizumab-treated  participants  (20.3%)  compared  to  placebotreated  participants  (11.7%). TE  eosinophilia  AEs  were  reported  at  a  similar  frequency  in  the lebrikizumab group (0.6%) compared to placebo (0.8%). A shift  to severely elevated eosinophil levels (greater  than  5000  cells/mm 3 )  was  detected  in  3  lebrikizumab-treated  participants  (0.4%)  and  0 placebo-treated participants during induction treatment. The eosinophilia  was transient and did not result in discontinuation. No eosinophil-related disorder AEs were reported.

<div style=\"page-break-after: always\"></div>

In the induction period, frequency of immediate hypersensitivity reactions was lower in LEB 250mg Q2W (n=22,  2.8%)  compared  to  placebo  (n=25,  6.2%).  In  the  maintenance  period,  the  frequency  of immediate hypersensitivity reactions was slightly higher in both lebrikizumab arms although the number of events is very small. No serious events of immediate hypersensitivity or anaphylaxis were reported in the AD program.

As  for  nonimmediate  hypersensitivity,  in  the  induction  period,  the  frequencies  of  nonimmediate hypersensitivity events were lower in the lebrikizumab group (n = 77, 9.9%) compared to placebo (n = 69, 17.1%), while in the maintenance period the frequencies were similar in LEB Q4W and placebo (n = 17, 14.4% and n = 8, 13.3%, respectively).

The frequency of non-immediate hypersensitivity reactions in adolescents receiving lebrikizumab Q4W is 17.6% in the maintenance period and 20.7% in any LEB exposure set compared to adults receiving the same dosing regimen (13.9% in maintenance and 10.2% in any LEB exposure) and higher compared to  adolescents  receiving placebo  (12.5%  in  maintenance)  or  adolescents  receiving  LEB  Q2W  (0  in maintenance and 14.3% in any LEB exposure set).

The incidence of  injection site  reactions was higher  in  the lebrikizumab-treated group  (n=20,  2.6%) compared to placebo (n=6, 1.5%) during the induction period but decreased over time and was similar between groups during  maintenance. All events were nonserious. One (0.1%)  event of  injection site dermatitis  which  occurred within  a  month  was severe and  led to  treatment  discontinuation.  Another participant  discontinued treatment  due to injection  site rash, which  occurred within  15  days of study drug administration.

## Serious adverse events

In total 4 deaths were recorded during the AD lebrikizumab clinical programme. One death occurred in placebo arm while  3  deaths  occurred in  patients  receiving lebrikizumab 250  mg  Q2W.  Investigators assessed all deaths as unrelated to study drug treatments.

The frequency of participants reporting  at least  1 SAE  was low and similar in the lebrikizumab  and placebo groups during both the induction and maintenance period (below 2%). During induction, frequencies of SAEs were similar for both treatment arms regardless of concomitant TCS. No SAE was reported by more than 1 participant in each treatment group during induction.

Serious infections  occurred in  two  patients  during  the  induction  period: one  (0.2%)  placebo-treated participant 2 serious events of cellulitis of the right extremity and sepsis and one (0.1%) lebrikizumabtreated participant reported a serious event of severe infectious colitis. Of the 1720 AD patients with any exposure to lebrikizumab 250 mg an additional two cases of COVID-19, one case of acarodermatitis and erysipelas and one case of pneumonia were classified as serious infections. All serious infections were recovered/resolved and did not lead to treatment discontinuation.

## Immunogenicity

In the combined phase 3 Studies KGAB, KGAC and KGAD, 3.4% of participants treated with lebrikizumab 250 mg  Q2W,  2.8%  of  participants  treated  with  lebrikizumab  250 mg  Q2W/Q4W,  and  0.9%  of participants treated with placebo  developed  treatment-emergent ADA over 12 months. Nearly all TE ADA positive participants  were also positive  for NAb  to  lebrikizumab but  most  ADAs  were low  titre  (only 2 participants had maximum titres of 1:320 and 1:640,  respectively). ADA/Nab  frequencies and titres were similar in the adolescents compared to the overall population.

<div style=\"page-break-after: always\"></div>

## Special populations

There were 53  participants  older than  65  and 15  participants older than  75 exposed to lebrikizumab during the  induction period. There were 99 adolescents exposed to  lebrikizumab during the induction period.

There were 270 adolescents exposed to any dose of lebrikizumab for at least 1 year. The total number of adolescents with AD exposed to any dose of lebrikizumab is 372. In the induction period overall SAEs, TEAEs,  discontinuations  and  TEAEs  within  special safety  topics  all  occurred with  lower  frequency in adolescents compared to adults in both lebrikizumab and placebo groups. Regarding weight, height and BMI in  adolescents,  the  mean  changes in  any LEB  group for  Z-score was  close  to  0  for  all  growth parameters.

The overall safety profile in all adolescents exposed to any dose of lebrikizumab was consistent with the safety profile in adults in terms of frequency and nature of adverse events. The most common TEAEs in adolescents occurring  more frequently in  the  lebrikizumab-treated adolescents compared to  placebo were conjunctivitis, nasopharyngitis, dry eye, and rhinitis allergic.

There is limited amount of data from the use of lebrikizumab in pregnant women. Animal studies do not indicate  direct  or  indirect  harmful  effects  with  respect  to  reproductive  toxicity.  As  a  precautionary measure, it is preferable to avoid the use of tralokinumab during pregnancy.

## 3.5. Uncertainties and limitations about unfavourable effects

The ADR list is generated based only on the first 16 weeks of treatment (the induction period). This is acceptable as only the induction period enabled comparison to true placebo and as no new information on the nature, frequency, severity or causal relationship of events is evident from the long-term data.

The long-term safety profile of lebrikizumab has not been fully characterised as long-term safety study in AD  patients is ongoing. The M-17923-32  study on long-term safety and efficacy of lebrikizumab in adult and adolescent patients with  moderate-to-severe atopic dermatitis will provide further long-term data. Long-term safety is listed as a missing information in the safety concerns in the RMP.

Lebrikizumab has not  been  studied  in pregnant  or breastfeeding women,  and no  information on  the excretion of lebrikizumab in human milk or effects on the nursing infant is available. There is currently insufficient  clinical  data  available to  draw conclusions  about  the  safety of  using  lebrikizumab during pregnancy. Animal studies have not shown any effects on male and female reproductive organs and on sperm count, motility, and morphology. As a precautionary measure, it is preferable to avoid the use of lebrikizumab during pregnancy (section 4.6 of SmPC). Use in pregnant and breastfeeding women has been added as a missing information in the list of safety concerns in the RMP. The safety of lebrikizumab us in pregnant and breastfeeding women will be monitored in an observational PASS.

<div style=\"page-break-after: always\"></div>

## 3.6. Effects Table

Table 73: Effects Table for Lebrikizumab in AD

| Effect                                         | Short Description                                                                    | Unit                 | LEB 250 mg (Q2W/Q4W)                                                     | Placebo              | Uncertainties/ Strength of evidence                                                                                                                                                                    | References                   |
|------------------------------------------------|--------------------------------------------------------------------------------------|----------------------|--------------------------------------------------------------------------|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|
| Favourable Effects                             | Favourable Effects                                                                   | Favourable Effects   | Favourable Effects                                                       | Favourable Effects   | Favourable Effects                                                                                                                                                                                     | Favourable Effects           |
| IGA 0/1 at week 16                             | Achievement of IGA 0 or 1 and a reduction ≥2 points from baseline                    | %                    | 250mg Q2W KGAB: 43.1 KGAC: 33.2 KGAD: 41.2                               | 12.7 10.8 22.1       | Superiority to placebo shown as monotherapy (KGAB and KGAC) and in combination with TCS (KGAD)                                                                                                         | CSRs                         |
| EASI 75 at week 16                             | Achievement of ≥75% reduction from baseline in EASI score                            | %                    | 250mg Q2W KGAB: 58.8 KGAC: 52.1 KGAD: 69.5                               | 16.2 18.1 42.2       | Superiority to placebo shown as monotherapy (KGAB and KGAC) and in combination with TCS (KGAD)                                                                                                         | CSRs                         |
| IGA 0/1 at week 52                             | Maintained IGA 0 or 1                                                                | %                    | 250mg Q2W/Q4W KGAB: 75.8/74.2 KGAC: 64.6/80.6 Pooled analysis: 71.2/76.9 | 46.5 49.8 47.9       | Q4W dose regimen as effective as Q2W in maintaining IGA 0 or 1 In pooled analysis (KGAB and KGAC), statistically significant difference vs. placebo with Q2W and Q4W                                   | CSRs SCE for the pooled data |
| EASI 75 at week 52                             | Maintained EASI 75 after achieving EASI 75 at week 16                                | %                    | 250mg Q2W/Q4W KGAB: 79.2/79.2 KGAC: 77.4/84.7 Pooled analysis:           | 61.3 72.0            | Q4W dose regimen as effective as Q2W in maintaining EASI 75 In pooled analysis (KGAB and KGAC), statistically significant difference vs. placebo with Q4W, but not with Q2W (p=0.147)                  | CSRs SCE for the pooled data |
| Unfavourable Effects                           | Unfavourable Effects                                                                 | Unfavourable Effects | Unfavourable Effects                                                     | Unfavourable Effects | Unfavourable Effects                                                                                                                                                                                   | Unfavourable Effects         |
| Conjunctiviti s/ conjunctiviti s allergic/kera | Incidence during 0-16 weeks induction                                                | %                    | 6.9/ 1.8/ 0.6/ 0.8                                                       | 1.8/ 0.7/ 0.3/ 0.2   | Incidence during 0-52/56 weeks was 14.2%/ 6.1%/ 0.7%/ 2% in lebrikizumab-treated participants.                                                                                                         | SCS                          |
| blepharitis Injection site reaction            | Incidence during 0-16 weeks induction                                                | %                    | 2.6                                                                      | 1.5                  | Incidence during 0-52/56 weeks was 2.0% in lebrikizumab-treated participants.                                                                                                                          | SCS                          |
| Eosinophilia                                   | Incidence of increase in blood eosinophils to >5000 per microliter during 0-16 weeks | %                    | 0.4                                                                      | 0                    | The frequency of participants with increased blood eosinophils at any time point post-baseline (0 to Week 16) was 20.3% in lebrikizumab-treated participants and 11.7% in placebo-treated participants | SCS                          |

Abbreviations:

Abbreviations: ADA= anti-drug antibody, ISI= integrated summary of immunogenicity, SCS=summary of clinical safety, LEB=lebrikizumab. PBO= placebo.

Notes: Conjunctivitis as identified in this table refers to conjunctivitis of various aetiologies (bacterial, viral, allergic).

<div style=\"page-break-after: always\"></div>

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

Although several therapies have recently become available for the treatment of moderate-to-severe AD, new therapies that are effective and safe particularly in the long-term treatment setting of this chronic disease are needed.

In the current marketing authorisation application, the applicant has clearly demonstrated the beneficial treatment effect of lebrikizumab 250 mg Q2W (with loading doses) as monotherapy and in combination with  TCS in patients with  a chronic moderate-to-severe AD,  whose disease is inadequately controlled with topical medication. The favourable effects seen in the co-primary endpoints were both statistically significant and clinically relevant in both adults and adolescent population studied.

Importantly, in addition to the investigator-assessed endpoints IGA 0,1 and EASI 75 that are to some extent overlapping measures, beneficial effects were also seen in patient-reported outcomes, including pruritus  NRS, DLQI  and sleep-loss scale that  measures the  interference of itch  on  sleep. Supportive evidence of effectiveness of lebrikizumab was provided by several other efficacy endpoints included in the pivotal studies.

In terms of  long-term treatment, the beneficial  effect of lebrikizumab  was well maintained up to 52 weeks in patients that achieved IGA 0,1 and/or EASI 75 at week 16. Some patients with initial partial response at week 16 benefit from continuation of the induction dose Q2W up to week 24. The Q4W dosing seemed as effective as Q2W dosing after induction period and appears to be the preferred dosing in long-term treatment.

In relation to safety, the number and total exposure of AD  patients treated with the intended dose of lebrikizumab is sufficient and thus, the safety profile has been sufficiently characterised. Lebrikizumab was well tolerated and has a similar safety profile in both adults and adolescents ≥12 years of age and ≥40kg.

Overall, the safety profile for lebrikizumab is manageable. No clinically meaningful differences in safety were  observed between  different  lebrikizumab  dosing  regimens  (Q2W  vs.  Q4W  in  the  maintenance phase).  No  differences  in  AE  pattern  were  seen  between  monotherapy  and  lebrikizumab +  topical treatment.

Patients with AD are known to be at an increased risk for clinically important co-morbidities such as skin infections, herpes infections, conjunctivitis, depression and sleep disorders. The risk for skin infections and conjunctivitis was reflected in the overall incidence of adverse events.

The overall safety profile of lebrikizumab is  overall acceptable and  considered manageable. The data suggest that most AEs occur within the first few months of drug treatment and that the AE pattern does not change over time, although some commonly occurring events such as conjunctivitis and conjunctivitis allergic  expectedly  had  higher  incidences  with  longer  follow-up.  The  immunogenicity  and  allergic potential of lebrikizumab is low.

Safety data are appropriately reported in the product information.

Further data on long term safety of lebrikizumab in AD will be provided post-approval (category 3 PASS, see RMP).

<div style=\"page-break-after: always\"></div>

## 3.7.2. Balance of benefits and risks

The efficacy of lebrikizumab for  the treatment  of moderate-to-severe atopic dermatitis  in  adults and adolescents 12  years of age  and older with  a body weight  of  at least  40  kg who  are candidates for systemic therapy has been demonstrated. The risks associated with lebrikizumab in the treatment  of moderate-to-severe atopic dermatitis in adults and adolescents 12 years of age and older with a body weight of at least 40 kg who are candidates for systemic therapy have been adequately characterised in the clinical programme. The applicant initially  applied for the  treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years of age and older who are candidates for systemic therapy. Considering  that  all  subjects  had  a  weight  of ≥ 40  kg,  the  final  indication  was  agreed  to  include bodyweight. Overall, based on the data presented the beneficial effects of lebrikizumab outweigh the unfavourable effects.

## 3.7.3. Additional considerations on the benefit-risk balance

Patient representatives provided their feedback and emphasised the impact of atopic eczema on quality of  life  and  everyday activities  regardless of  age,  gender,  socioeconomic or  other  differences. They expressed their perspective on how the disease can affect people's lives, starting from the early years, when caregivers are heavily  involved in  the  disease management,  throughout  the  adolescence and adulthood. Specifically, they pointed out that in clinical trials, both  men and women should be equally represented so  that  safety and  efficacy can  be  established  for each  group.  In  their  view,  it  is  also imperative that  a new  medicine is  assessed by individuals  from all  age,  gender, and  socioeconomic groups, in an equal manner. Further views on the disease and its management that still  need further attention were also provided.

The contribution of patient representatives is highly appreciated.

## 3.8. Conclusions

The overall benefit/risk balance of Ebglyss is positive, subject to the conditions stated in section 'Recommendations'.

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of Ebglyss is favourable in the following indication(s):

'Ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy'.

The CHMP therefore recommends the granting of the marketing authorisation subject to the following conditions:

## Conditions or restrictions regarding  supply and use

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2)

<div style=\"page-break-after: always\"></div>

## Other  conditions and requirements of the marketing  authorisation

- Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

The marketing authorisation holder shall submit the first periodic safety update report for this product within 6 months following authorisation.

## Conditions or restrictions with regard  to the safe and effective  use of the medicinal product

- Risk Management Plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

## New Active Substance Status

Based on the CHMP review of the available data, the CHMP considers that lebrikizumab is to be qualified as a new active substance in itself as it is not a constituent of a medicinal product previously authorised within the European Union.

## Paediatric  Data

Furthermore, the CHMP reviewed the available paediatric data of studies subject to the agreed Paediatric Investigation Plan P/0286/2021 and the results of these studies are reflected in the Summary of Product Characteristics (SmPC) and, as appropriate, the Package Leaflet.